{"5722eda3fd067b2e4c0667ae625d53b8711fa5f5": [["IntroductionPoxviruses, double-stranded DNA viruses that replicate entirely in the cytoplasm, are the largest known animal viruses.", [["cytoplasm", "ANATOMY", 83, 92], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["cytoplasm", "ORGANISM_SUBSTANCE", 83, 92], ["IntroductionPoxviruses", "TREATMENT", 0, 22], ["double-stranded DNA viruses", "TREATMENT", 24, 51], ["stranded DNA", "OBSERVATION_MODIFIER", 31, 43], ["viruses", "OBSERVATION", 44, 51], ["cytoplasm", "OBSERVATION_MODIFIER", 83, 92], ["largest", "OBSERVATION_MODIFIER", 102, 109], ["animal viruses", "OBSERVATION", 116, 130]]], ["[1] The most famous members of the poxvirus family are variola virus, the causative agent of smallpox, and vaccinia virus, which shares over 97 % amino acid sequence identity with variola, is used in the variola virus vaccine, and is widely used as a model poxvirus in the laboratory.", [["variola virus", "DISEASE", 55, 68], ["smallpox", "DISEASE", 93, 101], ["vaccinia virus", "DISEASE", 107, 121], ["amino acid", "CHEMICAL", 146, 156], ["amino acid", "CHEMICAL", 146, 156], ["poxvirus", "ORGANISM", 35, 43], ["variola virus", "ORGANISM", 55, 68], ["vaccinia virus", "ORGANISM", 107, 121], ["amino acid", "AMINO_ACID", 146, 156], ["variola virus", "ORGANISM", 204, 217], ["poxvirus", "ORGANISM", 257, 265], ["variola virus", "SPECIES", 55, 68], ["vaccinia virus", "SPECIES", 107, 121], ["variola virus vaccine", "SPECIES", 204, 225], ["variola virus", "SPECIES", 55, 68], ["vaccinia virus", "SPECIES", 107, 121], ["variola virus", "SPECIES", 204, 217], ["variola virus", "PROBLEM", 55, 68], ["smallpox", "TREATMENT", 93, 101], ["vaccinia virus", "PROBLEM", 107, 121], ["variola", "PROBLEM", 180, 187], ["the variola virus vaccine", "TREATMENT", 200, 225], ["a model poxvirus", "TREATMENT", 249, 265]]], ["[2] Smallpox is a devastating, highly transmissible, infectious disease with high morbidity and up to 40 % mortality.", [["a devastating", "PROBLEM", 16, 29], ["infectious disease", "PROBLEM", 53, 71], ["high morbidity", "PROBLEM", 77, 91], ["devastating", "OBSERVATION_MODIFIER", 18, 29], ["infectious", "OBSERVATION", 53, 63], ["high", "OBSERVATION_MODIFIER", 77, 81], ["morbidity", "OBSERVATION_MODIFIER", 82, 91]]], ["Following a global, intensive immunization campaign with the vaccinia virus vaccine, the World Health Organization (WHO) declared the worldwide eradication of smallpox in 1980.", [["smallpox", "DISEASE", 159, 167], ["vaccinia virus", "ORGANISM", 61, 75], ["vaccinia virus vaccine", "SPECIES", 61, 83], ["vaccinia virus", "SPECIES", 61, 75], ["intensive immunization campaign", "TREATMENT", 20, 51], ["the vaccinia virus vaccine", "TREATMENT", 57, 83]]], ["Three years later, variola virus stocks were either supposedly destroyed or submitted to one of the two WHO-approved laboratories situated at the US Center for Disease Control and Prevention (CDC) in Atlanta and at the Russian State Research Center of Virology and Biotechnology in Novosibirsk.", [["variola virus", "ORGANISM", 19, 32], ["variola virus", "SPECIES", 19, 32], ["variola virus stocks", "PROBLEM", 19, 39], ["Disease Control", "TREATMENT", 160, 175], ["virus stocks", "OBSERVATION", 27, 39]]], ["[3] The successful global immunization campaign resulted in a decreased demand for the development of therapies against variola virus because pharmaceutical companies had little interest in developing drugs for a disease that had already been eradicated.", [["variola virus", "DISEASE", 120, 133], ["variola virus", "ORGANISM", 120, 133], ["variola virus", "SPECIES", 120, 133], ["The successful global immunization campaign", "TREATMENT", 4, 47], ["a decreased demand", "PROBLEM", 60, 78], ["therapies", "TREATMENT", 102, 111], ["variola virus", "PROBLEM", 120, 133], ["a disease", "PROBLEM", 211, 220]]], ["However, owing to recent worldwide political developments, variola is nowadays widely regarded as one of the most significant bioterrorist threats.", [["variola", "DISEASE", 59, 66], ["variola", "PROBLEM", 59, 66], ["variola", "OBSERVATION", 59, 66]]], ["[4] In fact, the CDC has placed variola virus at the top of the high-threat agents list (category A) [5] because the impact of a smallpox pandemic in the human population today would be even more catastrophic than during the last century as a result of the vaccination programs being suspended, mainly because the vaccinia virus vaccines have substantial side effects.", [["smallpox", "DISEASE", 129, 137], ["variola virus", "ORGANISM", 32, 45], ["human", "ORGANISM", 154, 159], ["vaccinia virus", "ORGANISM", 314, 328], ["human", "SPECIES", 154, 159], ["variola virus", "SPECIES", 32, 45], ["human", "SPECIES", 154, 159], ["vaccinia virus", "SPECIES", 314, 328], ["variola virus", "PROBLEM", 32, 45], ["a smallpox pandemic", "TREATMENT", 127, 146], ["the vaccination programs", "TREATMENT", 253, 277], ["the vaccinia virus vaccines", "TREATMENT", 310, 337], ["substantial side effects", "PROBLEM", 343, 367], ["variola virus", "OBSERVATION", 32, 45]]], ["[6] Moreover, there is also a natural public threat arising from the emergence of zoonotic poxvirus infections such as the monkeypox virus, a virus that produces a disease in man that closely resembles smallpox, though less frequently fatal.", [["poxvirus infections", "DISEASE", 91, 110], ["monkeypox virus", "DISEASE", 123, 138], ["smallpox", "DISEASE", 202, 210], ["poxvirus", "ORGANISM", 91, 99], ["monkeypox virus", "ORGANISM", 123, 138], ["man", "ORGANISM", 175, 178], ["monkeypox virus", "SPECIES", 123, 138], ["man", "SPECIES", 175, 178], ["monkeypox virus", "SPECIES", 123, 138], ["a natural public threat", "PROBLEM", 28, 51], ["zoonotic poxvirus infections", "PROBLEM", 82, 110], ["the monkeypox virus", "PROBLEM", 119, 138], ["a virus", "PROBLEM", 140, 147], ["a disease", "PROBLEM", 162, 171], ["zoonotic", "OBSERVATION_MODIFIER", 82, 90], ["poxvirus", "OBSERVATION", 91, 99], ["monkeypox virus", "OBSERVATION", 123, 138], ["less frequently", "OBSERVATION_MODIFIER", 219, 234]]], ["[7] The bioterrorist threat, the growing concern about zoonotic infections, and the side effects of vaccines have re-established the need for efficient safe therapies for poxvirus infections.IntroductionRecently, several compounds have been identified that inhibit various steps in poxvirus infection, including DNA synthesis and virion morphogenesis.", [["zoonotic infections", "DISEASE", 55, 74], ["poxvirus infections", "DISEASE", 171, 190], ["infection", "DISEASE", 291, 300], ["poxvirus", "ORGANISM", 171, 179], ["poxvirus", "ORGANISM", 282, 290], ["DNA", "CELLULAR_COMPONENT", 312, 315], ["virion", "CELLULAR_COMPONENT", 330, 336], ["poxvirus", "SPECIES", 282, 290], ["zoonotic infections", "PROBLEM", 55, 74], ["vaccines", "TREATMENT", 100, 108], ["efficient safe therapies", "TREATMENT", 142, 166], ["poxvirus infections", "PROBLEM", 171, 190], ["poxvirus infection", "PROBLEM", 282, 300], ["DNA synthesis", "TREATMENT", 312, 325], ["virion morphogenesis", "TREATMENT", 330, 350], ["zoonotic", "OBSERVATION_MODIFIER", 55, 63], ["infections", "OBSERVATION", 64, 74], ["poxvirus", "OBSERVATION_MODIFIER", 282, 290], ["infection", "OBSERVATION", 291, 300], ["virion morphogenesis", "OBSERVATION", 330, 350]]], ["[8] The drugs currently recommended for short-term prophylaxis, adverse vaccination reactions, and emergency treatment against smallpox are cidofovir (CDV) and tecovirimat (ST-246; Figure 1 ).IntroductionCDV is an acyclic phosphonate derivative of cytosine that targets viral DNA polymerases.", [["smallpox", "DISEASE", 127, 135], ["cidofovir", "CHEMICAL", 140, 149], ["CDV", "CHEMICAL", 151, 154], ["tecovirimat", "CHEMICAL", 160, 171], ["ST-246", "CHEMICAL", 173, 179], ["IntroductionCDV", "CHEMICAL", 192, 207], ["cytosine", "CHEMICAL", 248, 256], ["cidofovir", "CHEMICAL", 140, 149], ["tecovirimat", "CHEMICAL", 160, 171], ["ST-246", "CHEMICAL", 173, 179], ["acyclic phosphonate", "CHEMICAL", 214, 233], ["cytosine", "CHEMICAL", 248, 256], ["cidofovir", "SIMPLE_CHEMICAL", 140, 149], ["CDV", "ORGANISM", 151, 154], ["tecovirimat", "SIMPLE_CHEMICAL", 160, 171], ["cytosine", "SIMPLE_CHEMICAL", 248, 256], ["DNA", "CELLULAR_COMPONENT", 276, 279], ["viral DNA polymerases", "PROTEIN", 270, 291], ["CDV", "SPECIES", 151, 154], ["The drugs", "TREATMENT", 4, 13], ["short-term prophylaxis", "TREATMENT", 40, 62], ["adverse vaccination reactions", "TREATMENT", 64, 93], ["emergency treatment", "TREATMENT", 99, 118], ["smallpox", "TREATMENT", 127, 135], ["cidofovir (CDV", "TREATMENT", 140, 154], ["tecovirimat", "TREATMENT", 160, 171], ["IntroductionCDV", "TREATMENT", 192, 207], ["an acyclic phosphonate derivative of cytosine", "TREATMENT", 211, 256], ["viral DNA polymerases", "PROBLEM", 270, 291]]], ["It has a broad-spectrum antivi-IntroductionThe synthesis and antiviral activity of a series of novel polycyclic analogues of the orthopoxvirus egress inhibitor tecovirimat (ST-246) is presented.", [["tecovirimat", "CHEMICAL", 160, 171], ["ST-246", "CHEMICAL", 173, 179], ["tecovirimat", "CHEMICAL", 160, 171], ["polycyclic analogues", "SIMPLE_CHEMICAL", 101, 121], ["orthopoxvirus", "SIMPLE_CHEMICAL", 129, 142], ["tecovirimat", "SIMPLE_CHEMICAL", 160, 171], ["ST-246", "SIMPLE_CHEMICAL", 173, 179], ["a broad-spectrum antivi-Introduction", "TREATMENT", 7, 43], ["The synthesis", "TREATMENT", 43, 56], ["novel polycyclic analogues", "TREATMENT", 95, 121], ["the orthopoxvirus egress inhibitor tecovirimat", "TREATMENT", 125, 171], ["broad", "OBSERVATION_MODIFIER", 9, 14], ["antiviral activity", "OBSERVATION", 61, 79]]], ["Several of these compounds display submicromolar activity against vaccinia virus, and were more potent than cidofovir (CDV).", [["cidofovir", "CHEMICAL", 108, 117], ["cidofovir", "CHEMICAL", 108, 117], ["vaccinia virus", "ORGANISM", 66, 80], ["cidofovir", "SIMPLE_CHEMICAL", 108, 117], ["CDV", "ORGANISM", 119, 122], ["vaccinia virus", "SPECIES", 66, 80], ["CDV", "SPECIES", 119, 122], ["submicromolar activity", "PROBLEM", 35, 57], ["vaccinia virus", "PROBLEM", 66, 80], ["cidofovir (CDV", "TREATMENT", 108, 122], ["submicromolar activity", "OBSERVATION", 35, 57], ["vaccinia virus", "OBSERVATION", 66, 80]]], ["The more active compounds were about 10-fold more active than CDV, with minimum cytotoxic concentrations above 100 mm.", [["CDV", "ORGANISM", 62, 65], ["CDV", "SPECIES", 62, 65], ["The more active compounds", "PROBLEM", 0, 25], ["minimum cytotoxic concentrations", "PROBLEM", 72, 104], ["more", "OBSERVATION_MODIFIER", 4, 8], ["active", "OBSERVATION_MODIFIER", 9, 15], ["compounds", "OBSERVATION", 16, 25]]], ["Chemical manipulations of the two carbon-carbon double bonds present in the compounds were carried out to further explore the structure-activity relationships of these new polycyclic imides.", [["carbon-carbon", "CHEMICAL", 34, 47], ["polycyclic imides", "CHEMICAL", 172, 189], ["carbon", "CHEMICAL", 34, 40], ["carbon", "CHEMICAL", 41, 47], ["polycyclic imides", "CHEMICAL", 172, 189], ["polycyclic imides", "SIMPLE_CHEMICAL", 172, 189], ["Chemical manipulations", "TREATMENT", 0, 22], ["the two carbon-carbon double bonds", "TREATMENT", 26, 60], ["these new polycyclic imides", "TREATMENT", 162, 189], ["double bonds", "OBSERVATION", 48, 60], ["polycyclic imides", "OBSERVATION", 172, 189]]], ["Hydrogenation of the two carbon-carbon double bonds decreases antiviral activity, whereas either cyclopropanation or epoxidation of the double bonds fully eliminates the antiviral activity. ral activity, proving to be effective against many poxviruses and herpesviruses.", [["carbon-carbon", "CHEMICAL", 25, 38], ["cyclopropanation", "CHEMICAL", 97, 113], ["carbon", "CHEMICAL", 25, 31], ["carbon", "CHEMICAL", 32, 38], ["carbon-carbon double bonds", "SIMPLE_CHEMICAL", 25, 51], ["cyclopropanation", "SIMPLE_CHEMICAL", 97, 113], ["ral", "GENE_OR_GENE_PRODUCT", 190, 193], ["herpesviruses", "ORGANISM", 256, 269], ["Hydrogenation", "TREATMENT", 0, 13], ["the two carbon-carbon double bonds", "TREATMENT", 17, 51], ["antiviral activity", "TREATMENT", 62, 80], ["cyclopropanation", "TREATMENT", 97, 113], ["epoxidation", "TREATMENT", 117, 128], ["the double bonds", "TREATMENT", 132, 148], ["herpesviruses", "PROBLEM", 256, 269], ["antiviral activity", "OBSERVATION", 62, 80], ["antiviral activity", "OBSERVATION", 170, 188]]], ["However, the low oral bioavailability of CDV and potential nephrotoxicity associated with its intravenous administration would be an issue in the case of a bioterrorist attack.", [["oral", "ANATOMY", 17, 21], ["intravenous", "ANATOMY", 94, 105], ["CDV", "CHEMICAL", 41, 44], ["nephrotoxicity", "DISEASE", 59, 73], ["oral", "ORGANISM_SUBDIVISION", 17, 21], ["CDV", "ORGANISM", 41, 44], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 105], ["CDV", "SPECIES", 41, 44], ["CDV", "PROBLEM", 41, 44], ["potential nephrotoxicity", "PROBLEM", 49, 73], ["its intravenous administration", "TREATMENT", 90, 120], ["a bioterrorist attack", "PROBLEM", 154, 175], ["low", "OBSERVATION_MODIFIER", 13, 16], ["nephrotoxicity", "OBSERVATION", 59, 73]]], ["Prodrugs of CDV have been prepared that significantly enhance its oral bioavailability.", [["oral", "ANATOMY", 66, 70], ["CDV", "ORGANISM", 12, 15], ["oral", "ORGANISM_SUBDIVISION", 66, 70], ["CDV", "SPECIES", 12, 15], ["Prodrugs", "TREATMENT", 0, 8], ["CDV", "PROBLEM", 12, 15], ["CDV", "OBSERVATION", 12, 15]]], ["[9] Tecovirimat, a new, potent, orally active antipoxviral agent recently disclosed by SIGA laboratories, features a polycyclic hydrocarbon moiety and an N-benzamido substituent.", [["[9] Tecovirimat", "CHEMICAL", 0, 15], ["polycyclic hydrocarbon", "CHEMICAL", 117, 139], ["N-benzamido", "CHEMICAL", 154, 165], ["[9] Tecovirimat", "CHEMICAL", 0, 15], ["polycyclic hydrocarbon", "CHEMICAL", 117, 139], ["N-benzamido", "CHEMICAL", 154, 165], ["[9] Tecovirimat", "SIMPLE_CHEMICAL", 0, 15], ["polycyclic hydrocarbon moiety", "SIMPLE_CHEMICAL", 117, 146], ["N-benzamido substituent", "SIMPLE_CHEMICAL", 154, 177], ["Tecovirimat", "TREATMENT", 4, 15], ["orally active antipoxviral agent", "TREATMENT", 32, 64], ["a polycyclic hydrocarbon moiety", "TREATMENT", 115, 146], ["an N-benzamido substituent", "TREATMENT", 151, 177], ["polycyclic", "OBSERVATION", 117, 127], ["hydrocarbon moiety", "OBSERVATION", 128, 146]]], ["[10] It targets the F13L protein of vaccinia virus, a membrane component required for the formation of extracellular viral particles.", [["membrane", "ANATOMY", 54, 62], ["extracellular", "ANATOMY", 103, 116], ["F13L", "GENE_OR_GENE_PRODUCT", 20, 24], ["vaccinia virus", "ORGANISM", 36, 50], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 116], ["F13L protein", "PROTEIN", 20, 32], ["vaccinia virus", "SPECIES", 36, 50], ["vaccinia virus", "PROBLEM", 36, 50], ["a membrane component", "PROBLEM", 52, 72], ["extracellular viral particles", "PROBLEM", 103, 132], ["vaccinia virus", "OBSERVATION", 36, 50], ["extracellular viral particles", "OBSERVATION", 103, 132]]], ["[11] Tecovirimat was shown to inhibit the growth of multiple orthopoxviruses in cell cultures, including two strains of variola virus.", [["cell cultures", "ANATOMY", 80, 93], ["[11] Tecovirimat", "CHEMICAL", 0, 16], ["variola virus", "DISEASE", 120, 133], ["[11] Tecovirimat", "CHEMICAL", 0, 16], ["[11] Tecovirimat", "SIMPLE_CHEMICAL", 0, 16], ["cell cultures", "CELL", 80, 93], ["variola virus", "ORGANISM", 120, 133], ["cell cultures", "CELL_LINE", 80, 93], ["variola virus", "SPECIES", 120, 133], ["variola virus", "SPECIES", 120, 133], ["Tecovirimat", "TREATMENT", 5, 16], ["multiple orthopoxviruses", "PROBLEM", 52, 76], ["cell cultures", "TEST", 80, 93], ["variola virus", "PROBLEM", 120, 133], ["multiple", "OBSERVATION_MODIFIER", 52, 60], ["orthopoxviruses", "OBSERVATION", 61, 76], ["cell cultures", "OBSERVATION", 80, 93], ["variola virus", "OBSERVATION", 120, 133]]], ["In addition, tecovirimat has demonstrated significant antiviral activity in various animal models of the poxvirus disease, including the complete protection of golden-mantled ground squirrels from lethal doses of monkeypox virus and protection of nonhuman primates from variola virus in lesional disease models.", [["tecovirimat", "CHEMICAL", 13, 24], ["poxvirus disease", "DISEASE", 105, 121], ["monkeypox virus", "DISEASE", 213, 228], ["lesional disease", "DISEASE", 287, 303], ["tecovirimat", "CHEMICAL", 13, 24], ["tecovirimat", "SIMPLE_CHEMICAL", 13, 24], ["poxvirus", "ORGANISM", 105, 113], ["squirrels", "ORGANISM", 182, 191], ["monkeypox virus", "ORGANISM", 213, 228], ["nonhuman primates", "ORGANISM", 247, 264], ["variola virus", "ORGANISM", 270, 283], ["golden-mantled ground squirrels", "SPECIES", 160, 191], ["monkeypox virus", "SPECIES", 213, 228], ["nonhuman primates", "SPECIES", 247, 264], ["variola virus", "SPECIES", 270, 283], ["tecovirimat", "TREATMENT", 13, 24], ["significant antiviral activity", "PROBLEM", 42, 72], ["the poxvirus disease", "PROBLEM", 101, 121], ["monkeypox virus", "TREATMENT", 213, 228], ["protection of nonhuman primates", "TREATMENT", 233, 264], ["variola virus in lesional disease models", "PROBLEM", 270, 310], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["antiviral activity", "OBSERVATION", 54, 72], ["poxvirus disease", "OBSERVATION", 105, 121], ["variola virus", "OBSERVATION", 270, 283], ["lesional disease", "OBSERVATION", 287, 303]]], ["[12] The agent demonstrated favorable safety, tolerability, and pharmacokinetics in a double-blind, randomized, placebo-controlled phase I ascending-dose study in healthy human volunteers.", [["human", "ORGANISM", 171, 176], ["volunteers", "ORGANISM", 177, 187], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 171, 176], ["placebo", "TREATMENT", 112, 119], ["favorable", "OBSERVATION_MODIFIER", 28, 37]]], ["These and other results support the use of tecovirimat to prevent smallpox disease in nonvaccinated individuals, as a postexposure therapeutic for use in nonsymptomatic individuals exposed to variola virus, as a treatment for confirmed smallpox infection, and as an adjuvant to vaccination with the smallpox vaccine.", [["tecovirimat", "CHEMICAL", 43, 54], ["smallpox disease", "DISEASE", 66, 82], ["smallpox infection", "DISEASE", 236, 254], ["tecovirimat", "CHEMICAL", 43, 54], ["tecovirimat", "SIMPLE_CHEMICAL", 43, 54], ["individuals", "ORGANISM", 169, 180], ["variola virus", "ORGANISM", 192, 205], ["variola virus", "SPECIES", 192, 205], ["smallpox", "SPECIES", 236, 244], ["tecovirimat", "TREATMENT", 43, 54], ["smallpox disease in nonvaccinated individuals", "PROBLEM", 66, 111], ["nonsymptomatic individuals", "PROBLEM", 154, 180], ["variola virus", "PROBLEM", 192, 205], ["a treatment", "TREATMENT", 210, 221], ["smallpox infection", "PROBLEM", 236, 254], ["an adjuvant to vaccination", "TREATMENT", 263, 289], ["the smallpox vaccine", "TREATMENT", 295, 315], ["variola virus", "OBSERVATION", 192, 205], ["infection", "OBSERVATION", 245, 254]]], ["[13] Recently, it has received both orphan drug designation and fast-track status from the US Food and Drug Administration (FDA), supporting development of tecovirimat for the prevention and treatment of smallpox infections.", [["tecovirimat", "CHEMICAL", 156, 167], ["infections", "DISEASE", 213, 223], ["tecovirimat", "SIMPLE_CHEMICAL", 156, 167], ["Drug Administration", "TREATMENT", 103, 122], ["tecovirimat", "TREATMENT", 156, 167], ["the prevention", "TREATMENT", 172, 186], ["smallpox infections", "PROBLEM", 204, 223], ["smallpox", "OBSERVATION_MODIFIER", 204, 212], ["infections", "OBSERVATION", 213, 223]]], ["[14] SIGA has disclosed structure-activity relationships on ST-246, mainly regarding the effects of the substitution of the aromatic ring.", [["ST-246", "CHEMICAL", 60, 66], ["[14] SIGA", "CHEMICAL", 0, 9], ["[14] SIGA", "SIMPLE_CHEMICAL", 0, 9], ["ST-246", "SIMPLE_CHEMICAL", 60, 66], ["ST", "TEST", 60, 62], ["the substitution of the aromatic ring", "TREATMENT", 100, 137], ["aromatic ring", "OBSERVATION", 124, 137]]], ["However, few efforts were made with regard to the replacement of the tricyclononene subunit ( Figure 2 ).", [["tricyclononene", "CHEMICAL", 69, 83], ["tricyclononene", "SIMPLE_CHEMICAL", 69, 83], ["tricyclononene subunit", "PROTEIN", 69, 91], ["the replacement of the tricyclononene subunit", "TREATMENT", 46, 91]]], ["[15] Results and Discussion For many years, our group has worked on the synthesis of polycyclic hydrocarbon derivatives, mainly from a synthetically oriented point of view.", [["polycyclic hydrocarbon", "CHEMICAL", 85, 107], ["polycyclic hydrocarbon", "CHEMICAL", 85, 107], ["polycyclic hydrocarbon derivatives", "SIMPLE_CHEMICAL", 85, 119], ["polycyclic hydrocarbon derivatives", "TREATMENT", 85, 119]]], ["[16] We believed that replacement of the tricyclononane subunit of ST-246 by other polycyclic hydrocarbon structures could lead to new compounds with potential antipoxviral activity.IntroductionDimethyl pentacyclo [6.4.0.0 2,10 .0 3,7 .0 4,9 ]dodeca-5,11-diene-8,9dicarboxylate (4) is a functionalized polycyclic compound that is easily available from cyclopentadiene and dimethyl acetylenedicarboxylate following a one-pot procedure.", [["tricyclononane", "CHEMICAL", 41, 55], ["ST-246", "CHEMICAL", 67, 73], ["polycyclic hydrocarbon", "CHEMICAL", 83, 105], ["Dimethyl pentacyclo [6.4.0.0 2,10 .0 3,7 .0 4,9 ]dodeca-5,11-diene-8,9dicarboxylate", "CHEMICAL", 194, 277], ["cyclopentadiene", "CHEMICAL", 352, 367], ["dimethyl acetylenedicarboxylate", "CHEMICAL", 372, 403], ["tricyclononane", "CHEMICAL", 41, 55], ["ST-246", "CHEMICAL", 67, 73], ["polycyclic hydrocarbon", "CHEMICAL", 83, 105], ["Dimethyl pentacyclo [6.4.0.0 2,10 .0 3,7 .0 4,9 ]dodeca-5,11-diene-8,9dicarboxylate", "CHEMICAL", 194, 277], ["cyclopentadiene", "CHEMICAL", 352, 367], ["dimethyl acetylenedicarboxylate", "CHEMICAL", 372, 403], ["tricyclononane", "SIMPLE_CHEMICAL", 41, 55], ["ST-246", "SIMPLE_CHEMICAL", 67, 73], ["polycyclic hydrocarbon", "SIMPLE_CHEMICAL", 83, 105], ["antipoxviral", "CANCER", 160, 172], ["Dimethyl pentacyclo [6.4.0.0 2,10 .0 3,7 .0 4,9 ]dodeca-5,11-diene-8,9dicarboxylate (4)", "SIMPLE_CHEMICAL", 194, 281], ["polycyclic compound", "SIMPLE_CHEMICAL", 302, 321], ["cyclopentadiene", "SIMPLE_CHEMICAL", 352, 367], ["dimethyl acetylenedicarboxylate", "SIMPLE_CHEMICAL", 372, 403], ["tricyclononane subunit", "PROTEIN", 41, 63], ["replacement of the tricyclononane subunit", "TREATMENT", 22, 63], ["ST", "TEST", 67, 69], ["other polycyclic hydrocarbon structures", "PROBLEM", 77, 116], ["potential antipoxviral activity", "TREATMENT", 150, 181], ["IntroductionDimethyl pentacyclo", "TEST", 182, 213], ["dodeca", "TEST", 243, 249], ["diene-8,9dicarboxylate", "TREATMENT", 255, 277], ["a functionalized polycyclic compound", "PROBLEM", 285, 321], ["cyclopentadiene", "TREATMENT", 352, 367], ["dimethyl acetylenedicarboxylate", "TREATMENT", 372, 403], ["a one-pot procedure", "TREATMENT", 414, 433], ["replacement", "OBSERVATION", 22, 33], ["antipoxviral activity", "OBSERVATION", 160, 181]]], ["[17] For more than 30 years this compound was the starting material for the synthesis of several theoretically interesting polycyclic compounds such as dodecahedrane, a C 16 -hexaquinacene, functionalized bisnoradamantane derivatives, and triquinacene derivatives.", [["dodecahedrane", "CHEMICAL", 152, 165], ["C 16 -hexaquinacene", "CHEMICAL", 169, 188], ["bisnoradamantane", "CHEMICAL", 205, 221], ["triquinacene", "CHEMICAL", 239, 251], ["dodecahedrane", "CHEMICAL", 152, 165], ["C 16 -hexaquinacene", "CHEMICAL", 169, 188], ["bisnoradamantane", "CHEMICAL", 205, 221], ["triquinacene", "CHEMICAL", 239, 251], ["polycyclic compounds", "SIMPLE_CHEMICAL", 123, 143], ["dodecahedrane", "SIMPLE_CHEMICAL", 152, 165], ["a C 16 -hexaquinacene", "SIMPLE_CHEMICAL", 167, 188], ["functionalized bisnoradamantane derivatives", "SIMPLE_CHEMICAL", 190, 233], ["triquinacene derivatives", "SIMPLE_CHEMICAL", 239, 263], ["the synthesis", "PROBLEM", 72, 85], ["a C", "TREATMENT", 167, 170], ["hexaquinacene", "TREATMENT", 175, 188], ["functionalized bisnoradamantane derivatives", "TREATMENT", 190, 233], ["triquinacene derivatives", "TREATMENT", 239, 263]]], ["[18] Herein we report the synthesis and potent antiviral activity of several ST-246 analogues containing a pentacyclo [6.4.0.0 2,10 .0 3,7 .0 4, 9 ] dodeca-5,11-diene moiety.", [["ST-246", "CHEMICAL", 77, 83], ["pentacyclo [6.4.0.0 2,10 .0 3,7 .0 4, 9 ] dodeca-5,11-diene", "CHEMICAL", 107, 166], ["pentacyclo [6.4.0.0 2,10 .0 3,7 .0 4, 9 ] dodeca-5,11-diene", "CHEMICAL", 107, 166], ["ST-246 analogues", "SIMPLE_CHEMICAL", 77, 93], ["pentacyclo [6.4.0.0 2,10 .0 3,7 .0 4, 9 ] dodeca-5,11-diene moiety", "SIMPLE_CHEMICAL", 107, 173], ["the synthesis", "TREATMENT", 22, 35], ["a pentacyclo", "TEST", 105, 117], ["dodeca", "TEST", 149, 155]]], ["To the best of our knowledge, these are the first biologically active compounds featuring this pentacyclic framework.", [["this pentacyclic framework", "TREATMENT", 90, 116]]], ["We also report the synthesis and evaluation of several analogues of ST-246 containing a tricyclo[3.3.0.0 3,7 ]octane (bisnoradamante) skeleton.", [["ST-246", "CHEMICAL", 68, 74], ["tricyclo[3.3.0.0 3,7 ]octane", "CHEMICAL", 88, 116], ["bisnoradamante", "CHEMICAL", 118, 132], ["tricyclo[3.3.0.0 3,7 ]octane", "CHEMICAL", 88, 116], ["bisnoradamante", "CHEMICAL", 118, 132], ["ST-246", "SIMPLE_CHEMICAL", 68, 74], ["tricyclo[3.3.0.0 3,7 ]octane", "SIMPLE_CHEMICAL", 88, 116], ["bisnoradamante", "SIMPLE_CHEMICAL", 118, 132], ["the synthesis", "TEST", 15, 28], ["evaluation", "TEST", 33, 43], ["ST", "TEST", 68, 70], ["a tricyclo", "TEST", 86, 96], ["skeleton", "ANATOMY", 134, 142]]], ["Note that although ST-246 and several analogues studied by SIGA had the two carbonyl groups of the imide moiety of the molecule attached to methyne carbon atoms, the compounds herein feature the carbonyl groups attached to quaternary carbon atoms ( Figure 3 ).IntroductionSynthesis of compounds 3 a-j was accomplished in two steps through condensation of an acyl hydrazide with the known bisnoradamantane anhydride (1), [19] followed by thermally induced dehydratation of the carboxylic acids 2 a-j to the N-benzamido imides 3 a-j (Scheme 1).IntroductionOn the other hand, starting from diester 4, [17] hydrolysis and dehydratation led to anhydride 5 in very high yield.", [["ST-246", "CHEMICAL", 19, 25], ["SIGA", "CHEMICAL", 59, 63], ["carbonyl", "CHEMICAL", 76, 84], ["methyne carbon atoms", "CHEMICAL", 140, 160], ["carbonyl", "CHEMICAL", 195, 203], ["3 a-j", "CHEMICAL", 295, 300], ["acyl hydrazide", "CHEMICAL", 358, 372], ["bisnoradamantane anhydride", "CHEMICAL", 388, 414], ["carboxylic acids", "CHEMICAL", 476, 492], ["N-benzamido imides", "CHEMICAL", 506, 524], ["diester 4, [17] hydrolysis", "CHEMICAL", 587, 613], ["anhydride 5", "CHEMICAL", 639, 650], ["carbonyl", "CHEMICAL", 76, 84], ["imide", "CHEMICAL", 99, 104], ["methyne", "CHEMICAL", 140, 147], ["carbon", "CHEMICAL", 148, 154], ["carbonyl", "CHEMICAL", 195, 203], ["carbon", "CHEMICAL", 234, 240], ["acyl hydrazide", "CHEMICAL", 358, 372], ["bisnoradamantane anhydride", "CHEMICAL", 388, 414], ["carboxylic acids", "CHEMICAL", 476, 492], ["N-benzamido imides", "CHEMICAL", 506, 524], ["diester", "CHEMICAL", 587, 594], ["anhydride", "CHEMICAL", 639, 648], ["ST-246", "SIMPLE_CHEMICAL", 19, 25], ["SIGA", "SIMPLE_CHEMICAL", 59, 63], ["methyne carbon atoms", "SIMPLE_CHEMICAL", 140, 160], ["carbonyl", "SIMPLE_CHEMICAL", 195, 203], ["quaternary carbon atoms", "SIMPLE_CHEMICAL", 223, 246], ["compounds 3 a-j", "SIMPLE_CHEMICAL", 285, 300], ["acyl hydrazide", "SIMPLE_CHEMICAL", 358, 372], ["bisnoradamantane anhydride (1)", "SIMPLE_CHEMICAL", 388, 418], ["[19]", "SIMPLE_CHEMICAL", 420, 424], ["carboxylic acids 2 a-j", "SIMPLE_CHEMICAL", 476, 498], ["N-benzamido imides", "SIMPLE_CHEMICAL", 506, 524], ["diester 4", "SIMPLE_CHEMICAL", 587, 596], ["[17] hydrolysis", "SIMPLE_CHEMICAL", 598, 613], ["anhydride 5", "SIMPLE_CHEMICAL", 639, 650], ["ST", "TEST", 19, 21], ["the imide moiety", "TREATMENT", 95, 111], ["methyne carbon atoms", "TREATMENT", 140, 160], ["the carbonyl groups", "TREATMENT", 191, 210], ["quaternary carbon atoms", "TREATMENT", 223, 246], ["an acyl hydrazide", "TREATMENT", 355, 372], ["the known bisnoradamantane anhydride", "TREATMENT", 378, 414], ["the carboxylic acids", "TREATMENT", 472, 492], ["the N-benzamido imides", "TREATMENT", 502, 524], ["a-j (Scheme", "TREATMENT", 527, 538], ["hydrolysis", "TREATMENT", 603, 613], ["dehydratation", "TREATMENT", 618, 631], ["anhydride", "TREATMENT", 639, 648]]], ["[20] Reaction of 5 with a series of acyl hydrazides in ethanol led to the corresponding mixtures of acids 6 and benzamido imides 7.", [["acyl hydrazides", "CHEMICAL", 36, 51], ["ethanol", "CHEMICAL", 55, 62], ["acids 6 and benzamido imides", "CHEMICAL", 100, 128], ["acyl hydrazides", "CHEMICAL", 36, 51], ["ethanol", "CHEMICAL", 55, 62], ["benzamido imides", "CHEMICAL", 112, 128], ["acyl hydrazides", "SIMPLE_CHEMICAL", 36, 51], ["ethanol", "SIMPLE_CHEMICAL", 55, 62], ["benzamido imides 7", "SIMPLE_CHEMICAL", 112, 130], ["acyl hydrazides in ethanol", "TREATMENT", 36, 62], ["the corresponding mixtures of acids", "TREATMENT", 70, 105], ["benzamido imides", "TREATMENT", 112, 128]]], ["Heating of these mixtures in toluene or xylene at reflux for 24 h led to the required imides 7 in good overall yields (Scheme 2).IntroductionTo explore the structure-activity relationship (SAR) of these new polycyclic imides further we carried out chemical manipu- .", [["toluene", "CHEMICAL", 29, 36], ["xylene", "CHEMICAL", 40, 46], ["reflux", "DISEASE", 50, 56], ["imides", "CHEMICAL", 86, 92], ["toluene", "CHEMICAL", 29, 36], ["xylene", "CHEMICAL", 40, 46], ["imides", "CHEMICAL", 86, 92], ["polycyclic imides", "CHEMICAL", 207, 224], ["toluene", "SIMPLE_CHEMICAL", 29, 36], ["xylene", "SIMPLE_CHEMICAL", 40, 46], ["polycyclic imides", "SIMPLE_CHEMICAL", 207, 224], ["manipu", "SIMPLE_CHEMICAL", 257, 263], ["the required imides", "TREATMENT", 73, 92], ["these new polycyclic imides", "TREATMENT", 197, 224]]], ["The stereoselectivity of the epoxidation reaction was unequivocally established for 8 s by X-ray crystallography ( Figure 4 ).", [["the epoxidation reaction", "PROBLEM", 25, 49], ["X-ray crystallography", "TEST", 91, 112]]], ["[21] Catalytic hydrogenation of 7 a and 7 d led to 9 a and 9 d, respectively, in nearly quantitative yields.", [["Catalytic hydrogenation", "TEST", 5, 28]]], ["The reduction of the two carbon-carbon double bonds of 7 b was accompanied by hydrogenolysis of the C\u00c0Br bond, leading to 9 e in quantitative yield.", [["carbon-carbon", "CHEMICAL", 25, 38], ["C\u00c0Br", "CHEMICAL", 100, 104], ["carbon", "CHEMICAL", 25, 31], ["carbon", "CHEMICAL", 32, 38], ["C\u00c0Br", "CHEMICAL", 100, 104], ["C\u00c0Br", "SIMPLE_CHEMICAL", 100, 104], ["the two carbon-carbon double bonds", "TREATMENT", 17, 51], ["hydrogenolysis of the C\u00c0Br bond", "PROBLEM", 78, 109], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["hydrogenolysis", "OBSERVATION", 78, 92]]], ["Finally, we explored the double cyclopropanation of the dienes.", [["dienes", "CHEMICAL", 56, 62], ["dienes", "CHEMICAL", 56, 62], ["dienes", "SIMPLE_CHEMICAL", 56, 62], ["the double cyclopropanation of the dienes", "TREATMENT", 21, 62]]], ["Because several attempts to achieve the cyclopropanation of 7 a failed, we carried out the cyclopropanation of anhydride 5 that led to anhydride 10.", [["anhydride 5", "CHEMICAL", 111, 122], ["anhydride", "CHEMICAL", 135, 144], ["anhydride", "CHEMICAL", 111, 120], ["anhydride", "CHEMICAL", 135, 144], ["anhydride 5", "SIMPLE_CHEMICAL", 111, 122], ["anhydride 10", "SIMPLE_CHEMICAL", 135, 147], ["the cyclopropanation", "TEST", 36, 56], ["the cyclopropanation of anhydride", "TREATMENT", 87, 120], ["anhydride", "TREATMENT", 135, 144]]], ["Reaction of 10 with selected acyl hydrazides, followed by thermally induced dehydratation of the carboxylic acids 11, led to N-benzamido imides 12 a,k,l,m,o,p in good overall yields (Scheme 3).", [["acyl hydrazides", "CHEMICAL", 29, 44], ["carboxylic acids", "CHEMICAL", 97, 113], ["N-benzamido imides", "CHEMICAL", 125, 143], ["acyl hydrazides", "CHEMICAL", 29, 44], ["carboxylic acids", "CHEMICAL", 97, 113], ["N-benzamido imides", "CHEMICAL", 125, 143], ["acyl hydrazides", "SIMPLE_CHEMICAL", 29, 44], ["carboxylic acids", "SIMPLE_CHEMICAL", 97, 113], ["N-benzamido imides", "SIMPLE_CHEMICAL", 125, 143], ["selected acyl hydrazides", "TREATMENT", 20, 44], ["the carboxylic acids", "TEST", 93, 113], ["N-benzamido imides", "TREATMENT", 125, 143]]], ["The stereose-lectivity of the cyclopropanation reaction was unequivocally established by X-ray crystallography ( Figure 5 ).", [["stereose", "SIMPLE_CHEMICAL", 4, 12], ["the cyclopropanation reaction", "PROBLEM", 26, 55], ["X-ray crystallography", "TEST", 89, 110]]], ["[21] The structures of all new compounds were confirmed by elemental analysis and/or accurate mass measurement, as well as IR, 1 H NMR, 13 C NMR, and mass spectral data.", [["1 H", "CHEMICAL", 127, 130], ["C", "CHEMICAL", 139, 140], ["elemental analysis", "TEST", 59, 77], ["accurate mass measurement", "TEST", 85, 110], ["NMR", "TEST", 131, 134], ["C NMR", "TEST", 139, 144], ["mass spectral data", "TEST", 150, 168], ["mass", "OBSERVATION", 94, 98]]], ["Moreover, the structural features of 3 e, 8 s, and 10 were further confirmed by X-ray crystallography ( Figure 6 ).", [["X-ray crystallography", "TEST", 80, 101]]], ["[21] Interestingly, in 3 e and in 8 s, the plane of the benzamido substituent is essentially orthogonal to the plane of the imide group.IntroductionFor the compounds of general structure 3, 7, 8, 9, and 12, CPE (cytopathic effect) reduction assays were performed to determine the antiviral activity against a broad panel of DNA and RNA viruses, that is, herpes simplex virus type 1 and type 2, and vaccinia virus (evaluated in infected human embryonic lung fibroblast (HEL) cells); feline coronavirus and feline herpesvirus (in Crandell-Rees Feline Kidney cells); vesicular stomatitis virus, Coxsackie B4 virus and respiratory syncytium virus (tested in HeLa cells); parainfluenza-3 virus, reovirus-1, Sindbis virus, and Punta Toro virus (tested in Vero cells); and influenza virus (in Madin-Darby canine kidney cells).", [["embryonic lung fibroblast (HEL) cells", "ANATOMY", 442, 479], ["Kidney cells", "ANATOMY", 549, 561], ["HeLa cells", "ANATOMY", 654, 664], ["Vero cells", "ANATOMY", 749, 759], ["kidney cells", "ANATOMY", 805, 817], ["benzamido", "CHEMICAL", 56, 65], ["herpes simplex", "DISEASE", 354, 368], ["feline coronavirus", "DISEASE", 482, 500], ["feline herpesvirus", "DISEASE", 505, 523], ["vesicular stomatitis", "DISEASE", 564, 584], ["influenza virus", "DISEASE", 766, 781], ["benzamido", "CHEMICAL", 56, 65], ["imide", "CHEMICAL", 124, 129], ["benzamido substituent", "SIMPLE_CHEMICAL", 56, 77], ["imide", "SIMPLE_CHEMICAL", 124, 129], ["CPE", "SIMPLE_CHEMICAL", 207, 210], ["DNA", "CELLULAR_COMPONENT", 324, 327], ["herpes simplex virus type 1", "ORGANISM", 354, 381], ["type 2", "ORGANISM", 386, 392], ["vaccinia virus", "ORGANISM", 398, 412], ["human", "ORGANISM", 436, 441], ["embryonic lung fibroblast (HEL) cells", "CELL", 442, 479], ["feline coronavirus", "ORGANISM", 482, 500], ["feline herpesvirus", "ORGANISM", 505, 523], ["Crandell-Rees Feline Kidney cells", "CELL", 528, 561], ["vesicular stomatitis virus", "ORGANISM", 564, 590], ["Coxsackie B4 virus", "ORGANISM", 592, 610], ["respiratory syncytium virus", "ORGANISM", 615, 642], ["HeLa cells", "CELL", 654, 664], ["parainfluenza-3 virus", "ORGANISM", 667, 688], ["reovirus-1", "ORGANISM", 690, 700], ["Sindbis virus", "ORGANISM", 702, 715], ["Punta Toro virus", "ORGANISM", 721, 737], ["Vero cells", "CELL", 749, 759], ["influenza virus", "ORGANISM", 766, 781], ["Madin-Darby canine kidney cells", "CELL", 786, 817], ["infected human embryonic lung fibroblast (HEL) cells", "CELL_LINE", 427, 479], ["HeLa cells", "CELL_LINE", 654, 664], ["Vero cells", "CELL_LINE", 749, 759], ["Madin-Darby canine kidney cells", "CELL_LINE", 786, 817], ["herpes simplex virus", "SPECIES", 354, 374], ["vaccinia virus", "SPECIES", 398, 412], ["human", "SPECIES", 436, 441], ["feline coronavirus", "SPECIES", 482, 500], ["feline herpesvirus", "SPECIES", 505, 523], ["vesicular stomatitis virus", "SPECIES", 564, 590], ["Coxsackie B4 virus", "SPECIES", 592, 610], ["respiratory syncytium virus", "SPECIES", 615, 642], ["parainfluenza-3 virus", "SPECIES", 667, 688], ["reovirus-1", "SPECIES", 690, 700], ["Sindbis virus", "SPECIES", 702, 715], ["Punta Toro virus", "SPECIES", 721, 737], ["influenza virus", "SPECIES", 766, 781], ["herpes simplex virus type 1", "SPECIES", 354, 381], ["vaccinia virus", "SPECIES", 398, 412], ["human", "SPECIES", 436, 441], ["feline coronavirus", "SPECIES", 482, 500], ["feline herpesvirus", "SPECIES", 505, 523], ["stomatitis virus", "SPECIES", 574, 590], ["Coxsackie B4 virus", "SPECIES", 592, 610], ["respiratory syncytium virus", "SPECIES", 615, 642], ["parainfluenza-3 virus", "SPECIES", 667, 688], ["reovirus-1", "SPECIES", 690, 700], ["Sindbis virus", "SPECIES", 702, 715], ["Punta Toro virus", "SPECIES", 721, 737], ["influenza virus", "SPECIES", 766, 781], ["canine", "SPECIES", 798, 804], ["the benzamido substituent", "TREATMENT", 52, 77], ["the imide group", "TREATMENT", 120, 135], ["CPE (cytopathic effect", "PROBLEM", 207, 229], ["reduction assays", "TEST", 231, 247], ["DNA", "PROBLEM", 324, 327], ["RNA viruses", "PROBLEM", 332, 343], ["herpes simplex virus type 1", "PROBLEM", 354, 381], ["vaccinia virus", "PROBLEM", 398, 412], ["infected human embryonic lung fibroblast (HEL) cells", "TEST", 427, 479], ["feline coronavirus and feline herpesvirus", "PROBLEM", 482, 523], ["Crandell", "TEST", 528, 536], ["vesicular stomatitis virus", "PROBLEM", 564, 590], ["Coxsackie B4 virus", "PROBLEM", 592, 610], ["respiratory syncytium virus", "PROBLEM", 615, 642], ["HeLa cells", "TEST", 654, 664], ["parainfluenza", "TEST", 667, 680], ["virus", "PROBLEM", 683, 688], ["reovirus", "TEST", 690, 698], ["Sindbis virus", "PROBLEM", 702, 715], ["Punta Toro virus", "PROBLEM", 721, 737], ["Vero cells", "PROBLEM", 749, 759], ["influenza virus", "PROBLEM", 766, 781], ["Darby canine kidney cells", "TREATMENT", 792, 817], ["RNA viruses", "OBSERVATION", 332, 343], ["lung", "ANATOMY", 452, 456], ["fibroblast", "OBSERVATION", 457, 467], ["Kidney cells", "ANATOMY", 549, 561], ["vesicular stomatitis", "ANATOMY", 564, 584], ["respiratory syncytium virus", "OBSERVATION", 615, 642], ["influenza virus", "OBSERVATION", 766, 781], ["kidney", "ANATOMY", 805, 811]]], ["[22] In studying the SAR of several analogues of ST-246, Bailey et al. have previously found that electron-withdrawing substi- 2074 www.chemmedchem.org tution on the meta or para position of the N-benzamido substituent provided the most potent inhibitors of orthopoxvirus.", [["ST-246", "CHEMICAL", 49, 55], ["substi- 2074", "CHEMICAL", 119, 131], ["N-benzamido", "CHEMICAL", 195, 206], ["substi- 2074", "CHEMICAL", 119, 131], ["N-benzamido", "CHEMICAL", 195, 206], ["ST-246", "SIMPLE_CHEMICAL", 49, 55], ["electron", "SIMPLE_CHEMICAL", 98, 106], ["substi- 2074", "SIMPLE_CHEMICAL", 119, 131], ["N-benzamido substituent", "SIMPLE_CHEMICAL", 195, 218], ["orthopoxvirus", "SIMPLE_CHEMICAL", 258, 271], ["ST", "TEST", 49, 51], ["electron", "TEST", 98, 106], ["substi", "TEST", 119, 125], ["the N-benzamido substituent", "TREATMENT", 191, 218], ["the most potent inhibitors", "TREATMENT", 228, 254], ["orthopoxvirus", "PROBLEM", 258, 271]]], ["[10, 15] We observed the same trend in our bisnoradamantane derivatives, the p-nitro (3 c) and 4-pyridyl (3 f) derivatives being the only active compounds against vaccinia virus (Table 1) .", [["bisnoradamantane", "CHEMICAL", 43, 59], ["p-nitro (3 c) and 4-pyridyl", "CHEMICAL", 77, 104], ["bisnoradamantane", "CHEMICAL", 43, 59], ["p-nitro", "CHEMICAL", 77, 84], ["4-pyridyl", "CHEMICAL", 95, 104], ["bisnoradamantane derivatives", "SIMPLE_CHEMICAL", 43, 71], ["p-nitro (3 c)", "SIMPLE_CHEMICAL", 77, 90], ["4-pyridyl (3 f) derivatives", "SIMPLE_CHEMICAL", 95, 122], ["vaccinia virus", "ORGANISM", 163, 177], ["vaccinia virus", "SPECIES", 163, 177], ["vaccinia virus", "SPECIES", 163, 177], ["our bisnoradamantane derivatives", "TREATMENT", 39, 71], ["the p-nitro (3 c) and 4-pyridyl (3 f) derivatives", "TREATMENT", 73, 122], ["vaccinia virus", "TREATMENT", 163, 177]]], ["For these reasons we only synthesized derivatives of 7, 8, 9, and 12 that have electron-withdrawing substituents on the benzamide ring.IntroductionThe two carbon-carbon double bonds were shown to be essential for good antiviral activity, as neither the epoxides nor the cyclopropanated derivatives were active (data not shown).", [["benzamide", "CHEMICAL", 120, 129], ["carbon-carbon", "CHEMICAL", 155, 168], ["cyclopropanated", "CHEMICAL", 270, 285], ["benzamide", "CHEMICAL", 120, 129], ["carbon", "CHEMICAL", 155, 161], ["carbon", "CHEMICAL", 162, 168], ["epoxides", "CHEMICAL", 253, 261], ["cyclopropanated", "CHEMICAL", 270, 285], ["electron-withdrawing substituents", "SIMPLE_CHEMICAL", 79, 112], ["benzamide ring", "SIMPLE_CHEMICAL", 120, 134], ["carbon-carbon double bonds", "SIMPLE_CHEMICAL", 155, 181], ["epoxides", "SIMPLE_CHEMICAL", 253, 261], ["cyclopropanated derivatives", "SIMPLE_CHEMICAL", 270, 297], ["the benzamide ring", "TREATMENT", 116, 134], ["The two carbon-carbon double bonds", "TREATMENT", 147, 181], ["the epoxides", "TREATMENT", 249, 261], ["the cyclopropanated derivatives", "TREATMENT", 266, 297], ["antiviral activity", "OBSERVATION", 218, 236]]], ["The hydrogenation also decreased the potency, with reduced compound 9 a being one order of magnitude less potent than the diene 7 a.", [["diene", "CHEMICAL", 122, 127], ["hydrogenation", "OBSERVATION", 4, 17], ["decreased", "OBSERVATION_MODIFIER", 23, 32], ["potency", "OBSERVATION_MODIFIER", 37, 44], ["less potent", "OBSERVATION_MODIFIER", 101, 112]]], ["Interestingly, within the dienes, although most of the derivatives that were para substituted with one electron-withdrawing group were active against vaccinia virus in the low micromolar order, introduction of a further electronwithdrawing group at the meta position led to sub-micromolar activities.", [["dienes", "CHEMICAL", 26, 32], ["dienes", "CHEMICAL", 26, 32], ["dienes", "SIMPLE_CHEMICAL", 26, 32], ["electron", "SIMPLE_CHEMICAL", 103, 111], ["vaccinia virus", "ORGANISM", 150, 164], ["vaccinia virus", "SPECIES", 150, 164], ["vaccinia virus", "TREATMENT", 150, 164], ["a further electronwithdrawing group", "TREATMENT", 210, 245], ["low micromolar", "OBSERVATION_MODIFIER", 172, 186], ["micromolar activities", "OBSERVATION", 278, 299]]], ["The more active compounds, 7 k, 7 l, and 7 m, showed sub-micromolar EC 50 values that were at least 10 times lower than cidofovir.", [["cidofovir", "CHEMICAL", 120, 129], ["cidofovir", "CHEMICAL", 120, 129], ["EC", "CELL", 68, 70], ["cidofovir", "SIMPLE_CHEMICAL", 120, 129], ["The more active compounds", "PROBLEM", 0, 25], ["k", "TEST", 29, 30], ["sub-micromolar EC", "TEST", 53, 70], ["cidofovir", "TREATMENT", 120, 129], ["more", "OBSERVATION_MODIFIER", 4, 8], ["active", "OBSERVATION_MODIFIER", 9, 15], ["compounds", "OBSERVATION_MODIFIER", 16, 25]]], ["However, if the electron-withdrawing substituent was only in the meta position, less potent compounds were found (compare 7 a and 7 r).IntroductionVery interestingly, most of the compounds showed no cytotoxicity (as determined by microscopy) at the highest concentration tested in HEL cells (100 mm).", [["HEL cells", "ANATOMY", 281, 290], ["electron", "SIMPLE_CHEMICAL", 16, 24], ["HEL cells", "CELL", 281, 290], ["HEL cells", "CELL_LINE", 281, 290], ["substituent", "TREATMENT", 37, 48], ["less potent compounds", "PROBLEM", 80, 101], ["cytotoxicity", "PROBLEM", 199, 211], ["microscopy", "TEST", 230, 240], ["less", "OBSERVATION_MODIFIER", 80, 84], ["potent", "OBSERVATION_MODIFIER", 85, 91], ["no", "UNCERTAINTY", 196, 198], ["cytotoxicity", "OBSERVATION", 199, 211], ["HEL cells", "OBSERVATION", 281, 290]]], ["None of the compounds displayed considerable activity (defined as an antiviral EC 50 value of 20 mm or less) against any of the other viruses tested.ConclusionsWe have synthesized a series of N-benzamido imides and tested them against vaccinia virus.", [["N-benzamido imides", "CHEMICAL", 192, 210], ["N-benzamido imides", "CHEMICAL", 192, 210], ["EC", "CELL", 79, 81], ["N-benzamido imides", "SIMPLE_CHEMICAL", 192, 210], ["vaccinia virus", "ORGANISM", 235, 249], ["vaccinia virus", "SPECIES", 235, 249], ["an antiviral EC", "TEST", 66, 81], ["N-benzamido imides", "TREATMENT", 192, 210], ["vaccinia virus", "PROBLEM", 235, 249], ["considerable", "OBSERVATION_MODIFIER", 32, 44], ["activity", "OBSERVATION_MODIFIER", 45, 53], ["viruses", "OBSERVATION", 134, 141]]], ["Although most of the bisnoradamantane derivatives were either inactive or active at high micromolar concentrations, most of the pentacyclo [6.4.0.0 2,10 .0 3,7 .0 4, 9 ] dodeca-5,11-diene derivatives showed low micromolar or sub-micromolar anti-vaccinia virus activities.", [["bisnoradamantane", "CHEMICAL", 21, 37], ["pentacyclo [6.4.0.0 2,10 .0 3,7 .0 4, 9 ] dodeca-5,11-diene", "CHEMICAL", 128, 187], ["bisnoradamantane", "CHEMICAL", 21, 37], ["pentacyclo [6.4.0.0 2,10 .0 3,7 .0 4, 9 ] dodeca-5,11-diene", "CHEMICAL", 128, 187], ["bisnoradamantane derivatives", "SIMPLE_CHEMICAL", 21, 49], ["pentacyclo [6.4.0.0 2,10 .0 3,7 .0 4, 9 ] dodeca-5,11-diene derivatives", "SIMPLE_CHEMICAL", 128, 199], ["the bisnoradamantane derivatives", "PROBLEM", 17, 49], ["active at high micromolar concentrations", "PROBLEM", 74, 114], ["the pentacyclo", "TEST", 124, 138], ["dodeca", "TEST", 170, 176], ["diene derivatives", "TREATMENT", 182, 199], ["low micromolar", "PROBLEM", 207, 221], ["sub-micromolar anti-vaccinia virus activities", "TREATMENT", 225, 270], ["active", "OBSERVATION_MODIFIER", 74, 80], ["low micromolar", "OBSERVATION_MODIFIER", 207, 221]]], ["The more active compounds were about 10-fold more active than cidofovir, with minimum cytotoxic concentrations above 100 mm.", [["cidofovir", "CHEMICAL", 62, 71], ["cidofovir", "CHEMICAL", 62, 71], ["cidofovir", "SIMPLE_CHEMICAL", 62, 71], ["The more active compounds", "PROBLEM", 0, 25], ["cidofovir", "TREATMENT", 62, 71], ["minimum cytotoxic concentrations", "TEST", 78, 110], ["more", "OBSERVATION_MODIFIER", 4, 8], ["active", "OBSERVATION_MODIFIER", 9, 15], ["compounds", "OBSERVATION", 16, 25]]], ["Hydrogenation of the two carbon-carbon double bonds decreased the antiviral activity, whereas either the cyclopropanation or the epoxidation of the double bonds fully eliminated the antiviral activity.Experimental SectionSynthesis of 2 a: A mixture of anhydride 1 (103 mg, 0.50 mmol), 4trifluoromethylbenzoic acid hydrazide (102 mg, 0.50 mmol), and a drop of diisopropylethylamine in absolute EtOH (2 mL) was heated under reflux for 5 h.", [["carbon-carbon", "CHEMICAL", 25, 38], ["cyclopropanation", "CHEMICAL", 105, 121], ["anhydride 1", "CHEMICAL", 252, 263], ["4trifluoromethylbenzoic acid hydrazide", "CHEMICAL", 285, 323], ["diisopropylethylamine", "CHEMICAL", 359, 380], ["EtOH", "CHEMICAL", 393, 397], ["reflux", "DISEASE", 422, 428], ["carbon", "CHEMICAL", 25, 31], ["carbon", "CHEMICAL", 32, 38], ["anhydride 1", "CHEMICAL", 252, 263], ["4trifluoromethylbenzoic acid hydrazide", "CHEMICAL", 285, 323], ["diisopropylethylamine", "CHEMICAL", 359, 380], ["EtOH", "CHEMICAL", 393, 397], ["carbon-carbon double bonds", "SIMPLE_CHEMICAL", 25, 51], ["anhydride 1", "SIMPLE_CHEMICAL", 252, 263], ["4trifluoromethylbenzoic acid hydrazide", "SIMPLE_CHEMICAL", 285, 323], ["diisopropylethylamine", "SIMPLE_CHEMICAL", 359, 380], ["EtOH", "SIMPLE_CHEMICAL", 393, 397], ["Hydrogenation", "TREATMENT", 0, 13], ["the two carbon-carbon double bonds", "TREATMENT", 17, 51], ["the cyclopropanation", "TREATMENT", 101, 121], ["the epoxidation", "TREATMENT", 125, 140], ["the double bonds", "TREATMENT", 144, 160], ["A mixture of anhydride", "TREATMENT", 239, 261], ["4trifluoromethylbenzoic acid hydrazide", "TREATMENT", 285, 323], ["a drop of diisopropylethylamine in absolute EtOH", "TREATMENT", 349, 397], ["antiviral activity", "OBSERVATION", 66, 84], ["antiviral activity", "OBSERVATION", 182, 200], ["reflux", "OBSERVATION", 422, 428]]], ["Upon cooling to room temperature, H 2 O (0.2 mL) was added.", [["H 2 O", "CHEMICAL", 34, 39], ["H 2 O", "CHEMICAL", 34, 39], ["H 2 O", "SIMPLE_CHEMICAL", 34, 39]]], ["The precipitate was collected by filtration and washed with cold EtOH (2 2 mL) to give compound 2 a as a white solid ( (7)), 55.7 (CH 2 ) and 56.0 (CH 2 ) (C2(8) and C4 (6) 3.0 (n = 2) > 100 7 d, 8.3 (n = 3) > 100 7 f, R= 4-pyridyl > 100 > 100 7 k, R= 3,4-di-Cl-C 6 H 3 0.48 (n = 2) 100 7 l, R= 3-Cl-4-Br-C 6 H 3 0.60 (n = 2) 100 7 m, R= 3-Br-4-Cl-C 6 H 3 0.16 (n = 2) 100 7 n, R= 3-CF 3 -4-Cl-C 6 H 3 0.8 (n = 2) > 100 7 o, R= 3-CH 3 -4-NO 2 -C 6 H 3 3 (n = 2) > 100 7 p, R= 6-Cl-3-pyridyl 48 (n = 2) > 100 7 q, R= 3,4-di-F-C 6 H 3 16 (n = 2) > 100 7 r, R= 3-CF 3 -C 6 H 4 16 (n = 2) > 100 7 s, R= 3,5-di-CF 3 -C 6 H 3 > 100 > 100 7 t, R= 3,5-di-Cl-C 6 H 3 > 20 > 100 7 u, R= 3,4,5-tri-F-C 6 H 2 32 (n = 2) > 100 9 a, R= 4-CF 3 -C 6 H 4 13.7 (n = 3) > 100 9 d, > 100 > 100 9 e, R= C 6 (CH, q, J C\u00c0F = 3.8 Hz, Ar-C3 (5)), 128.4 (CH, Ar-C2 (6)), 131.4 (C, q, J C\u00c0F = 31.9 Hz, Ar-C4), 136.6 (C, Ar-C1), 164.2 (C, ArCO), 170.9 (C, COOH), 173.6 ppm (C, C5-CONH); IR (KBr): \u00f1 = 3400-2850 (max. at 3271, 3188, 3086, 3003, 2971, 2891, 2872), 1715, 1678, 1629, 1500, 1479, 1328, 1307, 1168, 1122, 1065, 851, 702, 689 (10) (5)), 54.3 (CH 2 ) and 54.5 (CH 2 ) (C6 (10) and C9 (11)), 123.7 (C, q, J C\u00c0F = 272.2 Hz, CF 3 ), 125.8 (CH, q, J C\u00c0F = 3.8 Hz, Ar-C3 (5)), 128.6 (CH, Ar-C2 (6)), 132.3 (C, q, J C\u00c0F = 32.2 Hz, Ar-C4), 134.8 (C, Ar-C1), 163.6 (C, Ar-CONH), 173.8 ppm (C, C2 (4)); IR (KBr): \u00f1 = 3283, 2963, 2901, 2868, 1787, 1726, 1694, 1518, 1496, 1482, 1406, 1381, 1325, 1275, 1169, 1130, 1064, 1015, 855, 816 Compounds 3 b-i were prepared in a similar manner to 3 a; full experimental data for these compounds are given in the Supporting Information.Experimental SectionSynthesis of 3 j: A mixture of acetohydrazide (62 mg, 0.84 mmol), anhydride 1 (155 mg, 0.75 mmol), and a drop of diisopropylethylamine in absolute EtOH (2 mL) was heated under reflux for 6 h.", [["EtOH", "CHEMICAL", 65, 69], ["R= 4-pyridyl", "CHEMICAL", 219, 231], ["NO", "CHEMICAL", 438, 440], ["R= 6-Cl-3-pyridyl", "CHEMICAL", 473, 490], ["acetohydrazide", "CHEMICAL", 1699, 1713], ["anhydride 1", "CHEMICAL", 1734, 1745], ["diisopropylethylamine", "CHEMICAL", 1781, 1802], ["EtOH", "CHEMICAL", 1815, 1819], ["reflux", "DISEASE", 1844, 1850], ["EtOH", "CHEMICAL", 65, 69], ["4-pyridyl", "CHEMICAL", 222, 231], ["3,4-di-Cl-C", "CHEMICAL", 252, 263], ["3-Cl-4-Br-C", "CHEMICAL", 295, 306], ["3-Br-4-Cl-C 6 H", "CHEMICAL", 338, 353], ["3-CF 3 -4-Cl-C 6 H", "CHEMICAL", 381, 399], ["3-CH 3 -4-NO 2 -C", "CHEMICAL", 428, 445], ["6-Cl-3-pyridyl", "CHEMICAL", 476, 490], ["3,4-di-F-C 6 H", "CHEMICAL", 516, 530], ["3-CF 3 -C 6 H", "CHEMICAL", 558, 571], ["3,5-di-CF 3 -C", "CHEMICAL", 599, 613], ["3,5-di-Cl-C 6 H", "CHEMICAL", 640, 655], ["3,4,5-tri-F-C 6 H", "CHEMICAL", 677, 694], ["C", "CHEMICAL", 782, 783], ["CH", "CHEMICAL", 787, 789], ["CH", "CHEMICAL", 829, 831], ["ArCO", "CHEMICAL", 911, 915], ["C", "CHEMICAL", 925, 926], ["COOH", "CHEMICAL", 928, 932], ["C, C5-CONH", "CHEMICAL", 946, 956], ["KBr", "CHEMICAL", 963, 966], ["CH", "CHEMICAL", 1219, 1221], ["CH", "CHEMICAL", 1261, 1263], ["C", "CHEMICAL", 1322, 1323], ["C", "CHEMICAL", 1340, 1341], ["Ar-CONH", "CHEMICAL", 1343, 1350], ["C", "CHEMICAL", 1364, 1365], ["KBr", "CHEMICAL", 1380, 1383], ["acetohydrazide", "CHEMICAL", 1699, 1713], ["anhydride 1", "CHEMICAL", 1734, 1745], ["diisopropylethylamine", "CHEMICAL", 1781, 1802], ["EtOH", "CHEMICAL", 1815, 1819], ["EtOH", "SIMPLE_CHEMICAL", 65, 69], ["R= 4-pyridyl", "SIMPLE_CHEMICAL", 219, 231], ["R= 3,4-di-Cl-C 6 H 3", "SIMPLE_CHEMICAL", 249, 269], ["R= 3-Cl-4-Br-C 6 H 3", "SIMPLE_CHEMICAL", 292, 312], ["R= 3-Br-4-Cl-C 6 H 3 0.16 (n = 2", "SIMPLE_CHEMICAL", 335, 367], ["R= 3-CF 3 -4-Cl-C 6 H 3 0.8 (n = 2)", "SIMPLE_CHEMICAL", 378, 413], ["R= 3-CH 3 -4-NO 2 -C 6 H 3 3 (n = 2)", "SIMPLE_CHEMICAL", 425, 461], ["R= 6-Cl-3-pyridyl 48 (n = 2) > 100 7 q, R= 3,4-di-F-C 6 H 3 16 (n = 2)", "SIMPLE_CHEMICAL", 473, 543], ["R= 3-CF 3 -C 6 H 4 16 (n = 2)", "SIMPLE_CHEMICAL", 555, 584], ["R= 3,5-di-CF 3 -C 6 H 3", "SIMPLE_CHEMICAL", 596, 619], ["R= 3,5-di-Cl-C 6 H 3", "SIMPLE_CHEMICAL", 637, 657], ["R= 3,4,5-tri-F-C 6 H 2 32 (n = 2)", "SIMPLE_CHEMICAL", 674, 707], ["R= 4-CF 3 -C 6 H 4", "SIMPLE_CHEMICAL", 719, 737], ["R= C 6", "SIMPLE_CHEMICAL", 779, 785], ["Ar-C3 (5)", "SIMPLE_CHEMICAL", 810, 819], ["136.6 (C, Ar-C1)", "SIMPLE_CHEMICAL", 883, 899], ["164.2 (C, ArCO", "SIMPLE_CHEMICAL", 901, 915], ["170.9 (C, COOH)", "SIMPLE_CHEMICAL", 918, 933], ["C, C5-CONH", "SIMPLE_CHEMICAL", 946, 956], ["acetohydrazide", "SIMPLE_CHEMICAL", 1699, 1713], ["anhydride 1", "SIMPLE_CHEMICAL", 1734, 1745], ["diisopropylethylamine", "SIMPLE_CHEMICAL", 1781, 1802], ["EtOH", "SIMPLE_CHEMICAL", 1815, 1819], ["C2", "TEST", 156, 158], ["C4", "TEST", 166, 168], ["d", "TEST", 193, 194], ["f", "TEST", 216, 217], ["pyridyl", "TEST", 224, 231], ["k", "TEST", 246, 247], ["di", "TEST", 256, 258], ["Cl", "TEST", 259, 261], ["C", "TEST", 262, 263], ["H", "TEST", 266, 267], ["n", "TEST", 276, 277], ["l", "TEST", 289, 290], ["R", "TEST", 292, 293], ["Cl", "TEST", 297, 299], ["Br", "TEST", 302, 304], ["C", "TEST", 305, 306], ["H", "TEST", 309, 310], ["n", "TEST", 319, 320], ["m", "TEST", 332, 333], ["R", "TEST", 335, 336], ["Br", "TEST", 340, 342], ["Cl", "TEST", 345, 347], ["C", "TEST", 348, 349], ["H", "TEST", 352, 353], ["n", "TEST", 362, 363], ["n", "TEST", 375, 376], ["R", "TEST", 378, 379], ["CF", "TEST", 383, 385], ["Cl", "TEST", 391, 393], ["C", "TEST", 394, 395], ["H", "TEST", 398, 399], ["CH", "TEST", 430, 432], ["p", "TEST", 470, 471], ["R", "TEST", 473, 474], ["Cl", "TEST", 478, 480], ["pyridyl", "TEST", 483, 490], ["di", "TEST", 520, 522], ["C", "TEST", 525, 526], ["r", "TEST", 552, 553], ["CF", "TEST", 560, 562], ["C", "TEST", 566, 567], ["H", "TEST", 570, 571], ["s", "TEST", 593, 594], ["R", "TEST", 596, 597], ["di-", "TEST", 603, 606], ["CF", "TEST", 606, 608], ["C", "TEST", 612, 613], ["H", "TEST", 616, 617], ["t", "TEST", 634, 635], ["R", "TEST", 637, 638], ["di", "TEST", 644, 646], ["Cl", "TEST", 647, 649], ["C", "TEST", 650, 651], ["u", "TEST", 671, 672], ["tri", "TEST", 683, 686], ["C", "TEST", 689, 690], ["a", "TEST", 716, 717], ["CF", "TEST", 724, 726], ["C", "TEST", 730, 731], ["H", "TEST", 734, 735], ["n", "TEST", 744, 745], ["d", "TEST", 759, 760], ["C", "TEST", 782, 783], ["CH", "TEST", 787, 789], ["J C\u00c0F", "TEST", 794, 799], ["Hz", "TEST", 806, 808], ["Ar-", "TEST", 810, 813], ["C3", "TEST", 813, 815], ["CH", "TEST", 829, 831], ["Ar-C2", "TEST", 833, 838], ["C", "TEST", 852, 853], ["J C\u00c0F", "TEST", 858, 863], ["Hz", "TEST", 871, 873], ["Ar-", "TEST", 875, 878], ["C4", "TEST", 878, 880], ["C", "TEST", 890, 891], ["Ar-C1", "TEST", 893, 898], ["ArCO", "TEST", 911, 915], ["COOH", "TEST", 928, 932], ["ppm", "TEST", 941, 944], ["C", "TEST", 946, 947], ["C5", "TEST", 949, 951], ["CH", "TEST", 1126, 1128], ["CH", "TEST", 1143, 1145], ["C6", "TEST", 1151, 1153], ["C9", "TEST", 1163, 1165], ["C", "TEST", 1180, 1181], ["C\u00c0F", "TEST", 1188, 1191], ["Hz", "TEST", 1200, 1202], ["CF", "TEST", 1204, 1206], ["CH", "TEST", 1219, 1221], ["J C\u00c0F", "TEST", 1226, 1231], ["Hz", "TEST", 1238, 1240], ["Ar-", "TEST", 1242, 1245], ["C3", "TEST", 1245, 1247], ["CH", "TEST", 1261, 1263], ["Ar-C2", "TEST", 1265, 1270], ["C", "TEST", 1284, 1285], ["J C\u00c0F", "TEST", 1290, 1295], ["Hz", "TEST", 1303, 1305], ["Ar-", "TEST", 1307, 1310], ["C4", "TEST", 1310, 1312], ["C", "TEST", 1322, 1323], ["Ar-C1", "TEST", 1325, 1330], ["C", "TEST", 1340, 1341], ["Ar-CONH", "TEST", 1343, 1350], ["ppm", "TEST", 1359, 1362], ["C2", "TEST", 1367, 1369], ["IR (KBr", "TEST", 1376, 1383], ["these compounds", "TREATMENT", 1592, 1607], ["acetohydrazide", "TREATMENT", 1699, 1713], ["anhydride", "TREATMENT", 1734, 1743], ["a drop of diisopropylethylamine in absolute EtOH", "TREATMENT", 1771, 1819], ["C3", "ANATOMY_MODIFIER", 813, 815], ["C5", "ANATOMY_MODIFIER", 949, 951], ["C6", "ANATOMY", 1151, 1153], ["C3", "ANATOMY_MODIFIER", 1245, 1247], ["C4", "ANATOMY_MODIFIER", 1310, 1312], ["C2", "ANATOMY_MODIFIER", 1367, 1369], ["reflux", "OBSERVATION", 1844, 1850]]], ["Upon cooling to room temperature, H 2 O (0.2 mL) was added.", [["H 2 O", "CHEMICAL", 34, 39], ["H 2 O", "CHEMICAL", 34, 39], ["H 2 O", "SIMPLE_CHEMICAL", 34, 39]]], ["The solution (occasionally a suspension) was stored in the refrigerator overnight, and the precipitate was collected by filtration and washed with cold EtOH (2 2 mL).", [["EtOH", "CHEMICAL", 152, 156], ["EtOH", "CHEMICAL", 152, 156], ["EtOH", "SIMPLE_CHEMICAL", 152, 156], ["The solution", "TREATMENT", 0, 12]]], ["The solid was suspended in xylene (5 mL) and heated under reflux for 24 h in Dean-Stark apparatus.", [["xylene", "CHEMICAL", 27, 33], ["xylene", "CHEMICAL", 27, 33], ["xylene", "SIMPLE_CHEMICAL", 27, 33], ["solid", "OBSERVATION_MODIFIER", 4, 9], ["reflux", "OBSERVATION", 58, 64]]], ["The solution was concentrated in vacuo to give compound", [["The solution", "TREATMENT", 0, 12]]]], "789d8f8e801484da5740462f088a39aaf4e2a411": [["IntroductionElicitation of broadly cross-reactive HIV-1 neutralizing antibodies (bnAbs) in vivo is rare.", [["HIV-1 neutralizing antibodies", "GENE_OR_GENE_PRODUCT", 50, 79], ["bnAbs", "CANCER", 81, 86], ["HIV-1 neutralizing antibodies", "PROTEIN", 50, 79], ["bnAbs", "PROTEIN", 81, 86], ["HIV-1", "SPECIES", 50, 55], ["HIV-1", "SPECIES", 50, 55], ["broadly cross-reactive HIV", "PROBLEM", 27, 53], ["neutralizing antibodies", "TEST", 56, 79], ["broadly", "OBSERVATION_MODIFIER", 27, 34], ["cross-reactive HIV", "OBSERVATION", 35, 53]]], ["It is thought that this is likely due to protection of conserved structures of the virus envelope glycoprotein (Env) by variable loops, extensive glycosylation, occlusion within the oligomer, and conformational masking, and the rapid generation of HIV-1 mutants that outpace the development of such antibodies [2] [3] [4] [5] .", [["Env", "GENE_OR_GENE_PRODUCT", 112, 115], ["HIV-1", "ORGANISM", 248, 253], ["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 310, 325], ["virus envelope glycoprotein", "PROTEIN", 83, 110], ["Env", "PROTEIN", 112, 115], ["variable loops", "PROTEIN", 120, 134], ["HIV-1", "SPECIES", 248, 253], ["the virus envelope glycoprotein (Env)", "TREATMENT", 79, 116], ["variable loops", "PROBLEM", 120, 134], ["extensive glycosylation", "PROBLEM", 136, 159], ["occlusion within the oligomer", "PROBLEM", 161, 190], ["conformational masking", "PROBLEM", 196, 218], ["HIV", "PROBLEM", 248, 251], ["such antibodies", "TEST", 294, 309], ["likely due to", "UNCERTAINTY", 27, 40], ["extensive", "OBSERVATION_MODIFIER", 136, 145], ["glycosylation", "OBSERVATION", 146, 159], ["occlusion", "OBSERVATION", 161, 170]]], ["A number of Env-specific hmAbs have been identified [6] but only several exhibit neutralizing activity to primary isolates from different clades [4, 7] including IgG b12 [8, 9] , IgG 2G12 [10] [11] [12] , m14 [13] , m18 [14] , 447-52D [15] , IgG 2F5 [16] , IgG 4E10 [17, 18] , IgG m46 [19] , IgG m48 [20] , Fab X5 [21] and Fab Z13 [18] .", [["hmAbs", "GENE_OR_GENE_PRODUCT", 25, 30], ["IgG", "GENE_OR_GENE_PRODUCT", 162, 165], ["IgG", "GENE_OR_GENE_PRODUCT", 242, 245], ["IgG", "GENE_OR_GENE_PRODUCT", 257, 260], ["IgG", "GENE_OR_GENE_PRODUCT", 277, 280], ["IgG", "GENE_OR_GENE_PRODUCT", 292, 295], ["Env-specific hmAbs", "PROTEIN", 12, 30], ["IgG b12", "PROTEIN", 162, 169], ["IgG 2F5", "PROTEIN", 242, 249], ["IgG 4E10", "PROTEIN", 257, 265], ["IgG m46", "PROTEIN", 277, 284], ["IgG m48", "PROTEIN", 292, 299], ["Fab X5", "PROTEIN", 307, 313], ["Fab Z13", "PROTEIN", 323, 330], ["Env-specific hmAbs", "PROBLEM", 12, 30], ["primary isolates", "TEST", 106, 122], ["different clades", "TEST", 128, 144], ["IgG b12", "TEST", 162, 169], ["IgG 2G12", "TEST", 179, 187], ["m", "TEST", 205, 206], ["m", "TEST", 216, 217], ["IgG", "TEST", 242, 245], ["IgG", "TEST", 257, 260], ["4E10", "TEST", 261, 265], ["IgG", "TEST", 277, 280], ["m46", "TEST", 281, 284], ["IgG", "TEST", 292, 295], ["m48", "TEST", 296, 299], ["Fab", "TEST", 307, 310], ["Fab Z13", "TEST", 323, 330]]], ["Of those b12, 2G12, 2F5, 4E10 are best characterized and considered to exhibit on average the broadest and most potent neutralizing activity.", [["2G12", "GENE_OR_GENE_PRODUCT", 14, 18], ["2F5", "GENE_OR_GENE_PRODUCT", 20, 23], ["4E10", "GENE_OR_GENE_PRODUCT", 25, 29], ["b12", "PROTEIN", 9, 12], ["2G12", "PROTEIN", 14, 18], ["2F5", "PROTEIN", 20, 23], ["4E10", "PROTEIN", 25, 29], ["2G12, 2F5", "TREATMENT", 14, 23], ["most potent", "OBSERVATION_MODIFIER", 107, 118], ["neutralizing activity", "OBSERVATION", 119, 140]]], ["X5 exhibits comparable or even more potent and broad neutralizing activity which however is dependent on size -the smallest fragment (scFv) is the most potent followed by Fab and IgG [22] .", [["X5", "GENE_OR_GENE_PRODUCT", 0, 2], ["Fab", "GENE_OR_GENE_PRODUCT", 171, 174], ["scFv", "PROTEIN", 134, 138], ["Fab", "PROTEIN", 171, 174], ["IgG [22]", "PROTEIN", 179, 187], ["broad neutralizing activity", "PROBLEM", 47, 74], ["the smallest fragment (scFv", "PROBLEM", 111, 138], ["more potent", "OBSERVATION_MODIFIER", 31, 42], ["broad", "OBSERVATION_MODIFIER", 47, 52], ["neutralizing activity", "OBSERVATION", 53, 74], ["dependent", "OBSERVATION_MODIFIER", 92, 101], ["size", "OBSERVATION_MODIFIER", 105, 109], ["smallest", "OBSERVATION_MODIFIER", 115, 123], ["fragment", "OBSERVATION_MODIFIER", 124, 132]]], ["The full-size X5 antibody in the IgG1 format is significantly less potent although it can still neutralize some isolates.", [["IgG1", "GENE_OR_GENE_PRODUCT", 33, 37], ["full-size X5 antibody", "PROTEIN", 4, 25], ["IgG1", "PROTEIN", 33, 37], ["The full-size X5 antibody in the IgG1 format", "TEST", 0, 44], ["full", "OBSERVATION_MODIFIER", 4, 8], ["size", "OBSERVATION_MODIFIER", 9, 13], ["IgG1", "ANATOMY", 33, 37], ["significantly", "OBSERVATION_MODIFIER", 48, 61], ["less potent", "OBSERVATION_MODIFIER", 62, 73]]], ["The existence of bnAbs such as b12 has fueled the hope that the development of efficacious HIV vaccine is achievable provided that an immunogen containing the epitopes of these antibodies is appropriately designed.", [["bnAbs", "GENE_OR_GENE_PRODUCT", 17, 22], ["b12", "GENE_OR_GENE_PRODUCT", 31, 34], ["HIV", "ORGANISM", 91, 94], ["bnAbs", "PROTEIN", 17, 22], ["b12", "PROTEIN", 31, 34], ["epitopes", "PROTEIN", 159, 167], ["antibodies", "PROTEIN", 177, 187], ["HIV", "SPECIES", 91, 94], ["bnAbs", "TREATMENT", 17, 22], ["b12", "TREATMENT", 31, 34], ["efficacious HIV vaccine", "TREATMENT", 79, 102], ["an immunogen", "TREATMENT", 131, 143], ["these antibodies", "TEST", 171, 187]]], ["However, in spite of the tremendous amount of research, the goal of an antibody-based effective vaccine based on appropriately designed and exposed or empirically found vaccine immunogen has not been achieved [23] .", [["an antibody-based effective vaccine", "TREATMENT", 68, 103], ["vaccine immunogen", "TREATMENT", 169, 186], ["tremendous", "OBSERVATION_MODIFIER", 25, 35], ["amount", "OBSERVATION_MODIFIER", 36, 42]]], ["Our inability to achieve elicitation of such bnAbs in humans and the very low frequency of HIV-infected humans with potent bnAbs strongly suggest that there are still unknown fundamental immunological mechanisms that allow HIV to evade elicitation of bnAbs.", [["HIV-infected", "DISEASE", 91, 103], ["bnAbs", "GENE_OR_GENE_PRODUCT", 45, 50], ["humans", "ORGANISM", 54, 60], ["HIV", "ORGANISM", 91, 94], ["humans", "ORGANISM", 104, 110], ["bnAbs", "GENE_OR_GENE_PRODUCT", 123, 128], ["HIV", "ORGANISM", 223, 226], ["bnAbs", "GENE_OR_GENE_PRODUCT", 251, 256], ["bnAbs", "PROTEIN", 251, 256], ["humans", "SPECIES", 54, 60], ["HIV", "SPECIES", 91, 94], ["humans", "SPECIES", 104, 110], ["humans", "SPECIES", 54, 60], ["HIV", "SPECIES", 91, 94], ["humans", "SPECIES", 104, 110], ["HIV", "SPECIES", 223, 226], ["such bnAbs in humans", "PROBLEM", 40, 60], ["HIV", "PROBLEM", 91, 94], ["infected humans", "PROBLEM", 95, 110], ["potent bnAbs", "PROBLEM", 116, 128], ["HIV", "PROBLEM", 223, 226], ["bnAbs", "PROBLEM", 251, 256], ["very", "OBSERVATION_MODIFIER", 69, 73], ["low frequency", "OBSERVATION_MODIFIER", 74, 87], ["infected", "OBSERVATION", 95, 103]]], ["Understanding these mechanisms could provide novel tools for development of efficacious vaccines.IntroductionWe have previously analyzed the sequences of all known bnAbs and have found that they are highly divergent from germline antibodies [1, 24] .", [["bnAbs", "GENE_OR_GENE_PRODUCT", 164, 169], ["bnAbs", "PROTEIN", 164, 169], ["germline antibodies", "PROTEIN", 221, 240], ["efficacious vaccines", "TREATMENT", 76, 96], ["germline antibodies", "TEST", 221, 240]]], ["B12 is especially highly somatically hypermutated while X5 is relatively less divergent from germline antibodies.", [["B12", "CHEMICAL", 0, 3], ["B12", "CHEMICAL", 0, 3], ["B12", "SIMPLE_CHEMICAL", 0, 3], ["X5", "GENE_OR_GENE_PRODUCT", 56, 58], ["X5", "PROTEIN", 56, 58], ["germline antibodies", "PROTEIN", 93, 112], ["B12", "TEST", 0, 3], ["germline antibodies", "PROBLEM", 93, 112], ["germline antibodies", "OBSERVATION", 93, 112]]], ["We have hypothesized that the relatively high degree of specific somatic hypermutations may preclude binding of the HIV-1 envelope glycoprotein (Env) to closest germline antibodies, and that identifying antibodies that are intermediates in the pathways to maturation could help design novel vaccine immunogens to guide the immune system for their enhanced elicitation.", [["HIV-1", "ORGANISM", 116, 121], ["Env", "GENE_OR_GENE_PRODUCT", 145, 148], ["HIV-1 envelope glycoprotein", "PROTEIN", 116, 143], ["Env", "PROTEIN", 145, 148], ["germline antibodies", "PROTEIN", 161, 180], ["antibodies", "PROTEIN", 203, 213], ["HIV-1", "SPECIES", 116, 121], ["HIV-1", "SPECIES", 116, 121], ["specific somatic hypermutations", "PROBLEM", 56, 87], ["the HIV", "PROBLEM", 112, 119], ["closest germline antibodies", "TEST", 153, 180], ["antibodies", "PROBLEM", 203, 213], ["novel vaccine immunogens", "TREATMENT", 285, 309], ["high degree", "OBSERVATION_MODIFIER", 41, 52], ["somatic hypermutations", "OBSERVATION", 65, 87]]], ["In support of this hypothesis we have previously found that a germline-like b12 (monovalent and bivalent scFv as an Fc fusion protein or IgG) lacks measurable binding to an Env as measured by ELISA with a sensitivity in the \u00b5M range [1] .", [["b12", "GENE_OR_GENE_PRODUCT", 76, 79], ["Fc", "GENE_OR_GENE_PRODUCT", 116, 118], ["IgG", "GENE_OR_GENE_PRODUCT", 137, 140], ["Env", "GENE_OR_GENE_PRODUCT", 173, 176], ["germline", "DNA", 62, 70], ["b12", "PROTEIN", 76, 79], ["monovalent and bivalent scFv", "PROTEIN", 81, 109], ["Fc fusion protein", "PROTEIN", 116, 133], ["IgG", "PROTEIN", 137, 140], ["Env", "PROTEIN", 173, 176], ["a germline-like b12 (monovalent", "PROBLEM", 60, 91], ["bivalent scFv", "PROBLEM", 96, 109], ["an Fc fusion protein", "TEST", 113, 133], ["IgG", "TEST", 137, 140], ["measurable binding", "PROBLEM", 148, 166], ["ELISA", "TEST", 192, 197], ["a sensitivity", "TEST", 203, 216], ["germline", "OBSERVATION", 62, 70]]], ["In contrast, a germline-like scFv X5 bound Env with high (nM) affinity.IntroductionHere we present evidence confirming and expanding these findings for a panel of Envs.", [["Env", "GENE_OR_GENE_PRODUCT", 43, 46], ["Envs", "ORGANISM", 163, 167], ["germline", "DNA", 15, 23], ["scFv X5", "PROTEIN", 29, 36], ["Env", "PROTEIN", 43, 46], ["a germline-like scFv", "PROBLEM", 13, 33], ["high (nM) affinity", "TREATMENT", 52, 70], ["a panel", "TEST", 152, 159], ["germline", "OBSERVATION", 15, 23]]], ["We describe the identification of possible b12 intermediate antibodies that could serve as reagents for the identification of new vaccine immunogens that can help guide the immune system through the b12 maturation pathway.Binding of mature and germline-like scFv X5 to Env -dominant role of the heavy chainWe have previously found that germline-like X5 binds to Env with relatively high strength (low EC50) which is only slightly lower than that for the mature antibody (( Figure 1 ) and [1] ).", [["immune system", "ANATOMY", 173, 186], ["immune system", "ANATOMICAL_SYSTEM", 173, 186], ["b12", "GENE_OR_GENE_PRODUCT", 199, 202], ["scFv X5", "GENE_OR_GENE_PRODUCT", 258, 265], ["Env", "GENE_OR_GENE_PRODUCT", 269, 272], ["germline-like X5", "GENE_OR_GENE_PRODUCT", 336, 352], ["Env", "GENE_OR_GENE_PRODUCT", 362, 365], ["b12 intermediate antibodies", "PROTEIN", 43, 70], ["b12", "PROTEIN", 199, 202], ["germline", "DNA", 244, 252], ["scFv X5", "PROTEIN", 258, 265], ["Env", "PROTEIN", 269, 272], ["heavy chainWe", "PROTEIN", 295, 308], ["germline", "DNA", 336, 344], ["X5", "PROTEIN", 350, 352], ["Env", "PROTEIN", 362, 365], ["mature antibody", "PROTEIN", 454, 469], ["b12 intermediate antibodies", "PROBLEM", 43, 70], ["new vaccine immunogens", "TREATMENT", 126, 148], ["the immune system", "TREATMENT", 169, 186], ["the b12 maturation pathway", "TREATMENT", 195, 221], ["the mature antibody", "TEST", 450, 469], ["germline", "OBSERVATION", 336, 344], ["slightly lower", "OBSERVATION_MODIFIER", 421, 435]]], ["To further characterize this interaction and explore the relative contributions of the heavy and light chains to the interaction we generated, expressed and purified hybrid molecules containing the heavy chain of X5 combined with the light chain of the germline-like X5 (Figure 1c ).", [["X5", "GENE_OR_GENE_PRODUCT", 213, 215], ["heavy and light chains", "PROTEIN", 87, 109], ["purified hybrid molecules", "PROTEIN", 157, 182], ["heavy chain", "PROTEIN", 198, 209], ["X5", "PROTEIN", 213, 215], ["light chain", "PROTEIN", 234, 245], ["germline", "DNA", 253, 261], ["X5", "PROTEIN", 267, 269], ["germline", "OBSERVATION", 253, 261]]], ["The hybrid between the mature X5 heavy chain and its germline-like light chain bound better than did the germline-like X5 but similarly to the mature X5, underlying the dominant role of the heavy chain in determining the binding specificity and affinity (Figure 1d ).", [["X5 heavy chain", "GENE_OR_GENE_PRODUCT", 30, 44], ["X5", "GENE_OR_GENE_PRODUCT", 119, 121], ["X5", "GENE_OR_GENE_PRODUCT", 150, 152], ["mature X5 heavy chain", "PROTEIN", 23, 44], ["germline", "DNA", 53, 61], ["light chain", "PROTEIN", 67, 78], ["germline", "DNA", 105, 113], ["X5", "PROTEIN", 119, 121], ["mature X5", "PROTEIN", 143, 152], ["heavy chain", "PROTEIN", 190, 201], ["light chain bound", "PROBLEM", 67, 84], ["germline", "OBSERVATION", 105, 113], ["dominant", "OBSERVATION", 169, 177]]], ["Since X5 and b12 share the same germline light chain V and J genes, another hybrid between mature X5 heavy chain and mature b12 light chain was generated.", [["X5", "GENE_OR_GENE_PRODUCT", 6, 8], ["b12", "GENE_OR_GENE_PRODUCT", 13, 16], ["germline light chain V", "GENE_OR_GENE_PRODUCT", 32, 54], ["X5 heavy chain", "GENE_OR_GENE_PRODUCT", 98, 112], ["b12 light chain", "GENE_OR_GENE_PRODUCT", 124, 139], ["X5", "PROTEIN", 6, 8], ["b12", "PROTEIN", 13, 16], ["germline light chain V and J genes", "DNA", 32, 66], ["mature X5 heavy chain", "PROTEIN", 91, 112], ["mature b12 light chain", "PROTEIN", 117, 139], ["b12", "TREATMENT", 13, 16], ["b12 light", "OBSERVATION_MODIFIER", 124, 133]]], ["This hybrid bound weaker than the germline X5 ( Figure 1d ).", [["germline X5", "DNA", 34, 45], ["This hybrid bound", "PROBLEM", 0, 17], ["weaker", "OBSERVATION_MODIFIER", 18, 24]]], ["This is unlikely due to improper protein folding since the soluble expression of this particular hybrid is comparable to that of mature, germlinelike, and other hybrids of X5.", [["X5", "GENE_OR_GENE_PRODUCT", 172, 174], ["X5", "PROTEIN", 172, 174], ["improper protein folding", "PROBLEM", 24, 48], ["this particular hybrid", "PROBLEM", 81, 103], ["unlikely due to", "UNCERTAINTY", 8, 23], ["improper", "OBSERVATION", 24, 32], ["protein folding", "OBSERVATION", 33, 48]]], ["In all cases the hybrid molecules bound the Env suggesting that the heavy chain of the mature X5 and likely of the germline-like X5 dominates the interaction ( Figure 1 ).Germline-like X5 neutralized a subset of pseudoviruses neutralized by the mature X5To test the neutralizing activity of germline-like scFv X5 relative to the mature antibody we used a panel of pseudoviruses with Envs from isolates from Clades A, B, and C. The mature X5 neutralized all of them efficiently at the concentration used.", [["Env", "GENE_OR_GENE_PRODUCT", 44, 47], ["X5", "GENE_OR_GENE_PRODUCT", 94, 96], ["pseudoviruses", "CANCER", 212, 225], ["X5To", "GENE_OR_GENE_PRODUCT", 252, 256], ["scFv X5", "GENE_OR_GENE_PRODUCT", 305, 312], ["Envs", "ORGANISM", 383, 387], ["B", "CELL", 417, 418], ["X5", "GENE_OR_GENE_PRODUCT", 438, 440], ["hybrid molecules", "PROTEIN", 17, 33], ["Env", "PROTEIN", 44, 47], ["heavy chain", "PROTEIN", 68, 79], ["mature X5", "PROTEIN", 87, 96], ["germline", "DNA", 115, 123], ["X5", "PROTEIN", 129, 131], ["X5", "DNA", 185, 187], ["germline", "DNA", 291, 299], ["scFv X5", "PROTEIN", 305, 312], ["mature antibody", "PROTEIN", 329, 344], ["pseudoviruses neutralized", "TREATMENT", 212, 237], ["a panel", "TEST", 353, 360], ["pseudoviruses", "PROBLEM", 364, 377], ["Envs", "TREATMENT", 383, 387], ["X5 neutralized", "OBSERVATION_MODIFIER", 185, 199]]], ["The germline-like X5 neutralized all B clade, R5 or dual tropic isolates almost as efficiently as the mature one, but lost completely the neutralizing ability against B clade X4 tropic isolates as well as isolates from other clades ( Figure 2 ).", [["X5", "GENE_OR_GENE_PRODUCT", 18, 20], ["B clade", "ORGANISM", 37, 44], ["R5", "ORGANISM", 46, 48], ["B clade X4 tropic isolates", "ORGANISM", 167, 193], ["germline", "DNA", 4, 12], ["X5", "DNA", 18, 20], ["B clade X4", "SPECIES", 167, 177], ["B clade X4", "SPECIES", 167, 177], ["The germline", "TREATMENT", 0, 12], ["dual tropic isolates", "TREATMENT", 52, 72], ["B clade X4 tropic isolates", "TREATMENT", 167, 193], ["germline", "OBSERVATION", 4, 12]]], ["To confirm this observation, dose response curves were constructed for both mature and germline-like X5 against three representative isolates ( Figure 3 ).", [["germline", "DNA", 87, 95], ["this observation", "TEST", 11, 27], ["dose response curves", "TEST", 29, 49]]], ["While the mature and germline-like X5 exhibited similar IC50s against Bal pseudovirus, there was complete lack of neutralization by the germline-like X5 against IIIB and GXC-44.", [["X5", "GENE_OR_GENE_PRODUCT", 35, 37], ["Bal pseudovirus", "ORGANISM", 70, 85], ["GXC-44", "GENE_OR_GENE_PRODUCT", 170, 176], ["germline", "DNA", 21, 29], ["X5", "DNA", 35, 37], ["germline", "DNA", 136, 144], ["GXC", "PROTEIN", 170, 173], ["Bal pseudovirus", "SPECIES", 70, 85], ["Bal pseudovirus", "TEST", 70, 85], ["GXC", "TEST", 170, 173], ["germline", "OBSERVATION", 21, 29], ["neutralization", "OBSERVATION", 114, 128]]], ["These data, although based on a limited number of isolates tested, indicate a possible mechanism of how X5 could have evolved from a clade and tropism specific neutralizing antibody to a relatively broadly neutralizing antibody by acquiring somatic mutations.", [["X5", "GENE_OR_GENE_PRODUCT", 104, 106], ["X5", "PROTEIN", 104, 106], ["neutralizing antibody", "PROTEIN", 160, 181], ["neutralizing antibody", "PROTEIN", 206, 227], ["These data", "TEST", 0, 10], ["a clade", "PROBLEM", 131, 138], ["tropism specific neutralizing antibody", "PROBLEM", 143, 181], ["a relatively broadly neutralizing antibody", "PROBLEM", 185, 227], ["somatic mutations", "PROBLEM", 241, 258]]], ["However, note that this activity is measured for X5 in a scFv format.", [["X5", "PROTEIN", 49, 51]]], ["As discussed above full-size X5 is less potent than scFv X5 and its maturation pathway in vivo is likely to be complex.", [["scFv X5", "GENE_OR_GENE_PRODUCT", 52, 59], ["scFv X5", "PROTEIN", 52, 59], ["less potent", "OBSERVATION_MODIFIER", 35, 46], ["likely to be", "UNCERTAINTY", 98, 110]]], ["Binding characteristics of the scFv X5 in various forms including mature, germline (in this and subsequent figures the term germline is for convenience the representation of germline-like antibody in this study), and hybrids between various heavy and light chains. a and c.", [["scFv X5", "GENE_OR_GENE_PRODUCT", 31, 38], ["scFv X5", "PROTEIN", 31, 38], ["germline", "DNA", 74, 82], ["germline", "DNA", 124, 132], ["germline", "DNA", 174, 182], ["heavy and light chains", "PROTEIN", 241, 263], ["the scFv", "TREATMENT", 27, 35], ["germline-like antibody", "PROBLEM", 174, 196], ["this study", "TEST", 200, 210], ["light chains", "OBSERVATION_MODIFIER", 251, 263]]], ["Gel analysis of purified mature, germline and hybrid scFv X5.", [["scFv X5", "GENE_OR_GENE_PRODUCT", 53, 60], ["germline", "DNA", 33, 41], ["hybrid scFv X5", "PROTEIN", 46, 60], ["Gel analysis", "TEST", 0, 12], ["germline and hybrid scFv", "TREATMENT", 33, 57], ["hybrid scFv", "OBSERVATION", 46, 57]]], ["In a, M, molecular weight marker, 1 and 2 are mature and germline scFv X5 respectively; In c, M, molecular weight marker, 1 is the hybrid scFv between mature X5 heavy chain and germline X5 light chain, and 2 is the hybrid between matured X5 heavy chain and matured b12 heavy chain.", [["scFv X5", "GENE_OR_GENE_PRODUCT", 66, 73], ["X5 heavy chain", "GENE_OR_GENE_PRODUCT", 158, 172], ["X5 light chain", "GENE_OR_GENE_PRODUCT", 186, 200], ["X5 heavy chain", "GENE_OR_GENE_PRODUCT", 238, 252], ["b12 heavy chain", "GENE_OR_GENE_PRODUCT", 265, 280], ["germline scFv X5", "PROTEIN", 57, 73], ["hybrid scFv", "PROTEIN", 131, 142], ["mature X5 heavy chain", "PROTEIN", 151, 172], ["germline X5 light chain", "PROTEIN", 177, 200], ["X5 heavy chain", "PROTEIN", 238, 252], ["b12 heavy chain", "PROTEIN", 265, 280], ["molecular weight marker", "TEST", 9, 32], ["germline scFv", "OBSERVATION", 57, 70], ["b12 heavy chain", "OBSERVATION_MODIFIER", 265, 280]]], ["In b and d are bindings of purified proteins shown in a and c, respectively to bal gp120-CD4.", [["CD4", "GENE_OR_GENE_PRODUCT", 89, 92], ["purified proteins", "PROTEIN", 27, 44], ["gp120", "PROTEIN", 83, 88], ["CD4", "PROTEIN", 89, 92], ["purified proteins", "PROBLEM", 27, 44]]], ["Abbreviations in this and subsequenct figures are as following: math, matured heavy chain; germl, germline light chain; matl, matured light chain; and germh, germline heavy chain.Lack of measurable binding of germline-like b12 as scFv and as a bivalent Fc fusion protein to a panel of EnvsWe have previously found that germline-like b12 lacks measurable binding to an Env in our ELISA assay [1] .", [["germline light chain", "GENE_OR_GENE_PRODUCT", 98, 118], ["matl", "GENE_OR_GENE_PRODUCT", 120, 124], ["scFv", "GENE_OR_GENE_PRODUCT", 230, 234], ["EnvsWe", "GENE_OR_GENE_PRODUCT", 285, 291], ["Env", "GENE_OR_GENE_PRODUCT", 368, 371], ["matured heavy chain", "PROTEIN", 70, 89], ["germl, germline light chain", "PROTEIN", 91, 118], ["matl", "PROTEIN", 120, 124], ["matured light chain", "PROTEIN", 126, 145], ["germh, germline heavy chain", "PROTEIN", 151, 178], ["germline", "DNA", 209, 217], ["b12", "PROTEIN", 223, 226], ["scFv", "PROTEIN", 230, 234], ["bivalent Fc fusion protein", "PROTEIN", 244, 270], ["EnvsWe", "PROTEIN", 285, 291], ["germline", "DNA", 319, 327], ["b12", "PROTEIN", 333, 336], ["Env", "PROTEIN", 368, 371], ["measurable binding of germline", "PROBLEM", 187, 217], ["b12 as scFv", "PROBLEM", 223, 234], ["a bivalent Fc fusion protein", "TREATMENT", 242, 270], ["a panel", "TEST", 274, 281], ["germline-like b12 lacks measurable binding", "PROBLEM", 319, 361], ["our ELISA assay", "TEST", 375, 390], ["germline", "OBSERVATION", 98, 106], ["light chain", "OBSERVATION_MODIFIER", 107, 118], ["germline", "OBSERVATION", 158, 166], ["heavy chain", "OBSERVATION", 167, 178], ["germline", "OBSERVATION", 209, 217]]], ["Here we confirm and extend this observation to a panel of Envs.", [["Envs", "ORGANISM", 58, 62]]], ["In all cases we found that germline-like b12 in both formats, as a scFv and as a IgG lacks measurable binding to this panel of Envs ( Figure 4 ).", [["IgG", "GENE_OR_GENE_PRODUCT", 81, 84], ["germline", "DNA", 27, 35], ["b12", "PROTEIN", 41, 44], ["scFv", "PROTEIN", 67, 71], ["IgG", "PROTEIN", 81, 84], ["germline-like b12", "PROBLEM", 27, 44], ["a scFv", "PROBLEM", 65, 71], ["a IgG lacks measurable binding", "PROBLEM", 79, 109], ["germline", "OBSERVATION", 27, 35]]], ["In contrast, as expected the mature b12 bound strongly to all tested Envs ( Figure 4 ).Identification of possible intermediates in the maturation pathway of b12We began to identify possible b12 intermediates in its maturation pathway by introducing critical residues found in mature b12 back into the germline framework of b12.", [["b12", "GENE_OR_GENE_PRODUCT", 36, 39], ["b12We", "GENE_OR_GENE_PRODUCT", 157, 162], ["b12", "GENE_OR_GENE_PRODUCT", 190, 193], ["b12", "GENE_OR_GENE_PRODUCT", 323, 326], ["mature b12", "PROTEIN", 29, 39], ["b12We", "PROTEIN", 157, 162], ["b12", "PROTEIN", 190, 193], ["b12", "PROTEIN", 283, 286], ["b12", "PROTEIN", 323, 326], ["the mature b12 bound", "PROBLEM", 25, 45], ["b12 intermediates", "PROBLEM", 190, 207], ["critical residues", "PROBLEM", 249, 266], ["possible", "UNCERTAINTY", 105, 113], ["intermediates", "OBSERVATION_MODIFIER", 114, 127]]], ["We started with H2 for several reasons.", [["H2", "CHEMICAL", 16, 18], ["H2", "CHEMICAL", 16, 18], ["H2", "TREATMENT", 16, 18]]], ["First, the heavy chain is likely the major determinant for binding as indicated by the crystal structure of b12 in complex with gp120.", [["b12", "GENE_OR_GENE_PRODUCT", 108, 111], ["gp120", "GENE_OR_GENE_PRODUCT", 128, 133], ["heavy chain", "PROTEIN", 11, 22], ["b12", "PROTEIN", 108, 111], ["gp120", "PROTEIN", 128, 133]]], ["Secondly, most of the amino acid substitutions in H1 (4 of 5) between germline and mature forms are similar in nature.", [["amino acid", "CHEMICAL", 22, 32], ["amino acid", "CHEMICAL", 22, 32], ["amino acid", "AMINO_ACID", 22, 32], ["H1", "PROTEIN", 50, 52], ["germline", "DNA", 70, 78], ["the amino acid substitutions in H1", "TREATMENT", 18, 52], ["acid substitutions", "OBSERVATION", 28, 46], ["mature", "OBSERVATION_MODIFIER", 83, 89], ["similar", "OBSERVATION_MODIFIER", 100, 107]]], ["In contrast, all three mutations in H2 of the mature b12 resulted in amino acids that are very different from their germline counterparts.", [["amino acids", "CHEMICAL", 69, 80], ["amino acids", "CHEMICAL", 69, 80], ["b12", "GENE_OR_GENE_PRODUCT", 53, 56], ["amino acids", "AMINO_ACID", 69, 80], ["mature b12", "PROTEIN", 46, 56], ["germline counterparts", "CELL_TYPE", 116, 137], ["the mature b12", "TREATMENT", 42, 56], ["amino acids", "TREATMENT", 69, 80], ["amino acids", "OBSERVATION", 69, 80]]], ["A series of mutants were generated surrounding the germline b12 H2 region as described in the Methods.", [["germline b12 H2 region", "DNA", 51, 73], ["A series of mutants", "PROBLEM", 0, 19], ["germline b12", "OBSERVATION", 51, 63]]], ["In order to prevent potential poor expression or folding of certain mutants from distorting the data interpretation, all the mutants investigated were expressed and purified to homogeneity both as scFv and scFv-Fc soluble fusion proteins (Figure 5a ).", [["scFv", "GENE_OR_GENE_PRODUCT", 197, 201], ["scFv-Fc soluble fusion proteins", "GENE_OR_GENE_PRODUCT", 206, 237], ["scFv", "PROTEIN", 197, 201], ["scFv-Fc soluble fusion proteins", "PROTEIN", 206, 237], ["Figure 5a", "PROTEIN", 239, 248], ["folding of certain mutants", "PROBLEM", 49, 75], ["scFv and scFv-Fc soluble fusion proteins", "TREATMENT", 197, 237]]], ["The b12 germline-like antibdy was also expressed in the IgG format (Fig 5a) .", [["b12", "GENE_OR_GENE_PRODUCT", 4, 7], ["IgG", "GENE_OR_GENE_PRODUCT", 56, 59], ["b12 germline", "DNA", 4, 16], ["antibdy", "DNA", 22, 29], ["IgG", "PROTEIN", 56, 59], ["The b12 germline", "TEST", 0, 16], ["b12 germline", "OBSERVATION", 4, 16]]], ["In an initial screening with one single high antibody concentration, we found that a single mutation G53Y was sufficient to confer detectable binding ability to germline b12.", [["germline b12", "DNA", 161, 173], ["an initial screening", "TEST", 3, 23], ["a single mutation G53Y", "PROBLEM", 83, 105]]], ["Additional mutations, such as A52P, increased the binding ability significantly (Figure 5b ).", [["A52P", "DNA", 30, 34], ["Additional mutations", "PROBLEM", 0, 20], ["A52P", "TREATMENT", 30, 34]]], ["The bindings by the selected scFv were analyzed against bal gp120 in an ELISA (left panel).", [["scFv", "GENE_OR_GENE_PRODUCT", 29, 33], ["bal gp120", "GENE_OR_GENE_PRODUCT", 56, 65], ["scFv", "PROTEIN", 29, 33], ["bal gp120", "PROTEIN", 56, 65], ["the selected scFv", "TREATMENT", 16, 33], ["bal gp120", "TEST", 56, 65], ["an ELISA", "TEST", 69, 77], ["left", "ANATOMY_MODIFIER", 79, 83]]], ["Two concentrations including 8 (bar closer to Y-axis) and 2.7 \u00b5M of each scFv were used.", [["scFv", "PROTEIN", 73, 77], ["Two concentrations", "TREATMENT", 0, 18], ["each scFv", "TREATMENT", 68, 77], ["concentrations", "OBSERVATION_MODIFIER", 4, 18]]], ["BSA as an antigen was included as a specificity control (right panel).", [["BSA", "CHEMICAL", 0, 3], ["BSA", "SIMPLE_CHEMICAL", 0, 3], ["BSA", "TEST", 0, 3], ["an antigen", "TEST", 7, 17]]], ["The maximum value of Y-axis, which shows OD 405 from ELISA assay was set at 0.5 to reflect the weak bindings.", [["The maximum value of Y-axis", "TEST", 0, 27], ["ELISA assay", "TEST", 53, 64], ["the weak bindings", "PROBLEM", 91, 108], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["weak bindings", "OBSERVATION", 95, 108]]], ["Bindings of both mature b12 and A52P/G53Y reached saturation at both concentrations and were indicated.", [["b12", "GENE_OR_GENE_PRODUCT", 24, 27], ["A52P", "GENE_OR_GENE_PRODUCT", 32, 36], ["G53Y", "GENE_OR_GENE_PRODUCT", 37, 41], ["b12", "PROTEIN", 24, 27], ["A52P", "PROTEIN", 32, 36], ["G53Y", "PROTEIN", 37, 41]]], ["Determination of the strength of binding by various formats of b12.", [["b12", "GENE_OR_GENE_PRODUCT", 63, 66], ["b12", "PROTEIN", 63, 66], ["b12", "TREATMENT", 63, 66]]], ["ELISAs were performed using bal gp120 as the antigen.", [["bal gp120", "GENE_OR_GENE_PRODUCT", 28, 37], ["bal gp120", "PROTEIN", 28, 37], ["ELISAs", "TEST", 0, 6], ["bal gp120", "TEST", 28, 37]]], ["Various scFv (a) and scFv-Fc (b) b12 as indicated were analyzed for their bindings. c.", [["scFv", "GENE_OR_GENE_PRODUCT", 8, 12], ["scFv-Fc (b) b12", "GENE_OR_GENE_PRODUCT", 21, 36], ["scFv", "PROTEIN", 8, 12], ["scFv-Fc (b) b12", "PROTEIN", 21, 36], ["Various scFv (a) and scFv-Fc (b) b12", "TREATMENT", 0, 36], ["scFv", "OBSERVATION", 8, 12]]], ["Competition ELISA between various scFv b12 and the original scFv-Fc b12.", [["scFv b12", "PROTEIN", 34, 42], ["scFv", "PROTEIN", 60, 64], ["Fc b12", "PROTEIN", 65, 71], ["various scFv b12", "TREATMENT", 26, 42], ["the original scFv", "TREATMENT", 47, 64], ["Fc b12", "TREATMENT", 65, 71]]], ["Fixed amount of various scFv b12 at 20 \u00b5g was premixed with increasing amount of original scFv-Fc b12 in 100 \u00b5l of blocking buffer and applied to ELISA plate coated with bal gp120.", [["scFv b12", "PROTEIN", 24, 32], ["scFv", "PROTEIN", 90, 94], ["Fc b12", "PROTEIN", 95, 101], ["bal gp120", "PROTEIN", 170, 179], ["various scFv b12", "TREATMENT", 16, 32], ["original scFv", "TREATMENT", 81, 94], ["Fc b12", "TREATMENT", 95, 101], ["blocking buffer", "TREATMENT", 115, 130], ["ELISA plate coated", "TREATMENT", 146, 164], ["bal gp120", "TREATMENT", 170, 179], ["amount", "OBSERVATION_MODIFIER", 6, 12], ["various", "OBSERVATION_MODIFIER", 16, 23], ["scFv b12", "OBSERVATION", 24, 32]]], ["The amount of bound scFv was measured using anti-his-HRP. d.", [["scFv", "GENE_OR_GENE_PRODUCT", 20, 24], ["HRP", "GENE_OR_GENE_PRODUCT", 53, 56], ["scFv", "PROTEIN", 20, 24], ["anti-his-HRP", "PROTEIN", 44, 56], ["bound scFv", "PROBLEM", 14, 24], ["anti-his-HRP", "TREATMENT", 44, 56], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["bound scFv", "OBSERVATION", 14, 24]]], ["Specific competition between sCD4 and various forms of b12 in binding to bal gp120.", [["sCD4", "GENE_OR_GENE_PRODUCT", 29, 33], ["b12", "GENE_OR_GENE_PRODUCT", 55, 58], ["bal gp120", "GENE_OR_GENE_PRODUCT", 73, 82], ["sCD4", "PROTEIN", 29, 33], ["b12", "PROTEIN", 55, 58], ["bal gp120", "PROTEIN", 73, 82], ["b12", "TREATMENT", 55, 58], ["bal gp120", "TEST", 73, 82]]], ["Fixed amount of sCD4 at 2 ug was mixed with increasing amount of various b12-Fc fusion protein in 100 \u00b5l of blocking buffer and added to ELISA plate coated with bal gp120.", [["sCD4", "GENE_OR_GENE_PRODUCT", 16, 20], ["b12-Fc", "GENE_OR_GENE_PRODUCT", 73, 79], ["sCD4", "PROTEIN", 16, 20], ["b12", "PROTEIN", 73, 76], ["Fc fusion protein", "PROTEIN", 77, 94], ["bal gp120", "PROTEIN", 161, 170], ["sCD4", "PROBLEM", 16, 20], ["increasing amount of various b12", "PROBLEM", 44, 76], ["Fc fusion protein", "TREATMENT", 77, 94], ["blocking buffer", "TREATMENT", 108, 123], ["ELISA plate coated", "TREATMENT", 137, 155], ["bal gp120", "TREATMENT", 161, 170], ["amount", "OBSERVATION_MODIFIER", 6, 12], ["sCD4", "OBSERVATION", 16, 20], ["increasing", "OBSERVATION_MODIFIER", 44, 54], ["amount", "OBSERVATION_MODIFIER", 55, 61], ["various b12", "OBSERVATION", 65, 76]]], ["The bound sCD4 was detected with anti-his-HRP.Identification of possible intermediates in the maturation pathway of b12To confirm the data obtained in the initial screening with a single high concentration, we performed ELISA using a range of concentrations of various scFv and scFv-Fc b12.", [["sCD4", "GENE_OR_GENE_PRODUCT", 10, 14], ["anti-his-HRP", "GENE_OR_GENE_PRODUCT", 33, 45], ["b12To", "GENE_OR_GENE_PRODUCT", 116, 121], ["scFv", "GENE_OR_GENE_PRODUCT", 269, 273], ["scFv-Fc b12", "GENE_OR_GENE_PRODUCT", 278, 289], ["sCD4", "PROTEIN", 10, 14], ["anti-his-HRP", "PROTEIN", 33, 45], ["b12To", "PROTEIN", 116, 121], ["scFv", "PROTEIN", 269, 273], ["scFv", "PROTEIN", 278, 282], ["Fc b12", "PROTEIN", 283, 289], ["The bound sCD4", "TEST", 0, 14], ["anti-his-HRP", "TREATMENT", 33, 45], ["the initial screening", "TEST", 151, 172], ["ELISA", "TEST", 220, 225], ["various scFv", "TREATMENT", 261, 273], ["scFv-Fc b12", "TREATMENT", 278, 289], ["bound sCD4", "OBSERVATION", 4, 14], ["possible", "UNCERTAINTY", 64, 72], ["intermediates", "OBSERVATION_MODIFIER", 73, 86]]], ["The binding by the germline mutant G53Y was consistently detectable (Figures 6a, b) .", [["germline", "DNA", 19, 27]]], ["Interestingly, a hybrid between mature b12 light chain and germline b12 heavy chain also displayed binding ability albeit weak (Figures 6a,b) .", [["b12 light chain", "GENE_OR_GENE_PRODUCT", 39, 54], ["b12 light chain", "PROTEIN", 39, 54], ["germline b12 heavy chain", "PROTEIN", 59, 83], ["a hybrid between mature b12 light chain", "TREATMENT", 15, 54], ["germline b12 heavy chain", "TEST", 59, 83]]], ["The avidity effect was evident when the bindings by scFv and corresponding scFv-Fc were compared (Figures 6a, b) .", [["scFv", "GENE_OR_GENE_PRODUCT", 52, 56], ["scFv-Fc", "GENE_OR_GENE_PRODUCT", 75, 82], ["scFv", "PROTEIN", 52, 56], ["scFv-Fc", "PROTEIN", 75, 82], ["corresponding scFv-Fc", "TEST", 61, 82], ["avidity effect", "OBSERVATION", 4, 18]]], ["It is noteworthy that germline-like b12 consistently showed no binding even at the highest concentration.", [["germline", "DNA", 22, 30], ["b12", "PROTEIN", 36, 39], ["germline-like b12", "PROBLEM", 22, 39], ["binding", "PROBLEM", 63, 70], ["germline", "OBSERVATION", 22, 30]]], ["The binding characteristics of some of the intermediates are summarized in Table 1 .We added two more layers of specificity control in addition to BSA, which was used as a control antigen in all experiments.", [["BSA", "SIMPLE_CHEMICAL", 147, 150], ["BSA", "TREATMENT", 147, 150]]], ["First, we found that all the weak bindings detected by the b12 intermediates can be completely competed out by the mature b12 (Figure 6c) .", [["b12", "PROTEIN", 59, 62], ["mature b12", "PROTEIN", 115, 125], ["all the weak bindings", "PROBLEM", 21, 42]]], ["Further, all the b12 intermediates competed with sCD4 for binding to gp120, and the competition was proportional to their binding abilities.", [["sCD4", "GENE_OR_GENE_PRODUCT", 49, 53], ["gp120", "GENE_OR_GENE_PRODUCT", 69, 74], ["b12", "PROTEIN", 17, 20], ["sCD4", "PROTEIN", 49, 53], ["gp120", "PROTEIN", 69, 74]]], ["Germline-like b12, on the other hand, did not show any competition with sCD4 ( Figure 6d) .", [["sCD4", "GENE_OR_GENE_PRODUCT", 72, 76], ["b12", "PROTEIN", 14, 17], ["sCD4", "PROTEIN", 72, 76], ["Germline-like b12", "PROBLEM", 0, 17], ["b12", "OBSERVATION", 14, 17]]], ["These results indicate that the two mutations, G53Y and A52P, could play a role in the pathway from germline b12 to mature b12.", [["A52P", "GENE_OR_GENE_PRODUCT", 56, 60], ["b12", "GENE_OR_GENE_PRODUCT", 123, 126], ["germline b12", "DNA", 100, 112], ["mature b12", "PROTEIN", 116, 126], ["germline b12", "TREATMENT", 100, 112]]], ["Summary of the binding characteristics of the mature, germline-like and intermediate scFv and scFv-Fc b12 as determined by ELISA.", [["scFv", "GENE_OR_GENE_PRODUCT", 85, 89], ["scFv-Fc b12", "GENE_OR_GENE_PRODUCT", 94, 105], ["germline", "DNA", 54, 62], ["scFv", "PROTEIN", 85, 89], ["scFv-Fc b12", "PROTEIN", 94, 105], ["scFv-Fc b12", "TREATMENT", 94, 105], ["intermediate scFv", "OBSERVATION", 72, 89]]], ["The antigen is bal gp120.", [["bal gp120", "GENE_OR_GENE_PRODUCT", 15, 24], ["bal gp120", "PROTEIN", 15, 24], ["bal gp120", "OBSERVATION", 15, 24]]], ["Germh/matl, germline heavy chain fused with mature light chain.", [["germline heavy chain", "GENE_OR_GENE_PRODUCT", 12, 32], ["mature light chain", "GENE_OR_GENE_PRODUCT", 44, 62], ["Germh/matl, germline heavy chain", "PROTEIN", 0, 32], ["mature light chain", "PROTEIN", 44, 62], ["Germh", "TEST", 0, 5], ["heavy", "OBSERVATION_MODIFIER", 21, 26], ["chain fused", "OBSERVATION", 27, 38], ["mature", "OBSERVATION_MODIFIER", 44, 50], ["light chain", "OBSERVATION_MODIFIER", 51, 62]]], ["Math/germl, mature heavy chain fused with germline light chain.Inhibition of pseudovirus infection by b12 intermediatesThe neutralizing abilities of mature, germline-like and various intermediate b12s in their scFv-Fc format were tested against a panel of HIV Env pseudotyped viruses.", [["pseudovirus infection", "DISEASE", 77, 98], ["HIV Env pseudotyped viruses", "DISEASE", 256, 283], ["mature heavy chain", "GENE_OR_GENE_PRODUCT", 12, 30], ["germline light chain", "GENE_OR_GENE_PRODUCT", 42, 62], ["pseudovirus", "ORGANISM", 77, 88], ["b12s", "GENE_OR_GENE_PRODUCT", 196, 200], ["scFv-Fc", "GENE_OR_GENE_PRODUCT", 210, 217], ["HIV Env pseudotyped viruses", "ORGANISM", 256, 283], ["Math/germl, mature heavy chain", "PROTEIN", 0, 30], ["germline light chain", "PROTEIN", 42, 62], ["b12", "PROTEIN", 102, 105], ["germline", "DNA", 157, 165], ["b12s", "DNA", 196, 200], ["scFv-Fc", "PROTEIN", 210, 217], ["HIV", "SPECIES", 256, 259], ["HIV Env pseudotyped viruses", "SPECIES", 256, 283], ["germline light chain", "PROBLEM", 42, 62], ["pseudovirus infection", "PROBLEM", 77, 98], ["b12 intermediates", "PROBLEM", 102, 119], ["a panel", "TEST", 245, 252], ["HIV Env pseudotyped viruses", "PROBLEM", 256, 283], ["mature", "OBSERVATION_MODIFIER", 12, 18], ["heavy", "OBSERVATION_MODIFIER", 19, 24], ["light chain", "OBSERVATION_MODIFIER", 51, 62], ["pseudovirus", "OBSERVATION_MODIFIER", 77, 88], ["infection", "OBSERVATION", 89, 98], ["neutralizing", "OBSERVATION_MODIFIER", 123, 135], ["HIV Env", "OBSERVATION", 256, 263], ["pseudotyped viruses", "OBSERVATION", 264, 283]]], ["The mature b12-Fc neutralized efficiently all isolates from clade B except R2, which is a CD4 independent isolate.", [["b12-Fc", "GENE_OR_GENE_PRODUCT", 11, 17], ["CD4", "GENE_OR_GENE_PRODUCT", 90, 93], ["b12", "PROTEIN", 11, 14], ["Fc", "PROTEIN", 15, 17], ["CD4", "PROTEIN", 90, 93], ["The mature b12", "TEST", 0, 14]]], ["The mature b12-Fc also failed to inhibit two isolates from clade A and C including isolates GXC-44 and 92UG037.8.", [["b12-Fc", "GENE_OR_GENE_PRODUCT", 11, 17], ["GXC-44", "CELL", 92, 98], ["92UG037.8", "CELL", 103, 112], ["b12", "PROTEIN", 11, 14], ["Fc", "PROTEIN", 15, 17], ["The mature b12", "TEST", 0, 14], ["isolates GXC", "TEST", 83, 95]]], ["This is in agreement with previous findings that b12 is most efficient against B clade isolates [25] .", [["b12", "GENE_OR_GENE_PRODUCT", 49, 52], ["B", "ORGANISM", 79, 80], ["b12", "PROTEIN", 49, 52], ["b12", "TREATMENT", 49, 52]]], ["None of the b12 intermediates displayed significant neutralizing ability with the exception of the hybrid mature heavy chain/germline light chain (math/germl), which has relatively high binding affinity (34.5 nM) but neutralized IIIB with modest activity at a concentration significantly higher than the concentration needed for 50% binding (Figure 7) .", [["germline light chain", "GENE_OR_GENE_PRODUCT", 125, 145], ["b12", "PROTEIN", 12, 15], ["hybrid mature heavy chain", "PROTEIN", 99, 124], ["germline light chain", "PROTEIN", 125, 145], ["germl", "PROTEIN", 152, 157], ["the b12 intermediates", "TEST", 8, 29], ["significant neutralizing ability", "PROBLEM", 40, 72], ["relatively high binding affinity", "PROBLEM", 170, 202], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["neutralizing", "OBSERVATION", 52, 64]]], ["These results indicate that some potential b12 intermediate antibodies may not exert selection pressure for generation of HIV-1 mutants.Binding of germline-like and intermediate b12 antibodies to human cell linesThe accumulating numbers of somatic mutations during the b12 maturation contributed to the incremental increase in its binding to Envs.", [["cell lines", "ANATOMY", 202, 212], ["HIV-1", "ORGANISM", 122, 127], ["human", "ORGANISM", 196, 201], ["cell lines", "CELL", 202, 212], ["b12", "GENE_OR_GENE_PRODUCT", 269, 272], ["b12 intermediate antibodies", "PROTEIN", 43, 70], ["germline", "DNA", 147, 155], ["b12 antibodies", "PROTEIN", 178, 192], ["human cell lines", "CELL_LINE", 196, 212], ["b12", "PROTEIN", 269, 272], ["HIV-1", "SPECIES", 122, 127], ["human", "SPECIES", 196, 201], ["HIV-1", "SPECIES", 122, 127], ["human", "SPECIES", 196, 201], ["some potential b12 intermediate antibodies", "PROBLEM", 28, 70], ["HIV", "PROBLEM", 122, 125], ["Binding of germline", "TEST", 136, 155], ["intermediate b12 antibodies", "TREATMENT", 165, 192], ["human cell lines", "TREATMENT", 196, 212], ["somatic mutations", "PROBLEM", 240, 257], ["the b12 maturation", "PROBLEM", 265, 283], ["the incremental increase in its binding", "PROBLEM", 299, 338], ["germline", "OBSERVATION", 147, 155], ["cell lines", "OBSERVATION", 202, 212], ["accumulating", "OBSERVATION_MODIFIER", 216, 228], ["numbers", "OBSERVATION_MODIFIER", 229, 236], ["somatic mutations", "OBSERVATION", 240, 257], ["incremental", "OBSERVATION_MODIFIER", 303, 314], ["increase", "OBSERVATION_MODIFIER", 315, 323]]], ["To test how various b12 somatic mutations contribute to self antigen bindings we used three human cells lines in a flow cytometry analysis.", [["cells lines", "ANATOMY", 98, 109], ["b12", "GENE_OR_GENE_PRODUCT", 20, 23], ["human", "ORGANISM", 92, 97], ["cells lines", "CELL", 98, 109], ["b12", "PROTEIN", 20, 23], ["human cells lines", "CELL_LINE", 92, 109], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["various b12 somatic mutations", "PROBLEM", 12, 41], ["self antigen bindings", "PROBLEM", 56, 77], ["three human cells lines", "TREATMENT", 86, 109], ["a flow cytometry analysis", "TEST", 113, 138]]], ["We found that the mature b12 binds strongly to these cells (Figure 8 ) in agreement with previous data from Haynes group [26] .", [["cells", "ANATOMY", 53, 58], ["b12", "GENE_OR_GENE_PRODUCT", 25, 28], ["cells", "CELL", 53, 58], ["mature b12", "PROTEIN", 18, 28], ["the mature b12 binds", "PROBLEM", 14, 34]]], ["The germline-like b12 and intermediate b12 with small number of mutations (A52P/G53Y and A52/P) displayed much lower although measurable activities to these cell lines (Figure 8) .", [["cell lines", "ANATOMY", 157, 167], ["b12", "GENE_OR_GENE_PRODUCT", 18, 21], ["cell lines", "CELL", 157, 167], ["germline", "DNA", 4, 12], ["b12", "PROTEIN", 18, 21], ["intermediate b12", "PROTEIN", 26, 42], ["cell lines", "CELL_LINE", 157, 167], ["The germline", "TEST", 0, 12], ["b12", "TEST", 18, 21], ["intermediate b12", "TEST", 26, 42], ["mutations", "TEST", 64, 73], ["A52P", "TEST", 75, 79], ["germline", "OBSERVATION", 4, 12], ["intermediate b12", "OBSERVATION_MODIFIER", 26, 42], ["small", "OBSERVATION_MODIFIER", 48, 53], ["number", "OBSERVATION_MODIFIER", 54, 60], ["cell lines", "OBSERVATION", 157, 167]]], ["Interestingly, when the intermediates with large number of mutations, such as hybrid math/germl and germh/matl antibodies were tested, they showed significantly higher human cell binding approaching the level displayed by the mature b12.", [["cell", "ANATOMY", 174, 178], ["germl", "GENE_OR_GENE_PRODUCT", 90, 95], ["germh/matl antibodies", "GENE_OR_GENE_PRODUCT", 100, 121], ["human", "ORGANISM", 168, 173], ["cell", "CELL", 174, 178], ["b12", "GENE_OR_GENE_PRODUCT", 233, 236], ["hybrid math/germl and germh/matl antibodies", "PROTEIN", 78, 121], ["mature b12", "PROTEIN", 226, 236], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["mutations", "PROBLEM", 59, 68], ["hybrid math/germl", "TEST", 78, 95], ["germh/matl antibodies", "TEST", 100, 121], ["significantly higher human cell binding", "PROBLEM", 147, 186], ["large", "OBSERVATION_MODIFIER", 43, 48], ["human cell binding", "OBSERVATION", 168, 186], ["mature b12", "OBSERVATION", 226, 236]]], ["These findings indicate that specific binding to Env and self antigens were probably acquired concomitantly through the b12 maturation process.", [["Env", "GENE_OR_GENE_PRODUCT", 49, 52], ["b12", "GENE_OR_GENE_PRODUCT", 120, 123], ["Env", "PROTEIN", 49, 52], ["b12", "PROTEIN", 120, 123], ["specific binding to Env and self antigens", "PROBLEM", 29, 70], ["the b12 maturation process", "PROBLEM", 116, 142], ["b12 maturation", "OBSERVATION", 120, 134]]], ["In progress are experiments to determine the nature of the human molecules recognized by b12.DiscussionExtensive somatic mutations have been found in all identified broadly neutralizing HIV antibodies and in most other HIV specific antibodies.", [["human", "ORGANISM", 59, 64], ["b12", "GENE_OR_GENE_PRODUCT", 89, 92], ["HIV", "ORGANISM", 186, 189], ["HIV", "ORGANISM", 219, 222], ["human molecules", "PROTEIN", 59, 74], ["b12", "PROTEIN", 89, 92], ["HIV antibodies", "PROTEIN", 186, 200], ["HIV specific antibodies", "PROTEIN", 219, 242], ["human", "SPECIES", 59, 64], ["HIV", "SPECIES", 186, 189], ["HIV", "SPECIES", 219, 222], ["human", "SPECIES", 59, 64], ["HIV", "SPECIES", 186, 189], ["HIV", "SPECIES", 219, 222], ["Extensive somatic mutations", "PROBLEM", 103, 130], ["neutralizing HIV antibodies", "PROBLEM", 173, 200]]], ["This is in contrast to some of the potent neutralizing antibodies against acute infections [1, 24, [27] [28] [29] [30] .", [["infections", "DISEASE", 80, 90], ["[27] [28] [29", "SIMPLE_CHEMICAL", 99, 112], ["neutralizing antibodies", "PROTEIN", 42, 65], ["the potent neutralizing antibodies", "TEST", 31, 65], ["acute infections", "PROBLEM", 74, 90]]], ["These antibodies possess few if any mutations compared to their germline sequences.", [["antibodies", "PROTEIN", 6, 16], ["germline sequences", "DNA", 64, 82], ["These antibodies", "TEST", 0, 16], ["any mutations", "PROBLEM", 32, 45], ["their germline sequences", "TEST", 58, 82]]], ["Our knowledge of whether germline-like antibodies, corresponding to the HIV-1-neutralizing antibodies, possess neutralizing activity and how the somatic mutations can contribute to their binding and neutralizing function is limited.", [["HIV-1", "ORGANISM", 72, 77], ["germline", "DNA", 25, 33], ["antibodies", "PROTEIN", 39, 49], ["HIV-1-neutralizing antibodies", "PROTEIN", 72, 101], ["HIV-1", "SPECIES", 72, 77], ["HIV-1", "SPECIES", 72, 77], ["germline-like antibodies", "PROBLEM", 25, 49], ["the HIV", "TEST", 68, 75], ["neutralizing antibodies", "TREATMENT", 78, 101], ["neutralizing activity", "PROBLEM", 111, 132], ["the somatic mutations", "PROBLEM", 141, 162], ["neutralizing activity", "OBSERVATION", 111, 132]]], ["To begin to increase our understanding of these and other properties of the antibody maturation pathways we analyzed the binding and neutralizing abilities of mature and germline forms of two HIV-1 neutralizing antibodies, X5 and b12.DiscussionIgG1 X5 is a modestly neutralzing antibody targeting a highly conserved CD4i epitope.", [["HIV-1", "ORGANISM", 192, 197], ["X5", "GENE_OR_GENE_PRODUCT", 223, 225], ["b12", "GENE_OR_GENE_PRODUCT", 230, 233], ["CD4i", "GENE_OR_GENE_PRODUCT", 316, 320], ["HIV-1 neutralizing antibodies", "PROTEIN", 192, 221], ["X5", "PROTEIN", 223, 225], ["b12", "PROTEIN", 230, 233], ["X5", "PROTEIN", 249, 251], ["neutralzing antibody", "PROTEIN", 266, 286], ["CD4i epitope", "PROTEIN", 316, 328], ["HIV-1", "SPECIES", 192, 197], ["HIV-1", "SPECIES", 192, 197], ["the antibody maturation pathways", "PROBLEM", 72, 104], ["the binding", "PROBLEM", 117, 128], ["two HIV", "TEST", 188, 195], ["neutralizing antibodies", "TEST", 198, 221], ["b12", "TREATMENT", 230, 233], ["a modestly neutralzing antibody", "TREATMENT", 255, 286]]], ["Its corresponding germline antibody in a scFv format displayed high affinity to the Env tested in this study and neutralized efficiently several isolates.", [["Env", "GENE_OR_GENE_PRODUCT", 84, 87], ["germline antibody", "PROTEIN", 18, 35], ["scFv", "PROTEIN", 41, 45], ["Env", "PROTEIN", 84, 87], ["Its corresponding germline antibody", "TEST", 0, 35], ["a scFv format", "TEST", 39, 52], ["high affinity", "PROBLEM", 63, 76], ["this study", "TEST", 98, 108], ["germline antibody", "OBSERVATION", 18, 35]]], ["Intriguingly, all these neutralized isolates belong to B clade and are either R5 tropic or dual tropic.", [["B clade", "CELL", 55, 62], ["dual tropic", "OBSERVATION", 91, 102]]], ["On the other hand, the mature scFv X5 neutralized all isolates tested.", [["scFv X5", "GENE_OR_GENE_PRODUCT", 30, 37], ["mature scFv X5", "PROTEIN", 23, 37], ["the mature scFv", "TREATMENT", 19, 34], ["mature", "OBSERVATION_MODIFIER", 23, 29], ["scFv", "OBSERVATION", 30, 34]]], ["These isolates are from A, B and C clades.", [["B", "CELL", 27, 28], ["C", "GENE_OR_GENE_PRODUCT", 33, 34], ["A, B and C clades", "TREATMENT", 24, 41]]], ["These data suggest first that germline antibodies against certain epitopes on the HIV-1 Env, similarly to antibodies against other acute infections, do possess neutralizing ability.", [["acute infections", "DISEASE", 131, 147], ["HIV-1 Env", "ORGANISM", 82, 91], ["germline antibodies", "PROTEIN", 30, 49], ["epitopes", "PROTEIN", 66, 74], ["HIV-1 Env", "PROTEIN", 82, 91], ["antibodies", "PROTEIN", 106, 116], ["HIV-1", "SPECIES", 82, 87], ["HIV-1", "SPECIES", 82, 87], ["These data", "TEST", 0, 10], ["germline antibodies", "PROBLEM", 30, 49], ["certain epitopes", "PROBLEM", 58, 74], ["the HIV", "PROBLEM", 78, 85], ["other acute infections", "PROBLEM", 125, 147], ["acute", "OBSERVATION_MODIFIER", 131, 136], ["infections", "OBSERVATION", 137, 147]]], ["Secondly, the mutational process shifted or expanded the antibody binding epitope so that it became more inclusive leading to a more broadly neutralizing antibody.", [["antibody binding epitope", "PROTEIN", 57, 81], ["neutralizing antibody", "PROTEIN", 141, 162], ["the mutational process", "PROBLEM", 10, 32], ["the antibody binding epitope", "PROBLEM", 53, 81], ["a more broadly neutralizing antibody", "PROBLEM", 126, 162], ["neutralizing antibody", "OBSERVATION", 141, 162]]], ["This notion is supported by a previous observation that a synthetic HIV-1 inhibitor based on CH2, m1a1, has an epitope that partially overlaps with that of germline X5 as revealed by competition ELISA [1] .", [["HIV-1", "ORGANISM", 68, 73], ["m1a1", "GENE_OR_GENE_PRODUCT", 98, 102], ["germline X5", "GENE_OR_GENE_PRODUCT", 156, 167], ["CH2", "PROTEIN", 93, 96], ["m1a1", "PROTEIN", 98, 102], ["germline X5", "DNA", 156, 167], ["HIV-1", "SPECIES", 68, 73], ["a synthetic HIV", "TREATMENT", 56, 71]]], ["M1a1 has a tendency to neutralize only B clades, X4 tropic viruses in contrast to germlinelike X5.", [["M1a1", "CHEMICAL", 0, 4], ["M1a1", "GENE_OR_GENE_PRODUCT", 0, 4], ["B", "GENE_OR_GENE_PRODUCT", 39, 40], ["X4 tropic viruses", "ORGANISM", 49, 66], ["germlinelike X5", "GENE_OR_GENE_PRODUCT", 82, 97], ["M1a1", "PROTEIN", 0, 4], ["germlinelike X5", "PROTEIN", 82, 97], ["a tendency to neutralize", "PROBLEM", 9, 33]]], ["The epitope of m1a1 overlaps significantly more with that of the mature X5 than with germline X5 as also revealed by competition ELISA [31] .DiscussionBased on these data, one can speculate that X5 originated from a germline antibody recognizing a B clade, R5 tropic isolate.", [["m1a1", "GENE_OR_GENE_PRODUCT", 15, 19], ["X5", "GENE_OR_GENE_PRODUCT", 72, 74], ["germline X5", "GENE_OR_GENE_PRODUCT", 85, 96], ["X5", "GENE_OR_GENE_PRODUCT", 195, 197], ["B", "GENE_OR_GENE_PRODUCT", 248, 249], ["m1a1", "PROTEIN", 15, 19], ["mature X5", "PROTEIN", 65, 74], ["germline X5", "DNA", 85, 96], ["X5", "PROTEIN", 195, 197], ["germline antibody", "PROTEIN", 216, 233], ["these data", "TEST", 160, 170], ["a germline antibody", "TEST", 214, 233], ["a B clade", "TREATMENT", 246, 255], ["R5 tropic isolate", "TREATMENT", 257, 274], ["mature", "OBSERVATION", 65, 71]]], ["The subsequent mutations expanded its targets to include B clade, X4 tropic isolates and those from other clades.", [["B", "GENE_OR_GENE_PRODUCT", 57, 58], ["The subsequent mutations", "PROBLEM", 0, 24], ["B clade", "TREATMENT", 57, 64], ["X4 tropic isolates", "TREATMENT", 66, 84]]], ["X5 seems to follow a typical antibody maturation pathway, and this might explain partially the predominant presence of CD4i antibodies in HIV patients due to the fact that this epitope appears to be readily available for germline antibody recognition.", [["X5", "GENE_OR_GENE_PRODUCT", 0, 2], ["CD4i", "GENE_OR_GENE_PRODUCT", 119, 123], ["HIV", "ORGANISM", 138, 141], ["patients", "ORGANISM", 142, 150], ["X5", "PROTEIN", 0, 2], ["CD4i antibodies", "PROTEIN", 119, 134], ["germline antibody", "PROTEIN", 221, 238], ["HIV", "SPECIES", 138, 141], ["patients", "SPECIES", 142, 150], ["HIV", "SPECIES", 138, 141], ["CD4i antibodies", "PROBLEM", 119, 134], ["this epitope", "PROBLEM", 172, 184], ["germline antibody recognition", "PROBLEM", 221, 250]]], ["It remains to be seen if germline counterparts of other CD4i antibodies possess antigen binding and neutralizing abilities as observed with X5.", [["CD4i antibodies", "GENE_OR_GENE_PRODUCT", 56, 71], ["antigen", "GENE_OR_GENE_PRODUCT", 80, 87], ["CD4i antibodies", "PROTEIN", 56, 71], ["X5", "PROTEIN", 140, 142], ["other CD4i antibodies", "TEST", 50, 71], ["antigen binding", "PROBLEM", 80, 95]]], ["In contrast to X5 b12 appears to follow a different pathway.", [["X5 b12", "GENE_OR_GENE_PRODUCT", 15, 21], ["X5 b12", "PROTEIN", 15, 21], ["b12", "TREATMENT", 18, 21]]], ["The germline b12 lacks observable binding to a panel of Envs confirming and expanding our original observation for lack of measurable binding of germline-like b12 to one Env [1] .", [["germline b12", "DNA", 4, 16], ["germline", "DNA", 145, 153], ["b12", "PROTEIN", 159, 162], ["The germline b12", "TEST", 0, 16], ["measurable binding of germline", "PROBLEM", 123, 153]]], ["By systematic mutation of amino acid residues in the mature b12 into the corresponding locations on germline b12, we identified several possible intermediates at different stages along the maturation pathway of b12.", [["amino acid", "CHEMICAL", 26, 36], ["amino acid", "CHEMICAL", 26, 36], ["amino acid", "AMINO_ACID", 26, 36], ["b12", "GENE_OR_GENE_PRODUCT", 60, 63], ["b12", "GENE_OR_GENE_PRODUCT", 211, 214], ["mature b12", "PROTEIN", 53, 63], ["germline b12", "DNA", 100, 112], ["b12", "PROTEIN", 211, 214], ["amino acid residues", "PROBLEM", 26, 45], ["germline b12", "TEST", 100, 112], ["b12", "TREATMENT", 211, 214]]], ["Importantly, the increase in binding against the Env associated with the increasing number of somatic mutations in these intermediates seems to be closely related to their increase in binding to human antigens.", [["Env", "GENE_OR_GENE_PRODUCT", 49, 52], ["human", "ORGANISM", 195, 200], ["Env", "PROTEIN", 49, 52], ["human antigens", "PROTEIN", 195, 209], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 195, 200], ["the increase in binding", "PROBLEM", 13, 36], ["somatic mutations", "PROBLEM", 94, 111], ["increase", "OBSERVATION_MODIFIER", 17, 25], ["increasing", "OBSERVATION_MODIFIER", 73, 83], ["somatic mutations", "OBSERVATION", 94, 111]]], ["This revealed a potentially interesting interplay between the Env and human self antigens in the origination and maturation of b12.", [["Env", "GENE_OR_GENE_PRODUCT", 62, 65], ["human", "ORGANISM", 70, 75], ["b12", "GENE_OR_GENE_PRODUCT", 127, 130], ["Env and human self antigens", "PROTEIN", 62, 89], ["b12", "PROTEIN", 127, 130], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["b12", "TREATMENT", 127, 130], ["Env", "OBSERVATION", 62, 65]]], ["As was proposed in our previous study based on the lack of binding of germline b12 to HIV Envs, one or more alternative antigens, self-antigens included, were likely responsible for the initial activation of the B cells expressing b12 germline-like antibodies.", [["B cells", "ANATOMY", 212, 219], ["b12", "GENE_OR_GENE_PRODUCT", 79, 82], ["HIV Envs", "ORGANISM", 86, 94], ["B cells", "CELL", 212, 219], ["b12", "GENE_OR_GENE_PRODUCT", 231, 234], ["germline b12", "PROTEIN", 70, 82], ["self-antigens", "PROTEIN", 130, 143], ["B cells", "CELL_TYPE", 212, 219], ["b12 germline-like antibodies", "PROTEIN", 231, 259], ["HIV", "SPECIES", 86, 89], ["HIV", "SPECIES", 86, 89], ["our previous study", "TEST", 19, 37], ["germline b12", "PROBLEM", 70, 82], ["HIV Envs", "PROBLEM", 86, 94], ["the B cells", "TEST", 208, 219], ["b12 germline-like antibodies", "PROBLEM", 231, 259], ["likely responsible for", "UNCERTAINTY", 159, 181], ["b12 germline", "OBSERVATION", 231, 243]]], ["The somatic mutations ensued after the activation may have enabled b12 intermediate(s) to bind to other antigens including Envs.", [["Envs", "GENE_OR_GENE_PRODUCT", 123, 127], ["b12", "PROTEIN", 67, 70], ["antigens", "PROTEIN", 104, 112], ["Envs", "PROTEIN", 123, 127], ["The somatic mutations", "PROBLEM", 0, 21], ["somatic mutations", "OBSERVATION", 4, 21]]], ["The fact that a single mutation, G53Y, conferred detectable germline-like b12 binding to Env as found in this study indicates that this scenario is possible.", [["b12", "GENE_OR_GENE_PRODUCT", 74, 77], ["Env", "GENE_OR_GENE_PRODUCT", 89, 92], ["germline", "DNA", 60, 68], ["b12", "PROTEIN", 74, 77], ["Env", "PROTEIN", 89, 92], ["a single mutation", "PROBLEM", 14, 31], ["b12 binding", "PROBLEM", 74, 85], ["this study", "TEST", 105, 115]]], ["Note however, similar to X5 b12 was selected through phage display procedure.", [["X5 b12", "GENE_OR_GENE_PRODUCT", 25, 31], ["X5 b12", "PROTEIN", 25, 31], ["b12", "TREATMENT", 28, 31], ["procedure", "TREATMENT", 67, 76]]], ["Therefore the relevance of b12 as well as the intermediate binders identified in this study to in vivo situation remains hypothetical.", [["b12", "GENE_OR_GENE_PRODUCT", 27, 30], ["b12", "PROTEIN", 27, 30], ["b12", "TREATMENT", 27, 30], ["the intermediate binders", "TREATMENT", 42, 66], ["this study", "TEST", 81, 91]]], ["These intermediate antibodies are currently used as reagents to identify molecules that could serve as primary immunogens for initiation of the maturation of b12 or b12-like antibodies.", [["b12", "GENE_OR_GENE_PRODUCT", 158, 161], ["b12", "GENE_OR_GENE_PRODUCT", 165, 168], ["intermediate antibodies", "PROTEIN", 6, 29], ["b12", "PROTEIN", 158, 161], ["b12", "PROTEIN", 165, 168], ["These intermediate antibodies", "TREATMENT", 0, 29], ["primary immunogens", "TREATMENT", 103, 121], ["the maturation", "TEST", 140, 154], ["b12", "TEST", 158, 161], ["b12-like antibodies", "PROBLEM", 165, 184]]], ["The primary immunogens to be found could be used in combination with appropriately designed Envs exposing the b12 epitopes and lacking other immunodominant epitopes.", [["Envs", "ORGANISM", 92, 96], ["b12 epitopes", "PROTEIN", 110, 122], ["immunodominant epitopes", "PROTEIN", 141, 164], ["The primary immunogens", "TREATMENT", 0, 22], ["the b12 epitopes", "TREATMENT", 106, 122], ["lacking other immunodominant epitopes", "PROBLEM", 127, 164]]], ["This conceptually new two (or more) immunogen approach for guiding the immune system through the complex maturation pathways of known antibodies with high activity is more general and could be used to help design of vaccine immunogens also for other diseases including cancer.Primers, peptide and proteinsAll the primers used in this study were purchased from Invitrogen (Carlsbad, CA).", [["immune system", "ANATOMY", 71, 84], ["cancer", "ANATOMY", 269, 275], ["cancer", "DISEASE", 269, 275], ["cancer", "CANCER", 269, 275], ["Carlsbad, CA", "ORGANISM", 372, 384], ["antibodies", "PROTEIN", 134, 144], ["immunogen approach", "TREATMENT", 36, 54], ["the immune system", "TREATMENT", 67, 84], ["known antibodies", "PROBLEM", 128, 144], ["vaccine immunogens", "TREATMENT", 216, 234], ["other diseases", "PROBLEM", 244, 258], ["cancer", "PROBLEM", 269, 275], ["the primers", "TREATMENT", 309, 320], ["this study", "TEST", 329, 339], ["new", "OBSERVATION_MODIFIER", 18, 21], ["cancer", "OBSERVATION", 269, 275]]], ["Bal gp120-CD4 was provided by Tim Fouts (University of Maryland, Baltimore, MD) and other recombinant proteins (gp120s and gp140s) were provided by Christopher Broder (USUHS, Bethesda, MD).", [["CD4", "GENE_OR_GENE_PRODUCT", 10, 13], ["gp120s", "GENE_OR_GENE_PRODUCT", 112, 118], ["gp140s", "GENE_OR_GENE_PRODUCT", 123, 129], ["gp120", "PROTEIN", 4, 9], ["CD4", "PROTEIN", 10, 13], ["recombinant proteins", "PROTEIN", 90, 110], ["gp120s", "PROTEIN", 112, 118], ["gp140s", "PROTEIN", 123, 129], ["Bal gp120", "TEST", 0, 9]]], ["Codonoptimized sCD4 D1-2 was cloned into the expression vector pSecTag2B (Invitrogen) attaching a His tag to the C terminus of the sCD4 D1-2, transfected into 293 freestyle cells and expressed according to the manufacturer's suggested protocol.", [["293 freestyle cells", "ANATOMY", 159, 178], ["His", "CHEMICAL", 98, 101], ["sCD4 D1-2", "GENE_OR_GENE_PRODUCT", 15, 24], ["pSecTag2B", "GENE_OR_GENE_PRODUCT", 63, 72], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 74, 84], ["sCD4 D1-2", "GENE_OR_GENE_PRODUCT", 131, 140], ["293 freestyle cells", "CELL", 159, 178], ["sCD4 D1-2", "DNA", 15, 24], ["pSecTag2B", "PROTEIN", 63, 72], ["His tag", "DNA", 98, 105], ["C terminus", "PROTEIN", 113, 123], ["sCD4 D1-2", "PROTEIN", 131, 140], ["293 freestyle cells", "CELL_LINE", 159, 178], ["Codonoptimized sCD4 D1", "TREATMENT", 0, 22], ["a His tag", "TREATMENT", 96, 105], ["sCD4", "ANATOMY", 131, 135]]], ["The secreted sCD4 D1-2 was purified using a Nickle column from the culture medium (Qiagen, Hilden, Germany).Gene synthesis and expression plasmid constructionsScFv DNAs corresponding to mature and germline-like X5 and b12 were synthesized by Genescript (Genescript, Piscatawy, NJ).", [["sCD4 D1-2", "GENE_OR_GENE_PRODUCT", 13, 22], ["ScFv", "GENE_OR_GENE_PRODUCT", 159, 163], ["X5", "GENE_OR_GENE_PRODUCT", 211, 213], ["b12", "GENE_OR_GENE_PRODUCT", 218, 221], ["sCD4 D1-2", "PROTEIN", 13, 22], ["ScFv DNAs", "DNA", 159, 168], ["germline", "DNA", 197, 205], ["X5", "DNA", 211, 213], ["b12", "DNA", 218, 221], ["The secreted sCD4 D1", "TEST", 0, 20], ["a Nickle column", "TREATMENT", 42, 57], ["Gene synthesis", "TREATMENT", 108, 122], ["expression plasmid constructionsScFv DNAs", "TREATMENT", 127, 168], ["germline", "TEST", 197, 205], ["b12", "TREATMENT", 218, 221], ["secreted", "OBSERVATION_MODIFIER", 4, 12], ["sCD4", "OBSERVATION", 13, 17]]], ["The Vh of each of the antibodies was linked to the Vl via a (GGGGS) 3 linker.", [["Vh", "PROTEIN", 4, 6], ["antibodies", "PROTEIN", 22, 32], ["Vl", "DNA", 51, 53]]], ["The scFv fragment was cloned into the pComb3X plasmid (provided by Dennis Burton, Scripps Institute, La Jolla, Cal) for expression in bacteria.", [["plasmid", "ANATOMY", 46, 53], ["scFv fragment", "DNA", 4, 17], ["pComb3X plasmid", "DNA", 38, 53], ["The scFv fragment", "PROBLEM", 0, 17], ["the pComb3X plasmid", "TREATMENT", 34, 53], ["expression in bacteria", "PROBLEM", 120, 142], ["scFv fragment", "OBSERVATION", 4, 17], ["bacteria", "OBSERVATION", 134, 142]]], ["The DNA fragments encoding various b12 scFv antibodies were fused with Fc of human IgG1 and cloned into the mammalian cell expression vector pSecTag2B (Invitrogen) for expression of the scFv-Fc fusion proteins.", [["cell", "ANATOMY", 118, 122], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["human", "ORGANISM", 77, 82], ["IgG1", "GENE_OR_GENE_PRODUCT", 83, 87], ["mammalian cell", "CELL", 108, 122], ["pSecTag2B", "GENE_OR_GENE_PRODUCT", 141, 150], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 152, 162], ["scFv-Fc", "GENE_OR_GENE_PRODUCT", 186, 193], ["DNA fragments", "DNA", 4, 17], ["b12 scFv antibodies", "PROTEIN", 35, 54], ["Fc", "PROTEIN", 71, 73], ["human IgG1", "PROTEIN", 77, 87], ["pSecTag2B", "PROTEIN", 141, 150], ["scFv-Fc fusion proteins", "PROTEIN", 186, 209], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["The DNA fragments", "PROBLEM", 0, 17], ["various b12 scFv antibodies", "TEST", 27, 54], ["Fc of human IgG1", "TREATMENT", 71, 87], ["the scFv-Fc fusion proteins", "TREATMENT", 182, 209], ["fragments", "OBSERVATION_MODIFIER", 8, 17], ["mammalian cell", "OBSERVATION", 108, 122]]], ["The Vh and Vl of the germline b12 were further grafted to the pDR12 vector (provided by Dennis Burton) for conversion to IgG1 format.Identification of intermediate affinity b12 bindersThe degenerate primer B12H2 primer 5' atg gga tgg atc aac Sct KRc aat ggt aac aMa aaa tat TCA CAG 3' was used in an overlapping PCR to replace the residues at positions 52, 53, and 57 of the germline b12 H2 with corresponding residues from the b12 mature form.", [["Vl", "GENE_OR_GENE_PRODUCT", 11, 13], ["b12", "GENE_OR_GENE_PRODUCT", 30, 33], ["IgG1", "GENE_OR_GENE_PRODUCT", 121, 125], ["b12 H2", "GENE_OR_GENE_PRODUCT", 384, 390], ["Vh and Vl", "DNA", 4, 13], ["germline b12", "DNA", 21, 33], ["pDR12 vector", "DNA", 62, 74], ["IgG1", "PROTEIN", 121, 125], ["intermediate affinity b12 binders", "PROTEIN", 151, 184], ["degenerate primer B12H2 primer 5' atg gga tgg atc aac Sct KRc aat ggt aac aMa aaa tat TCA CAG 3'", "DNA", 188, 284], ["positions 52, 53, and 57", "DNA", 343, 367], ["germline b12 H2", "DNA", 375, 390], ["b12 mature form", "PROTEIN", 428, 443], ["the germline b12", "TEST", 17, 33], ["intermediate affinity b12 binders", "TREATMENT", 151, 184], ["The degenerate primer B12H2 primer", "TREATMENT", 184, 218], ["atg gga", "TREATMENT", 222, 229], ["tgg", "TEST", 230, 233], ["aac", "TEST", 238, 241], ["Sct", "TEST", 242, 245], ["KRc", "TEST", 246, 249], ["aat ggt aac", "TREATMENT", 250, 261], ["aaa tat TCA CAG", "TREATMENT", 266, 281], ["an overlapping PCR", "TREATMENT", 297, 315], ["the germline b12 H2", "TREATMENT", 371, 390], ["germline b12", "OBSERVATION", 21, 33], ["b12 mature", "OBSERVATION", 428, 438]]], ["A collection of germline b12 variants containing one, two or three residues from mature b12 form were generated through this process.Antibody expression and purificationFor scFv expression, E. coli strain HB2151 was transformed by the X5 and b12 scFv constructs described above.", [["b12", "GENE_OR_GENE_PRODUCT", 25, 28], ["b12", "GENE_OR_GENE_PRODUCT", 88, 91], ["scFv", "GENE_OR_GENE_PRODUCT", 173, 177], ["E. coli", "ORGANISM", 190, 197], ["strain HB2151", "ORGANISM", 198, 211], ["germline b12 variants", "DNA", 16, 37], ["mature b12 form", "PROTEIN", 81, 96], ["scFv", "PROTEIN", 173, 177], ["X5 and b12 scFv constructs", "DNA", 235, 261], ["E. coli", "SPECIES", 190, 197], ["E. coli", "SPECIES", 190, 197], ["HB2151", "SPECIES", 205, 211], ["germline b12 variants", "PROBLEM", 16, 37], ["Antibody expression", "TEST", 133, 152], ["purification", "TEST", 157, 169], ["scFv expression", "PROBLEM", 173, 188], ["E. coli strain", "PROBLEM", 190, 204], ["b12 scFv constructs", "TREATMENT", 242, 261], ["germline b12 variants", "OBSERVATION", 16, 37], ["mature b12", "OBSERVATION", 81, 91]]], ["Single clone was inoculated into 2YT supplemented with 100 units of ampicillin, 0.2 % glucose and incubated at 37\u00b0C with shaking.", [["clone", "ANATOMY", 7, 12], ["2YT", "CHEMICAL", 33, 36], ["ampicillin", "CHEMICAL", 68, 78], ["glucose", "CHEMICAL", 86, 93], ["ampicillin", "CHEMICAL", 68, 78], ["glucose", "CHEMICAL", 86, 93], ["clone", "CELL", 7, 12], ["ampicillin", "SIMPLE_CHEMICAL", 68, 78], ["glucose", "SIMPLE_CHEMICAL", 86, 93], ["Single clone", "TREATMENT", 0, 12], ["ampicillin", "TREATMENT", 68, 78], ["shaking", "PROBLEM", 121, 128]]], ["When the OD600 reached 0.9, IPTG was added to achieve a final concentration of 1 mM and the culture was continued with shaking for overnight at 30\u00b0C. Cells were then collected, lysed with polymyxin B (Sigma, St Louis) in PBS, and the supernatant was subjected to the Ni-NTA agarose bead (Qiagen) purification for the soluble scFvs.", [["Cells", "ANATOMY", 150, 155], ["supernatant", "ANATOMY", 234, 245], ["IPTG", "CHEMICAL", 28, 32], ["polymyxin B", "CHEMICAL", 188, 199], ["Ni-NTA", "CHEMICAL", 267, 273], ["IPTG", "CHEMICAL", 28, 32], ["polymyxin B", "CHEMICAL", 188, 199], ["Ni-NTA", "CHEMICAL", 267, 273], ["IPTG", "SIMPLE_CHEMICAL", 28, 32], ["Cells", "CELL", 150, 155], ["polymyxin B", "SIMPLE_CHEMICAL", 188, 199], ["Sigma", "SIMPLE_CHEMICAL", 201, 206], ["St Louis", "ORGANISM", 208, 216], ["scFvs", "GENE_OR_GENE_PRODUCT", 325, 330], ["soluble scFvs", "PROTEIN", 317, 330], ["IPTG", "TREATMENT", 28, 32], ["the culture", "TEST", 88, 99], ["shaking", "PROBLEM", 119, 126], ["Cells", "TEST", 150, 155], ["polymyxin B", "TREATMENT", 188, 199], ["the Ni-NTA agarose bead", "TREATMENT", 263, 286], ["Qiagen) purification", "TREATMENT", 288, 308], ["the soluble scFvs", "TREATMENT", 313, 330]]], ["The various b12 scFv-Fc constructs as well as the germline b12 IgG construct were transfected into the 293 freestyle cells with polyfectin transfection agent (Invitrogen).", [["293 freestyle cells", "ANATOMY", 103, 122], ["polyfectin", "CHEMICAL", 128, 138], ["293 freestyle cells", "CELL", 103, 122], ["polyfectin", "SIMPLE_CHEMICAL", 128, 138], ["b12 scFv-Fc constructs", "DNA", 12, 34], ["germline b12 IgG construct", "DNA", 50, 76], ["293 freestyle cells", "CELL_LINE", 103, 122], ["The various b12 scFv-Fc constructs", "TREATMENT", 0, 34], ["the germline b12 IgG construct", "TEST", 46, 76], ["polyfectin transfection agent", "TREATMENT", 128, 157], ["b12 scFv", "OBSERVATION", 12, 20]]], ["Four days after transfection, the culture medium was collected and the secreted scFv-Fc and IgG proteins were purified using a protein-A sepharose column (GE Healthcare, Piscataway, NJ).ELISADifferent protein antigens were diluted in the PBS buffer in concentrations ranging from 1-4 \u00b5g/mL and coated to the 96 well plate at 4\u00b0C for overnight.", [["scFv-Fc", "GENE_OR_GENE_PRODUCT", 80, 87], ["IgG", "GENE_OR_GENE_PRODUCT", 92, 95], ["scFv-Fc", "PROTEIN", 80, 87], ["IgG proteins", "PROTEIN", 92, 104], ["ELISADifferent protein antigens", "PROTEIN", 186, 217], ["transfection", "TREATMENT", 16, 28], ["the culture medium", "TEST", 30, 48], ["the secreted scFv-Fc", "TEST", 67, 87], ["IgG proteins", "TEST", 92, 104], ["a protein", "TEST", 125, 134], ["A sepharose column", "TREATMENT", 135, 153], ["ELISADifferent protein antigens", "TREATMENT", 186, 217], ["the PBS buffer", "TREATMENT", 234, 248], ["concentrations", "TEST", 252, 266]]], ["The plate was then blocked with PBS + 5% dry milk buffer.", [["milk", "ORGANISM_SUBSTANCE", 45, 49], ["The plate", "TREATMENT", 0, 9], ["PBS", "TREATMENT", 32, 35], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["Antibodies in various formats were diluted in the same blocking buffer and applied to the ELISA plate.", [["Antibodies in various formats", "PROBLEM", 0, 29], ["the same blocking buffer", "TREATMENT", 46, 70], ["ELISA plate", "OBSERVATION", 90, 101]]], ["The mouse-anti-His-HRP was used to detect the His tag at the C terminus end of each of the scFvs in most of the ELISA and the mouse-anti-human Fc-HRP was used to detect the scFv-Fc and IgG bindings.", [["His", "CHEMICAL", 46, 49], ["mouse", "ORGANISM", 4, 9], ["anti-His", "GENE_OR_GENE_PRODUCT", 10, 18], ["HRP", "GENE_OR_GENE_PRODUCT", 19, 22], ["scFvs", "GENE_OR_GENE_PRODUCT", 91, 96], ["mouse", "ORGANISM", 126, 131], ["Fc-HRP", "GENE_OR_GENE_PRODUCT", 143, 149], ["scFv-Fc", "GENE_OR_GENE_PRODUCT", 173, 180], ["IgG", "GENE_OR_GENE_PRODUCT", 185, 188], ["mouse-anti-His-HRP", "PROTEIN", 4, 22], ["His tag", "PROTEIN", 46, 53], ["C terminus end", "PROTEIN", 61, 75], ["scFvs", "PROTEIN", 91, 96], ["anti-human Fc", "PROTEIN", 132, 145], ["HRP", "PROTEIN", 146, 149], ["scFv-Fc", "PROTEIN", 173, 180], ["IgG", "PROTEIN", 185, 188], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 126, 131], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 126, 131], ["the scFvs", "TREATMENT", 87, 96], ["the ELISA", "TEST", 108, 117], ["IgG bindings", "PROBLEM", 185, 197], ["IgG bindings", "OBSERVATION", 185, 197]]], ["ABTS was then added to each well and OD 405 was taken 5-10 minutes afterward.", [["ABTS", "CHEMICAL", 0, 4], ["ABTS", "CHEMICAL", 0, 4], ["ABTS", "SIMPLE_CHEMICAL", 0, 4], ["ABTS", "TEST", 0, 4]]], ["To estimate the EC50s of some of the binders, data generated from the dose response bindings were analyzed using the weighted least-squares fitting of data to the function (Hill equation).Pseudovirus neutralization assayHIV Env pseudotyped virus preparation and neutralization was performed as previously described.", [["Pseudovirus", "GENE_OR_GENE_PRODUCT", 188, 199], ["pseudotyped", "SPECIES", 228, 239], ["Pseudovirus neutralization", "TREATMENT", 188, 214], ["Env pseudotyped virus preparation", "TREATMENT", 224, 257], ["neutralization", "TREATMENT", 262, 276]]], ["[32] The activity of each pseudovirus isolate with or without antibody treatment was expressed as a percentage of the corresponding control virus without antibody treatment, and the average percentages and standard deviations were then calculated.", [["pseudovirus", "ORGANISM", 26, 37], ["antibody treatment", "TREATMENT", 62, 80], ["antibody treatment", "TREATMENT", 154, 172]]]], "79f06ec9847023c5c7994aa674d148b0d45206de": [["IntroductionThe United States of America has been severely affected by the COVID-19 pandemic during the spring of 2020 [1] .", [["severely affected", "PROBLEM", 50, 67]]], ["The largely immigrant and densely populated neighborhoods of Queens, NY, served by a large public hospital, Elmhurst Hospital Center (NYC H+H/Elmhurst), have emerged as one of the hardest-hit areas in the country [2] .", [["largely", "OBSERVATION_MODIFIER", 4, 11], ["immigrant", "OBSERVATION", 12, 21], ["densely", "OBSERVATION_MODIFIER", 26, 33], ["populated", "OBSERVATION_MODIFIER", 34, 43], ["large", "OBSERVATION_MODIFIER", 85, 90]]], ["Newborns are at high risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from their infected mothers who delivered during this period; however, data remains limited [3] .", [["acute respiratory syndrome coronavirus", "DISEASE", 46, 84], ["Newborns", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 88, 98], ["mothers", "ORGANISM", 120, 127], ["Newborns", "SPECIES", 0, 8], ["severe acute respiratory syndrome coronavirus", "SPECIES", 39, 84], ["SARS-CoV-2", "SPECIES", 88, 98], ["acquiring severe acute respiratory syndrome coronavirus", "PROBLEM", 29, 84], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["respiratory syndrome", "OBSERVATION", 52, 72]]], ["We aim to describe the unique experience from our Baby Friendly hospital at the epicenter of the COVID-19 pandemic.MethodsIn this retrospective cross-sectional study, we identified live births to women who were tested for SARS-CoV-2 from March 19 to April 22, 2020 at NYC H+H/Elmhurst.", [["SARS", "DISEASE", 222, 226], ["women", "ORGANISM", 196, 201], ["women", "SPECIES", 196, 201], ["SARS-CoV", "SPECIES", 222, 230], ["pandemic", "PROBLEM", 106, 114], ["this retrospective cross-sectional study", "TEST", 125, 165], ["SARS", "PROBLEM", 222, 226]]], ["Data regarding demographic and clinical characteristics, SARS-CoV-2 test results, symptoms and signs of COVID-19, colocation (rooming-in), breastfeeding, and newborn follow-up were obtained from review of electronic medical records.", [["clinical characteristics", "TEST", 31, 55], ["SARS", "TEST", 57, 61], ["CoV-2 test results", "TEST", 62, 80], ["symptoms", "PROBLEM", 82, 90], ["COVID", "TEST", 104, 109]]], ["Descriptive statistics on the newborns of positive mothers along with maternal data is presented as overall results and percentages.", [["newborns", "ORGANISM", 30, 38], ["mothers", "ORGANISM", 51, 58]]], ["BioReference laboratories and our hospital laboratory (Cepheid Xpert Xpress) were used for SARS-CoV-2 reverse transcriptase polymerase chain reaction (PCR) test.", [["reverse transcriptase", "PROTEIN", 102, 123], ["SARS-CoV", "SPECIES", 91, 99], ["SARS", "TEST", 91, 95], ["CoV", "TEST", 96, 99], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 102, 149], ["PCR) test", "TEST", 151, 160]]], ["This study was approved under exempt status by the Institutional Review Board of Icahn School of Medicine at Mount Sinai (IRB number 20-03424), local ethics committee, and the office of research administration.ResultsThere were 118 live births to women who were tested for SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 273, 293], ["women", "ORGANISM", 247, 252], ["SARS-CoV-2", "ORGANISM", 273, 283], ["women", "SPECIES", 247, 252], ["SARS-CoV-2", "SPECIES", 273, 283], ["This study", "TEST", 0, 10], ["research administration", "TREATMENT", 186, 209], ["SARS", "PROBLEM", 273, 277], ["CoV", "PROBLEM", 278, 281], ["2 infection", "PROBLEM", 282, 293], ["infection", "OBSERVATION", 284, 293]]], ["Of these, 45 (38%) newborns were born to positive mothers and 30 (67%) births were vaginal.", [["vaginal", "ANATOMY", 83, 90], ["newborns", "ORGANISM", 19, 27], ["mothers", "ORGANISM", 50, 57], ["vaginal", "ANATOMY", 83, 90]]], ["The majority of positive mothers, 27 (60%), were asymptomatic.", [["mothers", "ORGANISM", 25, 32], ["asymptomatic", "PROBLEM", 49, 61], ["positive", "OBSERVATION_MODIFIER", 16, 24]]], ["Five (11%) well newborns were placed in isolation room as a part of our initial practice early in the pandemic.", [["newborns", "ORGANISM", 16, 24]]], ["Seven (16%) newborns were admitted to the neonatal intensive care unit (NICU) after birth due to prematurity or suspected sepsis.", [["prematurity", "DISEASE", 97, 108], ["sepsis", "DISEASE", 122, 128], ["newborns", "ORGANISM", 12, 20], ["prematurity", "PROBLEM", 97, 108], ["suspected sepsis", "PROBLEM", 112, 128], ["prematurity", "OBSERVATION", 97, 108], ["sepsis", "OBSERVATION", 122, 128]]], ["A total of 33 (73%) newborns colocated with their mothers and 31 of the 33 (94%) were breastfed with the initiation of breastfeeding within 1 h of birth.", [["newborns", "ORGANISM", 20, 28], ["mothers", "ORGANISM", 50, 57], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["All the newborns were tested for SARS-CoV-2 using a combined oropharyngeal and nasopharyngeal swab after birth following their first bath due to the long turnaround time of the test results.", [["oropharyngeal", "ANATOMY", 61, 74], ["nasopharyngeal swab", "ANATOMY", 79, 98], ["newborns", "ORGANISM", 8, 16], ["oropharyngeal", "ORGANISM_SUBDIVISION", 61, 74], ["nasopharyngeal swab", "ORGAN", 79, 98], ["SARS-CoV", "SPECIES", 33, 41], ["SARS", "PROBLEM", 33, 37], ["CoV", "TEST", 38, 41], ["a combined oropharyngeal and nasopharyngeal swab", "TREATMENT", 50, 98], ["the test", "TEST", 173, 181], ["oropharyngeal", "ANATOMY", 61, 74], ["nasopharyngeal", "ANATOMY", 79, 93]]], ["Testing from other sites such as rectal swabs was not performed.", [["sites", "ANATOMY", 19, 24], ["rectal swabs", "ANATOMY", 33, 45], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 33, 45], ["Testing from other sites", "PROBLEM", 0, 24], ["rectal swabs", "TEST", 33, 45], ["rectal", "ANATOMY", 33, 39]]], ["A total of 33 (73%) newborns tested negative and 3 (6.6%) tested positive (Fig. 1 ).", [["newborns", "ORGANISM", 20, 28], ["A total", "TEST", 0, 7], ["newborns", "TEST", 20, 28], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Those three newborns were monitored in the NICU until two consecutive tests obtained at least 24 h apart were negative and they remained asymptomatic, thus suggesting transient colonization.", [["newborns", "ORGANISM", 12, 20], ["two consecutive tests", "TEST", 54, 75], ["asymptomatic", "PROBLEM", 137, 149], ["transient colonization", "PROBLEM", 167, 189], ["suggesting", "UNCERTAINTY", 156, 166], ["transient", "OBSERVATION_MODIFIER", 167, 176], ["colonization", "OBSERVATION", 177, 189]]], ["None of the 45 newborns needed NICU admission for COVID-19-related symptoms.", [["COVID-19", "CHEMICAL", 50, 58], ["newborns", "ORGANISM", 15, 23], ["COVID", "TEST", 50, 55], ["related symptoms", "PROBLEM", 59, 75]]], ["Upon discharge, there was a 91% adherence (39 out of 43 discharged) to the initial in-person newborn visit.", [["person", "SPECIES", 86, 92]]], ["On these visits, none of the newborns were reported to have any symptoms consistent with COVID-19 and none had emergency department visits or hospital admissions related to COVID-19.", [["COVID-19", "CHEMICAL", 173, 181], ["newborns", "ORGANISM", 29, 37], ["any symptoms", "PROBLEM", 60, 72], ["COVID", "TEST", 89, 94], ["COVID", "TEST", 173, 178]]], ["Demographic and clinical data is summarized in Table 1 .DiscussionIn our experience of caring for newborns at a center with high incidence of maternal SARS-CoV-2, newborns did not show signs of infection after birth.", [["infection", "DISEASE", 194, 203], ["newborns", "ORGANISM", 98, 106], ["SARS-CoV-2", "ORGANISM", 151, 161], ["newborns", "ORGANISM", 163, 171], ["SARS-CoV", "SPECIES", 151, 159], ["maternal SARS", "PROBLEM", 142, 155], ["CoV", "TEST", 156, 159], ["infection", "PROBLEM", 194, 203], ["infection", "OBSERVATION", 194, 203]]], ["Moreover, we report no shortterm adverse neonatal outcomes with skin-to-skin care, rooming-in, or breastfeeding in infants of SARS-CoV-2 positive mothers in our population.", [["skin", "ANATOMY", 64, 68], ["skin", "ANATOMY", 72, 76], ["SARS", "DISEASE", 126, 130], ["skin", "ORGAN", 64, 68], ["skin", "ORGAN", 72, 76], ["infants", "ORGANISM", 115, 122], ["SARS-CoV-2", "ORGANISM", 126, 136], ["mothers", "ORGANISM", 146, 153], ["infants", "SPECIES", 115, 122], ["skin", "ANATOMY", 64, 68], ["skin", "ANATOMY", 72, 76]]], ["In contrast to early reports from China, majority of our newborns were born via vaginal delivery [4] .", [["vaginal", "ANATOMY", 80, 87], ["newborns", "ORGANISM", 57, 65], ["vaginal", "ORGANISM_SUBDIVISION", 80, 87], ["vaginal delivery", "TREATMENT", 80, 96]]], ["And although it has been shown that SARS-CoV-2 can be detected in the stool samples of mothers, routine testing in our cohort of newborns did not show a high incidence of positive PCR results [5] .", [["stool samples", "ANATOMY", 70, 83], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 36, 46], ["stool samples", "ORGANISM_SUBSTANCE", 70, 83], ["mothers", "ORGANISM", 87, 94], ["newborns", "ORGANISM", 129, 137], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "PROBLEM", 36, 40], ["CoV", "TEST", 41, 44], ["routine testing", "TEST", 96, 111], ["positive PCR results", "PROBLEM", 171, 191]]], ["A possible explanation for both of these observations could be the high number of asymptomatic or mildly symptomatic mothers in our study.DiscussionDuring the early period of the pandemic, our center tested only symptomatic pregnant women for SARS-CoV-2 and newborns of infected mothers were placed in isolation rooms based on the available literature at that time [6] .", [["SARS", "DISEASE", 243, 247], ["women", "ORGANISM", 233, 238], ["SARS-CoV-2", "ORGANISM", 243, 253], ["newborns", "ORGANISM", 258, 266], ["mothers", "ORGANISM", 279, 286], ["women", "SPECIES", 233, 238], ["SARS-CoV", "SPECIES", 243, 251], ["mildly symptomatic mothers", "PROBLEM", 98, 124], ["our study", "TEST", 128, 137], ["SARS", "PROBLEM", 243, 247], ["CoV", "TEST", 248, 251], ["possible explanation for", "UNCERTAINTY", 2, 26], ["mildly", "OBSERVATION_MODIFIER", 98, 104], ["symptomatic", "OBSERVATION_MODIFIER", 105, 116], ["infected", "OBSERVATION", 270, 278]]], ["However, due to the dramatic surge in the number of SARS-CoV-2 positive mothers delivering at our center after initiation of universal screening of all pregnant women admitted for delivery, the limited isolation spaces for the newborns, early postpartum discharges, the crowded housing conditions in our community and the desire to promote breastfeeding, we utilized shared decision-making and offered rooming-in of mothers with their newborns [7] .", [["SARS", "DISEASE", 52, 56], ["SARS-CoV-2", "ORGANISM", 52, 62], ["mothers", "ORGANISM", 72, 79], ["women", "ORGANISM", 161, 166], ["newborns", "ORGANISM", 227, 235], ["mothers", "ORGANISM", 416, 423], ["women", "SPECIES", 161, 166], ["SARS-CoV", "SPECIES", 52, 60], ["the dramatic surge", "PROBLEM", 16, 34], ["universal screening", "TEST", 125, 144], ["delivery", "TREATMENT", 180, 188], ["early postpartum discharges", "PROBLEM", 237, 264], ["dramatic", "OBSERVATION_MODIFIER", 20, 28]]], ["Mothers were encouraged to provide skin-to-skin care and breastfeeding while rooming-in, following appropriate isolation precautions based on the CDC guidance [8] .DiscussionNewborns were discharged to a healthy asymptomatic caregiver and were closely followed-up for 2 weeks after discharge.", [["skin", "ANATOMY", 35, 39], ["skin", "ANATOMY", 43, 47], ["Mothers", "ORGANISM", 0, 7], ["skin", "ORGAN", 35, 39], ["skin", "ORGAN", 43, 47], ["Newborns", "ORGANISM", 174, 182], ["skin care", "TREATMENT", 43, 52], ["breastfeeding", "TREATMENT", 57, 70], ["appropriate isolation precautions", "TREATMENT", 99, 132], ["skin", "ANATOMY", 35, 39], ["skin", "ANATOMY", 43, 47]]], ["Televisitation was utilized in addition to initial in-person visits that showed that the newborns remained asymptomatic after discharge.DiscussionAlthough our study has limitations of small sample size and only short-term outcomes, we believe that to date, our report has the largest number of mother-baby dyads cared for utilizing baby friendly practices when mother is tested positive for SARS-CoV-2.DiscussionThe practice of rooming-in and breastfeeding in our population provided a critical educational opportunity for the new mothers to learn isolation precautions, safe distancing, personal protective equipment use, and safe breastfeeding or pumping of breastmilk to reduce the risk of transmission of SARS-CoV-2 to the newborn.", [["SARS", "DISEASE", 391, 395], ["SARS", "DISEASE", 709, 713], ["newborns", "ORGANISM", 89, 97], ["SARS-CoV-2", "ORGANISM", 391, 401], ["SARS-CoV-2", "ORGANISM", 709, 719], ["newborn", "ORGANISM", 727, 734], ["SARS-CoV", "SPECIES", 391, 399], ["SARS-CoV", "SPECIES", 709, 717], ["asymptomatic", "PROBLEM", 107, 119], ["our study", "TEST", 155, 164], ["small sample size", "PROBLEM", 184, 201], ["SARS", "PROBLEM", 391, 395], ["isolation precautions", "TREATMENT", 548, 569], ["pumping of breastmilk", "TREATMENT", 649, 670], ["small", "OBSERVATION_MODIFIER", 184, 189], ["size", "OBSERVATION_MODIFIER", 197, 201], ["short-term", "OBSERVATION_MODIFIER", 211, 221]]], ["This may have prepared the SARS-CoV-2 positive mothers to better care for their newborns at home.", [["mothers", "ORGANISM", 47, 54], ["newborns", "ORGANISM", 80, 88]]], ["Given the variations in the guidance and at times some conflict amongst the national and international organizations regarding colocation and breastfeeding after delivery, our experience can help hospitals when planning around best practices for newborn care during the COVID-19 pandemic [9] .", [["colocation", "TREATMENT", 127, 137], ["delivery", "TREATMENT", 162, 170], ["newborn care", "TREATMENT", 246, 258]]]], "PMC7380912": [], "PMC7462839": [["IntroductionThe challenge of responding to the world's climate change is a worldwide environmental problem that will impact all countries around the globe.", [["a worldwide environmental problem", "PROBLEM", 73, 106], ["globe", "ANATOMY", 149, 154]]], ["Indeed, energy demand in developed and developing countries is rising dramatically.", [["energy demand", "OBSERVATION", 8, 21], ["rising", "OBSERVATION_MODIFIER", 63, 69]]], ["Since then, the global world interests to increase the use of renewable energy sources and reduce the GHGE as a key solution.IntroductionThe use of renewable energy sources (RES) can contribute to the decarbonization of the power system and to ensure a sustainable energy supply throughout the world [3], [4].", [["GHGE", "CHEMICAL", 102, 106], ["GHGE", "SIMPLE_CHEMICAL", 102, 106], ["renewable energy sources", "TREATMENT", 62, 86], ["the decarbonization of the power system", "TREATMENT", 197, 236]]], ["Over the past century, the share of renewable energy in the energy mix of many developed countries has increased considerably and this trend is expected to continue in the future [5].", [["renewable energy", "OBSERVATION", 36, 52], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["considerably", "OBSERVATION_MODIFIER", 113, 125]]], ["Many governments around the world have directed their transition policies to more sustainable and accessible energy systems [6], [7], [8], [9].", [["[8]", "SIMPLE_CHEMICAL", 134, 137]]], ["The electrical power production industry in Morocco is facing challenges involved with sustained growth of demand, added to environmental protection requirements, that's why energy security [11] and mitigation of emissions and environmental pollution are identified as the main motivating forces for the transformation of the existing electricity power supply system to a sustainable form of electricity [12], [13], [14], [15], [16], [17].IntroductionAt COP 21 conference held in Paris, Morocco is promising an optimistic and binding deal.", [["[13], [14], [15], [16]", "SIMPLE_CHEMICAL", 410, 432], ["[17]", "SIMPLE_CHEMICAL", 434, 438], ["sustained growth of demand", "PROBLEM", 87, 113], ["environmental protection requirements", "TREATMENT", 124, 161], ["mitigation of emissions", "TREATMENT", 199, 222], ["environmental pollution", "TREATMENT", 227, 250]]], ["It is in this perspective that the Moroccan government has launched a holistic plan to boost the percentage of renewable energy in the energy mix and substantially increase energy efficiency.", [["increase", "OBSERVATION_MODIFIER", 164, 172], ["energy efficiency", "OBSERVATION", 173, 190]]], ["In addition, to ensure these options, significant changes in the organization and functioning of electrical systems are required.IntroductionMany papers [10], [13], [17] have explored Morocco's renewable energy potential under various perspectives with a focus towards its national energy strategy development.", [["[13]", "SIMPLE_CHEMICAL", 159, 163], ["[17]", "SIMPLE_CHEMICAL", 165, 169], ["significant changes in the organization and functioning of electrical systems", "PROBLEM", 38, 115], ["significant", "OBSERVATION_MODIFIER", 38, 49]]], ["As well as it focuses on a general scope of the main actual trails and challenges facing the national energy strategy, with a clear and detailed roadmap of the key elements and guidelines to be followed by Morocco in order to achieve its objectives in terms of renewable energy and energy efficiency by 2030.Solar program ::: Current status of major RE projects in MoroccoMorocco has taken advantage of its geographical position and environment to gain an edge in the field of renewables, especially solar energy [28].", [["MoroccoMorocco", "CHEMICAL", 365, 379]]], ["The average incident solar radiation varies between 4.7 and 5.6 kWh/m2/day with a number of hours of sunshine that varies from 2700 hours/year in the North of Morocco to more than 3500 hours/year in the South.Solar program ::: Current status of major RE projects in MoroccoInitiated in 2009, the Moroccan Solar Plan is a very ambitious project.", [["The average incident solar radiation", "TREATMENT", 0, 36], ["average", "OBSERVATION_MODIFIER", 4, 11], ["solar radiation", "OBSERVATION", 21, 36]]], ["A number of solar power plants have been planned and scheduled to be installed as part of this project.", [["solar power plants", "TREATMENT", 12, 30]]], ["The Moroccan Agency for Solar Energy (MASEN) was set up specifically to execute these projects.", [["Solar Energy (MASEN)", "TREATMENT", 24, 44]]], ["Its mission is to implement all projects related to the National Energy Strategy and to co-ordinate and supervise all other activities connected with this initiative.", [["the National Energy Strategy", "TREATMENT", 52, 80]]], ["Table 2lists the major projects completed, in the process or planned in sites, with total investment estimated at approximately USD 9 billion through to 2020.Solar program ::: Current status of major RE projects in MoroccoWe note that PV technology is featured in all projects due to a decrease in the price of photovoltaic modules of more than 80% over the last ten years [29].", [["PV", "SPECIES", 235, 237], ["photovoltaic modules", "PROBLEM", 311, 331], ["decrease", "OBSERVATION_MODIFIER", 286, 294], ["photovoltaic modules", "OBSERVATION", 311, 331]]], ["As part of the Mediterranean Solar Plan, Ouarzazate plant has benefited from European co-financing.", [["Ouarzazate plant", "TREATMENT", 41, 57]]], ["Noor 4 based on photovoltaic technology has an output of 72 MW.", [["an output", "TEST", 44, 53], ["output", "OBSERVATION_MODIFIER", 47, 53]]], ["With a capacity of 160 MW, Noor 1 is currently one of the largest concentrated solar thermal (CSP) parabolic cylinder power plants in the world.Solar program ::: Current status of major RE projects in MoroccoThe solar power plant Noor 1 is mainly equipped with the advanced Concentrating Solar Power (CSP) generation, with Parabolic Trough Collector (PTC) [30].", [["Morocco", "SPECIES", 201, 208], ["the largest concentrated solar thermal (CSP) parabolic cylinder power plants", "TREATMENT", 54, 130], ["The solar power plant Noor", "TREATMENT", 208, 234], ["the advanced Concentrating Solar Power (CSP) generation", "TREATMENT", 261, 316], ["Parabolic Trough Collector (PTC)", "TREATMENT", 323, 355], ["largest", "OBSERVATION_MODIFIER", 58, 65]]], ["By comparing this technology to solar energy tower, linear Fresnel Reflector and parabolic dish collector, the PTC with thermal oil and molten salt storage is considered to be the simplest and most mature system [31], [32] Prospective sites for CSP plants are generally selected based on the global distribution of Direct Normal Irradiance (DNI) [33].", [["linear Fresnel Reflector and parabolic dish collector", "TREATMENT", 52, 105], ["the PTC", "TREATMENT", 107, 114], ["thermal oil and molten salt storage", "TREATMENT", 120, 155], ["Prospective sites", "TREATMENT", 223, 240], ["CSP plants", "TREATMENT", 245, 255], ["parabolic dish", "OBSERVATION", 81, 95]]], ["The Rankine cycle with molten salt storage is the operating principle of the Noor 1 plant (see Fig. 4) [35], [36].Solar program ::: Current status of major RE projects in MoroccoAs shown in Fig. 4, the Noor 1 plant consists of three parts, which are the solar field, the power block and the thermal storage system.", [["Morocco", "SPECIES", 171, 178], ["molten salt storage", "TREATMENT", 23, 42], ["the power block", "TREATMENT", 267, 282], ["the thermal storage system", "TREATMENT", 287, 313], ["power block", "OBSERVATION", 271, 282]]], ["The Noor 1 power plant's solar field consists of 400 parabolic trough loops arranged in parallel and connected to each other.", [["parabolic trough loops", "TREATMENT", 53, 75]]], ["Each loop consists of 4 arrays of solar collectors in series and each array is composed of 12 solar collector elements.", [["solar collector elements", "DNA", 94, 118], ["solar collectors in series and each array", "TREATMENT", 34, 75], ["loop", "OBSERVATION_MODIFIER", 5, 9], ["solar collectors", "OBSERVATION", 34, 50]]], ["The solar collectors composed of very reflective parabolic mirrors and heat collection elements (HCE) installed in the center of the dish.", [["heat collection elements", "DNA", 71, 95], ["The solar collectors", "TREATMENT", 0, 20], ["very reflective parabolic mirrors and heat collection elements", "PROBLEM", 33, 95], ["solar collectors", "OBSERVATION", 4, 20], ["very", "OBSERVATION_MODIFIER", 33, 37], ["reflective", "OBSERVATION_MODIFIER", 38, 48], ["parabolic mirrors", "OBSERVATION", 49, 66], ["heat", "OBSERVATION_MODIFIER", 71, 75], ["collection elements", "OBSERVATION", 76, 95], ["dish", "ANATOMY", 133, 137]]], ["A monitoring system allows the collectors to follow the sun from sunrise to sunset [37].", [["A monitoring system", "TEST", 0, 19]]], ["Once the direct solar irradiation is received on the solar field and reflected by the parabolic collectors to the absorber, where the heat is transferred to the heat transfer fluid (HTF).", [["the direct solar irradiation", "TREATMENT", 5, 33]]], ["A synthetic oil which is used as HTF circulates through the collectors.", [["oil", "ANATOMY", 12, 15], ["oil", "ORGANISM_SUBSTANCE", 12, 15], ["HTF", "SIMPLE_CHEMICAL", 33, 36], ["HTF", "PROTEIN", 33, 36], ["A synthetic oil", "TREATMENT", 0, 15]]], ["At the output of the solar field, the HTF is collected and then pumped to an expansion tank, which is connected to the power block unit to transfer its energy to water.", [["HTF", "DNA", 38, 41], ["output", "OBSERVATION_MODIFIER", 7, 13], ["HTF", "OBSERVATION", 38, 41], ["expansion", "OBSERVATION_MODIFIER", 77, 86], ["tank", "OBSERVATION_MODIFIER", 87, 91]]], ["The power block includes a steam generator, preheater, steam turbine, power generator, condenser, cooling systems (air condenser and cooling tower) and auxiliary equipment.", [["The power block", "TREATMENT", 0, 15], ["a steam generator", "TREATMENT", 25, 42], ["steam turbine", "TREATMENT", 55, 68], ["power generator", "TREATMENT", 70, 85], ["cooling systems", "TREATMENT", 98, 113], ["air condenser", "TREATMENT", 115, 128], ["auxiliary equipment", "TREATMENT", 152, 171]]], ["The steam generator has two heat exchanger trains including economizers, evaporators, superheaters and preheaters.", [["The steam generator", "TREATMENT", 0, 19], ["two heat exchanger trains", "TREATMENT", 24, 49], ["economizers", "TREATMENT", 60, 71], ["evaporators", "TREATMENT", 73, 84]]], ["The HTF flows through the two heat exchanger trains in order to produce steam at high temperature and pressure.Solar program ::: Current status of major RE projects in MoroccoThe Noor 1 plant has been designed with two tanks of an eutectic molten salt composed of a mixture of sodium nitrate and potassium nitrate (60% NaNO3 + 40% KNO3).", [["sodium nitrate", "CHEMICAL", 277, 291], ["potassium nitrate", "CHEMICAL", 296, 313], ["NaNO3", "CHEMICAL", 319, 324], ["KNO3", "CHEMICAL", 331, 335], ["sodium nitrate", "CHEMICAL", 277, 291], ["potassium nitrate", "CHEMICAL", 296, 313], ["NaNO3", "CHEMICAL", 319, 324], ["KNO3", "CHEMICAL", 331, 335], ["HTF", "SIMPLE_CHEMICAL", 4, 7], ["sodium nitrate", "SIMPLE_CHEMICAL", 277, 291], ["potassium nitrate", "SIMPLE_CHEMICAL", 296, 313], ["KNO3", "SIMPLE_CHEMICAL", 331, 335], ["The HTF flows", "TEST", 0, 13], ["the two heat exchanger trains", "TREATMENT", 22, 51], ["an eutectic molten salt", "TREATMENT", 228, 251], ["sodium nitrate", "TREATMENT", 277, 291], ["potassium nitrate", "TREATMENT", 296, 313], ["HTF flows", "OBSERVATION", 4, 13], ["pressure", "OBSERVATION_MODIFIER", 102, 110]]], ["This mixture has a high heat transfer coefficient and high thermal storage capacity.", [["high thermal storage capacity", "PROBLEM", 54, 83]]], ["The function of the thermal storage system is to store excess sensible heat from the solar field (charge mode) during daily sunshine hours, in order to extend plant operation during night or when solar irradiation is insufficient (discharge mode).", [["plant operation", "TREATMENT", 159, 174], ["solar irradiation", "TREATMENT", 196, 213]]], ["The HTF flows in heat exchanger to charge/discharge the thermal storage system.", [["HTF", "SIMPLE_CHEMICAL", 4, 7], ["heat exchanger", "TREATMENT", 17, 31], ["the thermal storage system", "TREATMENT", 52, 78], ["HTF flows", "OBSERVATION", 4, 13]]], ["The molten salt circulates from the cold storage tank through the heat exchanger and enters the hot salt storage tank, with temperature of approximately 368\u00b0C. The temperature of the cold molten salt is about 292\u00b0C. When the storage system is discharged, the molten salt from the hot storage tank is sent back to cold storage tank through the heat exchanger that is used to heat up the cold HTF.", [["HTF", "SIMPLE_CHEMICAL", 391, 394], ["the heat exchanger", "TREATMENT", 62, 80], ["temperature", "TEST", 124, 135], ["The temperature", "TEST", 160, 175], ["the molten salt", "TREATMENT", 255, 270], ["the heat exchanger", "TREATMENT", 339, 357], ["molten", "OBSERVATION_MODIFIER", 4, 10], ["salt circulates", "OBSERVATION", 11, 26]]], ["The heated HTF is then sent to the power block.Wind program ::: Current status of major RE projects in MoroccoThe favourable geographical location of Morocco provides it an important wind energy potential, estimated at about 6000 MW [13], [38].", [["HTF", "SIMPLE_CHEMICAL", 11, 14], ["heated HTF", "PROTEIN", 4, 14], ["Morocco", "SPECIES", 103, 110], ["The heated HTF", "TREATMENT", 0, 14], ["favourable", "OBSERVATION_MODIFIER", 114, 124], ["geographical", "OBSERVATION_MODIFIER", 125, 137]]], ["Most of Morocco's windiest regions are located in the extreme north on the Strait of Gibraltar side in the Tangier-Tetouan region, the Essaouira region, the South Atlantic area from Tarfaya to Lagouira and the Taza corridor between the Atlas and Rif mountain ranges.", [["Morocco's windiest regions", "DNA", 8, 34], ["Tarfaya", "TREATMENT", 182, 189], ["Lagouira", "TREATMENT", 193, 201], ["the Taza corridor", "TREATMENT", 206, 223], ["extreme", "OBSERVATION_MODIFIER", 54, 61], ["north", "OBSERVATION_MODIFIER", 62, 67], ["Tangier", "OBSERVATION", 107, 114], ["Tetouan", "ANATOMY", 115, 122], ["region", "ANATOMY_MODIFIER", 123, 129], ["South", "OBSERVATION_MODIFIER", 157, 162], ["Atlantic", "OBSERVATION_MODIFIER", 163, 171], ["Rif", "OBSERVATION_MODIFIER", 246, 249], ["mountain ranges", "OBSERVATION", 250, 265]]], ["The wind field is characterized by average wind speeds above 8 m/s for the windiest regions [17].Wind program ::: Current status of major RE projects in MoroccoUnder its energy strategy, Morocco has implemented an ambitious wind energy program to promote the deployment of renewable energies.", [["an ambitious wind energy program", "TREATMENT", 211, 243]]], ["Table 3shows the commissioned wind power plants and Table 4lists the projects in development [39].Wind program ::: Current status of major RE projects in MoroccoOne of the most important projects in wind energy program is the giant Tarfaya wind farm (see Fig. 5), which is operational.", [["giant", "OBSERVATION_MODIFIER", 226, 231]]], ["It is the largest wind energy project on the African continent.", [["largest", "OBSERVATION_MODIFIER", 10, 17]]], ["In addition to electricity production, the wind program also includes industrial integration of the wind energy sector, as well as the promotion of research and development and technical training in this field.", [["technical training", "TREATMENT", 177, 195], ["electricity production", "OBSERVATION", 15, 37]]], ["Installed hydropower capacity will be increased from 1,730 MW in 2008 to 2,000 MW in 2020 through the construction of new hydropower dams and Pumped Energy Transfer Station (PETS).Hydropower program ::: Current status of major RE projects in MoroccoMorocco currently has 1,770 MW of hydropower generation capacity, of which 464 MW is in PETS mode [41].", [["MoroccoMorocco", "CHEMICAL", 242, 256], ["hydropower capacity", "TREATMENT", 10, 29], ["new hydropower dams", "TREATMENT", 118, 137], ["hydropower generation capacity", "TEST", 283, 313], ["hydropower capacity", "OBSERVATION", 10, 29], ["increased", "OBSERVATION_MODIFIER", 38, 47]]], ["This production capacity is really achievable only when water reservoirs are at their maximum.", [["This production capacity", "PROBLEM", 0, 24]]], ["This is not always the case, rather the opposite; Morocco is a semi-arid country.", [["not always", "UNCERTAINTY", 8, 18]]], ["In hydraulics, the other element that must be taken into account in Morocco is irrigation.", [["irrigation", "TREATMENT", 79, 89], ["hydraulics", "OBSERVATION_MODIFIER", 3, 13]]], ["Thus, turbining to produce electricity is, therefore, dependent to a certain extent on irrigation needs.", [["irrigation needs", "TREATMENT", 87, 103]]], ["However, throughout the world, the production of hydroelectric power is always lower than the level of existing installed capacity dictates.", [["hydroelectric", "OBSERVATION_MODIFIER", 49, 62], ["power", "OBSERVATION_MODIFIER", 63, 68], ["lower", "OBSERVATION_MODIFIER", 79, 84]]], ["In 2011, for example, hydropower production is in sharp decline, with only 2.2 TWh compared to 3.7 TWh in 2010, a year with abundant rainfall in Morocco.", [["sharp decline", "PROBLEM", 50, 63], ["sharp", "OBSERVATION_MODIFIER", 50, 55], ["decline", "OBSERVATION_MODIFIER", 56, 63], ["abundant", "OBSERVATION_MODIFIER", 124, 132], ["rainfall", "OBSERVATION", 133, 141]]], ["PETSs that are constructed or under development are expected to serve as a storage mechanism for solar and wind energy Fig. 6shows The PETS of 350 MW at the Abdelmoumen site in the Agadir region which will increase the hydraulic capacity of Morocco to 2120 MW by the end of 2020.", [["PETSs", "SIMPLE_CHEMICAL", 0, 5], ["PETSs", "TREATMENT", 0, 5], ["The PETS", "TEST", 131, 139], ["350 MW", "OBSERVATION_MODIFIER", 143, 149], ["hydraulic capacity", "OBSERVATION_MODIFIER", 219, 237]]], ["Meanwhile, Morocco plans to build about sixty large dams over the next twenty years; however, most of them should be dedicated to water resource management, and therefore not necessarily to power generation.", [["resource management", "TREATMENT", 136, 155]]], ["Table 5shows the current situation of the hydro projects [39], and Table 6shows the future hydropower projects in Morocco [10].Biomass program ::: Current status of major RE projects in MoroccoIn addition to solar, wind and hydraulic power, the process of diversification of energy resources in Morocco also concerns biomass.", [["hydraulic power", "OBSERVATION_MODIFIER", 224, 239]]], ["Currently, Morocco has considerable biomass potential thanks to a forest area of more than 5,350,000 ha, Halfa areas of nearly 3,300,000 ha, an agricultural area of nearly 9,000,000 ha and a highly diversified livestock (cattle, sheep, goats, etc.) of around 7,000,000 livestock units [43].", [["cattle", "ORGANISM_SUBDIVISION", 221, 227], ["sheep", "ORGANISM_SUBDIVISION", 229, 234], ["goats", "ORGANISM_SUBDIVISION", 236, 241], ["cattle", "SPECIES", 221, 227], ["sheep", "SPECIES", 229, 234], ["goats", "SPECIES", 236, 241], ["cattle", "SPECIES", 221, 227], ["sheep", "SPECIES", 229, 234], ["goats", "SPECIES", 236, 241], ["considerable", "OBSERVATION_MODIFIER", 23, 35], ["biomass", "OBSERVATION", 36, 43], ["agricultural", "OBSERVATION_MODIFIER", 144, 156], ["diversified", "OBSERVATION_MODIFIER", 198, 209], ["livestock", "OBSERVATION", 210, 219]]], ["Despite its enormous resources in biomass, Morocco currently has only less than 1% of its potential capacity because of its high initial expenditure and the lack of knowledge about energy production techniques and processes [13].", [["enormous", "OBSERVATION_MODIFIER", 12, 20], ["biomass", "OBSERVATION_MODIFIER", 34, 41]]], ["Nevertheless, its main potential has yet to be covered by national policies, although some small companies already are involved in this sector.Biomass program ::: Current status of major RE projects in MoroccoIn order to organise the use of biomass efficiently, the Department of Energy and Mines in Morocco has initiated a national strategy for the energy recovery of biomass.", [["a national strategy", "TREATMENT", 322, 341], ["small", "OBSERVATION_MODIFIER", 91, 96]]], ["This initiative was initially based on an evaluation of the business potential of biomass, with an analysis of the main material flows, coming from the sectors of agriculture, forestry, waste management and wastewater treatment, according to the indications of the Department of Energy.", [["an evaluation", "TEST", 39, 52], ["biomass", "PROBLEM", 82, 89], ["an analysis", "TEST", 96, 107], ["waste management", "TREATMENT", 186, 202], ["wastewater treatment", "TREATMENT", 207, 227], ["main", "OBSERVATION_MODIFIER", 115, 119], ["material flows", "OBSERVATION", 120, 134]]], ["These two regions generate agricultural waste of the order of 1.3 million tonnes per year and 8,198 tonnes per year respectively.", [["agricultural waste", "OBSERVATION", 27, 45]]], ["The recovery of this waste shows a potential of 417,806 MWh in the northern region, i.e. a saving of 0.33 million tons of oil.", [["oil", "ANATOMY", 122, 125], ["oil", "ORGANISM_SUBSTANCE", 122, 125]]], ["In the Souss-Massa area, a few pilot projects, financed by donors, have already been tested.Biomass program ::: Current status of major RE projects in MoroccoOther projects are under development to promote the exploitation of biomass as an energy source, and the most important of them are:\u2022Program for disseminating biogas digesters in the Souss-Massa region;\u2022Development of new biofuels technologies.", [["donors", "ORGANISM", 59, 65], ["disseminating biogas digesters", "TREATMENT", 303, 333], ["Massa", "ANATOMY", 13, 18], ["area", "ANATOMY_MODIFIER", 19, 23], ["few", "OBSERVATION_MODIFIER", 27, 30], ["pilot", "OBSERVATION_MODIFIER", 31, 36], ["biogas digesters", "OBSERVATION", 317, 333], ["Massa", "ANATOMY", 347, 352], ["new", "OBSERVATION_MODIFIER", 376, 379], ["biofuels technologies", "OBSERVATION", 380, 401]]]], "e1d18533a984250b32398bc1e121abdb2cb05ae7": [["IntroductionMolecular-based treatment options for cancer patients have historically consisted of antimetabolites (Gemcitabine/Gemzar\u00ae), topoisomerase poisons (CPT11/Camptostar\u00ae), tubulin stabilizers (Paclitaxel/Taxol\u00ae), and, more recently, protein kinase inhibitors (Imatinib/Gleevec\u00ae), with several additional classes undergoing clinical evaluation (e.g., HDAC inhibitors, phosphatase inhibitors, PARP inhibitors).", [["cancer", "ANATOMY", 50, 56], ["cancer", "DISEASE", 50, 56], ["Gemcitabine", "CHEMICAL", 114, 125], ["Gemzar\u00ae", "CHEMICAL", 126, 133], ["Paclitaxel", "CHEMICAL", 200, 210], ["Taxol\u00ae", "CHEMICAL", 211, 217], ["Imatinib", "CHEMICAL", 267, 275], ["Gleevec\u00ae", "CHEMICAL", 276, 284], ["Gemcitabine", "CHEMICAL", 114, 125], ["Gemzar\u00ae", "CHEMICAL", 126, 133], ["Paclitaxel", "CHEMICAL", 200, 210], ["Taxol\u00ae", "CHEMICAL", 211, 217], ["Imatinib", "CHEMICAL", 267, 275], ["cancer", "CANCER", 50, 56], ["patients", "ORGANISM", 57, 65], ["Gemcitabine", "SIMPLE_CHEMICAL", 114, 125], ["Gemzar\u00ae", "SIMPLE_CHEMICAL", 126, 133], ["topoisomerase poisons", "SIMPLE_CHEMICAL", 136, 157], ["CPT11", "SIMPLE_CHEMICAL", 159, 164], ["Camptostar\u00ae", "SIMPLE_CHEMICAL", 165, 176], ["tubulin stabilizers", "SIMPLE_CHEMICAL", 179, 198], ["Paclitaxel", "SIMPLE_CHEMICAL", 200, 210], ["Taxol\u00ae", "SIMPLE_CHEMICAL", 211, 217], ["Imatinib", "SIMPLE_CHEMICAL", 267, 275], ["Gleevec\u00ae", "SIMPLE_CHEMICAL", 276, 284], ["HDAC", "GENE_OR_GENE_PRODUCT", 357, 361], ["PARP", "GENE_OR_GENE_PRODUCT", 398, 402], ["topoisomerase", "PROTEIN", 136, 149], ["PARP", "PROTEIN", 398, 402], ["patients", "SPECIES", 57, 65], ["Molecular-based treatment options", "TREATMENT", 12, 45], ["cancer", "PROBLEM", 50, 56], ["antimetabolites (Gemcitabine/Gemzar\u00ae)", "TREATMENT", 97, 134], ["topoisomerase poisons", "TREATMENT", 136, 157], ["CPT11/Camptostar\u00ae)", "TREATMENT", 159, 177], ["tubulin stabilizers", "TREATMENT", 179, 198], ["Paclitaxel/Taxol\u00ae)", "TREATMENT", 200, 218], ["protein kinase inhibitors", "TREATMENT", 240, 265], ["Imatinib/Gleevec\u00ae)", "TREATMENT", 267, 285], ["clinical evaluation", "TEST", 330, 349], ["HDAC inhibitors", "TREATMENT", 357, 372], ["phosphatase inhibitors", "TREATMENT", 374, 396], ["PARP inhibitors", "TREATMENT", 398, 413]]], ["The era of molecular oncology drugs began in 2001 with the FDA approval (for chronic myelogenous leukemia) of Gleevec\u00ae, an inhibitor of the protein kinase Bcr-Abl, and, shortly thereafter, of other protein kinase inhibitors (e.g., Tykerb\u00ae, Tarceva\u00ae, Nexavar\u00ae) for various malignancies.", [["chronic myelogenous leukemia", "ANATOMY", 77, 105], ["malignancies", "ANATOMY", 272, 284], ["chronic myelogenous leukemia", "DISEASE", 77, 105], ["Gleevec\u00ae", "CHEMICAL", 110, 118], ["Nexavar\u00ae", "CHEMICAL", 250, 258], ["malignancies", "DISEASE", 272, 284], ["chronic myelogenous leukemia", "CANCER", 77, 105], ["Gleevec\u00ae", "SIMPLE_CHEMICAL", 110, 118], ["Bcr-Abl", "GENE_OR_GENE_PRODUCT", 155, 162], ["Tykerb\u00ae", "SIMPLE_CHEMICAL", 231, 238], ["Tarceva\u00ae", "SIMPLE_CHEMICAL", 240, 248], ["Nexavar\u00ae", "SIMPLE_CHEMICAL", 250, 258], ["malignancies", "CANCER", 272, 284], ["protein kinase", "PROTEIN", 140, 154], ["Bcr", "PROTEIN", 155, 158], ["Abl", "PROTEIN", 159, 162], ["molecular oncology drugs", "TREATMENT", 11, 35], ["chronic myelogenous leukemia", "PROBLEM", 77, 105], ["Gleevec\u00ae", "TREATMENT", 110, 118], ["the protein kinase Bcr", "TEST", 136, 158], ["other protein kinase inhibitors", "PROBLEM", 192, 223], ["Tykerb\u00ae", "TREATMENT", 231, 238], ["Tarceva\u00ae", "TREATMENT", 240, 248], ["Nexavar\u00ae", "TREATMENT", 250, 258], ["various malignancies", "PROBLEM", 264, 284], ["myelogenous leukemia", "OBSERVATION", 85, 105], ["malignancies", "OBSERVATION", 272, 284]]], ["These kinase inhibitors were the first of a new class of antitumor agent (targeted effector) that was developed to deliver efficacy accompanied by a reduced number and severity of side effects, compared with those of traditional toxic chemotherapeutic agents.", [["antitumor", "ANATOMY", 57, 66], ["antitumor", "CANCER", 57, 66], ["These kinase inhibitors", "TREATMENT", 0, 23], ["antitumor agent", "TREATMENT", 57, 72], ["a reduced number", "PROBLEM", 147, 163], ["side effects", "PROBLEM", 180, 192], ["traditional toxic chemotherapeutic agents", "TREATMENT", 217, 258], ["reduced", "OBSERVATION_MODIFIER", 149, 156], ["side effects", "OBSERVATION_MODIFIER", 180, 192]]], ["The attractiveness of this therapeutic strategy resides in the existence of a multitude of kinases, each with an identifiable function critical to cell growth, suggesting that selective pharmacologic action is possible.", [["cell", "ANATOMY", 147, 151], ["cell", "CELL", 147, 151], ["kinases", "PROTEIN", 91, 98], ["selective pharmacologic action", "TREATMENT", 176, 206], ["cell growth", "OBSERVATION", 147, 158], ["selective", "OBSERVATION_MODIFIER", 176, 185], ["pharmacologic", "OBSERVATION", 186, 199]]], ["The new, molecular targeted drugs impact various signaling pathways by posttranslational modification-addition (kinases) or removal (phosphatases) of a phosphate group to or from a serine, threonine, or tyrosine of a target protein, resulting most often in activation or deactivation of an enzyme.", [["phosphate", "CHEMICAL", 152, 161], ["threonine", "CHEMICAL", 189, 198], ["tyrosine", "CHEMICAL", 203, 211], ["phosphate", "CHEMICAL", 152, 161], ["serine", "CHEMICAL", 181, 187], ["threonine", "CHEMICAL", 189, 198], ["tyrosine", "CHEMICAL", 203, 211], ["phosphate", "SIMPLE_CHEMICAL", 152, 161], ["serine", "AMINO_ACID", 181, 187], ["threonine", "AMINO_ACID", 189, 198], ["tyrosine", "AMINO_ACID", 203, 211], ["kinases", "PROTEIN", 112, 119], ["phosphatases", "PROTEIN", 133, 145], ["enzyme", "PROTEIN", 290, 296], ["molecular targeted drugs", "TREATMENT", 9, 33], ["posttranslational modification-addition (kinases", "TREATMENT", 71, 119], ["removal (phosphatases", "TREATMENT", 124, 145], ["a phosphate group", "TREATMENT", 150, 167], ["a serine, threonine", "TREATMENT", 179, 198], ["an enzyme", "TEST", 287, 296], ["new", "OBSERVATION_MODIFIER", 4, 7], ["targeted drugs", "OBSERVATION", 19, 33]]], ["A parallel, but more complex post translational modification strategy is afforded by the ubiquitin-proteasome pathway, in which the 76-amino acid protein tag ubiquitin is conjugated to (by sequential action of the E1 activating enzyme, E2 conjugating enzyme, and E3 ligase) or deconjugated from \u03b5-amino groups of lysines of specific target proteins.", [["amino acid", "CHEMICAL", 135, 145], ["E2", "CHEMICAL", 236, 238], ["amino acid", "CHEMICAL", 135, 145], ["\u03b5-amino", "CHEMICAL", 295, 302], ["lysines", "CHEMICAL", 313, 320], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 158, 167], ["E2 conjugating enzyme", "GENE_OR_GENE_PRODUCT", 236, 257], ["E3", "GENE_OR_GENE_PRODUCT", 263, 265], ["proteasome", "PROTEIN", 99, 109], ["76-amino acid protein tag ubiquitin", "PROTEIN", 132, 167], ["E1 activating enzyme", "PROTEIN", 214, 234], ["E2 conjugating enzyme", "PROTEIN", 236, 257], ["E3 ligase", "PROTEIN", 263, 272], ["target proteins", "PROTEIN", 333, 348], ["amino acid protein tag ubiquitin", "TREATMENT", 135, 167], ["the E1 activating enzyme", "TEST", 210, 234], ["E2 conjugating enzyme", "TEST", 236, 257], ["E3 ligase", "TREATMENT", 263, 272], ["lysines", "TREATMENT", 313, 320]]], ["Consequences of ubiquitylation/de-ubiquitylation include changes in cellular half-life (and thus activity) of target proteins, cellular compartmentation, and trafficking between cytosol and nucleus or between the cell membrane and vesicles containing proteases.", [["cellular", "ANATOMY", 68, 76], ["cellular", "ANATOMY", 127, 135], ["cytosol", "ANATOMY", 178, 185], ["nucleus", "ANATOMY", 190, 197], ["cell membrane", "ANATOMY", 213, 226], ["vesicles", "ANATOMY", 231, 239], ["cellular", "CELL", 68, 76], ["cellular", "CELL", 127, 135], ["cytosol", "CELLULAR_COMPONENT", 178, 185], ["nucleus", "CELLULAR_COMPONENT", 190, 197], ["cell membrane", "CELLULAR_COMPONENT", 213, 226], ["vesicles", "CELLULAR_COMPONENT", 231, 239], ["target proteins", "PROTEIN", 110, 125], ["proteases", "PROTEIN", 251, 260], ["ubiquitylation/de-ubiquitylation", "TREATMENT", 16, 48], ["cellular compartmentation", "TEST", 127, 152], ["trafficking between cytosol and nucleus", "PROBLEM", 158, 197], ["cellular compartmentation", "OBSERVATION", 127, 152], ["nucleus", "ANATOMY", 190, 197], ["cell membrane", "OBSERVATION", 213, 226], ["vesicles", "ANATOMY", 231, 239]]], ["As in the case of kinases/phosphatases, selective action is possible owing to the large numbers of E3 ligases (several hundreds) and DUBs (approximately eighty).", [["E3", "GENE_OR_GENE_PRODUCT", 99, 101], ["DUBs", "GENE_OR_GENE_PRODUCT", 133, 137], ["kinases", "PROTEIN", 18, 25], ["phosphatases", "PROTEIN", 26, 38], ["E3 ligases", "PROTEIN", 99, 109], ["DUBs", "PROTEIN", 133, 137], ["kinases/phosphatases", "TEST", 18, 38], ["E3 ligases", "PROBLEM", 99, 109], ["DUBs", "TEST", 133, 137], ["large", "OBSERVATION_MODIFIER", 82, 87]]], ["However, in contrast to phosphorylation, the ubiquitin pathway includes additional levels of complexity.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 45, 54], ["the ubiquitin pathway", "TEST", 41, 62]]], ["Firstly, a single ubiquitin may be conjugated to a target protein or to a ubiquitin already conjugated to a protein, resulting in poly-ubiquitin chains.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 18, 27], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 74, 83], ["poly-ubiquitin chains", "SIMPLE_CHEMICAL", 130, 151], ["ubiquitin", "PROTEIN", 18, 27], ["ubiquitin", "PROTEIN", 74, 83], ["poly-ubiquitin chains", "PROTEIN", 130, 151], ["a single ubiquitin", "TREATMENT", 9, 27], ["a target protein", "PROBLEM", 49, 65], ["a protein", "TEST", 106, 115], ["poly-ubiquitin chains", "PROBLEM", 130, 151], ["poly-ubiquitin chains", "OBSERVATION", 130, 151]]], ["Moreover, the poly-ubiquitin chain linkage may be linear or branched, and may involve one of several lysines contained in the ubiquitin molecule (e.g., K63, K48, K11).", [["lysines", "CHEMICAL", 101, 108], ["poly-ubiquitin chain", "PROTEIN", 14, 34], ["ubiquitin molecule", "PROTEIN", 126, 144], ["K63", "PROTEIN", 152, 155], ["K48", "PROTEIN", 157, 160], ["K11", "PROTEIN", 162, 165], ["K63", "TEST", 152, 155], ["may be", "UNCERTAINTY", 43, 49], ["linear", "OBSERVATION_MODIFIER", 50, 56], ["branched", "OBSERVATION_MODIFIER", 60, 68], ["several", "OBSERVATION_MODIFIER", 93, 100], ["lysines", "OBSERVATION", 101, 108], ["ubiquitin molecule", "OBSERVATION", 126, 144]]], ["Consequently, the potential for selective binding of a ubiquitin pathway enzyme and/or an enzyme inhibitor to the ubiquitylated target protein must be considered in a more 3-dimensional setting.", [["ubiquitin pathway enzyme", "PROTEIN", 55, 79], ["ubiquitylated target protein", "PROTEIN", 114, 142], ["a ubiquitin pathway enzyme", "TEST", 53, 79], ["an enzyme inhibitor", "TREATMENT", 87, 106]]], ["The ubiquitinproteasome pathway offers a third target class-the proteasome itself, which receives poly-ubiquitylated proteins and degrades them utilizing various proteolytic activities.", [["proteasome", "PROTEIN", 64, 74], ["poly-ubiquitylated proteins", "PROTEIN", 98, 125], ["poly-ubiquitylated proteins", "TREATMENT", 98, 125], ["various proteolytic activities", "TREATMENT", 154, 184]]], ["During the past two decades, these three molecular target classes (two that are relatively selective and one that is nonselective) have been studied and exploited for anticancer drug development.", [["anticancer", "ANATOMY", 167, 177], ["anticancer", "CANCER", 167, 177], ["anticancer drug development", "PROBLEM", 167, 194]]], ["In fact, it was the global target, the proteasome, not the target-selective DUBs or ligases, which produced the first positive drug discovery results and the first efficacious ubiquitin pathway drug for cancer treatment, bortezomib, in 2003.IntroductionThe following is not meant to be a comprehensive accounting of the current state of ubiquitin pathway-based drug development, but rather an impressionistic view of the field in 2012 with some necessary citations.", [["cancer", "ANATOMY", 203, 209], ["cancer", "DISEASE", 203, 209], ["bortezomib", "CHEMICAL", 221, 231], ["bortezomib", "CHEMICAL", 221, 231], ["DUBs", "GENE_OR_GENE_PRODUCT", 76, 80], ["cancer", "CANCER", 203, 209], ["bortezomib", "SIMPLE_CHEMICAL", 221, 231], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 337, 346], ["proteasome", "PROTEIN", 39, 49], ["DUBs", "PROTEIN", 76, 80], ["ligases", "PROTEIN", 84, 91], ["ubiquitin", "PROTEIN", 337, 346], ["the proteasome", "TREATMENT", 35, 49], ["cancer treatment", "TREATMENT", 203, 219], ["bortezomib", "TREATMENT", 221, 231], ["ubiquitin pathway", "PROBLEM", 337, 354], ["an impressionistic view", "TEST", 390, 413]]], ["It is focused on cancer, though ubiquitin is relevant to all cell processes and thus all pathologies, and it considers in order the proteasome, the E1-E2-E3 enzyme sequence, and the deubiquitylation reaction as potential or actual sources of new ubiquitin drugs.Bortezomib: an unanticipated success storyThe simple consequence of blocking cellular protein degradation in the proteasome is the accumulation of ubiquitylated proteins of all sorts, which appears upon first consideration to be an intolerable consequence for any cell.", [["cancer", "ANATOMY", 17, 23], ["cell", "ANATOMY", 61, 65], ["cellular", "ANATOMY", 339, 347], ["cell", "ANATOMY", 526, 530], ["cancer", "DISEASE", 17, 23], ["Bortezomib", "CHEMICAL", 262, 272], ["Bortezomib", "CHEMICAL", 262, 272], ["cancer", "CANCER", 17, 23], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 32, 41], ["cell", "CELL", 61, 65], ["E3", "GENE_OR_GENE_PRODUCT", 154, 156], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 246, 255], ["Bortezomib", "SIMPLE_CHEMICAL", 262, 272], ["cellular", "CELL", 339, 347], ["cell", "CELL", 526, 530], ["ubiquitin", "PROTEIN", 32, 41], ["proteasome", "PROTEIN", 132, 142], ["E1", "PROTEIN", 148, 150], ["E2", "PROTEIN", 151, 153], ["E3 enzyme sequence", "PROTEIN", 154, 172], ["proteasome", "PROTEIN", 375, 385], ["ubiquitylated proteins", "PROTEIN", 409, 431], ["cancer", "PROBLEM", 17, 23], ["all pathologies", "PROBLEM", 85, 100], ["the E1-E2-E3 enzyme sequence", "TEST", 144, 172], ["the deubiquitylation reaction", "PROBLEM", 178, 207], ["new ubiquitin drugs", "TREATMENT", 242, 261], ["blocking cellular protein degradation", "PROBLEM", 330, 367], ["ubiquitylated proteins", "PROBLEM", 409, 431], ["an intolerable consequence", "PROBLEM", 491, 517], ["any cell", "PROBLEM", 522, 530], ["cancer", "OBSERVATION", 17, 23], ["ubiquitin drugs", "OBSERVATION", 246, 261], ["simple", "OBSERVATION_MODIFIER", 308, 314], ["blocking cellular", "OBSERVATION", 330, 347], ["protein degradation", "OBSERVATION", 348, 367], ["accumulation", "OBSERVATION_MODIFIER", 393, 405], ["ubiquitylated proteins", "OBSERVATION", 409, 431], ["all sorts", "OBSERVATION_MODIFIER", 435, 444]]], ["The proteasome was thought of as the cell's garbage disposal unit, and its blockade assumed to result in a huge excess of unwanted proteins-a toxic event.", [["cell", "ANATOMY", 37, 41], ["cell", "CELL", 37, 41], ["proteasome", "PROTEIN", 4, 14], ["unwanted proteins", "PROTEIN", 122, 139], ["The proteasome", "TREATMENT", 0, 14], ["unwanted proteins", "PROBLEM", 122, 139], ["a toxic event", "PROBLEM", 140, 153]]], ["On the contrary, however, this global response has been harnessed to provide antitumor activity against multiple myeloma and mantle cell lymphomas in patients, accompanied by manageable toxicity.", [["antitumor", "ANATOMY", 77, 86], ["myeloma", "ANATOMY", 113, 120], ["mantle cell lymphomas", "ANATOMY", 125, 146], ["multiple myeloma", "DISEASE", 104, 120], ["mantle cell lymphomas", "DISEASE", 125, 146], ["toxicity", "DISEASE", 186, 194], ["antitumor", "CANCER", 77, 86], ["myeloma", "CANCER", 113, 120], ["mantle cell lymphomas", "CANCER", 125, 146], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["multiple myeloma", "PROBLEM", 104, 120], ["mantle cell lymphomas", "PROBLEM", 125, 146], ["manageable toxicity", "PROBLEM", 175, 194], ["myeloma", "OBSERVATION", 113, 120], ["mantle cell lymphomas", "OBSERVATION", 125, 146], ["manageable", "OBSERVATION_MODIFIER", 175, 185], ["toxicity", "OBSERVATION", 186, 194]]], ["In 2003 [1] , bortezomib, a dipeptidylboronic acid that binds reversibly to the \u03b25 subunit of the 20S degradation chamber of the proteasome and thereby inhibits it, was approved by the FDA for treatment of relapsed refractory multiple melanoma, following impressive activity in clinical trials [2] .", [["melanoma", "ANATOMY", 235, 243], ["bortezomib", "CHEMICAL", 14, 24], ["dipeptidylboronic acid", "CHEMICAL", 28, 50], ["multiple melanoma", "DISEASE", 226, 243], ["bortezomib", "CHEMICAL", 14, 24], ["dipeptidylboronic acid", "CHEMICAL", 28, 50], ["bortezomib", "SIMPLE_CHEMICAL", 14, 24], ["dipeptidylboronic acid", "SIMPLE_CHEMICAL", 28, 50], ["20S", "GENE_OR_GENE_PRODUCT", 98, 101], ["melanoma", "CANCER", 235, 243], ["\u03b25 subunit", "PROTEIN", 80, 90], ["20S", "PROTEIN", 98, 101], ["proteasome", "PROTEIN", 129, 139], ["bortezomib", "TREATMENT", 14, 24], ["a dipeptidylboronic acid", "TREATMENT", 26, 50], ["the proteasome", "TREATMENT", 125, 139], ["relapsed refractory multiple melanoma", "PROBLEM", 206, 243], ["relapsed", "OBSERVATION_MODIFIER", 206, 214], ["refractory", "OBSERVATION_MODIFIER", 215, 225], ["multiple", "OBSERVATION_MODIFIER", 226, 234], ["melanoma", "OBSERVATION", 235, 243]]], ["Subsequently, bortezomib was approved for first line treatment of multiple myeloma and for the treatment of relapsed mantle cell lymphoma [3] .", [["myeloma", "ANATOMY", 75, 82], ["mantle cell lymphoma", "ANATOMY", 117, 137], ["bortezomib", "CHEMICAL", 14, 24], ["multiple myeloma", "DISEASE", 66, 82], ["mantle cell lymphoma", "DISEASE", 117, 137], ["bortezomib", "CHEMICAL", 14, 24], ["bortezomib", "SIMPLE_CHEMICAL", 14, 24], ["myeloma", "CANCER", 75, 82], ["mantle cell lymphoma", "CANCER", 117, 137], ["bortezomib", "TREATMENT", 14, 24], ["first line treatment", "TREATMENT", 42, 62], ["multiple myeloma", "PROBLEM", 66, 82], ["relapsed mantle cell lymphoma", "PROBLEM", 108, 137], ["multiple", "OBSERVATION_MODIFIER", 66, 74], ["myeloma", "OBSERVATION", 75, 82], ["relapsed", "OBSERVATION_MODIFIER", 108, 116], ["mantle cell lymphoma", "OBSERVATION", 117, 137]]], ["This compound had been studied extensively during preclinical and clinical development to elucidate its mechanisms of cytotoxicity and its preference for tumor vs. normal cells (reviewed in [4] ).", [["tumor", "ANATOMY", 154, 159], ["cells", "ANATOMY", 171, 176], ["tumor", "DISEASE", 154, 159], ["tumor", "CANCER", 154, 159], ["cells", "CELL", 171, 176], ["normal cells", "CELL_TYPE", 164, 176], ["cytotoxicity", "PROBLEM", 118, 130], ["tumor vs", "PROBLEM", 154, 162], ["cells", "OBSERVATION", 171, 176]]], ["Because of bortezomib's clinical success, mechanism studies of this drug and other proteasome inhibitors have received less attention than the clinical studies, as bortezomib is active in numerous combinations and may have expanded clinical utility.", [["bortezomib", "CHEMICAL", 11, 21], ["bortezomib", "CHEMICAL", 164, 174], ["bortezomib", "CHEMICAL", 11, 21], ["bortezomib", "CHEMICAL", 164, 174], ["bortezomib", "SIMPLE_CHEMICAL", 11, 21], ["bortezomib", "SIMPLE_CHEMICAL", 164, 174], ["bortezomib", "PROBLEM", 11, 21], ["mechanism studies", "TEST", 42, 59], ["this drug", "TREATMENT", 63, 72], ["other proteasome inhibitors", "TREATMENT", 77, 104], ["the clinical studies", "TEST", 139, 159], ["bortezomib", "TREATMENT", 164, 174], ["bortezomib", "OBSERVATION", 11, 21], ["active", "OBSERVATION_MODIFIER", 178, 184]]], ["As expected, numerous proteins responsible for apoptosis (e.g. p53) were found to be degraded by the proteasome and it is now clear that inhibition of proteasome activity leads to apoptosis by sparing these proteins.", [["p53", "GENE_OR_GENE_PRODUCT", 63, 66], ["p53", "PROTEIN", 63, 66], ["proteasome", "PROTEIN", 101, 111], ["proteasome", "PROTEIN", 151, 161], ["numerous proteins", "PROBLEM", 13, 30], ["apoptosis", "PROBLEM", 47, 56], ["the proteasome", "TREATMENT", 97, 111], ["proteasome activity", "PROBLEM", 151, 170], ["apoptosis", "PROBLEM", 180, 189]]], ["Proteasome inhibitors may also induce apoptosis indirectly by inhibiting NF-\u03baB activation [5] , thereby preventing transcription of various anti-apoptotic proteins.", [["Proteasome", "GENE_OR_GENE_PRODUCT", 0, 10], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 73, 78], ["NF-\u03baB", "PROTEIN", 73, 78], ["anti-apoptotic proteins", "PROTEIN", 140, 163], ["Proteasome inhibitors", "TREATMENT", 0, 21], ["apoptosis", "PROBLEM", 38, 47], ["various anti-apoptotic proteins", "TREATMENT", 132, 163]]], ["In addition, cellular mechanism studies have suggested that bortezomib inhibits angiogenesis, which could contribute to its antitumor activity [6] , is efficacious in various combination therapies, and can overcome resistance to traditional cytotoxic therapies [7] .", [["cellular", "ANATOMY", 13, 21], ["antitumor", "ANATOMY", 124, 133], ["bortezomib", "CHEMICAL", 60, 70], ["bortezomib", "CHEMICAL", 60, 70], ["cellular", "CELL", 13, 21], ["bortezomib", "SIMPLE_CHEMICAL", 60, 70], ["antitumor", "CANCER", 124, 133], ["cellular mechanism studies", "TEST", 13, 39], ["bortezomib inhibits angiogenesis", "PROBLEM", 60, 92], ["various combination therapies", "TREATMENT", 167, 196], ["traditional cytotoxic therapies", "TREATMENT", 229, 260], ["bortezomib", "OBSERVATION", 60, 70]]], ["Thus, although bortezomib has a reasonable therapeutic index, it is a pleiotropic cytotoxic drug (producing peripheral neuropathy and other toxicities commonly associated with chemotherapeutic agents).", [["bortezomib", "CHEMICAL", 15, 25], ["peripheral neuropathy", "DISEASE", 108, 129], ["toxicities", "DISEASE", 140, 150], ["bortezomib", "CHEMICAL", 15, 25], ["bortezomib", "SIMPLE_CHEMICAL", 15, 25], ["bortezomib", "TREATMENT", 15, 25], ["a pleiotropic cytotoxic drug", "PROBLEM", 68, 96], ["peripheral neuropathy", "PROBLEM", 108, 129], ["other toxicities", "PROBLEM", 134, 150], ["chemotherapeutic agents", "TREATMENT", 176, 199], ["cytotoxic drug", "OBSERVATION", 82, 96], ["neuropathy", "OBSERVATION", 119, 129]]], ["Its therapeutic window is very narrow, as dose-limiting toxicities are evident just above the treatment dose.", [["toxicities", "DISEASE", 56, 66], ["Its therapeutic window", "TREATMENT", 0, 22], ["limiting toxicities", "PROBLEM", 47, 66], ["therapeutic window", "OBSERVATION", 4, 22], ["very", "OBSERVATION_MODIFIER", 26, 30], ["narrow", "OBSERVATION_MODIFIER", 31, 37]]], ["Moreover, due in part Table 1 Proteasome inhibitors currently in clinical development or approved by the FDA.Bortezomib: an unanticipated success storyto mutations in the \u03b25 chymotrypsin-like catalytic subunit of the proteasome, resistance to bortezomib is becoming evident [8, 9] .Other proteasome inhibitors in clinical trialWhile MLN-9708 and CEP-18770 are both reversible inhibitors like bortezomib, they offer the potential advantage of oral administration, which may improve patient experience even though they may not be superior to bortezomib in therapeutic index or susceptibility to resistance.", [["oral", "ANATOMY", 442, 446], ["Bortezomib", "CHEMICAL", 109, 119], ["bortezomib", "CHEMICAL", 243, 253], ["MLN-9708", "CHEMICAL", 333, 341], ["CEP-18770", "CHEMICAL", 346, 355], ["bortezomib", "CHEMICAL", 392, 402], ["bortezomib", "CHEMICAL", 540, 550], ["Bortezomib", "CHEMICAL", 109, 119], ["bortezomib", "CHEMICAL", 243, 253], ["MLN-9708", "CHEMICAL", 333, 341], ["CEP-18770", "CHEMICAL", 346, 355], ["bortezomib", "CHEMICAL", 392, 402], ["bortezomib", "CHEMICAL", 540, 550], ["Proteasome", "GENE_OR_GENE_PRODUCT", 30, 40], ["Bortezomib", "SIMPLE_CHEMICAL", 109, 119], ["\u03b25 chymotrypsin", "GENE_OR_GENE_PRODUCT", 171, 186], ["bortezomib", "SIMPLE_CHEMICAL", 243, 253], ["MLN-9708", "SIMPLE_CHEMICAL", 333, 341], ["CEP-18770", "SIMPLE_CHEMICAL", 346, 355], ["bortezomib", "SIMPLE_CHEMICAL", 392, 402], ["oral", "ORGANISM_SUBDIVISION", 442, 446], ["patient", "ORGANISM", 481, 488], ["bortezomib", "SIMPLE_CHEMICAL", 540, 550], ["\u03b25 chymotrypsin-like catalytic subunit", "PROTEIN", 171, 209], ["proteasome", "PROTEIN", 217, 227], ["patient", "SPECIES", 481, 488], ["MLN-9708", "SPECIES", 333, 341], ["Proteasome inhibitors", "TREATMENT", 30, 51], ["Bortezomib", "TREATMENT", 109, 119], ["an unanticipated success storyto mutations", "TREATMENT", 121, 163], ["the \u03b25 chymotrypsin", "TREATMENT", 167, 186], ["the proteasome", "TREATMENT", 213, 227], ["resistance to bortezomib", "TREATMENT", 229, 253], ["Other proteasome inhibitors", "TREATMENT", 282, 309], ["CEP", "TEST", 346, 349], ["bortezomib", "TREATMENT", 392, 402], ["oral administration", "TREATMENT", 442, 461], ["bortezomib", "TREATMENT", 540, 550]]], ["However, other latter-generation proteasome inhibitors now in clinical trial (Table 1 ) may have improved therapeutic index and in part due to a different mode of binding a diminished tendency to be compromised by resistance as compared with bortezomib [9] .", [["bortezomib", "CHEMICAL", 242, 252], ["bortezomib", "CHEMICAL", 242, 252], ["bortezomib", "SIMPLE_CHEMICAL", 242, 252], ["latter-generation proteasome inhibitors", "TREATMENT", 15, 54], ["a different mode of binding", "PROBLEM", 143, 170], ["a diminished tendency", "PROBLEM", 171, 192], ["bortezomib", "TREATMENT", 242, 252]]], ["To address these clinical challenges, two proteasome-related strategies have emerged.", [["proteasome", "PROTEIN", 42, 52], ["two proteasome-related strategies", "TREATMENT", 38, 71]]], ["For example, carfilzomib, the next inhibitor scheduled for FDA review, is an irreversible binder to the chymotrypsin-like \u03b25 site, in contrast to bortezomib, which binds reversibly.", [["carfilzomib", "CHEMICAL", 13, 24], ["bortezomib", "CHEMICAL", 146, 156], ["carfilzomib", "CHEMICAL", 13, 24], ["bortezomib", "CHEMICAL", 146, 156], ["carfilzomib", "SIMPLE_CHEMICAL", 13, 24], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 104, 116], ["bortezomib", "SIMPLE_CHEMICAL", 146, 156], ["chymotrypsin", "PROTEIN", 104, 116], ["\u03b25 site", "DNA", 122, 129], ["carfilzomib", "TREATMENT", 13, 24], ["the next inhibitor", "TREATMENT", 26, 44], ["an irreversible binder", "PROBLEM", 74, 96], ["the chymotrypsin", "TREATMENT", 100, 116], ["bortezomib", "TREATMENT", 146, 156]]], ["The epoxyketonecarfilzomib is a more potent inhibitor than bortezomib, contributing to an improved therapeutic index.", [["epoxyketonecarfilzomib", "CHEMICAL", 4, 26], ["bortezomib", "CHEMICAL", 59, 69], ["epoxyketonecarfilzomib", "CHEMICAL", 4, 26], ["bortezomib", "CHEMICAL", 59, 69], ["epoxyketonecarfilzomib", "SIMPLE_CHEMICAL", 4, 26], ["bortezomib", "SIMPLE_CHEMICAL", 59, 69], ["The epoxyketonecarfilzomib", "TREATMENT", 0, 26], ["a more potent inhibitor", "TREATMENT", 30, 53], ["bortezomib", "TREATMENT", 59, 69], ["an improved therapeutic index", "PROBLEM", 87, 116]]], ["The second strategy exploits proteasome heterogeneity.", [["proteasome", "PROTEIN", 29, 39], ["proteasome heterogeneity", "PROBLEM", 29, 53], ["proteasome heterogeneity", "OBSERVATION", 29, 53]]], ["In addition to the classical (\"constitutive\") proteasome, which is present in all cells, some cells contain a second proteasome that differs from the constitutive proteasome in the \u03b21, \u03b22, and \u03b25 catalytic subunits (denoted as \u03b21i, \u03b22i, and \u03b25i for the immunoproteasome) and contains an 11S regulatory particle [10] ).", [["cells", "ANATOMY", 82, 87], ["cells", "ANATOMY", 94, 99], ["cells", "CELL", 82, 87], ["cells", "CELL", 94, 99], ["\u03b21", "GENE_OR_GENE_PRODUCT", 181, 183], ["\u03b22", "GENE_OR_GENE_PRODUCT", 185, 187], ["\u03b25", "GENE_OR_GENE_PRODUCT", 193, 195], ["\u03b21i", "GENE_OR_GENE_PRODUCT", 227, 230], ["\u03b22i", "GENE_OR_GENE_PRODUCT", 232, 235], ["\u03b25i", "GENE_OR_GENE_PRODUCT", 241, 244], ["proteasome", "PROTEIN", 46, 56], ["proteasome", "PROTEIN", 117, 127], ["constitutive proteasome", "PROTEIN", 150, 173], ["\u03b21", "PROTEIN", 181, 183], ["\u03b22", "PROTEIN", 185, 187], ["\u03b25 catalytic subunits", "PROTEIN", 193, 214], ["\u03b21i", "PROTEIN", 227, 230], ["\u03b22i", "PROTEIN", 232, 235], ["\u03b25i", "PROTEIN", 241, 244], ["immunoproteasome", "PROTEIN", 253, 269], ["the classical (\"constitutive\") proteasome", "PROBLEM", 15, 56], ["some cells", "PROBLEM", 89, 99], ["the constitutive proteasome", "TREATMENT", 146, 173], ["constitutive proteasome", "OBSERVATION", 150, 173]]], ["Because this second proteasome type can be induced by interferon and generates antigenic peptides for the immune response, it is known as the immunoproteasome.", [["interferon", "PROTEIN", 54, 64], ["immunoproteasome", "PROTEIN", 142, 158], ["interferon", "TREATMENT", 54, 64], ["antigenic peptides", "TREATMENT", 79, 97], ["the immunoproteasome", "TREATMENT", 138, 158]]], ["The heterogeneity strategy is also exemplified by carfilzomib, which inhibits both constitutive proteasomes and immunoproteasomes and overcomes bortezomib resistance in preclinical models [11] .", [["carfilzomib", "CHEMICAL", 50, 61], ["bortezomib", "CHEMICAL", 144, 154], ["carfilzomib", "CHEMICAL", 50, 61], ["bortezomib", "CHEMICAL", 144, 154], ["carfilzomib", "SIMPLE_CHEMICAL", 50, 61], ["bortezomib", "SIMPLE_CHEMICAL", 144, 154], ["constitutive proteasomes", "PROTEIN", 83, 107], ["immunoproteasomes", "PROTEIN", 112, 129], ["The heterogeneity strategy", "PROBLEM", 0, 26], ["carfilzomib", "PROBLEM", 50, 61], ["constitutive proteasomes", "PROBLEM", 83, 107], ["immunoproteasomes", "TREATMENT", 112, 129], ["bortezomib resistance", "TREATMENT", 144, 165], ["heterogeneity", "OBSERVATION", 4, 17], ["carfilzomib", "OBSERVATION", 50, 61], ["constitutive proteasomes", "OBSERVATION", 83, 107]]], ["It is interesting to note that the most potent experimental immunoproteasome inhibitor, IPSI-001, preferentially targets the \u03b21i subunit of the immunoproteasome and, like carfilzomib, overcomes resistance to bortezomib [12] .", [["IPSI-001", "CHEMICAL", 88, 96], ["carfilzomib", "CHEMICAL", 171, 182], ["bortezomib", "CHEMICAL", 208, 218], ["IPSI-001", "CHEMICAL", 88, 96], ["carfilzomib", "CHEMICAL", 171, 182], ["bortezomib", "CHEMICAL", 208, 218], ["IPSI-001", "SIMPLE_CHEMICAL", 88, 96], ["\u03b21i", "GENE_OR_GENE_PRODUCT", 125, 128], ["carfilzomib", "SIMPLE_CHEMICAL", 171, 182], ["bortezomib", "SIMPLE_CHEMICAL", 208, 218], ["\u03b21i subunit", "PROTEIN", 125, 136], ["immunoproteasome", "PROTEIN", 144, 160], ["experimental immunoproteasome inhibitor", "TREATMENT", 47, 86], ["IPSI", "TREATMENT", 88, 92], ["the immunoproteasome", "TREATMENT", 140, 160], ["carfilzomib", "TREATMENT", 171, 182], ["bortezomib", "TREATMENT", 208, 218]]], ["An orally bioavailable truncated version of carfilzomib, ONX 0192, is in Phase I clinical trial.", [["carfilzomib", "CHEMICAL", 44, 55], ["ONX 0192", "CHEMICAL", 57, 65], ["carfilzomib", "CHEMICAL", 44, 55], ["ONX 0192", "CHEMICAL", 57, 65], ["carfilzomib", "SIMPLE_CHEMICAL", 44, 55], ["ONX", "SIMPLE_CHEMICAL", 57, 60], ["carfilzomib", "TREATMENT", 44, 55]]], ["Another potential means of overcoming resistance to bortezomib lies in the ability of the irreversible Phase I proteasome inhibitor NPI0052 which in contrast to bortezomib inhibits the trypsin-like as well as chymotrypsin-like protease activity [13] .Experimental (preclinical) proteasome inhibitorsProteasome inhibitors currently in preclinical development are addressing the issues of therapeutic index (including the need for activity in a broad spectrum of solid tumors) and resistance in various ways.", [["solid tumors", "ANATOMY", 461, 473], ["bortezomib", "CHEMICAL", 52, 62], ["NPI0052", "CHEMICAL", 132, 139], ["bortezomib", "CHEMICAL", 161, 171], ["tumors", "DISEASE", 467, 473], ["bortezomib", "CHEMICAL", 52, 62], ["NPI0052", "CHEMICAL", 132, 139], ["bortezomib", "CHEMICAL", 161, 171], ["bortezomib", "SIMPLE_CHEMICAL", 52, 62], ["Phase I proteasome", "GENE_OR_GENE_PRODUCT", 103, 121], ["NPI0052", "SIMPLE_CHEMICAL", 132, 139], ["bortezomib", "SIMPLE_CHEMICAL", 161, 171], ["trypsin", "GENE_OR_GENE_PRODUCT", 185, 192], ["chymotrypsin-like protease", "GENE_OR_GENE_PRODUCT", 209, 235], ["Proteasome", "GENE_OR_GENE_PRODUCT", 299, 309], ["solid tumors", "CANCER", 461, 473], ["Phase I proteasome", "PROTEIN", 103, 121], ["trypsin", "PROTEIN", 185, 192], ["chymotrypsin", "PROTEIN", 209, 221], ["protease", "PROTEIN", 227, 235], ["proteasome inhibitors", "PROTEIN", 278, 299], ["bortezomib", "TREATMENT", 52, 62], ["the irreversible Phase I proteasome inhibitor", "TREATMENT", 86, 131], ["bortezomib", "TREATMENT", 161, 171], ["the trypsin", "TREATMENT", 181, 192], ["chymotrypsin", "TREATMENT", 209, 221], ["Experimental (preclinical) proteasome inhibitors", "TREATMENT", 251, 299], ["Proteasome inhibitors", "TREATMENT", 299, 320], ["therapeutic index", "PROBLEM", 387, 404], ["solid tumors", "PROBLEM", 461, 473], ["tumors", "OBSERVATION", 467, 473]]], ["Following up on an observation in the Goldberg laboratory suggesting that allosteric interactions among the proteasome subunits may offer additional therapeutic strategies [14] , Kisselev et al. have developed inhibitors that are selective for \u03b21 (caspase-like [15] ) or \u03b22 (trypsin-like [16] ) subunits and have shown that trypsin site-selective inhibitors can sensitize myeloma cells to chymotrypsin-like site inhibitors such as bortezomib and, in combination with caspase-like site inhibitors, inhibit cell growth in the absence of chymotrypsin-like site inhibitors [16] .", [["myeloma cells", "ANATOMY", 372, 385], ["cell", "ANATOMY", 505, 509], ["myeloma", "DISEASE", 372, 379], ["bortezomib", "CHEMICAL", 431, 441], ["bortezomib", "CHEMICAL", 431, 441], ["\u03b21", "GENE_OR_GENE_PRODUCT", 244, 246], ["caspase-like [15]", "GENE_OR_GENE_PRODUCT", 248, 265], ["\u03b22", "GENE_OR_GENE_PRODUCT", 271, 273], ["trypsin", "GENE_OR_GENE_PRODUCT", 275, 282], ["trypsin", "GENE_OR_GENE_PRODUCT", 324, 331], ["myeloma cells", "CELL", 372, 385], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 389, 401], ["bortezomib", "SIMPLE_CHEMICAL", 431, 441], ["caspase", "GENE_OR_GENE_PRODUCT", 467, 474], ["cell", "CELL", 505, 509], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 535, 547], ["proteasome subunits", "PROTEIN", 108, 127], ["\u03b21", "PROTEIN", 244, 246], ["caspase", "PROTEIN", 248, 255], ["\u03b22 (trypsin-like [16] ) subunits", "PROTEIN", 271, 303], ["trypsin", "PROTEIN", 324, 331], ["myeloma cells", "CELL_LINE", 372, 385], ["chymotrypsin", "PROTEIN", 389, 401], ["caspase", "PROTEIN", 467, 474], ["chymotrypsin", "PROTEIN", 535, 547], ["an observation", "TEST", 16, 30], ["allosteric interactions", "PROBLEM", 74, 97], ["the proteasome subunits", "TREATMENT", 104, 127], ["additional therapeutic strategies", "TREATMENT", 138, 171], ["Kisselev et al", "TREATMENT", 179, 193], ["inhibitors", "TREATMENT", 210, 220], ["caspase", "TEST", 248, 255], ["\u03b22 (trypsin", "TREATMENT", 271, 282], ["subunits", "TREATMENT", 295, 303], ["trypsin site", "PROBLEM", 324, 336], ["selective inhibitors", "TREATMENT", 337, 357], ["myeloma cells", "PROBLEM", 372, 385], ["chymotrypsin", "TREATMENT", 389, 401], ["site inhibitors", "TREATMENT", 407, 422], ["bortezomib", "TREATMENT", 431, 441], ["caspase", "TREATMENT", 467, 474], ["site inhibitors", "TREATMENT", 480, 495], ["inhibit cell growth", "PROBLEM", 497, 516], ["chymotrypsin-like site inhibitors", "TREATMENT", 535, 568]]], ["Other studies have identified various known small molecules (e.g., chloroquine and more potent substituted chloroquines such as 5AHQ) as allosteric inhibitors with clinical potential (reviewed in [10] ) ( Table 2 ).", [["chloroquine", "CHEMICAL", 67, 78], ["chloroquines", "CHEMICAL", 107, 119], ["5AHQ", "CHEMICAL", 128, 132], ["chloroquine", "CHEMICAL", 67, 78], ["chloroquines", "CHEMICAL", 107, 119], ["5AHQ", "CHEMICAL", 128, 132], ["chloroquine", "SIMPLE_CHEMICAL", 67, 78], ["chloroquines", "SIMPLE_CHEMICAL", 107, 119], ["5AHQ", "SIMPLE_CHEMICAL", 128, 132], ["Other studies", "TEST", 0, 13], ["various known small molecules", "PROBLEM", 30, 59], ["chloroquine", "TREATMENT", 67, 78], ["more potent substituted chloroquines", "TREATMENT", 83, 119], ["allosteric inhibitors", "TREATMENT", 137, 158], ["small", "OBSERVATION_MODIFIER", 44, 49], ["molecules", "OBSERVATION", 50, 59]]], ["It is anticipated that allosteric proteasome inhibitors similar to these will enter clinical trial within the next few years.", [["allosteric proteasome inhibitors", "TREATMENT", 23, 55]]], ["Another class, represented by clioquinol, may work by binding metals that are essential to the proteasome [10] .", [["clioquinol", "CHEMICAL", 30, 40], ["clioquinol", "CHEMICAL", 30, 40], ["clioquinol", "SIMPLE_CHEMICAL", 30, 40], ["proteasome", "PROTEIN", 95, 105], ["clioquinol", "TREATMENT", 30, 40]]], ["Finally, deubiquitylating activity resident in the 19S regulatory portion of the intact proteasome has recently been identified as a novel anticancer target using the small molecule b-AP15, found in a functional screen [17] .", [["anticancer", "ANATOMY", 139, 149], ["anticancer", "CANCER", 139, 149], ["b-AP15", "GENE_OR_GENE_PRODUCT", 182, 188], ["19S regulatory portion", "PROTEIN", 51, 73], ["proteasome", "PROTEIN", 88, 98], ["small molecule b", "PROTEIN", 167, 183], ["AP15", "PROTEIN", 184, 188], ["the intact proteasome", "TREATMENT", 77, 98], ["a novel anticancer", "TREATMENT", 131, 149], ["a functional screen", "TEST", 199, 218], ["small", "OBSERVATION_MODIFIER", 167, 172]]], ["This compound selectively inhibited the deubiquitylating activity of the 19S associated DUBs UCH-L5 and Table 2 Experimental proteasome inhibitors.4USP14, resulting in a blockade of proteasome activity; it thus represents a very early but promising class of proteasome inhibitor.4An alternative strategy to targeting the proteasome is to target enzymes upstream of the proteasome.", [["4USP14", "CHEMICAL", 147, 153], ["UCH-L5", "GENE_OR_GENE_PRODUCT", 93, 99], ["4USP14", "SIMPLE_CHEMICAL", 147, 153], ["4An", "SIMPLE_CHEMICAL", 279, 282], ["19S associated DUBs UCH-L5 and Table 2", "PROTEIN", 73, 111], ["4USP14", "PROTEIN", 147, 153], ["proteasome", "PROTEIN", 182, 192], ["proteasome", "PROTEIN", 321, 331], ["proteasome", "PROTEIN", 369, 379], ["Experimental proteasome inhibitors", "TREATMENT", 112, 146], ["4USP14", "TREATMENT", 147, 153], ["a blockade of proteasome activity", "TREATMENT", 168, 201], ["proteasome inhibitor", "TREATMENT", 258, 278], ["the proteasome", "TREATMENT", 317, 331], ["the proteasome", "TREATMENT", 365, 379], ["L5", "ANATOMY", 97, 99], ["proteasome activity", "OBSERVATION", 182, 201]]], ["In general these enzymes are considered attractive targets due to the fact that there are multiple enzymes that modulate ubiquitin conjugation and deconjugation.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 121, 130], ["enzymes", "PROTEIN", 17, 24], ["these enzymes", "TEST", 11, 24], ["multiple enzymes", "PROBLEM", 90, 106], ["ubiquitin conjugation", "OBSERVATION", 121, 142]]], ["Thus, targeting these enzymes offers a greater degree of specificity and therefore a reduced potential for side effects.", [["enzymes", "PROTEIN", 22, 29], ["these enzymes", "TEST", 16, 29], ["side effects", "PROBLEM", 107, 119], ["greater degree", "OBSERVATION_MODIFIER", 39, 53]]], ["Below we discuss the current status of small molecule therapeutics that target ubiquitin conjugation (E1, E2 and E3) and deconjugation (DUBs).E1, E2, and E3 ligase inhibitorsThe three enzymes sequentially involved in target protein ubiquitylation (E1 activating, E2 conjugating, and E3 ligase enzymes) are currently active targets in anticancer drug discovery [18] .", [["anticancer", "ANATOMY", 334, 344], ["E2", "CHEMICAL", 106, 108], ["E2", "CHEMICAL", 146, 148], ["E2", "CHEMICAL", 263, 265], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 79, 88], ["E1", "GENE_OR_GENE_PRODUCT", 102, 104], ["E2", "GENE_OR_GENE_PRODUCT", 106, 108], ["E3", "GENE_OR_GENE_PRODUCT", 113, 115], ["DUBs", "GENE_OR_GENE_PRODUCT", 136, 140], ["E1", "GENE_OR_GENE_PRODUCT", 142, 144], ["E2", "GENE_OR_GENE_PRODUCT", 146, 148], ["E3", "GENE_OR_GENE_PRODUCT", 154, 156], ["E1", "GENE_OR_GENE_PRODUCT", 248, 250], ["E2", "GENE_OR_GENE_PRODUCT", 263, 265], ["E3", "GENE_OR_GENE_PRODUCT", 283, 285], ["anticancer", "CANCER", 334, 344], ["E1", "PROTEIN", 102, 104], ["E2", "PROTEIN", 106, 108], ["E3", "PROTEIN", 113, 115], ["DUBs", "PROTEIN", 136, 140], ["E1", "PROTEIN", 142, 144], ["E3 ligase inhibitors", "PROTEIN", 154, 174], ["E1", "PROTEIN", 248, 250], ["E3 ligase enzymes", "PROTEIN", 283, 300], ["small molecule therapeutics", "TREATMENT", 39, 66], ["target ubiquitin conjugation (E1, E2 and E3)", "TREATMENT", 72, 116], ["E1, E2", "TREATMENT", 142, 148], ["E3 ligase inhibitors", "TREATMENT", 154, 174], ["The three enzymes", "TEST", 174, 191], ["E3 ligase enzymes", "TEST", 283, 300], ["active", "OBSERVATION_MODIFIER", 316, 322]]], ["Eight human E1s, which activate ubiquitin or a ubiquitin-like protein and transfer it to the E2 conjugating enzyme, are known [19] .", [["E2", "CHEMICAL", 93, 95], ["human", "ORGANISM", 6, 11], ["E1s", "GENE_OR_GENE_PRODUCT", 12, 15], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 32, 41], ["human E1s", "PROTEIN", 6, 15], ["ubiquitin", "PROTEIN", 32, 41], ["ubiquitin-like protein", "PROTEIN", 47, 69], ["E2 conjugating enzyme", "PROTEIN", 93, 114], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 6, 11], ["Eight human E1s", "TREATMENT", 0, 15], ["a ubiquitin-like protein", "TREATMENT", 45, 69], ["the E2 conjugating enzyme", "TEST", 89, 114]]], ["Several dozen E2 enzymes and several hundred E3 ligases are known, although it is not clear how many of these are potentially therapeutically relevant.", [["E2", "CHEMICAL", 14, 16], ["E2", "GENE_OR_GENE_PRODUCT", 14, 16], ["E3", "GENE_OR_GENE_PRODUCT", 45, 47], ["E2 enzymes", "PROTEIN", 14, 24], ["E3 ligases", "PROTEIN", 45, 55], ["Several dozen E2 enzymes", "TEST", 0, 24], ["several hundred E3 ligases", "TEST", 29, 55]]], ["Nevertheless, data presented below support the argument that selective inhibitors of E1, E2, and E3 enzymes can be found or designed.E1 activating enzyme inhibitorsE1 catalyses the first step in the conjugation of ubiquitin or a ubiquitin-like protein to a target protein-an ATP-dependent covalent attachment of the ubiquitin or ubiquitin-like protein molecule to its active site cysteine [18] .", [["E2", "CHEMICAL", 89, 91], ["ATP", "CHEMICAL", 275, 278], ["ATP", "CHEMICAL", 275, 278], ["cysteine", "CHEMICAL", 380, 388], ["E1", "GENE_OR_GENE_PRODUCT", 85, 87], ["E2", "GENE_OR_GENE_PRODUCT", 89, 91], ["E3", "GENE_OR_GENE_PRODUCT", 97, 99], ["E1", "GENE_OR_GENE_PRODUCT", 133, 135], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 214, 223], ["ATP", "SIMPLE_CHEMICAL", 275, 278], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 316, 325], ["E1, E2, and E3 enzymes", "PROTEIN", 85, 107], ["E1 activating enzyme inhibitorsE1", "PROTEIN", 133, 166], ["ubiquitin", "PROTEIN", 214, 223], ["ubiquitin-like protein", "PROTEIN", 229, 251], ["ubiquitin or ubiquitin-like protein molecule", "PROTEIN", 316, 360], ["selective inhibitors of E1, E2, and E3 enzymes", "TEST", 61, 107], ["E1 activating enzyme", "TEST", 133, 153], ["a target protein", "TEST", 255, 271], ["an ATP", "TEST", 272, 278], ["the ubiquitin", "TREATMENT", 312, 325], ["ubiquitin-like protein molecule", "TREATMENT", 329, 360]]], ["An adenosine sulfamate analogue, MLN4924, inhibits the E1 enzyme responsible for NEDDylation, the covalent addition of an ubiquitin-like protein, NEDD8, to specific target proteins including SCF Skp2 [20] , an E3 ligase linked to cell cycle regulation.", [["cell", "ANATOMY", 230, 234], ["adenosine", "CHEMICAL", 3, 12], ["MLN4924", "CHEMICAL", 33, 40], ["adenosine sulfamate", "CHEMICAL", 3, 22], ["MLN4924", "CHEMICAL", 33, 40], ["adenosine sulfamate", "SIMPLE_CHEMICAL", 3, 22], ["MLN4924", "SIMPLE_CHEMICAL", 33, 40], ["NEDD8", "GENE_OR_GENE_PRODUCT", 146, 151], ["SCF Skp2 [20]", "GENE_OR_GENE_PRODUCT", 191, 204], ["E3", "GENE_OR_GENE_PRODUCT", 210, 212], ["cell", "CELL", 230, 234], ["E1 enzyme", "PROTEIN", 55, 64], ["ubiquitin-like protein", "PROTEIN", 122, 144], ["NEDD8", "PROTEIN", 146, 151], ["target proteins", "PROTEIN", 165, 180], ["SCF Skp2 [20", "PROTEIN", 191, 203], ["E3 ligase", "PROTEIN", 210, 219], ["An adenosine sulfamate analogue", "TREATMENT", 0, 31], ["the E1 enzyme", "TEST", 51, 64], ["NEDDylation", "PROBLEM", 81, 92], ["an ubiquitin-like protein", "TREATMENT", 119, 144], ["NEDD8", "TREATMENT", 146, 151], ["SCF Skp2", "TEST", 191, 199], ["an E3 ligase", "TEST", 207, 219], ["cell cycle regulation", "TREATMENT", 230, 251]]], ["In the case of Skp2, NEDDylation results in pro-growth activation, and MLN4924 is currently in Phase II clinical trial for hematologic cancers (Table 3) .", [["hematologic cancers", "ANATOMY", 123, 142], ["MLN4924", "CHEMICAL", 71, 78], ["hematologic cancers", "DISEASE", 123, 142], ["MLN4924", "CHEMICAL", 71, 78], ["Skp2", "GENE_OR_GENE_PRODUCT", 15, 19], ["MLN4924", "SIMPLE_CHEMICAL", 71, 78], ["hematologic cancers", "CANCER", 123, 142], ["Skp2", "PROTEIN", 15, 19], ["Skp2", "PROBLEM", 15, 19], ["hematologic cancers", "PROBLEM", 123, 142]]], ["Experimental inhibitors of E1 have also been reported, for example PYR-41, an irreversible ubiquitin E1 active site binder that enters cells and, while possibly too reactive to be a clinical candidate, is nonetheless useful as a tool compound [21] (Table 4 ).E2 conjugating enzymeUbiquitin activated by E1 is transferred to a cysteine of the E2 enzyme.", [["cells", "ANATOMY", 135, 140], ["PYR-41", "CHEMICAL", 67, 73], ["E2", "CHEMICAL", 259, 261], ["enzymeUbiquitin", "CHEMICAL", 274, 289], ["E2", "CHEMICAL", 342, 344], ["PYR-41", "CHEMICAL", 67, 73], ["cysteine", "CHEMICAL", 326, 334], ["E1", "GENE_OR_GENE_PRODUCT", 27, 29], ["PYR-41", "SIMPLE_CHEMICAL", 67, 73], ["cells", "CELL", 135, 140], ["E2", "GENE_OR_GENE_PRODUCT", 259, 261], ["enzymeUbiquitin", "GENE_OR_GENE_PRODUCT", 274, 289], ["E1", "GENE_OR_GENE_PRODUCT", 303, 305], ["cysteine", "AMINO_ACID", 326, 334], ["E2", "GENE_OR_GENE_PRODUCT", 342, 344], ["E1", "PROTEIN", 27, 29], ["ubiquitin E1 active site binder", "PROTEIN", 91, 122], ["enzymeUbiquitin", "PROTEIN", 274, 289], ["E1", "PROTEIN", 303, 305], ["E2 enzyme", "PROTEIN", 342, 351], ["Experimental inhibitors of E1", "PROBLEM", 0, 29], ["PYR", "TEST", 67, 70], ["an irreversible ubiquitin E1 active site binder", "TREATMENT", 75, 122], ["too reactive", "PROBLEM", 161, 173], ["the E2 enzyme", "TEST", 338, 351]]], ["E2 then interacts with an E3 ligase, which binds the target protein and transfers the ubiquitin from the E2 cysteine to a target protein lysine [18] .", [["E2", "CHEMICAL", 0, 2], ["E2", "CHEMICAL", 105, 107], ["lysine", "CHEMICAL", 137, 143], ["cysteine", "CHEMICAL", 108, 116], ["lysine", "CHEMICAL", 137, 143], ["E2", "GENE_OR_GENE_PRODUCT", 0, 2], ["E3", "GENE_OR_GENE_PRODUCT", 26, 28], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 86, 95], ["E2 cysteine", "GENE_OR_GENE_PRODUCT", 105, 116], ["E3 ligase", "PROTEIN", 26, 35], ["ubiquitin", "PROTEIN", 86, 95], ["an E3 ligase", "TREATMENT", 23, 35], ["the E2 cysteine", "TREATMENT", 101, 116], ["a target protein lysine", "TREATMENT", 120, 143]]], ["Recently a small molecule selective allosteric site inhibitor of the E2 enzyme hCdc34, named CC0651, was reported [22] .", [["E2", "CHEMICAL", 69, 71], ["hCdc34", "CHEMICAL", 79, 85], ["E2", "GENE_OR_GENE_PRODUCT", 69, 71], ["hCdc34", "GENE_OR_GENE_PRODUCT", 79, 85], ["E2 enzyme", "PROTEIN", 69, 78], ["hCdc34", "PROTEIN", 79, 85], ["a small molecule selective allosteric site inhibitor", "TREATMENT", 9, 61], ["the E2 enzyme", "TEST", 65, 78], ["small", "OBSERVATION_MODIFIER", 11, 16]]], ["Cdc34 ubiquitylates p27, among other target proteins, and inhibition of p27 ubiquitylation and degradation is predicted to prevent tumor cell cycle progression.", [["tumor cell", "ANATOMY", 131, 141], ["tumor", "DISEASE", 131, 136], ["Cdc34", "GENE_OR_GENE_PRODUCT", 0, 5], ["p27", "GENE_OR_GENE_PRODUCT", 20, 23], ["p27", "GENE_OR_GENE_PRODUCT", 72, 75], ["tumor cell", "CELL", 131, 141], ["Cdc34", "PROTEIN", 0, 5], ["p27", "PROTEIN", 20, 23], ["target proteins", "PROTEIN", 37, 52], ["p27", "PROTEIN", 72, 75], ["target proteins", "TEST", 37, 52], ["p27 ubiquitylation", "TREATMENT", 72, 90], ["tumor cell cycle progression", "PROBLEM", 131, 159], ["tumor cell", "OBSERVATION", 131, 141]]], ["Thus, compounds such as CC0651 are in preclinical development as potential anticancer agents.E3 ligaseThe E3 ligase is responsible for determining which target proteins are ubiquitylated in concert with E1 and E2; as approximately six hundred E3 ligases are known, selective inhibition of a given E3 ligase is likely to affect a limited number of cellular proteins, which under most circumstances translates to less complicated pharmacology and potentially limited side effects.", [["anticancer", "ANATOMY", 75, 85], ["cellular", "ANATOMY", 347, 355], ["CC0651", "CHEMICAL", 24, 30], ["E2", "CHEMICAL", 210, 212], ["CC0651", "CHEMICAL", 24, 30], ["CC0651", "SIMPLE_CHEMICAL", 24, 30], ["anticancer", "CANCER", 75, 85], ["E3", "GENE_OR_GENE_PRODUCT", 93, 95], ["E3", "GENE_OR_GENE_PRODUCT", 106, 108], ["E1", "GENE_OR_GENE_PRODUCT", 203, 205], ["E2", "GENE_OR_GENE_PRODUCT", 210, 212], ["E3", "GENE_OR_GENE_PRODUCT", 243, 245], ["E3", "GENE_OR_GENE_PRODUCT", 297, 299], ["cellular", "CELL", 347, 355], ["E3 ligase", "PROTEIN", 93, 102], ["E3 ligase", "PROTEIN", 106, 115], ["E1", "PROTEIN", 203, 205], ["E3 ligases", "PROTEIN", 243, 253], ["E3 ligase", "PROTEIN", 297, 306], ["cellular proteins", "PROTEIN", 347, 364], ["potential anticancer agents", "TREATMENT", 65, 92], ["The E3 ligase", "TEST", 102, 115], ["E1 and E2", "TREATMENT", 203, 212], ["a given E3 ligase", "TREATMENT", 289, 306], ["ligase", "OBSERVATION_MODIFIER", 96, 102], ["ligase", "OBSERVATION_MODIFIER", 109, 115], ["responsible for", "UNCERTAINTY", 119, 134], ["cellular proteins", "OBSERVATION", 347, 364]]], ["The majority of E3 ligases do not possess a classic active site, instead they mediate protein-protein interactions between the charged E2 and the protein substrate.", [["E2", "CHEMICAL", 135, 137], ["E3", "GENE_OR_GENE_PRODUCT", 16, 18], ["E2", "GENE_OR_GENE_PRODUCT", 135, 137], ["E3 ligases", "PROTEIN", 16, 26], ["charged E2", "PROTEIN", 127, 137], ["protein substrate", "PROTEIN", 146, 163], ["E3 ligases", "TREATMENT", 16, 26], ["a classic active site", "PROBLEM", 42, 63], ["the protein substrate", "TREATMENT", 142, 163]]], ["Therefore, perhaps not surprisingly, the most advanced ligase-based drug discovery strategy to date has been the development of antagonists of E3-substrate binding.", [["E3", "GENE_OR_GENE_PRODUCT", 143, 145], ["ligase", "PROTEIN", 55, 61], ["E3", "PROTEIN", 143, 145], ["antagonists of E3-substrate binding", "PROBLEM", 128, 163]]], ["Attempts to find an antagonist of the E3 ligase MDM2/HDM2 (HDM2 being the human enzyme) were among the earliest of these exercises, as MDM2 seemed to be a perfect anticancer target, being responsible for ubiquitylating the tumor suppressor pro-apoptotic protein p53.E3 ligaseThe prevailing view was that even though fewer than 50% of tumors possessed functional p53, that number represented a huge patient population that would benefit from therapy directed against MDM2.", [["anticancer", "ANATOMY", 163, 173], ["tumor", "ANATOMY", 223, 228], ["tumors", "ANATOMY", 334, 340], ["tumor", "DISEASE", 223, 228], ["tumors", "DISEASE", 334, 340], ["E3", "GENE_OR_GENE_PRODUCT", 38, 40], ["MDM2", "GENE_OR_GENE_PRODUCT", 48, 52], ["HDM2", "GENE_OR_GENE_PRODUCT", 53, 57], ["HDM2", "GENE_OR_GENE_PRODUCT", 59, 63], ["human", "ORGANISM", 74, 79], ["MDM2", "GENE_OR_GENE_PRODUCT", 135, 139], ["anticancer", "CANCER", 163, 173], ["tumor", "CANCER", 223, 228], ["p53.E3", "GENE_OR_GENE_PRODUCT", 262, 268], ["tumors", "CANCER", 334, 340], ["p53", "GENE_OR_GENE_PRODUCT", 362, 365], ["patient", "ORGANISM", 398, 405], ["MDM2", "GENE_OR_GENE_PRODUCT", 466, 470], ["E3 ligase", "PROTEIN", 38, 47], ["MDM2", "PROTEIN", 48, 52], ["HDM2", "PROTEIN", 53, 57], ["HDM2", "PROTEIN", 59, 63], ["human enzyme", "PROTEIN", 74, 86], ["MDM2", "PROTEIN", 135, 139], ["tumor suppressor pro-apoptotic protein", "PROTEIN", 223, 261], ["p53.E3 ligase", "PROTEIN", 262, 275], ["p53", "PROTEIN", 362, 365], ["MDM2", "PROTEIN", 466, 470], ["human", "SPECIES", 74, 79], ["patient", "SPECIES", 398, 405], ["human", "SPECIES", 74, 79], ["the E3 ligase MDM2", "TREATMENT", 34, 52], ["HDM2", "PROBLEM", 53, 57], ["the human enzyme", "TEST", 70, 86], ["the tumor suppressor", "TREATMENT", 219, 239], ["tumors", "PROBLEM", 334, 340], ["therapy", "TREATMENT", 441, 448], ["MDM2", "PROBLEM", 466, 470], ["tumors", "OBSERVATION", 334, 340], ["huge", "OBSERVATION_MODIFIER", 393, 397]]], ["Inhibition of MDM2 was one of many molecular oncology strategies employed in the last 10-15 years to maximize p53 presence and activity in tumors ( [28] ; reviewed in [25] ), and the two E3 ligase antagonists currently in clinical trial for cancer, RO5045337 (nutlin-3) and JNJ-26854165 (Table 3) , are directed at MDM2, specifically, at the regulation of its substrate, p53 [23] .", [["tumors", "ANATOMY", 139, 145], ["cancer", "ANATOMY", 241, 247], ["tumors", "DISEASE", 139, 145], ["cancer", "DISEASE", 241, 247], ["RO5045337", "CHEMICAL", 249, 258], ["nutlin-3", "CHEMICAL", 260, 268], ["JNJ-26854165", "CHEMICAL", 274, 286], ["RO5045337", "CHEMICAL", 249, 258], ["JNJ-26854165", "CHEMICAL", 274, 286], ["MDM2", "GENE_OR_GENE_PRODUCT", 14, 18], ["p53", "GENE_OR_GENE_PRODUCT", 110, 113], ["tumors", "CANCER", 139, 145], ["[25]", "SIMPLE_CHEMICAL", 167, 171], ["E3", "GENE_OR_GENE_PRODUCT", 187, 189], ["cancer", "CANCER", 241, 247], ["RO5045337", "SIMPLE_CHEMICAL", 249, 258], ["nutlin-3", "GENE_OR_GENE_PRODUCT", 260, 268], ["JNJ-26854165", "GENE_OR_GENE_PRODUCT", 274, 286], ["Table 3", "GENE_OR_GENE_PRODUCT", 288, 295], ["MDM2", "GENE_OR_GENE_PRODUCT", 315, 319], ["p53", "GENE_OR_GENE_PRODUCT", 371, 374], ["MDM2", "PROTEIN", 14, 18], ["p53", "PROTEIN", 110, 113], ["E3 ligase", "PROTEIN", 187, 196], ["MDM2", "PROTEIN", 315, 319], ["p53", "PROTEIN", 371, 374], ["Inhibition of MDM2", "TREATMENT", 0, 18], ["p53 presence", "PROBLEM", 110, 122], ["activity in tumors", "PROBLEM", 127, 145], ["the two E3 ligase antagonists", "TREATMENT", 179, 208], ["cancer", "PROBLEM", 241, 247], ["RO", "TEST", 249, 251], ["nutlin", "TEST", 260, 266], ["JNJ", "TEST", 274, 277], ["MDM2", "OBSERVATION", 14, 18]]], ["Several compounds inhibiting members of a family of E3 ligases known as anti-apoptotic proteins (IAPs) have also recently entered clinical trial [24] .", [["E3", "GENE_OR_GENE_PRODUCT", 52, 54], ["IAPs", "GENE_OR_GENE_PRODUCT", 97, 101], ["E3 ligases", "PROTEIN", 52, 62], ["anti-apoptotic proteins", "PROTEIN", 72, 95], ["IAPs", "PROTEIN", 97, 101], ["E3 ligases", "TREATMENT", 52, 62], ["anti-apoptotic proteins", "TREATMENT", 72, 95]]], ["These IAPs ubiquitylate proteins that are essential to apoptosis, eliminating their function and, thus, blocking apoptosis.", [["IAPs", "GENE_OR_GENE_PRODUCT", 6, 10], ["IAPs", "PROTEIN", 6, 10], ["These IAPs ubiquitylate proteins", "TEST", 0, 32], ["apoptosis", "PROBLEM", 55, 64], ["blocking apoptosis", "PROBLEM", 104, 122]]], ["Analogs of Smac, a naturally occurring protein that binds to the IAP, triggering its auto-ubiquitylation, subsume this function and restore apoptotic activity.", [["Smac", "GENE_OR_GENE_PRODUCT", 11, 15], ["IAP", "GENE_OR_GENE_PRODUCT", 65, 68], ["Smac", "PROTEIN", 11, 15], ["IAP", "PROTEIN", 65, 68], ["Analogs of Smac", "TREATMENT", 0, 15], ["Smac", "ANATOMY", 11, 15], ["apoptotic activity", "OBSERVATION", 140, 158]]], ["It was speculated in an opinion piece published in 2005 [26] that the nutlin compounds might not progress to clinical trial owing to poor animal efficacy and that E3s in general are perhaps too complex for drug discovery.", [["nutlin", "GENE_OR_GENE_PRODUCT", 70, 76], ["E3s", "GENE_OR_GENE_PRODUCT", 163, 166], ["E3s", "PROTEIN", 163, 166], ["the nutlin compounds", "TREATMENT", 66, 86]]], ["The fact that 7 years later there are two MDM2-p53 binding inhibitors (including a nutlin) and seven IAP antagonists in Phase I/II clinical trial suggests that E3 ligases constitute a viable, if not the most facile drug discovery area.E3 ligaseIn addition to MDM2 and the IAPs, at least nine E3 ligases have been linked to cancer; most of them, like MDM2, act as oncoproteins by inhibiting apoptosis or promoting cell cycling, so inhibitors would be potential anticancer drugs.", [["cancer", "ANATOMY", 323, 329], ["cell", "ANATOMY", 413, 417], ["anticancer", "ANATOMY", 460, 470], ["cancer", "DISEASE", 323, 329], ["MDM2-p53", "GENE_OR_GENE_PRODUCT", 42, 50], ["nutlin", "GENE_OR_GENE_PRODUCT", 83, 89], ["E3", "GENE_OR_GENE_PRODUCT", 160, 162], ["E3", "GENE_OR_GENE_PRODUCT", 235, 237], ["MDM2", "GENE_OR_GENE_PRODUCT", 259, 263], ["IAPs", "GENE_OR_GENE_PRODUCT", 272, 276], ["E3", "GENE_OR_GENE_PRODUCT", 292, 294], ["cancer", "CANCER", 323, 329], ["MDM2", "GENE_OR_GENE_PRODUCT", 350, 354], ["cell", "CELL", 413, 417], ["anticancer", "CANCER", 460, 470], ["MDM2", "PROTEIN", 42, 46], ["E3 ligases", "PROTEIN", 160, 170], ["E3 ligaseIn", "PROTEIN", 235, 246], ["MDM2", "PROTEIN", 259, 263], ["IAPs", "PROTEIN", 272, 276], ["E3 ligases", "PROTEIN", 292, 302], ["MDM2", "PROTEIN", 350, 354], ["oncoproteins", "PROTEIN", 363, 375], ["MDM2", "TEST", 42, 46], ["binding inhibitors", "TREATMENT", 51, 69], ["a nutlin)", "TREATMENT", 81, 90], ["seven IAP antagonists", "TREATMENT", 95, 116], ["E3 ligases", "PROBLEM", 160, 170], ["MDM2", "TREATMENT", 259, 263], ["the IAPs", "TEST", 268, 276], ["cancer", "PROBLEM", 323, 329], ["MDM2", "PROBLEM", 350, 354], ["promoting cell cycling", "TREATMENT", 403, 425], ["inhibitors", "TREATMENT", 430, 440], ["anticancer drugs", "TREATMENT", 460, 476], ["cancer", "OBSERVATION", 323, 329], ["MDM2", "OBSERVATION", 350, 354]]], ["Although efforts have been made to find inhibitors of these and other E3s (ubiquitylation endpoint), the search is complicated by the participation of three or four enzymes in the conjugation reaction [18] .", [["E3s", "GENE_OR_GENE_PRODUCT", 70, 73], ["E3s", "PROTEIN", 70, 73], ["enzymes", "PROTEIN", 165, 172], ["inhibitors", "TREATMENT", 40, 50], ["four enzymes", "TEST", 160, 172]]], ["To date no drugs targeting additional E3 ligases have entered the clinic, although several such inhibitors have been reported and are useful as tool compounds (Table 4) .", [["E3", "GENE_OR_GENE_PRODUCT", 38, 40], ["E3 ligases", "PROTEIN", 38, 48], ["drugs", "TREATMENT", 11, 16], ["several such inhibitors", "PROBLEM", 83, 106]]], ["For a comprehensive list of potential E3 ligase anticancer targets, see [27] .E3 ligaseThus, for all of the enzymes involved in conjugating ubiquitin to a protein, small molecule inhibitors are being developed, and, in the case of E1 and E3 enzymes, are being evaluated in the clinic for treatment of cancer.", [["anticancer", "ANATOMY", 48, 58], ["cancer", "ANATOMY", 301, 307], ["cancer", "DISEASE", 301, 307], ["E3", "GENE_OR_GENE_PRODUCT", 38, 40], ["anticancer", "CANCER", 48, 58], ["see [27] .E3 ligaseThus", "SIMPLE_CHEMICAL", 68, 91], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 140, 149], ["E1", "GENE_OR_GENE_PRODUCT", 231, 233], ["E3", "GENE_OR_GENE_PRODUCT", 238, 240], ["cancer", "CANCER", 301, 307], ["E3 ligase", "PROTEIN", 38, 47], ["enzymes", "PROTEIN", 108, 115], ["ubiquitin", "PROTEIN", 140, 149], ["E1", "PROTEIN", 231, 233], ["E3 enzymes", "PROTEIN", 238, 248], ["the enzymes", "TEST", 104, 115], ["small molecule inhibitors", "PROBLEM", 164, 189], ["cancer", "PROBLEM", 301, 307], ["cancer", "OBSERVATION", 301, 307]]], ["While the clinical progression of bortezomib was relatively rapid, data to date suggest that it may take longer to determine whether efficacious drugs will come from inhibitors of ubiquitin conjugation.DUB inhibitorsThere are approximately eighty known DUBS, proteases that hydrolyze isopeptide or \u03b1-peptide bonds linking ubiquitin to its target protein (in some cases another ubiquitin).", [["bortezomib", "CHEMICAL", 34, 44], ["bortezomib", "CHEMICAL", 34, 44], ["isopeptide", "CHEMICAL", 284, 294], ["\u03b1-peptide", "CHEMICAL", 298, 307], ["bortezomib", "SIMPLE_CHEMICAL", 34, 44], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 180, 189], ["DUB", "GENE_OR_GENE_PRODUCT", 202, 205], ["DUBS", "GENE_OR_GENE_PRODUCT", 253, 257], ["\u03b1-peptide bonds", "SIMPLE_CHEMICAL", 298, 313], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 322, 331], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 377, 386], ["DUB inhibitors", "PROTEIN", 202, 216], ["DUBS", "PROTEIN", 253, 257], ["proteases", "PROTEIN", 259, 268], ["ubiquitin", "PROTEIN", 322, 331], ["target protein", "PROTEIN", 339, 353], ["ubiquitin", "PROTEIN", 377, 386], ["bortezomib", "PROBLEM", 34, 44], ["efficacious drugs", "TREATMENT", 133, 150], ["ubiquitin conjugation", "TREATMENT", 180, 201], ["DUB inhibitors", "TREATMENT", 202, 216], ["hydrolyze isopeptide", "TREATMENT", 274, 294], ["\u03b1-peptide bonds linking ubiquitin", "PROBLEM", 298, 331], ["approximately", "OBSERVATION_MODIFIER", 226, 239], ["eighty known", "OBSERVATION_MODIFIER", 240, 252], ["DUBS", "OBSERVATION", 253, 257]]], ["Many of these have been validated as targets for cancer and other diseases [27, 37, 38] .", [["cancer", "ANATOMY", 49, 55], ["cancer", "DISEASE", 49, 55], ["cancer", "CANCER", 49, 55], ["cancer", "PROBLEM", 49, 55], ["other diseases", "PROBLEM", 60, 74]]], ["DUBs serve to recycle ubiquitin monomers to prevent proteasomal degradation of proteins tagged with ubiquitin, and to trim ubiquitin from tagged proteins [18, 39] .", [["proteasomal", "ANATOMY", 52, 63], ["DUBs", "GENE_OR_GENE_PRODUCT", 0, 4], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 100, 109], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 123, 132], ["DUBs", "PROTEIN", 0, 4], ["ubiquitin monomers", "PROTEIN", 22, 40], ["ubiquitin", "PROTEIN", 100, 109], ["trim ubiquitin", "PROTEIN", 118, 132], ["tagged proteins", "PROTEIN", 138, 153], ["recycle ubiquitin monomers", "TREATMENT", 14, 40], ["proteasomal degradation of proteins", "PROBLEM", 52, 87], ["ubiquitin", "TREATMENT", 100, 109], ["tagged proteins", "TEST", 138, 153]]], ["Proteasome-associated DUBs are a very recently described class of anticancer target; inhibitors of these enzymes are discussed above in the Proteasome section.", [["anticancer", "ANATOMY", 66, 76], ["Proteasome", "GENE_OR_GENE_PRODUCT", 0, 10], ["DUBs", "GENE_OR_GENE_PRODUCT", 22, 26], ["anticancer", "CANCER", 66, 76], ["Proteasome", "GENE_OR_GENE_PRODUCT", 140, 150], ["Proteasome-associated DUBs", "PROTEIN", 0, 26], ["enzymes", "PROTEIN", 105, 112], ["these enzymes", "TEST", 99, 112], ["the Proteasome section", "TREATMENT", 136, 158], ["DUBs", "OBSERVATION", 22, 26]]], ["It is the second functionsparing of target proteins by the removal of conjugated ubiquitin-that has made DUBs attractive targets for cancer and other diseases [18] .", [["cancer", "ANATOMY", 133, 139], ["cancer", "DISEASE", 133, 139], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 81, 90], ["cancer", "CANCER", 133, 139], ["target proteins", "PROTEIN", 36, 51], ["conjugated ubiquitin", "PROTEIN", 70, 90], ["DUBs", "PROTEIN", 105, 109], ["target proteins", "TREATMENT", 36, 51], ["the removal of conjugated ubiquitin", "TREATMENT", 55, 90], ["cancer", "PROBLEM", 133, 139], ["other diseases", "PROBLEM", 144, 158]]], ["If the DUB's target protein is beneficial, for example, a tumor suppressor, DUB activity would be therapeutically advantageous as it would increase the half-life of the beneficial protein.", [["tumor", "ANATOMY", 58, 63], ["tumor", "DISEASE", 58, 63], ["DUB", "GENE_OR_GENE_PRODUCT", 7, 10], ["tumor", "CANCER", 58, 63], ["DUB", "GENE_OR_GENE_PRODUCT", 76, 79], ["DUB", "PROTEIN", 7, 10], ["DUB", "PROTEIN", 76, 79], ["the DUB's target protein", "TEST", 3, 27], ["a tumor suppressor", "TREATMENT", 56, 74], ["DUB activity", "TREATMENT", 76, 88]]], ["In this case, activators of the DUB would be therapeutically useful, and there are examples of well-studied DUBs that would require activation for therapy [27] .", [["DUB", "GENE_OR_GENE_PRODUCT", 32, 35], ["DUBs", "GENE_OR_GENE_PRODUCT", 108, 112], ["DUB", "PROTEIN", 32, 35], ["DUBs", "PROTEIN", 108, 112], ["the DUB", "TEST", 28, 35], ["well-studied DUBs", "PROBLEM", 95, 112], ["therapy", "TREATMENT", 147, 154]]], ["It has been difficult, however, to discover and develop enzyme activators (as compared with receptor agonists), so the opposite strategy has been more widely pursued-the use of DUB inhibitors to prevent the sparing of a deleterious target protein (for example, an oncogenic protein) upon deubiquitylation, ensuring it is degraded, thereby decreasing its cellular half-life.", [["cellular", "ANATOMY", 354, 362], ["DUB", "GENE_OR_GENE_PRODUCT", 177, 180], ["cellular", "CELL", 354, 362], ["target protein", "PROTEIN", 232, 246], ["oncogenic protein", "PROTEIN", 264, 281], ["enzyme activators", "PROBLEM", 56, 73], ["receptor agonists", "TEST", 92, 109], ["DUB inhibitors", "TREATMENT", 177, 191], ["a deleterious target protein", "PROBLEM", 218, 246], ["more widely", "OBSERVATION_MODIFIER", 146, 157]]], ["In the past 10-15 years, tool compounds and/or preclinical development candidate small molecule DUB inhibitors have been reported; these compounds were identified as inhibitors of several DUBs and have a range of reported selectivities with respect to other DUBs and other cysteine proteases [31, 32, 35] .", [["cysteine", "CHEMICAL", 273, 281], ["DUB", "GENE_OR_GENE_PRODUCT", 96, 99], ["DUBs", "GENE_OR_GENE_PRODUCT", 188, 192], ["DUBs", "GENE_OR_GENE_PRODUCT", 258, 262], ["DUBs", "PROTEIN", 188, 192], ["DUBs", "PROTEIN", 258, 262], ["cysteine proteases", "PROTEIN", 273, 291], ["tool compounds", "PROBLEM", 25, 39], ["small molecule DUB inhibitors", "PROBLEM", 81, 110], ["several DUBs", "TEST", 180, 192], ["other cysteine proteases", "TEST", 267, 291], ["small", "OBSERVATION_MODIFIER", 81, 86], ["molecule DUB", "OBSERVATION", 87, 99]]], ["Four examples of these inhibitors are given below; their story is a chronicle of the state of DUB-based anticancer drug development up to the present time (Table 5) .Pan-DUB inhibitorsAmong the earliest reported DUB inhibitors are cyclopentenone prostaglandins that induce apoptosis and also increase the cellular content of poly-ubiquitylated proteins [29] .", [["anticancer", "ANATOMY", 104, 114], ["cellular", "ANATOMY", 305, 313], ["cyclopentenone prostaglandins", "CHEMICAL", 231, 260], ["cyclopentenone prostaglandins", "CHEMICAL", 231, 260], ["DUB", "GENE_OR_GENE_PRODUCT", 94, 97], ["anticancer", "CANCER", 104, 114], ["Pan-DUB", "GENE_OR_GENE_PRODUCT", 166, 173], ["DUB", "GENE_OR_GENE_PRODUCT", 212, 215], ["cyclopentenone prostaglandins", "SIMPLE_CHEMICAL", 231, 260], ["cellular", "CELL", 305, 313], ["DUB", "PROTEIN", 94, 97], ["poly-ubiquitylated proteins", "PROTEIN", 325, 352], ["these inhibitors", "TREATMENT", 17, 33], ["DUB", "PROBLEM", 94, 97], ["Pan-DUB inhibitors", "TREATMENT", 166, 184], ["DUB inhibitors", "TREATMENT", 212, 226], ["cyclopentenone prostaglandins", "TREATMENT", 231, 260], ["apoptosis", "PROBLEM", 273, 282], ["cellular content", "OBSERVATION", 305, 321]]], ["The latter suggests they are nonselective DUB inhibitors.", [["DUB", "GENE_OR_GENE_PRODUCT", 42, 45], ["nonselective DUB inhibitors", "TREATMENT", 29, 56]]], ["A small molecule discovered in screening for DUB inhibitors, PR-619, is selective for DUBs over other cysteine proteases, but inhibits all DUBs tested with moderate potency.", [["PR-619", "CHEMICAL", 61, 67], ["PR-619", "CHEMICAL", 61, 67], ["cysteine", "CHEMICAL", 102, 110], ["DUB", "GENE_OR_GENE_PRODUCT", 45, 48], ["PR-619", "SIMPLE_CHEMICAL", 61, 67], ["DUBs", "GENE_OR_GENE_PRODUCT", 86, 90], ["DUB", "PROTEIN", 45, 48], ["PR", "PROTEIN", 61, 63], ["DUBs", "PROTEIN", 86, 90], ["cysteine proteases", "PROTEIN", 102, 120], ["DUBs", "PROTEIN", 139, 143], ["A small molecule", "PROBLEM", 0, 16], ["screening", "TEST", 31, 40], ["DUB inhibitors", "TREATMENT", 45, 59], ["PR", "TEST", 61, 63], ["DUBs over other cysteine proteases", "PROBLEM", 86, 120], ["all DUBs", "TEST", 135, 143], ["small", "OBSERVATION_MODIFIER", 2, 7], ["molecule", "OBSERVATION", 8, 16], ["moderate", "OBSERVATION_MODIFIER", 156, 164], ["potency", "OBSERVATION_MODIFIER", 165, 172]]], ["PR-619 is cell permeant and thus is useful as a tool compound [30] .", [["cell", "ANATOMY", 10, 14], ["PR-619", "CHEMICAL", 0, 6], ["PR-619", "GENE_OR_GENE_PRODUCT", 0, 6], ["cell", "CELL", 10, 14], ["PR", "PROTEIN", 0, 2], ["PR", "TEST", 0, 2], ["cell permeant", "TEST", 10, 23]]], ["More recently, HBX 41,108 which was originally reported to be a USP7 inhibitor was confirmed to be a non-selective DUB inhibitor [31, 32] .UCH-L1 inhibitorsConsiderable work has been performed on a series of UCH-L1Cterminal DUB inhibitors [33] .", [["HBX 41,108", "CHEMICAL", 15, 25], ["HBX 41,108", "CHEMICAL", 15, 25], ["HBX 41,108", "SIMPLE_CHEMICAL", 15, 25], ["USP7", "GENE_OR_GENE_PRODUCT", 64, 68], ["DUB", "GENE_OR_GENE_PRODUCT", 115, 118], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 139, 145], ["UCH-L1Cterminal", "SIMPLE_CHEMICAL", 208, 223], ["DUB", "GENE_OR_GENE_PRODUCT", 224, 227], ["USP7", "PROTEIN", 64, 68], ["DUB", "PROTEIN", 115, 118], ["HBX", "TEST", 15, 18], ["a USP7 inhibitor", "TREATMENT", 62, 78], ["a non-selective DUB inhibitor", "TREATMENT", 99, 128], ["UCH-L1 inhibitors", "TREATMENT", 139, 156], ["UCH", "TEST", 208, 211], ["L1Cterminal DUB inhibitors", "TREATMENT", 212, 238]]], ["UCH-L1 is one of the earliest described DUBs and it has been of therapeutic interest in both neurodegenerative disease and cancer [40] .", [["cancer", "ANATOMY", 123, 129], ["neurodegenerative disease", "DISEASE", 93, 118], ["cancer", "DISEASE", 123, 129], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 0, 6], ["DUBs", "GENE_OR_GENE_PRODUCT", 40, 44], ["cancer", "CANCER", 123, 129], ["UCH", "PROTEIN", 0, 3], ["L1", "DNA", 4, 6], ["DUBs", "PROTEIN", 40, 44], ["both neurodegenerative disease", "PROBLEM", 88, 118], ["cancer", "PROBLEM", 123, 129], ["L1", "ANATOMY", 4, 6], ["DUBs", "OBSERVATION", 40, 44], ["therapeutic", "OBSERVATION_MODIFIER", 64, 75], ["neurodegenerative disease", "OBSERVATION", 93, 118], ["cancer", "OBSERVATION", 123, 129]]], ["Like the pan-DUB inhibitors, these inhibitors are of moderate potency and enter cells; in addition, many are selective for UCH-L1, making them valuable tool compounds for translational research in cancer and neurodegenerative disease.USP7/HAUSP inhibitorsA classic example of the strategy of ablating oncoproteins by inhibiting the DUBs that protect them from ubiquitylation and degradation is exemplified in the search for suitable inhibitors of USP7/HAUSP, one of the first therapeutically relevant DUBs to be described and arguably the most actively pursued DUB target in cancer drug discovery today [41] [42] [43] .", [["cells", "ANATOMY", 80, 85], ["cancer", "ANATOMY", 197, 203], ["cancer", "ANATOMY", 575, 581], ["cancer", "DISEASE", 197, 203], ["neurodegenerative disease", "DISEASE", 208, 233], ["cancer", "DISEASE", 575, 581], ["pan-DUB", "GENE_OR_GENE_PRODUCT", 9, 16], ["cells", "CELL", 80, 85], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 123, 129], ["cancer", "CANCER", 197, 203], ["USP7", "GENE_OR_GENE_PRODUCT", 234, 238], ["HAUSP", "GENE_OR_GENE_PRODUCT", 239, 244], ["DUBs", "GENE_OR_GENE_PRODUCT", 332, 336], ["USP7", "GENE_OR_GENE_PRODUCT", 447, 451], ["HAUSP", "GENE_OR_GENE_PRODUCT", 452, 457], ["DUB", "GENE_OR_GENE_PRODUCT", 561, 564], ["cancer", "CANCER", 575, 581], ["[41] [42] [43]", "SIMPLE_CHEMICAL", 603, 617], ["UCH", "PROTEIN", 123, 126], ["USP7", "PROTEIN", 234, 238], ["oncoproteins", "PROTEIN", 301, 313], ["DUBs", "PROTEIN", 332, 336], ["USP7", "PROTEIN", 447, 451], ["HAUSP", "PROTEIN", 452, 457], ["DUBs", "PROTEIN", 501, 505], ["DUB", "PROTEIN", 561, 564], ["the pan-DUB inhibitors", "TREATMENT", 5, 27], ["these inhibitors", "TREATMENT", 29, 45], ["moderate potency and enter cells", "PROBLEM", 53, 85], ["translational research in cancer", "PROBLEM", 171, 203], ["neurodegenerative disease", "PROBLEM", 208, 233], ["USP7/HAUSP inhibitors", "TREATMENT", 234, 255], ["ablating oncoproteins", "TREATMENT", 292, 313], ["the DUBs", "PROBLEM", 328, 336], ["USP7/HAUSP", "TREATMENT", 447, 457], ["moderate", "OBSERVATION_MODIFIER", 53, 61], ["L1", "ANATOMY", 127, 129], ["cancer", "OBSERVATION", 197, 203], ["neurodegenerative disease", "OBSERVATION", 208, 233]]], ["Although USP7, like all DUBS, deconjugates ubiquitin from several target proteins, inhibition of USP7 promotes the degradation of its primary cellular target, HDM2, resulting in net p53 stabilization and activation [30, 42, 43] .", [["cellular", "ANATOMY", 142, 150], ["USP7", "GENE_OR_GENE_PRODUCT", 9, 13], ["DUBS", "GENE_OR_GENE_PRODUCT", 24, 28], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 43, 52], ["USP7", "GENE_OR_GENE_PRODUCT", 97, 101], ["cellular", "CELL", 142, 150], ["HDM2", "GENE_OR_GENE_PRODUCT", 159, 163], ["p53", "GENE_OR_GENE_PRODUCT", 182, 185], ["USP7", "PROTEIN", 9, 13], ["DUBS", "PROTEIN", 24, 28], ["ubiquitin", "PROTEIN", 43, 52], ["USP7", "PROTEIN", 97, 101], ["HDM2", "PROTEIN", 159, 163], ["p53", "PROTEIN", 182, 185], ["USP7", "TEST", 9, 13], ["deconjugates ubiquitin", "PROBLEM", 30, 52], ["inhibition of USP7", "TREATMENT", 83, 101], ["net p53 stabilization", "TREATMENT", 178, 199], ["net", "OBSERVATION_MODIFIER", 178, 181], ["p53 stabilization", "OBSERVATION", 182, 199]]], ["Several series of small molecule USP7/HAUSP inhibitors including HBX 19,818 and the P005091 analog P050429 have achieved cellular proof of concept (anticipated cellular effects on MDM2 and p53dependent protein activities [30, 32, 34] ); some of these compounds are in preclinical development, but no compound has entered clinical trial.", [["cellular", "ANATOMY", 121, 129], ["cellular", "ANATOMY", 160, 168], ["HBX 19,818", "CHEMICAL", 65, 75], ["P005091", "CHEMICAL", 84, 91], ["P050429", "CHEMICAL", 99, 106], ["HBX 19,818", "CHEMICAL", 65, 75], ["P005091", "CHEMICAL", 84, 91], ["P050429", "CHEMICAL", 99, 106], ["USP7", "GENE_OR_GENE_PRODUCT", 33, 37], ["HAUSP", "GENE_OR_GENE_PRODUCT", 38, 43], ["HBX 19,818", "SIMPLE_CHEMICAL", 65, 75], ["P005091", "SIMPLE_CHEMICAL", 84, 91], ["P050429", "SIMPLE_CHEMICAL", 99, 106], ["cellular", "CELL", 121, 129], ["cellular", "CELL", 160, 168], ["MDM2", "GENE_OR_GENE_PRODUCT", 180, 184], ["p53dependent", "GENE_OR_GENE_PRODUCT", 189, 201], ["USP7", "PROTEIN", 33, 37], ["MDM2", "PROTEIN", 180, 184], ["p53dependent protein", "PROTEIN", 189, 209], ["small molecule USP7", "TREATMENT", 18, 37], ["HAUSP inhibitors", "TREATMENT", 38, 54], ["HBX", "TEST", 65, 68], ["MDM2", "TEST", 180, 184], ["p53dependent protein activities", "TEST", 189, 220], ["small", "OBSERVATION_MODIFIER", 18, 23], ["molecule USP7", "OBSERVATION", 24, 37]]], ["Other USP7 inhibitors that are not developable are nonetheless being used as tool compounds.Viral DUB inhibitorsDUB inhibitor studies are not restricted to mammalian enzymes.", [["USP7", "GENE_OR_GENE_PRODUCT", 6, 10], ["DUB", "GENE_OR_GENE_PRODUCT", 98, 101], ["USP7", "PROTEIN", 6, 10], ["DUB", "PROTEIN", 98, 101], ["mammalian enzymes", "PROTEIN", 156, 173], ["Other USP7 inhibitors", "TREATMENT", 0, 21], ["Viral DUB inhibitorsDUB inhibitor studies", "TEST", 92, 133], ["mammalian enzymes", "TEST", 156, 173], ["DUB", "OBSERVATION", 98, 101]]], ["For example, the competitive small molecule inhibitor, GRL0617 was demonstrated to inhibit the SARS Coronavirus protease and isopeptidase Papain-like protease (Plpro) in vitro and in cellular viral replication assays [36] .", [["cellular", "ANATOMY", 183, 191], ["GRL0617", "CHEMICAL", 55, 62], ["GRL0617", "CHEMICAL", 55, 62], ["GRL0617", "SIMPLE_CHEMICAL", 55, 62], ["isopeptidase Papain-like protease", "GENE_OR_GENE_PRODUCT", 125, 158], ["Plpro", "GENE_OR_GENE_PRODUCT", 160, 165], ["cellular", "CELL", 183, 191], ["SARS Coronavirus protease", "PROTEIN", 95, 120], ["isopeptidase Papain-like protease", "PROTEIN", 125, 158], ["Plpro", "PROTEIN", 160, 165], ["the competitive small molecule inhibitor", "TREATMENT", 13, 53], ["the SARS Coronavirus protease", "TREATMENT", 91, 120], ["isopeptidase Papain", "TREATMENT", 125, 144], ["protease (Plpro)", "TREATMENT", 150, 166], ["vitro", "TREATMENT", 170, 175], ["viral replication", "OBSERVATION", 192, 209]]], ["Notably the authors were able to obtain a co-crystal structure of GRL0617 bound to Plpro, which is predicted to accelerate preclinical development of this series.Viral DUB inhibitorsThus, while DUBs with well defined active sites appear to be simpler biochemical targets than E3 ligases, DUB-based anticancer drug development is proceeding with no more facility than is ligasebased development, to judge by compounds in the clinic or in late preclinical development.ConclusionsThe foregoing illustrates a major paradox in the application of the enormously complex ubiquitin proteasome pathway to cancer therapeutics, which can be articulated in the following question: why has ubiquitin-based therapy heretofore been more readily achieved by using a nonselective approach (carpet bombing with proteasome inhibitors) than by employing a selective approach (surgical strike with highly selective E3 ligase or DUB inhibitors)?", [["anticancer", "ANATOMY", 298, 308], ["cancer", "ANATOMY", 596, 602], ["GRL0617", "CHEMICAL", 66, 73], ["cancer", "DISEASE", 596, 602], ["GRL0617", "CHEMICAL", 66, 73], ["GRL0617", "SIMPLE_CHEMICAL", 66, 73], ["Plpro", "GENE_OR_GENE_PRODUCT", 83, 88], ["DUB", "GENE_OR_GENE_PRODUCT", 168, 171], ["DUBs", "GENE_OR_GENE_PRODUCT", 194, 198], ["E3", "GENE_OR_GENE_PRODUCT", 276, 278], ["DUB", "GENE_OR_GENE_PRODUCT", 288, 291], ["anticancer", "CANCER", 298, 308], ["cancer", "CANCER", 596, 602], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 677, 686], ["E3", "GENE_OR_GENE_PRODUCT", 894, 896], ["DUB", "GENE_OR_GENE_PRODUCT", 907, 910], ["GRL0617", "PROTEIN", 66, 73], ["Plpro", "PROTEIN", 83, 88], ["Viral DUB inhibitors", "PROTEIN", 162, 182], ["DUBs", "PROTEIN", 194, 198], ["E3 ligases", "PROTEIN", 276, 286], ["DUB", "PROTEIN", 288, 291], ["ubiquitin proteasome", "PROTEIN", 564, 584], ["ubiquitin", "PROTEIN", 677, 686], ["E3 ligase", "PROTEIN", 894, 903], ["DUB", "PROTEIN", 907, 910], ["this series", "TEST", 150, 161], ["Viral DUB inhibitors", "TREATMENT", 162, 182], ["well defined active sites", "PROBLEM", 204, 229], ["E3 ligases", "TREATMENT", 276, 286], ["DUB-based anticancer drug", "TREATMENT", 288, 313], ["the enormously complex ubiquitin proteasome pathway", "TREATMENT", 541, 592], ["cancer therapeutics", "TREATMENT", 596, 615], ["ubiquitin-based therapy", "TREATMENT", 677, 700], ["a nonselective approach", "TREATMENT", 748, 771], ["proteasome inhibitors", "TREATMENT", 793, 814], ["a selective approach (surgical strike", "TREATMENT", 834, 871], ["highly selective E3 ligase", "TREATMENT", 877, 903], ["DUB inhibitors", "TREATMENT", 907, 921], ["DUB inhibitors", "OBSERVATION", 168, 182], ["ubiquitin proteasome", "OBSERVATION", 564, 584]]], ["A trivial answer may be that the biochemistry of certain malignancies (proteasome inhibitors have not yet demonstrated utility over a broad range of tumor types) makes them hypersensitive to proteasome inhibitor-induced apoptosis, hence a therapeutic window.", [["malignancies", "ANATOMY", 57, 69], ["tumor", "ANATOMY", 149, 154], ["malignancies", "DISEASE", 57, 69], ["tumor", "DISEASE", 149, 154], ["malignancies", "CANCER", 57, 69], ["tumor", "CANCER", 149, 154], ["proteasome", "PROTEIN", 191, 201], ["certain malignancies", "PROBLEM", 49, 69], ["proteasome inhibitors", "TREATMENT", 71, 92], ["proteasome inhibitor", "TREATMENT", 191, 211], ["apoptosis", "PROBLEM", 220, 229], ["a therapeutic window", "TREATMENT", 237, 257], ["trivial", "OBSERVATION", 2, 9]]], ["An interesting alternative explanation is that sparing a large number of proteins from degradation by inhibiting the proteasome ensures that multiple pro-apoptotic, anti-survival activities are allowed to proceed, while blocking a single oncogenic DUB or E3 ligase with an exquisitely selective inhibitor has a limited effect owing to circumvention by functional redundancy or compensation by other enzymes.", [["DUB", "GENE_OR_GENE_PRODUCT", 248, 251], ["E3", "GENE_OR_GENE_PRODUCT", 255, 257], ["proteasome", "PROTEIN", 117, 127], ["oncogenic DUB", "PROTEIN", 238, 251], ["E3 ligase", "PROTEIN", 255, 264], ["enzymes", "PROTEIN", 399, 406], ["the proteasome", "TREATMENT", 113, 127], ["E3 ligase", "TREATMENT", 255, 264], ["an exquisitely selective inhibitor", "TREATMENT", 270, 304], ["other enzymes", "TEST", 393, 406], ["large", "OBSERVATION_MODIFIER", 57, 62]]], ["It is possible that inhibitors of limited, rather than absolute selectivity against DUBs or ligases will exhibit improved efficacy, as in the case of recently approved dual kinase inhibitors [44] .", [["DUBs", "GENE_OR_GENE_PRODUCT", 84, 88], ["DUBs", "PROTEIN", 84, 88], ["inhibitors", "TREATMENT", 20, 30], ["DUBs or ligases", "PROBLEM", 84, 99], ["dual kinase inhibitors", "TREATMENT", 168, 190]]], ["Ongoing work with new inhibitors of the proteasome and of ubiquitin pathway enzymes will help to answer these questions.ConclusionsWork performed in accordance with Uniform Requirements for manuscripts submitted to biochemical journals http://www.icmje.org.", [["proteasome", "PROTEIN", 40, 50], ["ubiquitin pathway enzymes", "PROTEIN", 58, 83], ["new inhibitors", "TREATMENT", 18, 32], ["the proteasome", "TREATMENT", 36, 50], ["ubiquitin pathway enzymes", "TREATMENT", 58, 83]]]], "671291d6b0141d9920ffc82e45bc9aef32c6b391": [["IntroductionShortly after its emergence in southern China in 2002/2003, Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) was confirmed to be the cause of SARS .", [["Acute Respiratory Syndrome coronavirus", "DISEASE", 79, 117], ["SARS", "DISEASE", 119, 123], ["SARS", "DISEASE", 162, 166], ["Severe Acute Respiratory Syndrome coronavirus", "ORGANISM", 72, 117], ["SARS-CoV", "ORGANISM", 119, 127], ["Severe Acute Respiratory Syndrome coronavirus", "SPECIES", 72, 117], ["SARS-CoV", "SPECIES", 119, 127], ["Severe Acute Respiratory Syndrome coronavirus", "PROBLEM", 72, 117], ["SARS", "PROBLEM", 162, 166], ["Severe", "OBSERVATION_MODIFIER", 72, 78], ["Acute", "OBSERVATION_MODIFIER", 79, 84], ["Respiratory Syndrome", "OBSERVATION", 85, 105], ["SARS", "OBSERVATION", 162, 166]]], ["There has been a total of 8096 laboratory-confirmed cases of SARS, leading to 774 mortalities in 11 countries (World Health Organization, 2004) .", [["SARS", "DISEASE", 61, 65], ["SARS", "PROBLEM", 61, 65]]], ["Subsequently, SARS-related CoV (SARSr-CoV) was found in palm civets from live animal markets in Guangdong province .", [["SARS", "DISEASE", 14, 18], ["SARS-related CoV", "ORGANISM", 14, 30], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 32, 41], ["palm", "ORGANISM_SUBDIVISION", 56, 60], ["SARSr-CoV", "SPECIES", 32, 41], ["SARS", "TEST", 14, 18]]], ["However, the initial hypothesis that civets may act as animal reservoir of SARS-CoV was soon overturned by several observations.", [["civets", "CHEMICAL", 37, 43], ["SARS", "DISEASE", 75, 79], ["SARS-CoV", "ORGANISM", 75, 83], ["SARS-CoV", "SPECIES", 75, 83], ["SARS", "PROBLEM", 75, 79], ["CoV", "PROBLEM", 80, 83]]], ["Firstly, SARSr-CoV was only detected in civets from the market, but not those in the wild (Kan et al., 2005; Tu et al., 2004) .", [["SARSr-CoV", "ORGANISM", 9, 18], ["SARSr-CoV", "PROTEIN", 9, 18], ["SARSr-CoV", "SPECIES", 9, 18], ["SARSr-CoV", "PROBLEM", 9, 18]]], ["Secondly, the high ratio of nonsynonymous to synonymous mutation rates (Ka/Ks ratios) of the Spike (S), open reading frame (ORF) 3a and non-structural protein (nsp) genes in civet SARSr-CoVs collected in both the 2003 and the minor 2004 outbreaks suggested that the virus was undergoing rapid evolutionary gene adaptation in civets (Song et al., 2005) .", [["Spike", "GENE_OR_GENE_PRODUCT", 93, 98], ["non-structural protein (nsp)", "GENE_OR_GENE_PRODUCT", 136, 164], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 180, 190], ["Spike (S)", "DNA", 93, 102], ["open reading frame", "DNA", 104, 122], ["ORF", "DNA", 124, 127], ["non-structural protein (nsp) genes", "DNA", 136, 170], ["civet SARSr-CoVs", "DNA", 174, 190], ["synonymous mutation rates", "TEST", 45, 70], ["Ka/Ks ratios", "TEST", 72, 84], ["the Spike (S)", "PROBLEM", 89, 102], ["open reading frame (ORF)", "TEST", 104, 128], ["non-structural protein (nsp) genes", "TEST", 136, 170], ["SARSr", "TEST", 180, 185], ["CoVs", "TEST", 186, 190], ["the virus", "PROBLEM", 262, 271]]], ["Thirdly, compared with SARS-CoV collected from human during the 2003 epidemic, functional changes have been observed in the S protein of civet SARSr-CoV and the SARS-CoV isolated from the 2004 minor outbreak.", [["SARS-CoV", "ORGANISM", 23, 31], ["human", "ORGANISM", 47, 52], ["SARSr-CoV", "ORGANISM", 143, 152], ["SARS-CoV", "ORGANISM", 161, 169], ["S protein", "PROTEIN", 124, 133], ["human", "SPECIES", 47, 52], ["SARS-CoV", "SPECIES", 23, 31], ["human", "SPECIES", 47, 52], ["SARSr-CoV", "SPECIES", 143, 152], ["SARS-CoV", "SPECIES", 161, 169], ["SARS", "TEST", 23, 27], ["functional changes", "PROBLEM", 79, 97], ["the S protein", "TEST", 120, 133], ["SARSr", "TEST", 143, 148], ["the SARS", "PROBLEM", 157, 165]]], ["The latter showed less efficient use of the human angiotensin converting enzyme 2 (ACE2) receptor (Li et al., 2005b) and demonstrated resistance to antibody inhibition (Yang et al., 2005) .", [["angiotensin", "CHEMICAL", 50, 61], ["human", "ORGANISM", 44, 49], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 50, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 83, 87], ["human angiotensin converting enzyme 2 (ACE2) receptor", "PROTEIN", 44, 97], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["the human angiotensin converting enzyme", "TREATMENT", 40, 79], ["resistance to antibody inhibition", "PROBLEM", 134, 167], ["less", "OBSERVATION_MODIFIER", 18, 22]]], ["Finally, while significant levels of antibody to SARS-CoV were detected in 80% of the civets from one animal market in Guangzhou, low seroprevalence rates in civets from various civet farms in China suggested that civets were largely brought to the animal market infection-free Tu et al., 2004) .", [["SARS", "DISEASE", 49, 53], ["infection", "DISEASE", 263, 272], ["SARS-CoV", "ORGANISM", 49, 57], ["SARS-CoV", "SPECIES", 49, 57], ["significant levels of antibody to SARS", "PROBLEM", 15, 53], ["CoV", "TEST", 54, 57], ["low seroprevalence rates", "TREATMENT", 130, 154]]], ["The SARSr-CoV was likely contracted during later mixing and trading.IntroductionIn view of these observations, we carried out a molecular surveillance study in various mammals in Hong Kong to hunt for the ultimate source of the virus .", [["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 4, 13], ["SARSr-CoV", "SPECIES", 4, 13], ["a molecular surveillance study", "TEST", 126, 156], ["the virus", "PROBLEM", 224, 233], ["CoV", "ANATOMY", 10, 13], ["likely", "UNCERTAINTY", 18, 24], ["contracted", "OBSERVATION", 25, 35], ["virus", "OBSERVATION", 228, 233]]], ["Among the 127 bats (including 8 bat species), 20 monkeys and 60 rodents surveyed, SARSr-CoV was only detected in 39% of the fecal samples of 59 Chinese horseshoe bats (Rhinolophus sinicus, Rs) .", [["fecal samples", "ANATOMY", 124, 137], ["monkeys", "ORGANISM", 49, 56], ["SARSr-CoV", "ORGANISM", 82, 91], ["fecal samples", "ORGANISM_SUBSTANCE", 124, 137], ["Rhinolophus sinicus", "ORGANISM", 168, 187], ["monkeys", "SPECIES", 49, 56], ["Rhinolophus sinicus", "SPECIES", 168, 187], ["SARSr-CoV", "SPECIES", 82, 91], ["Chinese horseshoe bats", "SPECIES", 144, 166], ["Rhinolophus sinicus", "SPECIES", 168, 187], ["8 bat species", "TEST", 30, 43], ["SARSr-CoV", "TEST", 82, 91], ["the fecal samples", "TEST", 120, 137], ["fecal", "ANATOMY", 124, 129], ["horseshoe bats", "OBSERVATION", 152, 166]]], ["Western blot analysis showed that antibodies against the nucleocapsid (N) protein of bat SARSr-CoV was present in 67% of the serum samples of Chinese horseshoe bats, while 8% of the serum of Chinese horseshoe bats were tested positive for human SARS-CoV-neutralizing antibody with titer \u22651:20 .", [["serum samples", "ANATOMY", 125, 138], ["serum", "ANATOMY", 182, 187], ["antibodies against the nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 34, 73], ["bat SARSr-CoV", "ORGANISM", 85, 98], ["serum samples", "ORGANISM_SUBSTANCE", 125, 138], ["serum", "ORGANISM_SUBSTANCE", 182, 187], ["horseshoe bats", "ORGANISM", 199, 213], ["human", "ORGANISM", 239, 244], ["SARS-CoV", "ORGANISM", 245, 253], ["antibodies", "PROTEIN", 34, 44], ["nucleocapsid (N) protein", "PROTEIN", 57, 81], ["SARSr", "PROTEIN", 89, 94], ["CoV", "PROTEIN", 95, 98], ["human SARS-CoV-neutralizing antibody", "PROTEIN", 239, 275], ["human", "SPECIES", 239, 244], ["SARSr-CoV", "SPECIES", 89, 98], ["Chinese horseshoe bats", "SPECIES", 142, 164], ["Chinese horseshoe bats", "SPECIES", 191, 213], ["human SARS-CoV", "SPECIES", 239, 253], ["Western blot analysis", "TEST", 0, 21], ["antibodies", "TEST", 34, 44], ["the nucleocapsid", "TEST", 53, 69], ["protein", "TEST", 74, 81], ["bat SARSr", "TEST", 85, 94], ["CoV", "TEST", 95, 98], ["the serum samples", "TEST", 121, 138], ["Chinese horseshoe bats", "PROBLEM", 142, 164], ["the serum", "TEST", 178, 187], ["Chinese horseshoe bats", "TEST", 191, 213], ["human SARS", "TEST", 239, 249], ["CoV", "TEST", 250, 253], ["neutralizing antibody", "TEST", 254, 275], ["horseshoe bats", "OBSERVATION", 150, 164]]], ["Shortly afterward, another independent group also reported the detection of SARSr-CoV in Chinese horseshoe bats, greater horseshoe bats (Rhinolophus ferrumequinum, Rf), and big-eared horseshoe bats (Rhinolophus macrotis, Rm) in Hubei and Guangxi provinces of China (Li et al., 2005a) .", [["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 76, 85], ["Rhinolophus ferrumequinum", "ORGANISM", 137, 162], ["horseshoe", "ORGANISM", 183, 192], ["Rhinolophus macrotis", "ORGANISM", 199, 219], ["Rhinolophus ferrumequinum", "SPECIES", 137, 162], ["Rhinolophus macrotis", "SPECIES", 199, 219], ["SARSr-CoV", "SPECIES", 76, 85], ["Chinese horseshoe bats", "SPECIES", 89, 111], ["horseshoe bats", "SPECIES", 121, 135], ["Rhinolophus ferrumequinum", "SPECIES", 137, 162], ["big-eared horseshoe bats", "SPECIES", 173, 197], ["Rhinolophus macrotis", "SPECIES", 199, 219], ["SARSr", "PROBLEM", 76, 81], ["CoV in Chinese horseshoe bats", "PROBLEM", 82, 111], ["greater horseshoe bats", "PROBLEM", 113, 135], ["big-eared horseshoe bats", "PROBLEM", 173, 197], ["horseshoe bats", "OBSERVATION", 97, 111], ["greater", "OBSERVATION_MODIFIER", 113, 120], ["horseshoe bats", "OBSERVATION", 121, 135], ["horseshoe bats", "OBSERVATION", 183, 197]]], ["In the past few years, SARSr-CoVs have been isolated from a variety of horseshoe bats in Yunnan province of China by several groups (Ge et al., 2013; He et al., 2014; Hu et al., 2017; Lau et al., 2015) .IntroductionThree hundred and thirty nine SARSr-CoV genomes have been sequenced from 2003 to 2018.", [["SARSr-CoVs", "CHEMICAL", 23, 33], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 23, 33], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 245, 254], ["SARSr", "PROTEIN", 23, 28], ["CoVs", "PROTEIN", 29, 33], ["SARSr-CoV genomes", "DNA", 245, 262], ["SARSr-CoV", "SPECIES", 245, 254], ["SARSr-CoVs", "PROBLEM", 23, 33]]], ["These include 274 genomes from human, 18 from civets and 47 from bats.", [["civets", "ANATOMY", 46, 52], ["human", "ORGANISM", 31, 36], ["civets", "CANCER", 46, 52], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36]]], ["The human SARS-CoV and civet SARSr-CoV were collected in 2003/2004, while bat SARSr-CoVs were continuously detected even after the cessation of the SARS epidemic.", [["SARS", "DISEASE", 148, 152], ["human", "ORGANISM", 4, 9], ["SARS-CoV", "ORGANISM", 10, 18], ["SARSr-CoV", "ORGANISM", 29, 38], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 78, 88], ["human SARS-CoV and civet SARSr-CoV", "DNA", 4, 38], ["bat SARSr-CoVs", "DNA", 74, 88], ["human", "SPECIES", 4, 9], ["human SARS-CoV", "SPECIES", 4, 18], ["SARSr-CoV", "SPECIES", 29, 38], ["The human SARS", "TEST", 0, 14], ["civet SARSr", "TEST", 23, 34], ["CoV", "TEST", 35, 38], ["the SARS epidemic", "PROBLEM", 144, 161]]], ["In this article, we review our current understanding of the molecular epidemiology, evolution and, phylogeny of SARSr-CoVs based on analysis of these 339 genomes.The SARS-CoV genomeThe genome size of the SARS-CoV varies from 29.0 kb to 30.2 kb.", [["SARS", "DISEASE", 166, 170], ["SARS", "DISEASE", 204, 208], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 112, 122], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 166, 174], ["SARS-CoV", "ORGANISM", 204, 212], ["SARSr", "DNA", 112, 117], ["CoVs", "DNA", 118, 122], ["339 genomes", "DNA", 150, 161], ["SARS-CoV genome", "DNA", 166, 181], ["SARS-CoV", "DNA", 204, 212], ["SARS-CoV", "SPECIES", 166, 174], ["SARS-CoV", "SPECIES", 204, 212], ["analysis", "TEST", 132, 140], ["The SARS", "PROBLEM", 162, 170], ["the SARS", "TEST", 200, 208], ["CoV varies", "TEST", 209, 219], ["CoV genome", "OBSERVATION", 171, 181], ["genome", "OBSERVATION_MODIFIER", 185, 191], ["size", "OBSERVATION_MODIFIER", 192, 196], ["SARS", "OBSERVATION", 204, 208], ["CoV", "ANATOMY", 209, 212]]], ["Its genome structure follows the characteristic gene order of other known CoVs: the 5\u2032 two thirds of the genome comprises ORF1ab encoding replicase polyproteins, while the 3\u2032 one third consists of genes encoding structural proteins including S, envelope (E), membrane (M), and N proteins (Fig. 1 ).", [["membrane", "ANATOMY", 259, 267], ["CoVs", "GENE_OR_GENE_PRODUCT", 74, 78], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 122, 128], ["S, envelope (E)", "GENE_OR_GENE_PRODUCT", 242, 257], ["membrane", "CELLULAR_COMPONENT", 259, 267], ["CoVs", "DNA", 74, 78], ["ORF1ab", "DNA", 122, 128], ["replicase polyproteins", "PROTEIN", 138, 160], ["structural proteins", "PROTEIN", 212, 231], ["S", "PROTEIN", 242, 243], ["envelope (E), membrane (M)", "PROTEIN", 245, 271], ["N proteins", "PROTEIN", 277, 287], ["Fig. 1", "PROTEIN", 289, 295], ["encoding replicase polyproteins", "PROBLEM", 129, 160], ["genes encoding structural proteins", "PROBLEM", 197, 231], ["envelope (E), membrane (M)", "TEST", 245, 271], ["CoVs", "OBSERVATION", 74, 78], ["replicase polyproteins", "OBSERVATION", 138, 160], ["structural proteins", "OBSERVATION", 212, 231]]], ["Both the 5\u2032 and 3\u2032 ends of the SARS-CoV genome contain short untranslated regions.", [["5\u2032", "GENE_OR_GENE_PRODUCT", 9, 11], ["5\u2032 and 3\u2032 ends", "DNA", 9, 23], ["SARS-CoV genome", "DNA", 31, 46], ["short untranslated regions", "DNA", 55, 81], ["SARS-CoV", "SPECIES", 31, 39], ["short untranslated regions", "PROBLEM", 55, 81], ["SARS", "OBSERVATION", 31, 35], ["CoV genome", "OBSERVATION", 36, 46], ["short", "OBSERVATION_MODIFIER", 55, 60]]], ["The translational product of ORF1ab is cleaved by proteases encoded by SARS-CoV itself into 16 nsps, which include major enzymes such as papain-like protease(s) (PL pro ), chymotrypsin-like protease (3CL pro ), RNA-dependent RNA polymerase (RdRp) and helicase (Hel) (Fig. 1) .", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 29, 35], ["SARS-CoV", "ORGANISM", 71, 79], ["nsps", "GENE_OR_GENE_PRODUCT", 95, 99], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 137, 157], ["PL pro", "GENE_OR_GENE_PRODUCT", 162, 168], ["chymotrypsin-like protease", "GENE_OR_GENE_PRODUCT", 172, 198], ["3CL pro", "GENE_OR_GENE_PRODUCT", 200, 207], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 211, 239], ["ORF1ab", "PROTEIN", 29, 35], ["proteases", "PROTEIN", 50, 59], ["16 nsps", "PROTEIN", 92, 99], ["major enzymes", "PROTEIN", 115, 128], ["papain-like protease(s)", "PROTEIN", 137, 160], ["PL pro", "PROTEIN", 162, 168], ["chymotrypsin-like protease", "PROTEIN", 172, 198], ["3CL pro", "PROTEIN", 200, 207], ["RNA-dependent RNA polymerase", "PROTEIN", 211, 239], ["RdRp", "PROTEIN", 241, 245], ["helicase", "PROTEIN", 251, 259], ["Hel", "PROTEIN", 261, 264], ["Fig. 1", "PROTEIN", 267, 273], ["SARS-CoV", "SPECIES", 71, 79], ["major enzymes", "TREATMENT", 115, 128], ["papain-like protease", "TREATMENT", 137, 157], ["chymotrypsin-like protease", "TREATMENT", 172, 198], ["RNA-dependent RNA polymerase (RdRp", "TREATMENT", 211, 245], ["helicase (Hel)", "TREATMENT", 251, 265]]], ["In contrast to the genome of viruses belonging to lineage A Betacoronavirus (recently renamed as subgenera Embecovirus), haemagglutinin-esterase gene is absent from the genome of SARS-CoV.", [["SARS", "DISEASE", 179, 183], ["lineage A Betacoronavirus", "ORGANISM", 50, 75], ["Embecovirus", "GENE_OR_GENE_PRODUCT", 107, 118], ["haemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 121, 144], ["SARS-CoV", "ORGANISM", 179, 187], ["haemagglutinin-esterase gene", "DNA", 121, 149], ["SARS-CoV", "SPECIES", 179, 187], ["subgenera Embecovirus", "TEST", 97, 118], ["haemagglutinin-esterase gene", "TEST", 121, 149]]], ["In addition, SARS-CoV contains 6-7 accessory proteins, encoded by ORF3a, ORF3b, ORF6, ORF7a, ORF7b and ORF8 [or ORF8a and ORF8b as a result of a 29-nucleotide (nt) deletion].", [["SARS", "DISEASE", 13, 17], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["ORF3a", "GENE_OR_GENE_PRODUCT", 66, 71], ["ORF3b", "GENE_OR_GENE_PRODUCT", 73, 78], ["ORF6", "GENE_OR_GENE_PRODUCT", 80, 84], ["ORF7a", "GENE_OR_GENE_PRODUCT", 86, 91], ["ORF7b", "GENE_OR_GENE_PRODUCT", 93, 98], ["ORF8", "GENE_OR_GENE_PRODUCT", 103, 107], ["ORF8a", "GENE_OR_GENE_PRODUCT", 112, 117], ["ORF8b", "GENE_OR_GENE_PRODUCT", 122, 127], ["SARS-CoV contains 6-7 accessory proteins", "PROTEIN", 13, 53], ["ORF3a", "PROTEIN", 66, 71], ["ORF3b", "PROTEIN", 73, 78], ["ORF6", "PROTEIN", 80, 84], ["ORF7a", "PROTEIN", 86, 91], ["ORF7b", "PROTEIN", 93, 98], ["ORF8", "PROTEIN", 103, 107], ["ORF8a", "PROTEIN", 112, 117], ["ORF8b", "PROTEIN", 122, 127], ["29-nucleotide (nt) deletion", "DNA", 145, 172], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "PROBLEM", 13, 17], ["a 29-nucleotide (nt) deletion", "PROBLEM", 143, 172]]], ["This is unique to lineage B Betacoronavirus, a subgenus recently renamed Sarbecovirus and contains all SARSr-CoVs (Fig. 2) .The SARS-CoV genomeStudies in the past 15 years have partly revealed the biochemical functions of these accessory proteins (Liu et al., 2014) .", [["lineage B Betacoronavirus", "CELL", 18, 43], ["SARS-CoV", "ORGANISM", 128, 136], ["SARSr-CoVs", "PROTEIN", 103, 113], ["accessory proteins", "PROTEIN", 228, 246], ["B Betacoronavirus", "SPECIES", 26, 43], ["SARS-CoV", "SPECIES", 128, 136], ["a subgenus recently renamed Sarbecovirus", "PROBLEM", 45, 85], ["all SARSr-CoVs", "PROBLEM", 99, 113], ["The SARS-CoV genomeStudies", "PROBLEM", 124, 150], ["lineage B Betacoronavirus", "OBSERVATION", 18, 43], ["all", "OBSERVATION_MODIFIER", 99, 102], ["SARSr-CoVs", "OBSERVATION", 103, 113]]], ["Protein 3a triggers apoptosis and induces the production of proinflammatory cytokines such as RANTES (Regulated on Activation, Normal T cell Expressed and Secreted; also known as C-C motif chemokine ligand 5, CCL5) and CXCL8 (C-X-C motif chemokine ligand 8).", [["T cell", "ANATOMY", 134, 140], ["Protein 3a", "GENE_OR_GENE_PRODUCT", 0, 10], ["RANTES", "GENE_OR_GENE_PRODUCT", 94, 100], ["T cell", "CELL", 134, 140], ["C-C motif chemokine ligand 5", "GENE_OR_GENE_PRODUCT", 179, 207], ["CCL5", "GENE_OR_GENE_PRODUCT", 209, 213], ["CXCL8", "GENE_OR_GENE_PRODUCT", 219, 224], ["C-X-C motif chemokine ligand 8", "GENE_OR_GENE_PRODUCT", 226, 256], ["Protein 3a", "PROTEIN", 0, 10], ["proinflammatory cytokines", "PROTEIN", 60, 85], ["RANTES", "PROTEIN", 94, 100], ["Regulated on Activation, Normal T cell Expressed and Secreted", "PROTEIN", 102, 163], ["C-C motif chemokine ligand 5", "PROTEIN", 179, 207], ["CCL5", "PROTEIN", 209, 213], ["CXCL8", "PROTEIN", 219, 224], ["C-X-C motif chemokine ligand 8", "PROTEIN", 226, 256], ["Protein 3a triggers apoptosis", "PROBLEM", 0, 29], ["proinflammatory cytokines", "PROBLEM", 60, 85], ["C-C motif chemokine ligand", "TREATMENT", 179, 205], ["CCL5", "TEST", 209, 213], ["CXCL8", "TEST", 219, 224], ["C", "TEST", 226, 227], ["-X-C motif chemokine ligand", "TREATMENT", 227, 254], ["proinflammatory cytokines", "OBSERVATION", 60, 85]]], ["Protein 3b inhibits type I interferon and also induces apoptosis.", [["Protein 3b", "GENE_OR_GENE_PRODUCT", 0, 10], ["type I interferon", "GENE_OR_GENE_PRODUCT", 20, 37], ["Protein 3b", "PROTEIN", 0, 10], ["type I interferon", "PROTEIN", 20, 37], ["Protein", "TEST", 0, 7], ["type I interferon", "TREATMENT", 20, 37], ["apoptosis", "PROBLEM", 55, 64], ["apoptosis", "OBSERVATION", 55, 64]]], ["Protein 6 inhibits interferon signaling and stimulates DNA synthesis.", [["interferon", "GENE_OR_GENE_PRODUCT", 19, 29], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["Protein 6", "PROTEIN", 0, 9], ["interferon", "PROTEIN", 19, 29], ["Protein", "TEST", 0, 7], ["interferon signaling", "PROBLEM", 19, 39], ["stimulates DNA synthesis", "PROBLEM", 44, 68]]], ["Protein 7a activates NF-\u03baB (nuclear factor kappa B) and MAPK8 (mitogen-activated protein kinase 8) for CXCL8 and RANTES production.", [["Protein 7a", "GENE_OR_GENE_PRODUCT", 0, 10], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 21, 26], ["nuclear factor kappa B", "GENE_OR_GENE_PRODUCT", 28, 50], ["MAPK8", "GENE_OR_GENE_PRODUCT", 56, 61], ["mitogen-activated protein kinase 8", "GENE_OR_GENE_PRODUCT", 63, 97], ["CXCL8", "GENE_OR_GENE_PRODUCT", 103, 108], ["RANTES", "GENE_OR_GENE_PRODUCT", 113, 119], ["NF-\u03baB", "PROTEIN", 21, 26], ["nuclear factor kappa B", "PROTEIN", 28, 50], ["MAPK8", "PROTEIN", 56, 61], ["mitogen-activated protein kinase 8", "PROTEIN", 63, 97], ["CXCL8", "PROTEIN", 103, 108], ["RANTES", "PROTEIN", 113, 119], ["Protein", "TEST", 0, 7], ["NF", "TEST", 21, 23], ["nuclear factor kappa B", "TEST", 28, 50], ["MAPK8", "TEST", 56, 61], ["mitogen", "TEST", 63, 70], ["activated protein kinase", "TEST", 71, 95], ["CXCL8", "TEST", 103, 108], ["RANTES production", "PROBLEM", 113, 130]]], ["The function of protein 7b is not well characterized yet.", [["protein 7b", "GENE_OR_GENE_PRODUCT", 16, 26], ["protein 7b", "PROTEIN", 16, 26], ["The function of protein 7b", "TEST", 0, 26], ["protein 7b", "OBSERVATION", 16, 26], ["well characterized", "OBSERVATION_MODIFIER", 34, 52]]], ["ORF8 is present in all SARSr-CoV genomes in bats and civets, as well as in SARS-CoVs isolated from human during the early phase of the epidemic.", [["SARS-CoVs", "DISEASE", 75, 84], ["ORF8", "GENE_OR_GENE_PRODUCT", 0, 4], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 23, 32], ["SARS-CoVs", "ORGANISM", 75, 84], ["human", "ORGANISM", 99, 104], ["ORF8", "DNA", 0, 4], ["SARSr-CoV genomes", "DNA", 23, 40], ["human", "SPECIES", 99, 104], ["SARSr-CoV", "SPECIES", 23, 32], ["SARS-CoVs", "SPECIES", 75, 84], ["human", "SPECIES", 99, 104]]], ["Protein 8 activates the ATF6 (activating transcription factor 6) branch of unfolded protein response.", [["Protein 8", "GENE_OR_GENE_PRODUCT", 0, 9], ["ATF6 (activating transcription factor 6", "GENE_OR_GENE_PRODUCT", 24, 63], ["Protein 8", "PROTEIN", 0, 9], ["ATF6 (activating transcription factor 6", "PROTEIN", 24, 63], ["Protein", "TEST", 0, 7], ["the ATF6 (activating transcription factor", "TREATMENT", 20, 61], ["unfolded protein response", "PROBLEM", 75, 100], ["unfolded", "OBSERVATION_MODIFIER", 75, 83], ["protein response", "OBSERVATION", 84, 100]]], ["In the genomes of SARS-CoVs isolated from human during the late phase of the epidemic, there was a signature 29-nt deletion in ORF8, splitting it into two separate ORFs 8a and 8b.", [["SARS-CoVs", "DISEASE", 18, 27], ["SARS-CoVs", "ORGANISM", 18, 27], ["human", "ORGANISM", 42, 47], ["ORF8", "GENE_OR_GENE_PRODUCT", 127, 131], ["29-nt deletion", "DNA", 109, 123], ["ORF8", "DNA", 127, 131], ["ORFs 8a and 8b", "DNA", 164, 178], ["human", "SPECIES", 42, 47], ["SARS-CoVs", "SPECIES", 18, 27], ["human", "SPECIES", 42, 47], ["SARS", "PROBLEM", 18, 22], ["CoVs", "PROBLEM", 23, 27], ["a signature 29-nt deletion in ORF8", "PROBLEM", 97, 131], ["SARS", "OBSERVATION", 18, 22]]], ["Protein 8a includes caspase-dependent apoptosis whereas protein 8b modulates cellular DNA synthesis.Unique phylogenetic position of SARS-CoVBefore the SARS epidemic, there were just around 10 CoVs with complete genome sequences available.", [["cellular", "ANATOMY", 77, 85], ["SARS", "DISEASE", 132, 136], ["SARS", "DISEASE", 151, 155], ["Protein 8a", "GENE_OR_GENE_PRODUCT", 0, 10], ["caspase", "GENE_OR_GENE_PRODUCT", 20, 27], ["protein 8b", "GENE_OR_GENE_PRODUCT", 56, 66], ["cellular DNA", "CELLULAR_COMPONENT", 77, 89], ["CoVs", "CANCER", 192, 196], ["caspase", "PROTEIN", 20, 27], ["protein 8b", "PROTEIN", 56, 66], ["CoVs", "DNA", 192, 196], ["genome sequences", "DNA", 211, 227], ["Protein", "TEST", 0, 7], ["caspase", "TEST", 20, 27], ["dependent apoptosis", "PROBLEM", 28, 47], ["protein", "TEST", 56, 63], ["cellular DNA synthesis", "PROBLEM", 77, 99], ["SARS", "PROBLEM", 132, 136], ["the SARS epidemic", "PROBLEM", 147, 164], ["complete genome sequences", "TEST", 202, 227], ["dependent apoptosis", "OBSERVATION_MODIFIER", 28, 47], ["cellular DNA synthesis", "OBSERVATION", 77, 99], ["phylogenetic", "OBSERVATION_MODIFIER", 107, 119], ["position", "OBSERVATION_MODIFIER", 120, 128]]], ["These CoVs were classified into three groups: Group 1, Group 2 and Group 3.", [["CoVs", "CANCER", 6, 10]]], ["In 2011, the Coronavirus Study Group of the International Committee for Taxonomy of Viruses renamed these three groups into three genera: Alphacoronavirus, Betacoronavirus, and Gammacoronavirus (de Groot et al., 2011) .", [["Betacoronavirus", "ORGANISM", 156, 171], ["the Coronavirus Study", "TEST", 9, 30], ["Taxonomy of Viruses", "PROBLEM", 72, 91], ["Alphacoronavirus", "TREATMENT", 138, 154], ["Betacoronavirus", "TREATMENT", 156, 171]]], ["When SARS-CoV was first discovered in 2003, phylogenetic analysis of the SARS-CoV genome showed that it occupied a unique position in Betacoronavirus, which was subsequently placed into the subgenus Sarbecovirus.", [["SARS", "DISEASE", 5, 9], ["SARS-CoV", "ORGANISM", 5, 13], ["SARS-CoV", "ORGANISM", 73, 81], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 134, 149], ["SARS-CoV genome", "DNA", 73, 88], ["SARS-CoV", "SPECIES", 5, 13], ["SARS-CoV", "SPECIES", 73, 81], ["SARS", "PROBLEM", 5, 9], ["phylogenetic analysis", "TEST", 44, 65], ["the SARS", "PROBLEM", 69, 77], ["CoV genome", "TEST", 78, 88], ["position", "OBSERVATION_MODIFIER", 122, 130], ["subgenus Sarbecovirus", "OBSERVATION", 190, 211]]], ["The traditional betaCoVs (e.g. mouse hepatitis virus, human CoV OC43, bovine CoV) were classified as Embecovirus (Fig. 2) .", [["hepatitis virus", "DISEASE", 37, 52], ["betaCoVs", "GENE_OR_GENE_PRODUCT", 16, 24], ["mouse hepatitis virus", "ORGANISM", 31, 52], ["human", "ORGANISM", 54, 59], ["CoV OC43", "ORGANISM", 60, 68], ["bovine", "ORGANISM", 70, 76], ["CoV", "ORGANISM", 77, 80], ["mouse", "SPECIES", 31, 36], ["hepatitis virus", "SPECIES", 37, 52], ["human", "SPECIES", 54, 59], ["bovine", "SPECIES", 70, 76], ["mouse hepatitis virus", "SPECIES", 31, 52], ["human CoV OC43", "SPECIES", 54, 68], ["bovine CoV", "SPECIES", 70, 80], ["The traditional betaCoVs", "TREATMENT", 0, 24], ["mouse hepatitis virus", "PROBLEM", 31, 52], ["human CoV OC43", "TEST", 54, 68], ["bovine CoV", "TEST", 70, 80], ["Embecovirus", "TEST", 101, 112]]], ["After the SARS epidemic, an unprecedented number of novel CoVs were discovered (Lau et al., 2016; Lau et al., 2007; Lau et al., 2012a; Lau et al., 2012b; Lau et al., 2014; Woo et al., 2005; Woo et al., 2014a; Woo et al., 2014b) .", [["SARS", "DISEASE", 10, 14], ["CoVs", "GENE_OR_GENE_PRODUCT", 58, 62], ["the SARS epidemic", "PROBLEM", 6, 23], ["et al.", "TEST", 194, 200], ["et al.", "TEST", 213, 219]]], ["This led to the description of lineage C Betacoronavirus, which comprises important members such as Tylonycteris bat coronavirus HKU4, Pipistrellus bat coronavirus HKU5, Hypsugo bat coronavirus HKU25 and Middle East Respiratory Syndrome CoV Lau et al., 2018b; Woo et al., 2007; Woo et al., 2006a) , and lineage D Betacoronavirus (Lau et al., 2010b) as well as a novel genus Deltacoronavirus (Lau et al., 2018a; Woo et al., 2012; Woo et al., 2017) (Fig. 2 ).", [["lineage C Betacoronavirus", "CELL", 31, 56], ["Tylonycteris bat coronavirus", "ORGANISM", 100, 128], ["HKU4", "ORGANISM", 129, 133], ["Pipistrellus bat coronavirus", "ORGANISM", 135, 163], ["HKU5", "ORGANISM", 164, 168], ["Hypsugo bat coronavirus", "ORGANISM", 170, 193], ["HKU25", "ORGANISM", 194, 199], ["Tylonycteris", "SPECIES", 100, 112], ["bat coronavirus", "SPECIES", 113, 128], ["Pipistrellus bat coronavirus", "SPECIES", 135, 163], ["Hypsugo bat coronavirus", "SPECIES", 170, 193], ["Tylonycteris bat coronavirus", "SPECIES", 100, 128], ["Pipistrellus bat coronavirus", "SPECIES", 135, 163], ["Hypsugo bat coronavirus", "SPECIES", 170, 193], ["Middle East Respiratory Syndrome CoV", "SPECIES", 204, 240], ["lineage C Betacoronavirus", "PROBLEM", 31, 56], ["Tylonycteris", "TEST", 100, 112], ["Pipistrellus bat coronavirus", "PROBLEM", 135, 163], ["Hypsugo", "TEST", 170, 177], ["Middle East Respiratory Syndrome", "PROBLEM", 204, 236], ["Middle", "ANATOMY_MODIFIER", 204, 210]]], ["Lineage C and lineage D Betacoronavirus were now renamed as subgenera Merbecovirus and Nobecovirus.Circulation of SARSr-CoV in horseshoe bats in 2004 to 2018Since its first discovery in Chinese horseshoe bats in 2004 , SARSr-CoVs have been continuously found in various horseshoe bat species in the last 13 years (Drexler et al., 2010; Ge et al., 2013; He et al., 2014; Hu et al., 2017; Lau et al., 2005; Lau et al., 2010a; Li et al., 2005a; Tang et al., 2006; Wu et al., 2016; Yang et al., 2013; Yang et al., 2015; Zeng et al., 2016) .", [["Lineage C", "CELL", 0, 9], ["lineage D Betacoronavirus", "CELL", 14, 39], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 114, 123], ["horseshoe bats", "ORGANISM", 127, 141], ["horseshoe bats", "ORGANISM", 194, 208], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 219, 229], ["SARSr-CoVs", "DNA", 219, 229], ["SARSr-CoV", "SPECIES", 114, 123], ["Chinese horseshoe bats", "SPECIES", 186, 208], ["Lineage C and lineage D Betacoronavirus", "PROBLEM", 0, 39], ["Nobecovirus", "TREATMENT", 87, 98], ["SARSr", "TEST", 114, 119], ["et al.", "TEST", 502, 508], ["Zeng", "TEST", 516, 520], ["lineage D Betacoronavirus", "OBSERVATION", 14, 39], ["horseshoe bat", "ANATOMY", 270, 283]]], ["This is in contrast to the case for civets and human, where SARSr-CoVs were only found in 2003/2004, and never reported afterward.", [["human", "ORGANISM", 47, 52], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 60, 70], ["SARSr-CoVs", "DNA", 60, 70], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["SARSr", "TEST", 60, 65]]], ["For the 47 bat SARSr-CoV genomes, 30 are from Chinese horseshoe bats, 9 from greater horseshoe bats, 2 from big-eared horseshoe bat, 2 from least horseshoe bat (Rhinolophus pusillus, Rp), and 1 each from intermediate horseshoe bat (Rhinolophus affinis, Ra), Blasius's horseshoe bat (Rhinolophus blasii, Rb), Stoliczka's Asian trident bat (Aselliscus stoliczkanus, As) in the neighboring family Hipposideridae and wrinkled-lipped free-tailed bat (Chaerephon plicata, Cp) in the genetically more distant family Molossidae.", [["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 15, 24], ["Rhinolophus pusillus", "ORGANISM", 161, 181], ["horseshoe bat", "ORGANISM", 217, 230], ["Rhinolophus affinis", "ORGANISM", 232, 251], ["Blasius's horseshoe bat", "ORGANISM", 258, 281], ["Rhinolophus blasii", "ORGANISM", 283, 301], ["Rb", "GENE_OR_GENE_PRODUCT", 303, 305], ["trident bat", "ORGANISM", 326, 337], ["Aselliscus stoliczkanus", "ORGANISM", 339, 362], ["bat", "ORGANISM", 441, 444], ["Chaerephon plicata", "ORGANISM", 446, 464], ["SARSr-CoV genomes", "DNA", 15, 32], ["horseshoe bat", "SPECIES", 118, 131], ["horseshoe bat", "SPECIES", 146, 159], ["Rhinolophus pusillus", "SPECIES", 161, 181], ["Rhinolophus affinis", "SPECIES", 232, 251], ["horseshoe bat", "SPECIES", 268, 281], ["Rhinolophus blasii", "SPECIES", 283, 301], ["Asian trident bat", "SPECIES", 320, 337], ["Aselliscus stoliczkanus", "SPECIES", 339, 362], ["Chaerephon plicata", "SPECIES", 446, 464], ["bat SARSr-CoV", "SPECIES", 11, 24], ["Chinese horseshoe bats", "SPECIES", 46, 68], ["big-eared horseshoe bat", "SPECIES", 108, 131], ["Rhinolophus pusillus", "SPECIES", 161, 181], ["horseshoe bat", "SPECIES", 217, 230], ["Rhinolophus affinis", "SPECIES", 232, 251], ["Blasius's horseshoe bat", "SPECIES", 258, 281], ["Rhinolophus blasii", "SPECIES", 283, 301], ["Asian trident bat", "SPECIES", 320, 337], ["Aselliscus stoliczkanus", "SPECIES", 339, 362], ["Chaerephon plicata", "SPECIES", 446, 464], ["horseshoe bat", "TEST", 118, 131], ["horseshoe bat", "TEST", 146, 159], ["Rhinolophus pusillus", "PROBLEM", 161, 181], ["intermediate horseshoe bat", "PROBLEM", 204, 230], ["Blasius's horseshoe bat", "TEST", 258, 281], ["Hipposideridae", "TREATMENT", 394, 408], ["tailed bat (Chaerephon plicata", "TREATMENT", 434, 464], ["Cp", "PROBLEM", 466, 468], ["horseshoe bat", "ANATOMY", 118, 131], ["horseshoe bat", "ANATOMY", 146, 159], ["horseshoe bat", "ANATOMY", 217, 230], ["Ra", "ANATOMY", 253, 255], ["horseshoe bat", "ANATOMY", 268, 281]]], ["SARSr-CoVs have also been detected in countries other than China, including Thailand, Italy, Luxembourg, Bulgaria, Slovenia, Hungary, Japan, Kenya, etc. However, only partial sequences were available for these isolates.", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARSr", "PROTEIN", 0, 5], ["CoVs", "PROTEIN", 6, 10], ["these isolates", "TEST", 204, 218], ["CoVs", "OBSERVATION", 6, 10]]], ["Nevertheless, the immediate progenitor of SARS-CoV has not been pinpointed.Geographical gradient of SARSr-CoVAmong the 45 SARSr-CoV genomes from bats in China, 11 of them were from Hong Kong, 2 were from Guangdong, 2 from Guangxi, 5 from Hubei, 20 from Yunnan and one each from Shaanxi, Shanxi, Jilin, Guizhou, Hebei, respectively.", [["SARS", "DISEASE", 42, 46], ["progenitor", "CELL", 28, 38], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 42, 50], ["SARSr-CoV", "ORGANISM", 122, 131], ["SARSr-CoVAmong the 45 SARSr-CoV genomes", "DNA", 100, 139], ["SARS-CoV", "SPECIES", 42, 50], ["SARSr-CoV", "SPECIES", 122, 131], ["SARS", "PROBLEM", 42, 46], ["CoV", "PROBLEM", 47, 50], ["Geographical gradient", "TEST", 75, 96], ["SARSr", "TEST", 100, 105], ["CoVAmong", "TEST", 106, 114], ["Shaanxi", "TREATMENT", 278, 285], ["Shanxi", "TREATMENT", 287, 293], ["gradient", "OBSERVATION_MODIFIER", 88, 96]]], ["Overall, it is observed that the SARSr-CoV genomes from bats in Yunnan possess relatively higher, whereas those from Guangdong, Jilin, Shanxi and Hebei possess relatively lower nt identity to those from civets (Fig. 3A) .", [["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 33, 42], ["bats", "ORGANISM", 56, 60], ["SARSr-CoV genomes", "DNA", 33, 50], ["SARSr-CoV", "SPECIES", 33, 42], ["Jilin", "TREATMENT", 128, 133], ["Shanxi", "TREATMENT", 135, 141], ["higher", "OBSERVATION_MODIFIER", 90, 96]]], ["This is an interesting phenomenon since the SARS epidemic that emerged in late 2002 was first noticed in Guangdong province as an outbreak of acute community-acquired atypical pneumonia syndrome.", [["SARS", "DISEASE", 44, 48], ["atypical pneumonia syndrome", "DISEASE", 167, 194], ["an interesting phenomenon", "PROBLEM", 8, 33], ["the SARS epidemic", "PROBLEM", 40, 57], ["acute community-acquired atypical pneumonia syndrome", "PROBLEM", 142, 194], ["acute", "OBSERVATION_MODIFIER", 142, 147], ["atypical", "OBSERVATION_MODIFIER", 167, 175], ["pneumonia", "OBSERVATION", 176, 185]]], ["Severe cases were later retrospectively traced back to five cities around Guangzhou, with the index case reported in Foshan, a city 24 km away from Guangzhou.", [["Severe cases", "PROBLEM", 0, 12]]], ["This mismatch between clinical events and apparent gradient of nt identity could either be due to a missing link during evolutionary adaptation among the SARSr-CoVs in different provinces or simply as a result of sampling error.Recombination and evolutionThe high frequency of homologous RNA recombination is one of the major factors contributing to a plastic genome underpinning the evolutionary force in CoVs.", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 154, 164], ["CoVs", "GENE_OR_GENE_PRODUCT", 406, 410], ["SARSr-CoVs", "DNA", 154, 164], ["plastic genome", "DNA", 352, 366], ["CoVs", "DNA", 406, 410], ["This mismatch between clinical events", "PROBLEM", 0, 37], ["apparent gradient of nt identity", "PROBLEM", 42, 74], ["a missing link", "PROBLEM", 98, 112], ["sampling error", "PROBLEM", 213, 227], ["homologous RNA recombination", "TREATMENT", 277, 305], ["high", "OBSERVATION_MODIFIER", 259, 263], ["plastic genome", "OBSERVATION", 352, 366]]], ["This has resulted in different genotypes or even different CoVs adapted to new hosts (Herrewegh et al., 1998; Lau et al., 2011; Terada et al., 2014; Woo et al., 2006b) .", [["CoVs", "GENE_OR_GENE_PRODUCT", 59, 63], ["different genotypes", "PROBLEM", 21, 40]]], ["As for SARSr-CoVs, it is evident from both multiple alignments and phylogenetic analyses that some genes of a particular SARSr-CoV from bats may possess higher while other genes possess much lower nt identity to the corresponding genes of SARSr-CoV genomes from human/civets, resulting in shifting of phylogenetic position in different phylogenetic trees.", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 7, 17], ["SARSr-CoV", "ORGANISM", 121, 130], ["bats", "ORGANISM", 136, 140], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 239, 248], ["human", "ORGANISM", 262, 267], ["SARSr", "PROTEIN", 7, 12], ["CoVs", "DNA", 13, 17], ["SARSr", "DNA", 121, 126], ["CoV", "DNA", 127, 130], ["SARSr-CoV genomes", "DNA", 239, 256], ["human", "SPECIES", 262, 267], ["SARSr-CoV", "SPECIES", 121, 130], ["SARSr-CoV", "SPECIES", 239, 248], ["human", "SPECIES", 262, 267], ["SARSr-CoVs", "PROBLEM", 7, 17], ["CoVs", "OBSERVATION", 13, 17], ["multiple", "OBSERVATION_MODIFIER", 43, 51], ["alignments", "OBSERVATION", 52, 62], ["phylogenetic position", "OBSERVATION", 301, 322], ["phylogenetic trees", "OBSERVATION", 336, 354]]], ["This phenomenon is frequently observed in SARSr-CoVs and likely explains the generation of novel SARSr-CoVs that could jump from bat to civet and subsequently to human.S protein of SARSr-BatCoVsTrimers of S protein form spikes on the surface of CoVs particles.", [["surface", "ANATOMY", 234, 241], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 42, 52], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 97, 107], ["human", "ORGANISM", 162, 167], ["SARSr", "GENE_OR_GENE_PRODUCT", 181, 186], ["S protein", "GENE_OR_GENE_PRODUCT", 205, 214], ["surface", "CELLULAR_COMPONENT", 234, 241], ["CoVs", "GENE_OR_GENE_PRODUCT", 245, 249], ["SARSr", "PROTEIN", 97, 102], ["CoVs", "PROTEIN", 103, 107], ["S protein", "PROTEIN", 168, 177], ["SARSr", "PROTEIN", 181, 186], ["BatCoVsTrimers", "PROTEIN", 187, 201], ["S protein", "PROTEIN", 205, 214], ["CoVs particles", "CELL_TYPE", 245, 259], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 162, 167], ["This phenomenon", "PROBLEM", 0, 15], ["S protein", "TEST", 168, 177], ["SARSr", "TEST", 181, 186], ["S protein form spikes", "PROBLEM", 205, 226], ["CoVs particles", "PROBLEM", 245, 259], ["CoVs particles", "OBSERVATION", 245, 259]]], ["It comprises two functionally distinct subunits -S1 and S2 domains which are involved in receptor binding and fusion respectively.", [["S2", "GENE_OR_GENE_PRODUCT", 56, 58], ["S1", "PROTEIN", 49, 51], ["S2 domains", "PROTEIN", 56, 66], ["two", "OBSERVATION_MODIFIER", 13, 16], ["functionally", "OBSERVATION_MODIFIER", 17, 29], ["distinct", "OBSERVATION_MODIFIER", 30, 38], ["subunits", "OBSERVATION_MODIFIER", 39, 47], ["S1", "ANATOMY_MODIFIER", 49, 51], ["S2", "ANATOMY", 56, 58], ["receptor binding", "OBSERVATION", 89, 105]]], ["Like other class I viral fusion proteins, the S protein undergoes a series of events including receptor recognition, proteolytic cleavage to shed the S1 subunit and conformational changes in S2 that ultimately lead to fusion of the viral and host membranes.", [["membranes", "ANATOMY", 247, 256], ["S2", "GENE_OR_GENE_PRODUCT", 191, 193], ["host membranes", "CELLULAR_COMPONENT", 242, 256], ["class I viral fusion proteins", "PROTEIN", 11, 40], ["S protein", "PROTEIN", 46, 55], ["S1 subunit", "PROTEIN", 150, 160], ["S2", "PROTEIN", 191, 193], ["viral fusion proteins", "PROBLEM", 19, 40], ["receptor recognition", "TEST", 95, 115], ["proteolytic cleavage", "PROBLEM", 117, 137], ["conformational changes in S2", "PROBLEM", 165, 193], ["fusion", "TREATMENT", 218, 224], ["the viral and host membranes", "PROBLEM", 228, 256], ["viral fusion", "OBSERVATION", 19, 31], ["viral", "OBSERVATION", 232, 237], ["host membranes", "OBSERVATION", 242, 256]]], ["It has been well established that human SARS-CoV utilizes ACE2 as a functional receptor.", [["SARS", "DISEASE", 40, 44], ["human", "ORGANISM", 34, 39], ["SARS-CoV", "ORGANISM", 40, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["ACE2", "PROTEIN", 58, 62], ["human", "SPECIES", 34, 39], ["human SARS-CoV", "SPECIES", 34, 48], ["ACE2", "TREATMENT", 58, 62], ["a functional receptor", "TREATMENT", 66, 87]]], ["The receptorbinding motifs in the C-terminal domain of S1 are implicated in receptor recognition.", [["C", "CHEMICAL", 34, 35], ["S1", "GENE_OR_GENE_PRODUCT", 55, 57], ["receptorbinding motifs", "DNA", 4, 26], ["C-terminal domain", "PROTEIN", 34, 51], ["S1", "PROTEIN", 55, 57], ["The receptorbinding motifs", "PROBLEM", 0, 26], ["terminal", "ANATOMY_MODIFIER", 36, 44], ["S1", "ANATOMY", 55, 57]]], ["Substitutions within the S1 receptor-binding domain (RBD) confers adaptability to new or orthologous entry receptors, thus altering the viral tropism (Hulswit et al., 2016) .", [["S1 receptor-binding domain", "PROTEIN", 25, 51], ["RBD", "PROTEIN", 53, 56], ["orthologous entry receptors", "PROTEIN", 89, 116], ["Substitutions", "PROBLEM", 0, 13], ["viral tropism", "OBSERVATION", 136, 149]]], ["Undoubtedly, the ability to bind human ACE2 is an indispensable step in establishing cross-species transmission.S protein of SARSr-BatCoVsAs we have previously hypothesized, the five amino acid (a.a.) deletion, twelve a.a. deletion as well as a.a. substitutions at 5 critical residues for binding serve as determining factors for the S protein-ACE2 interaction (Table 1) .", [["amino acid", "CHEMICAL", 183, 193], ["amino acid", "CHEMICAL", 183, 193], ["human", "ORGANISM", 33, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["SARSr-BatCoVsAs", "GENE_OR_GENE_PRODUCT", 125, 140], ["amino acid", "AMINO_ACID", 183, 193], ["ACE2", "GENE_OR_GENE_PRODUCT", 344, 348], ["human ACE2", "PROTEIN", 33, 43], ["S protein", "PROTEIN", 112, 121], ["SARSr", "PROTEIN", 125, 130], ["BatCoVsAs", "PROTEIN", 131, 140], ["S protein", "PROTEIN", 334, 343], ["ACE2", "PROTEIN", 344, 348], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["SARSr", "TEST", 125, 130], ["BatCoVsAs", "TREATMENT", 131, 140], ["the five amino acid (a.a.) deletion", "TREATMENT", 174, 209]]], ["A critical pre-requisite for reliable ACE2 utilization is the absence of 5 a.a. and 12 a.a. deletions and, preferably, the presence of at least two out of five human-adapted residues.", [["ACE2", "GENE_OR_GENE_PRODUCT", 38, 42], ["human", "ORGANISM", 160, 165], ["ACE2", "PROTEIN", 38, 42], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 160, 165]]], ["Based on these analyses, SARSr-Rs-BatCoV WIV1 is one of the strains most advantageously conformed genotypically for ACE2 utilization.", [["SARSr-Rs", "GENE_OR_GENE_PRODUCT", 25, 33], ["ACE2", "GENE_OR_GENE_PRODUCT", 116, 120], ["SARSr-Rs-BatCoV WIV1", "DNA", 25, 45], ["ACE2", "PROTEIN", 116, 120], ["these analyses", "TEST", 9, 23], ["SARSr", "TEST", 25, 30], ["the strains", "PROBLEM", 56, 67], ["ACE2 utilization", "TREATMENT", 116, 132]]], ["It has been shown to be able to directly infect well-differentiated primary human airway epithelial cell cultures (Menachery et al., 2016) .", [["airway epithelial cell cultures", "ANATOMY", 82, 113], ["human", "ORGANISM", 76, 81], ["airway epithelial cell cultures", "CELL", 82, 113], ["primary human airway epithelial cell cultures", "CELL_LINE", 68, 113], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["epithelial cell cultures", "TEST", 89, 113], ["airway", "ANATOMY", 82, 88], ["epithelial cell", "OBSERVATION", 89, 104]]], ["In addition, neutralization assays using convalescent sera from SARS-CoV infected patients showed robust neutralization against tissue culture infectious dose 50 of WIV1 (Ge et al., 2013) .S protein of SARSr-BatCoVsSARSr-Rs-BatCoV RsSHC014, a strain discovered in Chinese horseshoe bats in 2012, contains two of the five a.a. residues in civet strain civet007 but none of the five human-adapted residues.", [["sera", "ANATOMY", 54, 58], ["tissue", "ANATOMY", 128, 134], ["SARS-CoV infected", "DISEASE", 64, 81], ["convalescent", "ORGANISM", 41, 53], ["sera", "ORGANISM_SUBSTANCE", 54, 58], ["SARS-CoV", "ORGANISM", 64, 72], ["patients", "ORGANISM", 82, 90], ["tissue", "TISSUE", 128, 134], ["SARSr-BatCoVsSARSr-Rs-BatCoV RsSHC014", "GENE_OR_GENE_PRODUCT", 202, 239], ["human", "ORGANISM", 381, 386], ["S protein", "PROTEIN", 189, 198], ["BatCoVsSARSr", "PROTEIN", 208, 220], ["Rs", "PROTEIN", 221, 223], ["BatCoV RsSHC014", "PROTEIN", 224, 239], ["a.a. residues", "PROTEIN", 321, 334], ["patients", "SPECIES", 82, 90], ["human", "SPECIES", 381, 386], ["SARS-CoV", "SPECIES", 64, 72], ["Chinese horseshoe bats", "SPECIES", 264, 286], ["human", "SPECIES", 381, 386], ["neutralization assays", "TEST", 13, 34], ["convalescent sera", "TEST", 41, 58], ["SARS", "PROBLEM", 64, 68], ["robust neutralization", "PROBLEM", 98, 119], ["tissue culture", "TEST", 128, 142], ["S protein", "TEST", 189, 198], ["SARSr-", "TEST", 202, 208], ["BatCoVsSARSr", "TEST", 208, 220]]], ["It retains both the 5 a.a. and 12 a.a. deletion sites.", [["5 a.a. and 12 a.a. deletion sites", "DNA", 20, 53], ["both", "OBSERVATION_MODIFIER", 11, 15]]], ["This genotype is shared by SARSr-Rs-BatCoV Rs4231 and Rs4084.", [["SARSr", "PROTEIN", 27, 32], ["Rs", "PROTEIN", 33, 35], ["Rs4084", "DNA", 54, 60], ["Rs", "TEST", 54, 56]]], ["Recombinant mouse-adapted SARS-CoV expressing the S protein of RsSHC014 was still able to utilize ACE2 for viral entry, causing cytopathic changes in Vero cells and weight loss in mice model, despite the apparent failure in pseudovirus infectivity assay (Menachery et al., 2015) .", [["Vero cells", "ANATOMY", 150, 160], ["weight loss", "DISEASE", 165, 176], ["mouse", "ORGANISM", 12, 17], ["SARS-CoV", "ORGANISM", 26, 34], ["RsSHC014", "GENE_OR_GENE_PRODUCT", 63, 71], ["ACE2", "GENE_OR_GENE_PRODUCT", 98, 102], ["Vero cells", "CELL", 150, 160], ["mice", "ORGANISM", 180, 184], ["pseudovirus", "ORGANISM", 224, 235], ["S protein", "PROTEIN", 50, 59], ["RsSHC014", "PROTEIN", 63, 71], ["ACE2", "PROTEIN", 98, 102], ["Vero cells", "CELL_LINE", 150, 160], ["mouse", "SPECIES", 12, 17], ["mice", "SPECIES", 180, 184], ["mouse", "SPECIES", 12, 17], ["SARS-CoV", "SPECIES", 26, 34], ["mice", "SPECIES", 180, 184], ["ACE2", "TEST", 98, 102], ["viral entry", "PROBLEM", 107, 118], ["cytopathic changes in Vero cells", "PROBLEM", 128, 160], ["weight loss in mice model", "PROBLEM", 165, 190], ["the apparent failure in pseudovirus infectivity assay", "PROBLEM", 200, 253], ["cytopathic", "OBSERVATION_MODIFIER", 128, 138], ["Vero cells", "OBSERVATION", 150, 160], ["failure", "OBSERVATION", 213, 220]]], ["However, significantly slower viral replication rate was observed, suggesting that deletions in RBDs were more critical in receptor recognition while the presence of ACE2adapted critical residues modulated entry efficiency.", [["RBDs", "GENE_OR_GENE_PRODUCT", 96, 100], ["RBDs", "PROTEIN", 96, 100], ["significantly slower viral replication rate", "PROBLEM", 9, 52], ["deletions in RBDs", "PROBLEM", 83, 100], ["ACE2adapted critical residues modulated entry efficiency", "PROBLEM", 166, 222], ["significantly", "OBSERVATION_MODIFIER", 9, 22], ["slower", "OBSERVATION_MODIFIER", 23, 29], ["viral replication", "OBSERVATION", 30, 47], ["entry efficiency", "OBSERVATION", 206, 222]]], ["In contrary to the WIV1 strain, neither neutralizing human monoclonal antibody nor existing double-inactivated whole SARS-CoV vaccine provided protective effect against infection caused by SHC014-harboring recombinant virus strain, indicating key difference in a.a. sequences determining antigenicity (Menachery et al., 2015) .S protein of SARSr-BatCoVsA phylogenetic tree was constructed from the RBDs of SARSr-CoVs (Fig. 4) .", [["infection", "DISEASE", 169, 178], ["SHC014", "CHEMICAL", 189, 195], ["WIV1 strain", "ORGANISM", 19, 30], ["human", "ORGANISM", 53, 58], ["SARS-CoV", "ORGANISM", 117, 125], ["SHC014", "GENE_OR_GENE_PRODUCT", 189, 195], ["recombinant virus strain", "ORGANISM", 206, 230], ["SARSr", "GENE_OR_GENE_PRODUCT", 340, 345], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 406, 416], ["human monoclonal antibody", "PROTEIN", 53, 78], ["SHC014", "PROTEIN", 189, 195], ["SARSr", "PROTEIN", 340, 345], ["BatCoVsA", "PROTEIN", 346, 354], ["CoVs", "DNA", 412, 416], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["SARS-CoV", "SPECIES", 117, 125], ["the WIV1 strain", "PROBLEM", 15, 30], ["neutralizing human monoclonal antibody", "TEST", 40, 78], ["double-inactivated whole SARS-CoV vaccine", "TREATMENT", 92, 133], ["infection", "PROBLEM", 169, 178], ["harboring recombinant virus strain", "PROBLEM", 196, 230], ["protein", "TEST", 329, 336], ["SARSr", "TEST", 340, 345]]], ["Surprisingly, SARSr-Ra-BatCoV LYRa11, a strain discovered in intermediate horseshoe bat in Baoshan, Yunnan (He et al., 2014) , around 375 km from Kunming, sits closest to the civet/human SARSr-CoVs despite its lower overall nt identity.", [["SARSr-Ra-BatCoV LYRa11", "GENE_OR_GENE_PRODUCT", 14, 36], ["horseshoe bat", "ORGANISM", 74, 87], ["human", "ORGANISM", 181, 186], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 187, 197], ["SARSr", "PROTEIN", 14, 19], ["Ra-BatCoV LYRa11", "PROTEIN", 20, 36], ["civet/human SARSr-CoVs", "DNA", 175, 197], ["human", "SPECIES", 181, 186], ["human", "SPECIES", 181, 186], ["SARSr", "TEST", 14, 19], ["a strain", "PROBLEM", 38, 46], ["CoVs", "PROBLEM", 193, 197], ["intermediate horseshoe", "OBSERVATION", 61, 83]]], ["This is likely due to the presence of 7 nt in civet/human SARS-CoV that is found exclusively in SARSr-Ra-BatCoV LYRa11.", [["human", "ORGANISM", 52, 57], ["SARS-CoV", "ORGANISM", 58, 66], ["SARSr-Ra-BatCoV LYRa11", "DNA", 96, 118], ["human", "SPECIES", 52, 57], ["human SARS-CoV", "SPECIES", 52, 66], ["likely due to", "UNCERTAINTY", 8, 21]]], ["Such a unique S gene in relation to civet/ human SARS-CoV would therefore challenge the previous hypothesis that the origin of RBD was solely from Chinese horseshoe bats in (Campanella et al., 2003) .", [["SARS", "DISEASE", 49, 53], ["RBD", "DISEASE", 127, 130], ["human", "ORGANISM", 43, 48], ["SARS-CoV", "ORGANISM", 49, 57], ["RBD", "GENE_OR_GENE_PRODUCT", 127, 130], ["S gene", "DNA", 14, 20], ["RBD", "PROTEIN", 127, 130], ["human", "SPECIES", 43, 48], ["human SARS-CoV", "SPECIES", 43, 57], ["Chinese horseshoe bats", "SPECIES", 147, 169], ["RBD", "PROBLEM", 127, 130]]], ["(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Table 1Summary of the critical elements for ACE2 utilization present in the S protein of various SARSr-BatCoVs.SARS-CoV andY Retained L N T Y Civet SARSr-CoV SZ3 1 Retained Y Retained L K S Y Civet SARSr-CoV civet007 1 Retained Y Retained P R S Y SARSr-Rs-BatCoV WIV1 2 Retained S Retained F N N Y SARSr-Rs-BatCoV WIV16 1 Retained S Retained F N N Y SARSr-Rs-BatCoV Rs4874 1 Retained S Retained F N N Y SARSr-Ra-BatCoV LYRa11 2 Retained S Retained F N N Y SARSr-Rs-BatCoV Rs7327 2 Retained S Retained F N N Y SARSr-Rs-BatCoV RsSHC014 2 Retained W Retained P R A H SARSr-Rs-BatCoV Rs4231 1 Retained W Retained P R A H SARSr-Rs-BatCoV Rs4084 2 Retained W Retained P R A H SARSr-Rs-BatCoV Rs4081 3 Deleted S Deleted Deleted S V Y SARSr-Rs-BatCoV Rs4075 * - Deleted S Deleted Deleted S P Y SARSr-Rs-BatCoV Rs4085 * - Deleted S Deleted G S N Y SARSr-Rf-BatCoV Rf4092 3 Deleted S Deleted Deleted S V Y SARSr-Rf-BatCoV YNLF_31C 3 Deleted S Deleted Deleted S V YSARSr-BatCoVs that could replicate in cell linesSARSr-BatCoVs that were reported to have slower replication kinetics (Menachery et al. 2015) SARSr-BatCoVs that failed to replicate in cell lines # Critical a.a. residues on S protein determining interaction with ACE2 * Only RBD sequences are available in Genbank (caption on next page) H.K.H. Luk, et al. Infection, Genetics and Evolution 71 (2019) 21-30 Kunming.", [["cell lines", "ANATOMY", 1122, 1132], ["cell lines", "ANATOMY", 1267, 1277], ["SARS", "DISEASE", 241, 245], ["ACE2", "GENE_OR_GENE_PRODUCT", 174, 178], ["cell lines", "CELL", 1122, 1132], ["SARSr-BatCoVs", "CELL", 1132, 1145], ["SARSr-BatCoVs", "GENE_OR_GENE_PRODUCT", 1225, 1238], ["cell lines", "CELL", 1267, 1277], ["ACE2", "GENE_OR_GENE_PRODUCT", 1345, 1349], ["ACE2", "PROTEIN", 174, 178], ["S protein", "PROTEIN", 206, 215], ["Rf-BatCoV YNLF_31C 3 Deleted S Deleted Deleted S V YSARSr-BatCoVs", "DNA", 1032, 1097], ["cell lines", "CELL_LINE", 1122, 1132], ["BatCoVs", "CELL_LINE", 1138, 1145], ["BatCoVs", "PROTEIN", 1231, 1238], ["cell lines", "CELL_LINE", 1267, 1277], ["S protein", "PROTEIN", 1306, 1315], ["ACE2", "PROTEIN", 1345, 1349], ["RBD", "PROTEIN", 1357, 1360], ["SARS-CoV", "SPECIES", 241, 249], ["ACE2 utilization", "TREATMENT", 174, 190], ["Civet", "TEST", 272, 277], ["SARSr", "TEST", 278, 283], ["SZ3", "TEST", 288, 291], ["Civet", "TEST", 322, 327], ["SARSr", "TEST", 328, 333], ["civet007", "TEST", 338, 346], ["SARSr", "TEST", 377, 382], ["BatCoV", "TEST", 386, 392], ["WIV1", "TEST", 393, 397], ["SARSr", "TEST", 428, 433], ["BatCoV", "TEST", 437, 443], ["SARSr", "TEST", 480, 485], ["Rs", "TEST", 496, 498], ["SARSr-", "TEST", 533, 539], ["Ra-BatCoV", "TEST", 539, 548], ["LYRa11", "TEST", 549, 555], ["SARSr", "TEST", 586, 591], ["BatCoV", "TEST", 595, 601], ["Rs", "TEST", 602, 604], ["SARSr", "TEST", 639, 644], ["BatCoV", "TEST", 648, 654], ["SARSr", "TEST", 694, 699], ["BatCoV", "TEST", 703, 709], ["Rs", "TEST", 710, 712], ["SARSr", "TEST", 747, 752], ["BatCoV", "TEST", 756, 762], ["Rs", "TEST", 763, 765], ["SARSr", "TEST", 800, 805], ["Rs", "TEST", 816, 818], ["SARSr", "TEST", 857, 862], ["Rs", "TEST", 873, 875], ["SARSr", "TEST", 916, 921], ["BatCoV", "TEST", 925, 931], ["Rs", "TEST", 932, 934], ["G S", "TEST", 961, 964], ["SARSr", "TEST", 969, 974], ["Rf", "TEST", 975, 977], ["Rf", "TEST", 985, 987], ["Deleted S", "TEST", 994, 1003], ["Deleted S", "TEST", 1012, 1021], ["SARSr", "TEST", 1026, 1031], ["Rf", "TEST", 1032, 1034], ["BatCoV YNLF_31C", "TREATMENT", 1035, 1050], ["YSARSr", "TEST", 1083, 1089], ["BatCoVs", "TREATMENT", 1090, 1097], ["SARSr", "TEST", 1132, 1137], ["SARSr", "TEST", 1225, 1230], ["Critical a.a. residues", "PROBLEM", 1280, 1302], ["RBD sequences", "TEST", 1357, 1370], ["Infection", "PROBLEM", 1438, 1447], ["cell lines", "OBSERVATION", 1122, 1132], ["cell lines", "OBSERVATION", 1267, 1277]]], ["Nevertheless, the S proteins of the majority of bat SARSr-CoVs found in Chinese horseshoe bats in various part of China including Yunnan resemble the genotype of SARSr-Rs-BatCoV HKU3 but not the human ACE2-utilizing genotype of SARSr-Rs-BatCoV WIV1.", [["bat", "ORGANISM", 48, 51], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 52, 62], ["horseshoe bats", "ORGANISM", 80, 94], ["SARSr-Rs-BatCoV HKU3", "GENE_OR_GENE_PRODUCT", 162, 182], ["human", "ORGANISM", 195, 200], ["ACE2", "GENE_OR_GENE_PRODUCT", 201, 205], ["SARSr-Rs", "GENE_OR_GENE_PRODUCT", 228, 236], ["S proteins", "PROTEIN", 18, 28], ["SARSr", "PROTEIN", 52, 57], ["CoVs", "PROTEIN", 58, 62], ["SARSr-Rs-BatCoV HKU3", "DNA", 162, 182], ["ACE2", "PROTEIN", 201, 205], ["SARSr", "PROTEIN", 228, 233], ["Rs", "PROTEIN", 234, 236], ["BatCoV WIV1", "PROTEIN", 237, 248], ["human", "SPECIES", 195, 200], ["Chinese horseshoe bats", "SPECIES", 72, 94], ["human", "SPECIES", 195, 200], ["the S proteins", "TEST", 14, 28], ["CoVs", "PROBLEM", 58, 62], ["Chinese horseshoe bats", "PROBLEM", 72, 94], ["SARSr", "TEST", 228, 233], ["horseshoe bats", "OBSERVATION", 80, 94]]], ["This raises question on how SARSr-BatCoVs manage to have two distinct genotypes of S infecting the same host (Rs).", [["SARSr", "GENE_OR_GENE_PRODUCT", 28, 33], ["BatCoVs", "GENE_OR_GENE_PRODUCT", 34, 41], ["SARSr", "PROTEIN", 28, 33], ["BatCoVs", "PROTEIN", 34, 41]]], ["There is a possibility that two cellular receptors for SARSr-CoVs are present in Chinese horseshoe bats.", [["cellular", "ANATOMY", 32, 40], ["cellular", "CELL", 32, 40], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 55, 65], ["horseshoe bats", "ORGANISM", 89, 103], ["cellular receptors", "PROTEIN", 32, 50], ["SARSr", "PROTEIN", 55, 60], ["CoVs", "PROTEIN", 61, 65], ["Chinese horseshoe bats", "SPECIES", 81, 103], ["horseshoe bats", "OBSERVATION", 89, 103]]], ["Interestingly, two novel SARSr-Rp-BatCoV strains ZXC21 and ZC45 isolated from least horseshoe bat in Zhoushan, Zhejiang province in eastern China were shown to be able to infect suckling rats, causing inflammation in the brain tissue and histological changes in the lung and intestine despite failed viral isolation in VeroE6 cells.", [["brain tissue", "ANATOMY", 221, 233], ["lung", "ANATOMY", 266, 270], ["intestine", "ANATOMY", 275, 284], ["VeroE6 cells", "ANATOMY", 319, 331], ["inflammation", "DISEASE", 201, 213], ["SARSr-Rp", "GENE_OR_GENE_PRODUCT", 25, 33], ["ZC45", "ORGANISM", 59, 63], ["rats", "ORGANISM", 187, 191], ["brain tissue", "TISSUE", 221, 233], ["lung", "ORGAN", 266, 270], ["intestine", "ORGAN", 275, 284], ["VeroE6 cells", "CELL", 319, 331], ["SARSr", "PROTEIN", 25, 30], ["ZC45", "DNA", 59, 63], ["VeroE6 cells", "CELL_LINE", 319, 331], ["rats", "SPECIES", 187, 191], ["BatCoV strains ZXC21", "TREATMENT", 34, 54], ["ZC45", "TREATMENT", 59, 63], ["inflammation in the brain tissue", "PROBLEM", 201, 233], ["histological changes in the lung and intestine", "PROBLEM", 238, 284], ["failed viral isolation in VeroE6 cells", "PROBLEM", 293, 331], ["horseshoe bat", "OBSERVATION", 84, 97], ["inflammation", "OBSERVATION", 201, 213], ["brain tissue", "ANATOMY", 221, 233], ["histological", "OBSERVATION", 238, 250], ["lung", "ANATOMY", 266, 270], ["intestine", "ANATOMY", 275, 284], ["viral isolation", "OBSERVATION", 300, 315], ["VeroE6 cells", "OBSERVATION", 319, 331]]], ["Phylogenetically, these two strains represented a separate clade, lying between the susceptible clade of SARSr-Ra-BatCoV LYRa11 and the non-susceptible clade of SARSr-Rf-BatCoV Rf1.", [["SARSr", "GENE_OR_GENE_PRODUCT", 105, 110], ["SARSr-Rf-BatCoV Rf1", "GENE_OR_GENE_PRODUCT", 161, 180], ["SARSr", "PROTEIN", 105, 110], ["Ra-BatCoV LYRa11", "PROTEIN", 111, 127], ["SARSr-Rf-BatCoV Rf1", "DNA", 161, 180], ["SARSr", "TEST", 105, 110], ["SARSr", "TEST", 161, 166], ["BatCoV Rf1", "TREATMENT", 170, 180], ["clade", "OBSERVATION_MODIFIER", 59, 64]]], ["However, the mechanism of such infectivity in suckling rats was not investigated further, especially in light of the two retained deletion sites in the S genes of ZXC21 and ZC45, which should have imposed inter-species barrier in terms of receptor specificity based on previous discussion (Hu et al., 2018) .SARSr-CoV in Chinese horseshoe bats and greater horseshoe batsAmong all the horseshoe bats, SARSr-CoVs are most commonly found in Chinese horseshoe bats and greater horseshoe bats.", [["suckling rats", "ORGANISM", 46, 59], ["ZXC21", "GENE_OR_GENE_PRODUCT", 163, 168], ["ZC45", "GENE_OR_GENE_PRODUCT", 173, 177], ["SARSr-CoV", "ORGANISM", 308, 317], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 400, 410], ["deletion sites", "DNA", 130, 144], ["S genes", "DNA", 152, 159], ["ZXC21", "DNA", 163, 168], ["ZC45", "DNA", 173, 177], ["SARSr-CoVs", "DNA", 400, 410], ["rats", "SPECIES", 55, 59], ["SARSr-CoV", "SPECIES", 308, 317], ["Chinese horseshoe bats", "SPECIES", 321, 343], ["Chinese horseshoe bats", "SPECIES", 438, 460], ["such infectivity", "PROBLEM", 26, 42], ["the two retained deletion sites", "PROBLEM", 113, 144], ["ZXC21", "TREATMENT", 163, 168], ["ZC45", "TREATMENT", 173, 177], ["Chinese horseshoe bats", "PROBLEM", 321, 343], ["greater horseshoe bats", "PROBLEM", 348, 370], ["retained", "OBSERVATION_MODIFIER", 121, 129], ["deletion", "OBSERVATION", 130, 138], ["horseshoe bats", "OBSERVATION", 329, 343], ["greater", "OBSERVATION_MODIFIER", 348, 355], ["horseshoe bats", "OBSERVATION", 356, 370], ["horseshoe bats", "OBSERVATION", 384, 398], ["horseshoe bats", "OBSERVATION", 446, 460], ["greater", "OBSERVATION_MODIFIER", 465, 472], ["horseshoe bats", "OBSERVATION", 473, 487]]], ["Detailed analysis of their genomes revealed several intriguing phenomena.", [["Detailed analysis", "TEST", 0, 17], ["several intriguing phenomena", "PROBLEM", 44, 72], ["several", "OBSERVATION_MODIFIER", 44, 51], ["intriguing phenomena", "OBSERVATION", 52, 72]]], ["Firstly, ORF1a and ORF1b in SARSr-Rf-BatCoV YNLF_31C isolated from greater horseshoe bats in Lufeng, Yunnan by our group has the highest nt identity to civet SARSr-CoV, especially at the regions nsp5, nsp10, nsp12 and nsp13 (Fig. 3A) .", [["ORF1a", "GENE_OR_GENE_PRODUCT", 9, 14], ["ORF1b", "GENE_OR_GENE_PRODUCT", 19, 24], ["SARSr-Rf", "GENE_OR_GENE_PRODUCT", 28, 36], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 158, 167], ["nsp5", "GENE_OR_GENE_PRODUCT", 195, 199], ["nsp10", "GENE_OR_GENE_PRODUCT", 201, 206], ["nsp12", "GENE_OR_GENE_PRODUCT", 208, 213], ["nsp13", "GENE_OR_GENE_PRODUCT", 218, 223], ["ORF1a", "PROTEIN", 9, 14], ["ORF1b", "PROTEIN", 19, 24], ["SARSr", "PROTEIN", 28, 33], ["Rf", "DNA", 34, 36], ["BatCoV YNLF_31C", "DNA", 37, 52], ["civet SARSr-CoV", "DNA", 152, 167], ["nsp5", "DNA", 195, 199], ["nsp10", "DNA", 201, 206], ["nsp12", "DNA", 208, 213], ["nsp13", "DNA", 218, 223], ["SARSr-CoV", "SPECIES", 158, 167], ["ORF1a", "TEST", 9, 14], ["ORF1b", "TEST", 19, 24], ["SARSr", "TEST", 28, 33], ["BatCoV YNLF_31C", "TREATMENT", 37, 52], ["nsp10", "TEST", 201, 206], ["nsp12", "TEST", 208, 213], ["horseshoe bats", "OBSERVATION", 75, 89], ["regions", "ANATOMY_MODIFIER", 187, 194]]], ["This raised the possibility that Lufeng, Yunnan could be a potential gene pool for the progenitor of ORF1 of SARS-CoV.", [["progenitor", "ANATOMY", 87, 97], ["Lufeng", "CHEMICAL", 33, 39], ["SARS", "DISEASE", 109, 113], ["Lufeng", "SIMPLE_CHEMICAL", 33, 39], ["ORF1", "GENE_OR_GENE_PRODUCT", 101, 105], ["SARS-CoV", "ORGANISM", 109, 117], ["ORF1", "DNA", 101, 105], ["SARS-CoV", "SPECIES", 109, 117], ["CoV", "PROBLEM", 114, 117]]], ["Secondly, as previously illustrated, for most regions along the genome of SARSr-CoV except ORF8, SARSr-Rs-BatCoVs from Chinese horseshoe bats are predominantly closer to civet SARSr-CoV.", [["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 74, 83], ["ORF8", "GENE_OR_GENE_PRODUCT", 91, 95], ["SARSr-Rs-BatCoVs", "GENE_OR_GENE_PRODUCT", 97, 113], ["horseshoe bats", "ORGANISM", 127, 141], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 176, 185], ["SARSr", "DNA", 74, 79], ["CoV", "DNA", 80, 83], ["ORF8", "DNA", 91, 95], ["SARSr", "DNA", 97, 102], ["Rs", "DNA", 103, 105], ["BatCoVs", "DNA", 106, 113], ["CoV", "DNA", 182, 185], ["SARSr-CoV", "SPECIES", 74, 83], ["Chinese horseshoe bats", "SPECIES", 119, 141], ["SARSr-CoV", "SPECIES", 176, 185], ["SARSr", "TEST", 74, 79], ["CoV", "TEST", 80, 83], ["ORF8", "TEST", 91, 95], ["SARSr", "TEST", 97, 102]]], ["However, the ORF8 of SARSr-Rf-BatCoV has higher a.a. identity to civet SARSr-CoV ORF8.", [["ORF8", "GENE_OR_GENE_PRODUCT", 13, 17], ["SARSr-Rf-BatCoV", "GENE_OR_GENE_PRODUCT", 21, 36], ["SARSr-CoV ORF8", "GENE_OR_GENE_PRODUCT", 71, 85], ["ORF8", "PROTEIN", 13, 17], ["SARSr", "PROTEIN", 21, 26], ["Rf", "DNA", 27, 29], ["BatCoV", "DNA", 30, 36], ["civet SARSr-CoV ORF8", "DNA", 65, 85], ["SARSr-CoV", "SPECIES", 71, 80], ["SARSr", "TEST", 21, 26]]], ["In addition, V90 and I113 are the two Rf-specific residues present in the ORF8 of SARSr-Rf-BatCoV Rf4092, which could evolutionarily bridge the ORF8 of SARSr-Rf-BatCoV to SARSr-Rs-BatCoV that had very high identity to civet/human SARS-CoV (Fig. 5) .", [["V90", "GENE_OR_GENE_PRODUCT", 13, 16], ["I113", "GENE_OR_GENE_PRODUCT", 21, 25], ["ORF8", "GENE_OR_GENE_PRODUCT", 74, 78], ["SARSr", "GENE_OR_GENE_PRODUCT", 82, 87], ["ORF8", "GENE_OR_GENE_PRODUCT", 144, 148], ["SARSr-Rf-BatCoV", "GENE_OR_GENE_PRODUCT", 152, 167], ["SARSr-Rs-BatCoV", "GENE_OR_GENE_PRODUCT", 171, 186], ["human", "ORGANISM", 224, 229], ["SARS-CoV", "ORGANISM", 230, 238], ["Fig. 5", "ORGANISM", 240, 246], ["V90", "DNA", 13, 16], ["ORF8", "DNA", 74, 78], ["SARSr", "PROTEIN", 82, 87], ["Rf", "DNA", 88, 90], ["BatCoV Rf4092", "DNA", 91, 104], ["ORF8", "DNA", 144, 148], ["SARSr", "DNA", 152, 157], ["Rf", "DNA", 158, 160], ["BatCoV", "DNA", 161, 167], ["SARSr", "DNA", 171, 176], ["Rs", "DNA", 177, 179], ["BatCoV", "DNA", 180, 186], ["human", "SPECIES", 224, 229], ["human SARS-CoV", "SPECIES", 224, 238], ["SARSr", "TEST", 152, 157], ["SARSr", "TEST", 171, 176]]], ["SARS-Rf-BatCoV was thus hypothesized to be the origin of human SARS-CoV ORF8 gene through recombination events.SARSr-CoV in Chinese horseshoe bats and greater horseshoe batsIn fact, at least three genotypes of ORF8 have been found to circulate in nature (Wu et al., 2016) .", [["SARS", "DISEASE", 0, 4], ["SARS-Rf-BatCoV", "GENE_OR_GENE_PRODUCT", 0, 14], ["human", "ORGANISM", 57, 62], ["SARS-CoV ORF8", "GENE_OR_GENE_PRODUCT", 63, 76], ["SARSr-CoV", "ORGANISM", 111, 120], ["ORF8", "GENE_OR_GENE_PRODUCT", 210, 214], ["Rf", "DNA", 5, 7], ["BatCoV", "DNA", 8, 14], ["human SARS-CoV ORF8 gene", "DNA", 57, 81], ["ORF8", "PROTEIN", 210, 214], ["human", "SPECIES", 57, 62], ["human SARS-CoV", "SPECIES", 57, 71], ["SARSr-CoV", "SPECIES", 111, 120], ["Chinese horseshoe bats", "SPECIES", 124, 146], ["Chinese horseshoe bats", "PROBLEM", 124, 146], ["greater horseshoe bats", "PROBLEM", 151, 173], ["horseshoe bats", "OBSERVATION", 132, 146], ["greater", "OBSERVATION_MODIFIER", 151, 158], ["horseshoe bats", "OBSERVATION", 159, 173]]], ["Type I is genetically closest to ORF8 of civet SARSr-CoV (96.2-98.1% nt identity).", [["Type I", "GENE_OR_GENE_PRODUCT", 0, 6], ["ORF8", "GENE_OR_GENE_PRODUCT", 33, 37], ["SARSr-CoV", "ORGANISM", 47, 56], ["Type I", "PROTEIN", 0, 6], ["ORF8", "DNA", 33, 37], ["civet SARSr-CoV", "SPECIES", 41, 56], ["civet", "TEST", 41, 46], ["SARSr", "TEST", 47, 52], ["CoV", "TEST", 53, 56]]], ["There are eleven such strains isolated from bats so far, with eight of them originating from Chinese horseshoe bats and three from greater horseshoe bats.", [["Chinese horseshoe bats", "SPECIES", 93, 115], ["eleven such strains", "PROBLEM", 10, 29], ["horseshoe bats", "OBSERVATION", 101, 115], ["horseshoe bats", "OBSERVATION", 139, 153]]], ["Type II ORF8 has lower (70.8-82.8%) nt identity to ORF8 of civet SARSr-CoV.", [["Type II ORF8", "GENE_OR_GENE_PRODUCT", 0, 12], ["ORF8", "GENE_OR_GENE_PRODUCT", 51, 55], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 65, 74], ["Type II ORF8", "PROTEIN", 0, 12], ["ORF8", "PROTEIN", 51, 55], ["civet SARSr-CoV", "DNA", 59, 74], ["SARSr-CoV", "SPECIES", 65, 74], ["Type II ORF8", "PROBLEM", 0, 12], ["civet", "TEST", 59, 64], ["CoV", "ANATOMY", 71, 74]]], ["It is prevalent only in SARSr-Rf-BatCoV and demonstrates genetic stability regardless of geographical distribution with similar ORF8s detected in Korea, Shanxi, Hubei, and Hebei.", [["SARSr-Rf-BatCoV", "GENE_OR_GENE_PRODUCT", 24, 39], ["ORF8s", "GENE_OR_GENE_PRODUCT", 128, 133], ["Rf", "DNA", 30, 32], ["BatCoV", "DNA", 33, 39], ["ORF8s", "DNA", 128, 133], ["BatCoV", "TREATMENT", 33, 39], ["genetic stability", "PROBLEM", 57, 74], ["genetic stability", "OBSERVATION", 57, 74], ["geographical distribution", "OBSERVATION", 89, 114]]], ["SARSr-Rs-BatCoV has not been found to process type II ORF8.", [["SARSr-Rs-BatCoV", "GENE_OR_GENE_PRODUCT", 0, 15], ["type II ORF8", "GENE_OR_GENE_PRODUCT", 46, 58], ["SARSr", "PROTEIN", 0, 5], ["Rs", "PROTEIN", 6, 8], ["BatCoV", "PROTEIN", 9, 15], ["type II ORF8", "PROTEIN", 46, 58], ["SARSr", "TEST", 0, 5]]], ["Yet another strain, the SARSr-Rp-BatCoV F46 isolated from least horseshoe bats, processes an ORF8 with a phylogenetic position right between type I and type II ORF8s with 93.2% nt identity to civet SARSr-CoV, further complicating the analysis (Fig. 6) .", [["SARSr-Rp-BatCoV F46", "GENE_OR_GENE_PRODUCT", 24, 43], ["ORF8", "GENE_OR_GENE_PRODUCT", 93, 97], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 198, 207], ["SARSr", "DNA", 24, 29], ["Rp", "DNA", 30, 32], ["BatCoV F46", "DNA", 33, 43], ["ORF8", "DNA", 93, 97], ["type I and type II ORF8s", "DNA", 141, 165], ["civet SARSr-CoV", "SPECIES", 192, 207], ["another strain", "PROBLEM", 4, 18], ["the SARSr", "TEST", 20, 29], ["type I and type II ORF8s", "PROBLEM", 141, 165], ["SARSr", "TEST", 198, 203], ["the analysis", "TEST", 230, 242], ["horseshoe bats", "OBSERVATION", 64, 78]]], ["The rest of the ORF8 genes from sequenced SARSr-BatCoV strains belong to type III.", [["ORF8", "GENE_OR_GENE_PRODUCT", 16, 20], ["SARSr", "GENE_OR_GENE_PRODUCT", 42, 47], ["ORF8 genes", "DNA", 16, 26], ["SARSr-BatCoV strains", "DNA", 42, 62], ["BatCoV strains", "PROBLEM", 48, 62]]], ["These type III ORF8 genes possess 53.9-57.7% Fig. 4 .", [["type III ORF8", "GENE_OR_GENE_PRODUCT", 6, 19], ["type III ORF8 genes", "DNA", 6, 25], ["possess", "TEST", 26, 33]]], ["Phylogenetic tree constructed based on the nt sequences of the RBD of the S protein of SARS-CoVs and SARSr-CoV.", [["SARS", "DISEASE", 87, 91], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 87, 96], ["SARSr-CoV", "ORGANISM", 101, 110], ["nt sequences", "DNA", 43, 55], ["RBD", "PROTEIN", 63, 66], ["S protein", "PROTEIN", 74, 83], ["SARS-CoVs and SARSr-CoV", "PROTEIN", 87, 110], ["SARS-CoVs", "SPECIES", 87, 96], ["SARSr-CoV", "SPECIES", 101, 110], ["the nt sequences", "TEST", 39, 55], ["SARS", "PROBLEM", 87, 91], ["CoVs", "PROBLEM", 92, 96]]], ["SARSr-Rf-BatCoVs are labeled with dots.", [["SARSr-Rf-BatCoVs", "GENE_OR_GENE_PRODUCT", 0, 16], ["SARSr", "PROTEIN", 0, 5], ["Rf", "DNA", 6, 8], ["BatCoVs", "DNA", 9, 16], ["SARSr", "TEST", 0, 5]]], ["Brackets in red, orange, yellow and blue represented the descending order of nt identity with respect to civet SARSr-CoV SZ16.", [["Brackets", "CHEMICAL", 0, 8], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 111, 120], ["CoV SZ16", "PROTEIN", 117, 125], ["SARSr-CoV", "SPECIES", 111, 120], ["yellow and blue", "PROBLEM", 25, 40], ["red", "OBSERVATION", 12, 15], ["descending", "ANATOMY", 57, 67]]], ["The phylogenetic tree was constructed by Maximum Likelihood method with T92 + G as the substitution model by MEGA 6.0.", [["T92 + G", "GENE_OR_GENE_PRODUCT", 72, 79], ["T92 + G", "TREATMENT", 72, 79], ["the substitution model", "TEST", 83, 105], ["phylogenetic tree", "OBSERVATION", 4, 21]]], ["The test of phylogeny was statistically supported by the bootstraps value calculated from 1000 trees.", [["the bootstraps value", "TEST", 53, 73]]], ["(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) (caption on next page) H.K.H. Luk, et al. Infection, Genetics and Evolution 71 (2019) 21-30 nt identity to the ORF8 of civet SARSr-CoV and have the greatest genetic distance observed over the whole genome of SARSr-CoV (Fig. 3B ).", [["ORF8", "GENE_OR_GENE_PRODUCT", 242, 246], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 256, 265], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 339, 348], ["Fig. 3B", "ORGANISM", 350, 357], ["ORF8", "DNA", 242, 246], ["CoV", "DNA", 262, 265], ["CoV", "DNA", 345, 348], ["civet SARSr-CoV", "SPECIES", 250, 265], ["SARSr-CoV", "SPECIES", 339, 348], ["Infection", "PROBLEM", 173, 182], ["SARSr", "TEST", 339, 344], ["CoV", "ANATOMY", 345, 348]]], ["They are detected across a wide range of bat species including R. sinicus, R. macrotis, R. pusillus, R. affinis, A. stoliczkanus and C. plicata, except R. ferrumequinum in which type III ORF8 has not been found.", [["bat", "ORGANISM", 41, 44], ["R. sinicus", "ORGANISM", 63, 73], ["R. macrotis", "ORGANISM", 75, 86], ["R. pusillus", "ORGANISM", 88, 99], ["R. affinis", "ORGANISM", 101, 111], ["A. stoliczkanus", "ORGANISM", 113, 128], ["C. plicata", "ORGANISM", 133, 143], ["R. ferrumequinum", "ORGANISM", 152, 168], ["type III ORF8", "GENE_OR_GENE_PRODUCT", 178, 191], ["type III ORF8", "PROTEIN", 178, 191], ["R. sinicus", "SPECIES", 63, 73], ["R. macrotis", "SPECIES", 75, 86], ["R. pusillus", "SPECIES", 88, 99], ["R. affinis", "SPECIES", 101, 111], ["A. stoliczkanus", "SPECIES", 113, 128], ["C. plicata", "SPECIES", 133, 143], ["R. ferrumequinum", "SPECIES", 152, 168], ["R. sinicus", "SPECIES", 63, 73], ["R. macrotis", "SPECIES", 75, 86], ["R. pusillus", "SPECIES", 88, 99], ["R. affinis", "SPECIES", 101, 111], ["A. stoliczkanus", "SPECIES", 113, 128], ["C. plicata", "SPECIES", 133, 143], ["R. ferrumequinum", "SPECIES", 152, 168], ["C. plicata", "PROBLEM", 133, 143], ["R. ferrumequinum", "PROBLEM", 152, 168], ["R. macrotis", "ANATOMY", 75, 86], ["R. pusillus", "ANATOMY", 88, 99], ["R. affinis", "ANATOMY", 101, 111], ["C. plicata", "OBSERVATION", 133, 143]]], ["In short, the ORF8 of SARSr-Rf-BatCoV from greater horseshoe bats is phylogenetically closer to ORF8 of human/civet SARS-CoV.", [["ORF8", "GENE_OR_GENE_PRODUCT", 14, 18], ["SARSr-Rf-BatCoV", "GENE_OR_GENE_PRODUCT", 22, 37], ["horseshoe bats", "ORGANISM", 51, 65], ["ORF8", "GENE_OR_GENE_PRODUCT", 96, 100], ["human", "ORGANISM", 104, 109], ["civet SARS-CoV", "ORGANISM", 110, 124], ["ORF8", "DNA", 14, 18], ["SARSr", "PROTEIN", 22, 27], ["Rf", "DNA", 28, 30], ["BatCoV", "DNA", 31, 37], ["ORF8", "DNA", 96, 100], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["SARS-CoV", "SPECIES", 116, 124], ["SARSr", "TEST", 22, 27], ["BatCoV", "TREATMENT", 31, 37]]], ["As mentioned above, ORF8 in the late-phase human epidemic was split into 8a and 8b due to a unique 29 nt deletion.", [["ORF8", "GENE_OR_GENE_PRODUCT", 20, 24], ["human", "ORGANISM", 43, 48], ["ORF8", "PROTEIN", 20, 24], ["29 nt deletion", "DNA", 99, 113], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["ORF8", "TREATMENT", 20, 24], ["a unique 29 nt deletion", "PROBLEM", 90, 113]]], ["A similar 5-nt deletion was observed in the type I ORF8 isolated from the strain SARSr-Rs-BatCoV Rs4084.", [["type I ORF8", "GENE_OR_GENE_PRODUCT", 44, 55], ["5-nt deletion", "DNA", 10, 23], ["type I ORF8", "DNA", 44, 55], ["strain SARSr-Rs-BatCoV Rs4084", "DNA", 74, 103], ["A similar 5-nt deletion", "PROBLEM", 0, 23]]], ["However, since the majority of SARSr-Rs-BatCoVs' ORF8 genes belong to the type III ORF8 genotype, it raises the speculation that this minority of type I ORF8 plays a non-essential role in the Chinese horseshoe bats host environment.SARSr-CoV in Chinese horseshoe bats and greater horseshoe batsIn a recent study, recombinant SARS-CoV carrying three forms of ORF8 were constructed, including complete ORF8 as seen in the early phase of the 2003 human epidemic and civets, ORF8 that contained the characteristic 29 nt deletion, and a variant strain with ORF8 replaced by a 5 nt spacer sequence.", [["SARSr-Rs", "GENE_OR_GENE_PRODUCT", 31, 39], ["BatCoVs", "GENE_OR_GENE_PRODUCT", 40, 47], ["ORF8", "GENE_OR_GENE_PRODUCT", 49, 53], ["type III ORF8", "GENE_OR_GENE_PRODUCT", 74, 87], ["type I ORF8", "GENE_OR_GENE_PRODUCT", 146, 157], ["SARSr-CoV", "ORGANISM", 232, 241], ["SARS-CoV", "ORGANISM", 325, 333], ["ORF8", "GENE_OR_GENE_PRODUCT", 358, 362], ["ORF8", "GENE_OR_GENE_PRODUCT", 400, 404], ["human", "ORGANISM", 444, 449], ["ORF8", "GENE_OR_GENE_PRODUCT", 471, 475], ["ORF8", "GENE_OR_GENE_PRODUCT", 552, 556], ["SARSr-Rs-BatCoVs' ORF8 genes", "DNA", 31, 59], ["type I ORF8", "PROTEIN", 146, 157], ["ORF8", "PROTEIN", 358, 362], ["ORF8", "DNA", 400, 404], ["ORF8", "DNA", 471, 475], ["29 nt deletion", "DNA", 510, 524], ["ORF8", "DNA", 552, 556], ["5 nt spacer sequence", "DNA", 571, 591], ["human", "SPECIES", 444, 449], ["Chinese horseshoe bats", "SPECIES", 192, 214], ["SARSr-CoV", "SPECIES", 232, 241], ["Chinese horseshoe bats", "SPECIES", 245, 267], ["SARS-CoV", "SPECIES", 325, 333], ["human", "SPECIES", 444, 449], ["SARSr", "TEST", 31, 36], ["Chinese horseshoe bats", "PROBLEM", 245, 267], ["greater horseshoe bats", "PROBLEM", 272, 294], ["a recent study", "TEST", 297, 311], ["the characteristic 29 nt deletion", "PROBLEM", 491, 524], ["a variant strain", "PROBLEM", 530, 546], ["ORF8", "TREATMENT", 552, 556], ["a 5 nt spacer sequence", "TREATMENT", 569, 591], ["horseshoe bats", "OBSERVATION", 253, 267], ["greater", "OBSERVATION_MODIFIER", 272, 279], ["horseshoe bats", "OBSERVATION", 280, 294]]], ["Replication assay in VeroFM cells demonstrated a phenotypic hierarchy that the infectious clone with full type I ORF8 exhibited significantly more efficient growth than other variants.", [["VeroFM cells", "ANATOMY", 21, 33], ["clone", "ANATOMY", 90, 95], ["VeroFM cells", "CELL", 21, 33], ["clone", "CELL", 90, 95], ["type I ORF8", "GENE_OR_GENE_PRODUCT", 106, 117], ["VeroFM cells", "CELL_LINE", 21, 33], ["I ORF8", "PROTEIN", 111, 117], ["Replication assay", "TEST", 0, 17], ["the infectious clone", "PROBLEM", 75, 95], ["infectious", "OBSERVATION_MODIFIER", 79, 89]]], ["The same hierarchy of viral replication was observed in human airway epithelial cell cultures and several \"non-host\" cell lines transduced to express human ACE2, including R. alcyone lung epithelial cell line, cotton rat airway epithelial cell line, and goat and sheep lung cell lines.", [["airway epithelial cell cultures", "ANATOMY", 62, 93], ["cell lines", "ANATOMY", 117, 127], ["lung epithelial cell line", "ANATOMY", 183, 208], ["airway epithelial cell line", "ANATOMY", 221, 248], ["lung cell lines", "ANATOMY", 269, 284], ["human", "ORGANISM", 56, 61], ["airway epithelial cell cultures", "CELL", 62, 93], ["non-host", "CELL", 107, 115], ["cell lines", "CELL", 117, 127], ["human", "ORGANISM", 150, 155], ["ACE2", "GENE_OR_GENE_PRODUCT", 156, 160], ["alcyone lung epithelial cell line", "CELL", 175, 208], ["rat", "ORGANISM", 217, 220], ["airway epithelial cell line", "CELL", 221, 248], ["goat", "ORGANISM", 254, 258], ["sheep lung cell lines", "CELL", 263, 284], ["human airway epithelial cell cultures", "CELL_LINE", 56, 93], ["non-host\" cell lines", "CELL_LINE", 107, 127], ["human ACE2", "PROTEIN", 150, 160], ["R. alcyone lung epithelial cell line", "CELL_LINE", 172, 208], ["cotton rat airway epithelial cell line", "CELL_LINE", 210, 248], ["goat and sheep lung cell lines", "CELL_LINE", 254, 284], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 150, 155], ["rat", "SPECIES", 217, 220], ["goat", "SPECIES", 254, 258], ["sheep", "SPECIES", 263, 268], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 150, 155], ["R. alcyone", "SPECIES", 172, 182], ["cotton", "SPECIES", 210, 216], ["goat", "SPECIES", 254, 258], ["sheep", "SPECIES", 263, 268], ["viral replication", "TREATMENT", 22, 39], ["human airway epithelial cell cultures", "TEST", 56, 93], ["several \"non-host\" cell lines", "TREATMENT", 98, 127], ["human ACE2", "TEST", 150, 160], ["R. alcyone lung epithelial cell line", "TREATMENT", 172, 208], ["cotton rat airway epithelial cell line", "TREATMENT", 210, 248], ["goat and sheep lung cell lines", "TREATMENT", 254, 284], ["hierarchy", "OBSERVATION_MODIFIER", 9, 18], ["viral replication", "OBSERVATION", 22, 39], ["airway", "ANATOMY", 62, 68], ["epithelial cell", "OBSERVATION", 69, 84], ["cell lines", "OBSERVATION", 117, 127], ["lung", "ANATOMY", 183, 187], ["epithelial cell line", "OBSERVATION", 188, 208], ["airway", "ANATOMY", 221, 227], ["epithelial cell line", "OBSERVATION", 228, 248], ["sheep lung cell lines", "OBSERVATION", 263, 284]]], ["This study suggests that the 29 nt deletion actually conferred a loss of viral fitness during the initial phase of human-to-human transmission, contradicting the previous belief that the truncated products ORF8a and ORF8b favored adaptation to human (Muth et al., 2018) .Genomic overview of SARSr-BatCoVsComplete genome analysis has been carried out for all sequenced SARSr-CoV with respect to civet SARSr-CoV.", [["human", "ORGANISM", 115, 120], ["human", "ORGANISM", 124, 129], ["ORF8a", "GENE_OR_GENE_PRODUCT", 206, 211], ["ORF8b", "GENE_OR_GENE_PRODUCT", 216, 221], ["human", "ORGANISM", 244, 249], ["SARSr", "GENE_OR_GENE_PRODUCT", 291, 296], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 368, 377], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 400, 409], ["29 nt deletion", "DNA", 29, 43], ["truncated products", "PROTEIN", 187, 205], ["ORF8a", "PROTEIN", 206, 211], ["ORF8b", "PROTEIN", 216, 221], ["SARSr", "DNA", 291, 296], ["BatCoVsComplete genome", "DNA", 297, 319], ["civet SARSr-CoV", "DNA", 394, 409], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 244, 249], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 244, 249], ["SARSr-CoV", "SPECIES", 368, 377], ["SARSr-CoV", "SPECIES", 400, 409], ["This study", "TEST", 0, 10], ["the 29 nt deletion", "PROBLEM", 25, 43], ["a loss of viral fitness", "PROBLEM", 63, 86], ["the truncated products", "TREATMENT", 183, 205], ["SARSr", "TEST", 291, 296], ["BatCoVsComplete genome analysis", "TEST", 297, 328], ["civet", "TEST", 394, 399], ["viral fitness", "OBSERVATION", 73, 86]]], ["The importance of civet SARSr-CoV is underlined by its close genetic relationship to human SARS-CoV along the entire genome and especially at the RBD region where nt identity approaches 98.8-99.8%.", [["SARS", "DISEASE", 91, 95], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 24, 33], ["human", "ORGANISM", 85, 90], ["SARS-CoV", "ORGANISM", 91, 99], ["civet SARSr-CoV", "DNA", 18, 33], ["human SARS-CoV", "DNA", 85, 99], ["RBD region", "DNA", 146, 156], ["human", "SPECIES", 85, 90], ["civet SARSr-CoV", "SPECIES", 18, 33], ["human SARS-CoV", "SPECIES", 85, 99], ["human SARS", "PROBLEM", 85, 95], ["CoV", "PROBLEM", 96, 99], ["nt identity", "TEST", 163, 174], ["RBD", "ANATOMY", 146, 149], ["region", "ANATOMY_MODIFIER", 150, 156]]], ["Moreover, the genetic diversity within the group of civet SARSr-CoV strains is minimal, further supporting that civets are only recently infected.", [["SARSr-CoV", "ORGANISM", 58, 67], ["SARSr-CoV", "SPECIES", 58, 67], ["CoV strains", "PROBLEM", 64, 75], ["diversity", "OBSERVATION_MODIFIER", 22, 31], ["minimal", "OBSERVATION_MODIFIER", 79, 86]]], ["Adaptation of SARSr-BatCoV to civet as intermediate amplification host is likely needed, which is further corroborated by the phylogenetic position of civet ACE2 in-between bat and human ACE2.", [["SARSr-BatCoV", "GENE_OR_GENE_PRODUCT", 14, 26], ["civet", "GENE_OR_GENE_PRODUCT", 30, 35], ["ACE2", "GENE_OR_GENE_PRODUCT", 157, 161], ["bat", "ORGANISM", 173, 176], ["human", "ORGANISM", 181, 186], ["ACE2", "GENE_OR_GENE_PRODUCT", 187, 191], ["SARSr", "PROTEIN", 14, 19], ["BatCoV", "PROTEIN", 20, 26], ["civet ACE2", "PROTEIN", 151, 161], ["human ACE2", "PROTEIN", 181, 191], ["human", "SPECIES", 181, 186], ["human", "SPECIES", 181, 186], ["SARSr", "TREATMENT", 14, 19], ["BatCoV", "TREATMENT", 20, 26], ["ACE2", "TEST", 157, 161]]], ["Recently, direct bat-to-human transmission of SARSr-CoV was proposed by some groups in view of the fact that some SARSr-BatCoVs could utilize human ACE2 receptors in vitro and that seropositive sera against SARSr-BatCoVs were detected in Yunnan residents (Menachery et al., 2015; Wang et al., 2018) , despite the fact that human/civet SARS-CoV has never been reported in Yunnan.", [["sera", "ANATOMY", 194, 198], ["SARS", "DISEASE", 335, 339], ["human", "ORGANISM", 24, 29], ["SARSr-CoV", "ORGANISM", 46, 55], ["SARSr", "GENE_OR_GENE_PRODUCT", 114, 119], ["BatCoVs", "GENE_OR_GENE_PRODUCT", 120, 127], ["human", "ORGANISM", 142, 147], ["ACE2", "GENE_OR_GENE_PRODUCT", 148, 152], ["sera", "ORGANISM_SUBSTANCE", 194, 198], ["SARSr-BatCoVs", "GENE_OR_GENE_PRODUCT", 207, 220], ["human", "ORGANISM", 323, 328], ["civet SARS-CoV", "ORGANISM", 329, 343], ["SARSr", "PROTEIN", 46, 51], ["SARSr", "PROTEIN", 114, 119], ["BatCoVs", "PROTEIN", 120, 127], ["human ACE2 receptors", "PROTEIN", 142, 162], ["SARSr", "PROTEIN", 207, 212], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 323, 328], ["human", "SPECIES", 24, 29], ["SARSr-CoV", "SPECIES", 46, 55], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 323, 328], ["SARS-CoV", "SPECIES", 335, 343], ["CoV", "PROBLEM", 52, 55], ["human ACE2 receptors", "TREATMENT", 142, 162], ["seropositive sera", "TEST", 181, 198], ["CoV", "PROBLEM", 340, 343]]], ["Our findings provide substantial evidence against this hypothesis from a phyloepidemiologic point of view and demonstrated the significance of an intermediate host during the transmission cascade (Fig. 3) .Genomic overview of SARSr-BatCoVsReferring to Fig. 3A , SARSr-Rs-BatCoV Rs4084 was one of the two strains that possess the highest genome identity to civet/human SARSr-CoV.", [["SARSr", "GENE_OR_GENE_PRODUCT", 226, 231], ["SARSr-Rs", "GENE_OR_GENE_PRODUCT", 262, 270], ["human", "ORGANISM", 362, 367], ["SARSr-CoV", "ORGANISM", 368, 377], ["SARSr", "PROTEIN", 226, 231], ["Rs", "PROTEIN", 268, 270], ["human SARSr-CoV", "PROTEIN", 362, 377], ["human", "SPECIES", 362, 367], ["human SARSr-CoV", "SPECIES", 362, 377], ["this hypothesis", "PROBLEM", 50, 65], ["SARSr", "TEST", 262, 267], ["the two strains", "PROBLEM", 296, 311], ["intermediate host", "OBSERVATION", 146, 163]]], ["It is so far the only SARSr-BatCoV that possessed at least 70% nt identity in all parts of the genome, including the four hypervariable regions.", [["SARSr", "GENE_OR_GENE_PRODUCT", 22, 27], ["BatCoV", "GENE_OR_GENE_PRODUCT", 28, 34], ["SARSr", "PROTEIN", 22, 27], ["BatCoV", "DNA", 28, 34], ["hypervariable regions", "DNA", 122, 143], ["all parts", "ANATOMY_MODIFIER", 78, 87], ["genome", "OBSERVATION", 95, 101], ["four", "OBSERVATION_MODIFIER", 117, 121], ["hypervariable", "OBSERVATION_MODIFIER", 122, 135]]], ["The region sharing lowest similarity to civet/human SARSr-CoV was the N-terminal domain (NTD) of the S protein which was likely non-critical.", [["N-", "CHEMICAL", 70, 72], ["human", "ORGANISM", 46, 51], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 52, 61], ["civet", "DNA", 40, 45], ["human SARSr-CoV", "DNA", 46, 61], ["N-terminal domain", "PROTEIN", 70, 87], ["NTD", "PROTEIN", 89, 92], ["S protein", "PROTEIN", 101, 110], ["human", "SPECIES", 46, 51], ["human SARSr-CoV", "SPECIES", 46, 61], ["civet", "TEST", 40, 45], ["human SARSr", "TEST", 46, 57], ["the N-terminal domain", "PROBLEM", 66, 87], ["the S protein", "TEST", 97, 110], ["likely", "UNCERTAINTY", 121, 127], ["non-critical", "OBSERVATION_MODIFIER", 128, 140]]], ["As mentioned above, SARSr-Rs-BatCoV Rs4084 was predicted to be able to utilize human ACE2 as functional receptor since its RBD region is genetically similar to RsSHC014.", [["SARSr-Rs", "GENE_OR_GENE_PRODUCT", 20, 28], ["human", "ORGANISM", 79, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["SARSr", "PROTEIN", 20, 25], ["Rs", "PROTEIN", 26, 28], ["BatCoV Rs4084", "DNA", 29, 42], ["human ACE2", "PROTEIN", 79, 89], ["RBD region", "PROTEIN", 123, 133], ["RsSHC014", "PROTEIN", 160, 168], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["SARSr", "TEST", 20, 25], ["human ACE2", "TREATMENT", 79, 89]]], ["SARSr-Rs-BatCoV Rs4084 has not been studied either as whole virus or in the form of recombinant virus in terms of accessory protein function, tissue infectivity assay and replication kinetics; leaving a potential field for future investigations.", [["tissue", "ANATOMY", 142, 148], ["Rs4084", "CHEMICAL", 16, 22], ["recombinant virus", "ORGANISM", 84, 101], ["tissue", "TISSUE", 142, 148], ["SARSr", "TEST", 0, 5], ["whole virus", "PROBLEM", 54, 65], ["recombinant virus", "PROBLEM", 84, 101], ["accessory protein function", "PROBLEM", 114, 140], ["tissue infectivity assay", "TEST", 142, 166], ["future investigations", "TEST", 223, 244], ["virus", "OBSERVATION", 96, 101]]], ["Animal experiment using civet model would offer great promise in the studying of such virus, along with other SARSr-BatCoVs that could utilize human ACE2.Concluding remarksThe > 300 genome sequences of SARS-CoV in human, civets and bats accumulated in the last 15 years allowed us to understand the cause of such a highly fatal epidemic that affected us in a global scale in 2003.", [["SARS", "DISEASE", 202, 206], ["SARSr-BatCoVs", "GENE_OR_GENE_PRODUCT", 110, 123], ["human", "ORGANISM", 143, 148], ["ACE2", "GENE_OR_GENE_PRODUCT", 149, 153], ["SARS-CoV", "ORGANISM", 202, 210], ["human", "ORGANISM", 214, 219], ["SARSr", "PROTEIN", 110, 115], ["BatCoVs", "PROTEIN", 116, 123], ["human ACE2", "PROTEIN", 143, 153], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 143, 148], ["SARS-CoV", "SPECIES", 202, 210], ["human", "SPECIES", 214, 219], ["civet model", "TREATMENT", 24, 35], ["such virus", "PROBLEM", 81, 91], ["human ACE2", "TREATMENT", 143, 153], ["SARS", "PROBLEM", 202, 206], ["a highly fatal epidemic", "PROBLEM", 313, 336]]], ["After 15 years of work, we are now much closer to fully understand the origin of SARS-CoV and its evolution, as genomes with fragments that contain gene sequences with higher and higher nt identities to the SARS-CoV found in human were observed.", [["SARS", "DISEASE", 81, 85], ["SARS", "DISEASE", 207, 211], ["SARS-CoV", "ORGANISM", 81, 89], ["SARS-CoV", "ORGANISM", 207, 215], ["human", "ORGANISM", 225, 230], ["SARS-CoV", "DNA", 207, 215], ["human", "SPECIES", 225, 230], ["SARS-CoV", "SPECIES", 81, 89], ["SARS-CoV", "SPECIES", 207, 215], ["human", "SPECIES", 225, 230], ["SARS", "PROBLEM", 81, 85], ["CoV", "PROBLEM", 86, 89], ["genomes with fragments", "PROBLEM", 112, 134], ["gene sequences", "TEST", 148, 162], ["the SARS", "PROBLEM", 203, 211], ["CoV", "PROBLEM", 212, 215], ["SARS", "OBSERVATION", 81, 85]]], ["Our current model on the origin of SARS is that the human SARS-CoV that caused the epidemic in 2003 was probably a result of multiple recombination events from a number of SARS-CoV ancestors.", [["SARS", "DISEASE", 35, 39], ["SARS", "DISEASE", 58, 62], ["SARS", "DISEASE", 172, 176], ["human", "ORGANISM", 52, 57], ["SARS-CoV", "ORGANISM", 58, 66], ["SARS-CoV", "ORGANISM", 172, 180], ["human", "SPECIES", 52, 57], ["human SARS-CoV", "SPECIES", 52, 66], ["SARS-CoV", "SPECIES", 172, 180], ["multiple recombination events", "PROBLEM", 125, 154]]], ["Yunnan is the province in China with the largest diversity of horseshoe bat species.", [["horseshoe bat species", "PROBLEM", 62, 83], ["largest", "OBSERVATION_MODIFIER", 41, 48], ["horseshoe bat species", "OBSERVATION", 62, 83]]], ["It is also the area shown to have a high variety of SARS-CoV ancestors.", [["SARS", "DISEASE", 52, 56], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 52, 60], ["SARS-CoV", "SPECIES", 52, 60]]], ["Further in-depth molecular epidemiology studies in this and other provinces in its proximity, including Guangxi and Guangdong, will hopefully give us an even clearer picture on the origin and early evolution of SARS-CoV.", [["SARS", "DISEASE", 211, 215], ["SARS-CoV", "ORGANISM", 211, 219], ["SARS-CoV", "SPECIES", 211, 219], ["SARS", "PROBLEM", 211, 215], ["CoV", "PROBLEM", 216, 219]]], ["Phylogenetic tree constructed based on the nt sequences of ORF8 of SARS-CoVs.", [["SARS", "DISEASE", 67, 71], ["ORF8", "GENE_OR_GENE_PRODUCT", 59, 63], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 67, 76], ["nt sequences", "DNA", 43, 55], ["ORF8", "DNA", 59, 63], ["SARS-CoVs", "DNA", 67, 76], ["SARS-CoVs", "SPECIES", 67, 76], ["the nt sequences", "TEST", 39, 55], ["SARS", "PROBLEM", 67, 71]]], ["SARSr-Rf-BatCoVs are labeled with dots.", [["SARSr-Rf-BatCoVs", "GENE_OR_GENE_PRODUCT", 0, 16], ["SARSr", "PROTEIN", 0, 5], ["Rf", "DNA", 6, 8], ["BatCoVs", "DNA", 9, 16], ["SARSr", "TEST", 0, 5]]], ["Brackets in red, orange, yellow and blue represented descending order of nt identity with respect to civet SARSr-CoV SZ16.", [["Brackets", "CHEMICAL", 0, 8], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 107, 116], ["CoV SZ16", "PROTEIN", 113, 121], ["SARSr-CoV", "SPECIES", 107, 116], ["red", "OBSERVATION", 12, 15], ["descending", "OBSERVATION_MODIFIER", 53, 63]]], ["The phylogenetic tree was constructed by Maximum Likelihood method with T92 + G as the substitution model by MEGA 6.0.", [["T92 + G", "GENE_OR_GENE_PRODUCT", 72, 79], ["T92 + G", "TREATMENT", 72, 79], ["the substitution model", "TEST", 83, 105], ["phylogenetic tree", "OBSERVATION", 4, 21]]], ["The test of phylogeny was statistically supported by the bootstraps value calculated from 1000 trees.", [["the bootstraps value", "TEST", 53, 73]]]], "b796389c53b12c40b7a16dbad08302a59a87145c": [["To the Editor-From the first identified cases of COVID-19 onward, the pandemic spread of COVID-19 has presented difficult challenges for the scientific community.", [["COVID-19", "CHEMICAL", 89, 97], ["COVID", "TEST", 49, 54], ["COVID", "TEST", 89, 94]]], ["Many countries have already experienced periods of social lockdown, with the aim of containing the virus but with dramatic economic consequences.", [["the virus", "PROBLEM", 95, 104], ["dramatic economic consequences", "PROBLEM", 114, 144]]], ["To balance health and economic and social needs in the long term, de-escalation of quarantine restrictions has been proposed in many countries.", [["quarantine restrictions", "TREATMENT", 83, 106]]]], "PMC7239786": [], "PMC7397941": [["IntroductionThere is growing evidence of business adoption of digital technologies as part of the wider digitalisation of the economy and wider society (Malecki & Moriset, 2008; OECD, 2017).", [["digital technologies", "TREATMENT", 62, 82]]], ["These developments have created new opportunities for business processes and improved efficiency, but they have also had disruptive effects on markets and practices with new sources of competition and business models emerging (Brynjolfsson, 2011; OECD, 2018).", [["new", "OBSERVATION_MODIFIER", 32, 35], ["improved", "OBSERVATION_MODIFIER", 77, 85], ["efficiency", "OBSERVATION_MODIFIER", 86, 96]]], ["In recent decades, policy makers have sought to respond to this challenge with an emphasis on supply-side measures aiming to improve the availability of broadband to businesses and citizens (Graham & Marvin, 1996; Grubesic & Mack, 2016; Tranos, 2013).", [["this challenge", "TREATMENT", 59, 73], ["supply-side measures", "TREATMENT", 94, 114]]], ["Attention has been given to demand-side measures such as supporting small businesses to adopt and make use of digital technologies (Belloc et al., 2012; Price et al., 2018).IntroductionDigital transformation affects the technologies adopted and used within small and medium-sized enterprises (SMEs) and the wider society, but also the policies themselves (Falch, 2007; Falch & Henten, 2018; Van Der Meer & Van Winden, 2003).", [["demand-side measures", "TREATMENT", 28, 48], ["small", "OBSERVATION_MODIFIER", 257, 262]]], ["This is an area that has seen governments introduce digital technologies to improve their internal administration processes, and their delivery of services, and strengthen their reach and accessibility of services to citizens (European Commission, 2016).", [["digital technologies", "TREATMENT", 52, 72]]], ["While these developments reflect a broad transition towards online information provision by government, little is known about how advisory policies for SMEs aimed at digital technology adoption1are adapting to this context, nor how far the interactive processes of advice, and its bespoke content, could be digitised (Mole et al., 2014).IntroductionThis paper argues that digitalisation presents an important challenge for policy makers in how best to manage SME advisory policies in this changing context, both in terms of the technologies they advise on, but also the mechanisms by which such advice is provided.", [["broad", "OBSERVATION_MODIFIER", 35, 40]]], ["While documenting digitalisation and its impacts, the paper teases out its effects and prospects for future policy development.", [["digitalisation", "PROBLEM", 18, 32]]], ["It does so with the aid of a case-study of Wales (UK), highlighting the multilevel nature of the policy mix for demand-side digital advisory policy for SMEs over a ten-year period.Demand-side broadband policies ::: Literature reviewBroadband research has begun to give increasing attention to the role of demand-side policies in supporting businesses and the wider society to raise awareness of the benefits of connectivity and consequent use of digital technologies.", [["demand-side policies", "TREATMENT", 305, 325], ["digital technologies", "TREATMENT", 446, 466]]], ["Other researchers emphasise that demand-side policies may go beyond demand stimulation by assisting businesses in the use of broadband and associated technologies (Gillett et al., 2004; OECD, 2008).", [["demand-side policies", "TREATMENT", 33, 53]]], ["This points to the potential for broadband demand-side policies to work alongside supply-side policy measures in an interactive manner, strengthening the use of broadband infrastructure, and addressing low uptake and use in particular groups such as small businesses (Price et al., 2018).", [["broadband demand-side policies", "TREATMENT", 33, 63], ["broadband infrastructure", "TREATMENT", 161, 185], ["low uptake", "PROBLEM", 202, 212], ["small", "OBSERVATION_MODIFIER", 250, 255]]], ["It may also suggest new opportunities for public and private actors to collaborate in the delivery of supply- and demand-side policies (G\u00f3mez-Barroso & Feij\u00f3o, 2010).Demand-side broadband policies ::: Literature reviewThe rationale for demand-side policies rests on innovation diffusion and network effects (Belloc et al., 2012; Rogers, 2003).", [["demand-side policies", "TREATMENT", 114, 134], ["demand-side policies", "TREATMENT", 236, 256], ["innovation diffusion", "TEST", 266, 286], ["may also suggest", "UNCERTAINTY", 3, 19], ["new", "OBSERVATION_MODIFIER", 20, 23]]], ["SMEs have been identified as an important target group for demand-side policies, with Spurge and Roberts (2005: 522) arguing that while \u2018SMEs have been equipped with the tools [they] are not equipped with skills to use them effectively\u2019.", [["demand-side policies", "TREATMENT", 59, 79]]], ["Indeed, studies of SME adoption of digital technologies have shown that while such firms can often lag in their rates of access (Price et al., 2018), active usage can benefit their productivity (Haller & Lyons, 2015).Demand-side broadband policies ::: Literature reviewA wide range of broadband demand-side policies have been identified in the literature.", [["digital technologies", "TEST", 35, 55], ["broadband demand-side policies", "TREATMENT", 285, 315]]], ["Much of the research in this area has sought to establish typologies of policy measures.", [["policy measures", "TREATMENT", 72, 87]]], ["In Belloc et al. (2012)'s study, for example, demand-side policies are found to be most relevant to later stages of broadband diffusion, where the focus moves from infrastructure deployment to business usage.", [["'s study", "TEST", 23, 31], ["broadband diffusion", "PROBLEM", 116, 135]]], ["This leads them to conclude that studies on the nature and role of demand-side policies are underdeveloped.", [["demand-side policies", "TREATMENT", 67, 87], ["underdeveloped", "OBSERVATION", 92, 106]]], ["519).Demand-side broadband policies ::: Literature reviewFor the most part, studies of demand-side policies tend to focus on assessing their rationale, categorising and outcomes (Belloc et al., 2012; Gillett et al., 2004; Price et al., 2018).", [["demand-side policies", "TREATMENT", 87, 107]]], ["While this has helped to shed important light on the emergence of demand-side policies, it has tended to give limited attention to the processes that underpin the policies, nor how they may evolve over time.", [["demand-side policies", "TREATMENT", 66, 86]]], ["This can be seen, for example, in the challenge of managing multiple demand- and supply-side measures in a particular regional or national policy environment (OECD, 2008), and in the potential for tensions and trade-offs to emerge with respect to policy objectives in areas outside of broadband (Henderson and Roche, 2020).SME information and advisory services ::: Literature reviewIn order to provide greater analytical focus to demand-side policies this paper draws on the complementary literature on SME support policies (Bennett, 2012; Storey, 1994).", [["multiple demand", "TREATMENT", 60, 75], ["supply-side measures", "TREATMENT", 81, 101]]], ["This research area has identified the presence of SME support policies in most developed economies, with technology support identified as part of a range of measures including regulatory, financial and softer forms of policy such as information, advice and consultancy (Bennett, 2012; Storey, 1994).", [["technology support", "TREATMENT", 105, 123]]]]}